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Abstract 
Broad-Spectrum Chemokine Inhibitors (BSCIs) are a novel type of anti-
inflammatory drug, discovered by Fox and colleagues, which act through the 
receptor SSTR2. Chapter 1 consists of the story of the development of current BSCIs 
and a literature review of existing SSTR2 ligands.  
In Chapter 2 a series of receptor probes were synthesised based on existing SSTR2 
ligands, BSCIs and a hybrid of the two. Biological data were gained determining 
their SSTR2 binding ability and their extent of leukocyte migration inhibition. 
In Chapter 3 a series of small molecules were synthesised based on the structure of 
highly potent BSCIs. Once again biological data were gained determining their 
SSTR2 binding ability and their extent of leukocyte migration inhibition. 
In Chapter 4 a series of BSCIs were synthesised which contained substituted 
aromatic groups using  an iron-cross coupling reaction. Biological data were gained 
to determine these compounds SSTR2 binding ability. Further iron cross-coupling 
reactions were carried out to determine the scope of these reactions and their 
applications in medicinal synthetic chemistry. 
This works has gained evidence to support a split binding site theory for SSTR2. 
Somatostatin and BSCIs bind in slightly different area of the binding site, and 
through functional selectivity somatostatin structural analogues can exert an anti-
inflammatory effect while somatostatin does not.  
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Chapter 1 – Introduction 
1.1 Inflammation 
Inflammation can be defined by the four latin words calor, dolor, rubor and tumor 
meaning heat, pain, redness and swelling. These are the physical effects seen when 
inflammation is present and are caused by the actions of inflammatory mediators on 
the local blood vessels.
1
 
Inflammation is a component of the innate immune system, that is the first line of 
defence against a wound, injury or infection, the aim being to allow the healing 
process to begin by removing the harmful stimuli. Without the process of 
inflammation, the affected tissue would be destroyed and would fail to heal. 
However, inappropriate inflammation can cause or contribute to such diseases as hay 
fever,
2
 asthma,
3
 atherosclerosis,
4
 rheumatoid arthritis
5
 and cancer.
6
  
1.1.1 The Process of Inflammation 
When circulating leukocytes encounter a foreign body they engulf and destroy it. On 
destroying it they send out messenger molecules, including chemokines, which 
recruit more leukocytes to the site of infection in the process of leukocyte 
extravasation. Leukocyte extravasation is the movement of leukocytes out of the 
circulatory system to the affected area. This occurs in three steps. Initially, 
leukocytes are recruited to the endothelium of the affected area. Subsequently, 
leukocytes move between the endothelial cells and pass in to the tissue in a process 
called transmigration, and finally the leukocytes migrate to the site of inflammation. 
This accumulation of leukocytes intended to fight the infection brings about the 
characteristics of inflammation. Figure 1 shows healthy lung tissue compared to 
severely inflamed lung tissue. The purple dots are leukocytes (labelled M for 
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monocytes); they are confined to the tissue in the healthy lung. In the inflamed lung 
they have migrated to the alveoli consequently inhibiting breathing. The labels are: C 
capillary, E endothelial cell, P1 and P2 pericytes. To facilitate these processes blood 
vessels dilate leading to an increase in blood flow and reduction in blood flow 
velocity in the affected area. The endothelial cells lining the blood vessels are 
activated to express adhesion molecules which bind circulating leukocytes helping 
them migrate from the blood vessels into the tissue. This causes fluid to leak to the 
surrounding areas explaining the symptoms of heat, redness and swelling.
1
 
 
Figure 1 Healthy lung tissue
7
 (left) severely inflamed lung tissue
8
 (right) (taken from Young and 
Heath's Functional Histology and Stevens, Lowe and Young's, Basic Histopathology) 
1.1.2 Current Anti-Inflammatory Drugs - NSAIDs 
As previously mentioned inappropriate and chronic inflammation is a component of 
many diseases, consequently anti-inflammatory drugs make up about half of 
analgesics; they act by reducing inflammation thus reducing pain. Anti-inflammatory 
drugs fall into two main categories, steroidal and non-steroidal anti-inflammatory 
drugs (NSAIDs) which work via different mechanisms. In 2010 however, three of 
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the top twenty best selling drugs in America were tumour necrosis factor alpha 
(TNF-α) inhibitors, which act by a still different mechanism. TNF-α is a cytokine 
which regulates inflammation. The importance of its role can be deduced by the fact 
it has been referred to as the ‘master regulator’ of inflammation.9 All of the TNF-α 
inhibitors function by binding TNF-α, thereby acting as an inhibitor. Remicade10 is a 
human-mouse chimeric monoclonal antibody while Humira
11
 is a fully human 
monoclonal antibody. Enbrel
12
 is a construct which is the fusion of the TNF-α 
receptor to the immunoglobin IgG1, and acts as a decoy receptor. It has a longer 
half-life than the un-fused receptor giving a longer lasting pharmacological effect. 
Small molecule NSAIDs act by inhibiting the enzyme cyclooxygenase (COX) which 
catalyses the synthesis of the inflammatory mediators prostaglandins.
13
 These are 
often referred to as COX inhibitors. Arachidonic acid is derived from the cellular 
phospholipid bilayer by the enzyme phospholipase A2. COX catalyses the formation 
of PGG2, the precursor for inflammatory mediators prostaglandins, from arachidonic 
acid, as illustrated in Figure 2.
14
 Therefore, inhibiting COX decreases the production 
of prostaglandins hence reduces inflammation.
15, 16
 Aspirin is one of the most 
famous examples of an NSAID with others including ibuprofen and naproxen. 
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Figure 2 COX mediated production of PGG2 from arachidonic acid 
However, the NSAIDs industry is not without its problems. A major side affect of 
NSAIDs is stomach irritation, thought to be due to inhibiting prostaglandin. 
Prostaglandins play an important role in the production of gastric mucosa which has 
a protective effect on the stomach and has a role in preventing conditions such as 
stomach ulcers.
17
 COX-1 expression is much higher in the gastrointestinal (GI) 
tract
18
 and therefore selective COX-2 inhibitors have been developed to overcome 
this side effect. Celecoxib (1.01) (Figure 3) is a selective COX-2 inhibitor marketed 
by Pfizer which is used for the treatment of osteoarthritis and rheumatoid arthritis.
19
 
Vioxx (1.02) (Figure 3) is another COX-2 inhibitor structurally similar to Celecoxib 
marketed by Merck. It was withdrawn from the market in 2004 due to safety 
concerns causing huge losses for the company.
20
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Figure 3 Celecoxib 1.01 and Vioxx 1.02  
1.1.3 Current Anti-Inflammatory Drugs - Steroids 
Glucocorticoids are steroids that act by binding to the glucocorticoid receptors and 
therefore are often referred to as corticosteroids. They are a group of naturally 
occurring steroids produced in the adrenal cortex and have a variety of physiological 
functions including regulation of inflammation. They work by downregulating the 
gene expression of inflammatory mediators. The receptor is located in the cell 
membrane, once bound to the steroid the receptor-ligand translocates into the cell 
nucleus to bind to glucocorticoid response elements on the promoter region of the 
gene thereby regulating gene expression. Cytokines, chemokines, adhesion 
molecules and inflammatory enzymes, receptors and proteins are downregulated. 
The protein lipocortin, also known as annexin, that inhibits phospholipase A2 is also 
upregulated, preventing the synthesis of arachidonic acid, thereby having an anti-
inflammatory affect. Corticosteroids are one of the most common drugs used in the 
treatment of asthma.
21, 22
 Dexamethasone (1.03) (Figure 4), an example of a 
glucocorticoid drug, is 20-30 times more potent than the naturally occurring cortisol 
(1.04) (Figure 4) and it is used in the treatment of autoimmune diseases and 
rheumatoid arthritis. Like NSAIDs, steroidal anti-inflammatory drugs pose 
problems. Side effects include loss of bone density, mood changes, problems with 
growth and weight gain.
23
 The fourth best selling drug in America in 2010 was 
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Advair (1.05) (Figure 5) which is a combination of fluticasone propionate, a 
corticosteroid, and salmerterol.
24
 
 
Figure 4 Dexamethasone 1.03 and cortisol 1.04  
 
Figure 5 Advair (1.05) 
1.1.4 Chemokines and Inflammation 
The final stage of leukocyte extravasation, the migration of leukocytes to the area of 
inflammation, is caused by chemokines. Chemokines are a type of cytokine, named 
after their ability to induce chemotaxis, the directed movement of cells in response to 
the surrounding chemical environment. Interleukin-8 (IL-8) was discovered in 1987 
and revealed the existence of this new type of cytokine.
25
 Chemokines act as 
chemoattractants and leukocytes follow the signal of increasing chemokine 
concentration towards the source - the affected area. The major use of chemotaxis is 
to fight infection however in cases when inflammation is detrimental to the health of 
the individual, the inhibition of chemokines presents a mechanism by which 
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inflammation can be inhibited. Pathological inflammation has been shown to be 
reduced, or even abolished, by reducing chemokine signalling using methods such as 
genetic deletion or neutralising antibodies.
26
 For example inflammation is reduced 
following treatment with non-specific pro-inflammatory stimulus, bacterial 
lipopolysaccharide (LPS) after mice were given neutralising antibodies against a 
range of chemokines.
27, 28
 These results imply that chemokines are a likely 
pharmaceutical target in the development of anti-inflammatory agents. Chemokine 
regulation has to be undertaken with care, as chemokines play a vital role in 
defending the body against invading pathogens.
29
 
1.1.5 Chemokine Structure and Chemokine Receptors 
Chemokines are small proteins, being only 8-12 kDa in size.
30
 There are four classes 
and they are divided according to the number of amino acid residues between the 
first and second cysteine residues closest to the N-terminus. These cysteine residues 
create the tertiary structure of the protein by forming a disulfide bonds to the third 
and fourth cysteine residues from the N-terminus. The classes are: 
  1) CC, where the first and second cysteine residues are adjacent. Examples 
 include RANTES, macrophage inflammatory protein (MIP-1α) and 
 monocyte chemotactic protein (MCP-1) which attract leukocytes such as  T-
 cells and monocytes.  
  2) CXC, in which there is one residue separating the first two cysteine 
 residues, for example IL-8 which attracts neutrophils. 
 3) CX3C, in which the cysteine residues are three residues apart. 
 4) C, which is unique in only containing two cysteine residues.  
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These last two classes of chemokines are much less abundant.
31, 32
 
Chemokine receptors are G-protein coupled receptors (GPCRs) which are integral 
membrane proteins.
30
 They contain a 7-transmembrane region with the extracellular 
loops able to form disulfide bridges to stabilise their tertiary structure, which 
resembles a barrel. Ligand binding occurs within a cavity of the transmembrane 
domain at the N-terminus. The C-terminus is therefore intracellular and is bound to 
the G-proteins. GPCRs convey their signal in a guanosine triphosphate (GTP) 
dependent manner via a complex of three proteins (Gα, Gβ and Gγ) known as 
heterotrimeric G proteins. When guanosine diphosphate (GDP) is bound the complex 
is inactive and Gα binds with high affinity to Gβγ. However, when GTP is bound Gα 
dissociates from Gβγ and functions as a regulator or effectors protein.33 This change 
in activity is thought to be due to the terminal phosphate group which, in the GTP-
bound form, stabilises the Gα protein. In the GDP bound form this does not occur 
however the Gβγ complex stabilises it instead.34 The exchange of GDP to GTP 
occurs due to the effects of a ligand binding, inducing a conformational change and 
causing GDP to dissociate. GTP is then able to bind, effecting another 
conformational change causing the GTP-Gα to dissociate and the ligand to dissociate 
(Figure 6). Gα has GTPase activity, which hydrolyses GTP back to GDP, thereby 
acting as an internal clock and switching the receptor 'off' to its original state as the 
Gα reassociates with the Gβγ unit.33 GPCRs account for 80 % of the cross membrane 
signal transduction. They are extremely diverse, with ligands including ions, 
odorants, fatty acids, amino acids, neurotransmitters and polypeptides.
35
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Figure 6 GPCR in the inactive and ligand bound active forms 
The chemokine system is very complex; there are over 50 known chemokines and 20 
receptors.
36
 Different chemokines are selectively produced by a range of tissues and 
the receptors are expressed by a diverse array of inflammatory cells.
37
 Cells can only 
respond if they possess a receptor that recognises the chemokine in the local 
environment, therefore each receptor-chemokine combination may direct a different 
inflammatory response and this response can be tailored by the body based on the 
type of injury, or threat. Receptors can only bind to one class of chemokine, but they 
can bind to many chemokines in that class - leading to large amounts of 
redundancy.
38
 This leads to two approaches for pharmaceutical targets - chemokine 
receptor antagonists, which target single chemokine/chemokine receptor 
combinations, or chemokine inhibitors which target a range of 
chemokine/chemokine receptor combinations. 
There are a number of cell migration inhibitors under development, with the majority 
being chemokine receptor antagonists. BX 471 (1.06) (Figure 7) is a potent non-
peptide CCR1 antagonist which inhibits leukocyte migration and shows a 10,000-
10 
 
fold selectivity for CCR1 over other receptors.
39
 BX 471 has undergone clinical 
trials.
40
 ChemoCentryx have a number of clinical candidates, including the lead 
candidate Traficet-EN, a CCR9 antagonist for the treatment of Crohn's disease, 
which has completed phase III clinical trials.
41
 
 
Figure 7 BX 471 (1.06) 
These examples are all based upon specific receptor-chemokine combinations. Fox 
and colleagues have developed a novel form of anti-inflammatory chemokine 
inhibitors, Broad-Spectrum Chemokine-Inhibitors or BSCIs. 
1.2 Broad-Spectrum Chemokine Inhibitors - BSCIs 
1.2.1 Peptide 3 and NR58, 3.14.3 
BSCIs are anti-inflammatory molecules which function by inhibiting leukocyte 
chemotaxis induced by chemokines. The first BSCI produced by Grainger et al was 
"Peptide 3" which is comprised of residues 51-62 of the chemokine MCP-1, 
conserved across human, mouse and chicken species.
42
 It is 12 amino acid residues 
long with the sequence EICADPKQKWVQ which inhibits five different 
chemokines: MCP-1, MIP-1α, RANTES, IL-8 and SDF-1α, with a potency of ~ 10 
μM. However, it does not affect leukocyte migration caused by other 
chemoattractants such as N-formylmethionine leucyl-phenylalanine (fMLP) and 
tumour growth factor beta (TGF-β). NR58, 3.14.3 (1.07) (Figure 8) was developed 
from "Peptide 3" (Figure 9), being a cyclic retroinverse analogue with a similar 
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peptide sequence.
43
 Synthesising the retroinverse analogue of a compound means 
changing all the amino acids to the opposite enantiomer, in this case L to D, and 
reversing the direction of the chain. The residues' functionalities are in the same 
position, but are less susceptible to proteolytic cleavage, because the proteolytic 
enzymes in the body are specific for L-amino acids. NR58, 3.14.3 was found to have 
an increased potency of over 1000 times greater than "Peptide 3".
43
 The development 
of both of these as drugs is hindered due to poor oral availability and a short plasma 
half life;
44
 NR58, 3.14.3 is cleared from blood plasma with a t1/2 of less than 30 
minutes following intravenous injection.
45
 A solution to this problem is to synthesise 
smaller non-peptide analogues. 
 
Figure 8  NR58, 3.14.3 
1.2.2 Structure Activity Relationship 
In order to synthesise smaller non-peptide alternatives the critical structural motif in 
"Peptide 3" for activity had to be determined. "Peptide 3" was divided into two 
hexapeptides (Figure 9). Both of these hexapeptides inhibited leukocyte migration 
induced by the chemokine MCP-1, but only the C-terminal end retained the same 
potency as "Peptide 3". The C-terminal end was then cut into two tripeptides. The 
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KQK tripeptide inhibited only MCP-1 while the WVQ tripeptide inhibited all five of 
the chemokines that "Peptide 3" did with similar potency (2-10 μM).  
AcNH-E-I-C-A-D-P-K-Q-K-W-V-Q-OH
'peptide 3' 10 M
AcNH-E-I-C-A-D-P-OH             AcNH-K-Q-K-W-V-Q-OH
AcNH-W-V-Q-OHAcNH-KQK-OH
50 M 6 M
12 M 4 M  
Figure 9 ED50 values of "Peptide 3" and derivatives 
The dipeptides WV, WQ and VQ were tested but showed no activity as chemokine 
inhibitors so the focus was placed on the tripeptide WVQ. Replacing the tryptophan 
residue with any non-aromatic residues led to loss of activity, indicating the 
importance of a large hydrophobic group in this position. All activity was lost when 
replacing the glutamine residue with any other residue. In conclusion a large 
hydrophobic group is required at an appropriate distance from a primary amide.
45
 
NR58, 3.14.3 was cut down to the tripeptide WIQ, which is similar to the WVQ 
sequence of "Peptide 3". Isoleucine and valine both have a branched alkyl side chain, 
with valine just missing a CH2 component. This fits into the conclusion drawn before 
that for high potency, BSCIs require a hydrophobic group and a primary amide.  
1.2.3 Non-peptide BSCIs 
Based on this conclusion, some potential BSCIs were synthesised. A series of 
glutamine peptide mimics including glutamine itself and hydrophobic groups 
(tryptophan mimics) were produced (Figure 10). The compound with the highest 
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potency of 5 nM, 2000 times higher than the next most potent compound, was NR58, 
4 (1.08) (Figure 11). NR58, 4 is an acylaminoglutarimide with an unsaturated side 
chain. Compared to the (R)-enantiomer, the (S)-aminoglutarimide has a much higher 
potency.
45
  
 
Figure 10 Q mimics and hydrophobic groups (W mimics) 
 
Figure 11 NR58, 4 
1.2.4 NR58, 4 
NR58, 4 has been shown to be an effective anti-inflammatory agent in models of 
acute inflammation, but less effective in models of chronic inflammation.
45
 This is 
thought to be due to the susceptibility of aminoglutarimide rings to enzyme-
catalysed metabolism.
46
 A tritium labelled analogue of NR58, 4 was synthesised and 
injected intravenously into groups of rats, blood samples were taken at various times 
after injection. The total tritium content was determined by high-performance liquid 
chromatography (HPLC) as was the fraction of tritium in the unchanged drug. The 
total tritium content had a half life of 56 hours, however, only 48 hours after 
injection, none of the tritium was present in the form of the injected drug. This 
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suggests it was undergoing rapid metabolism to yield stable metabolites. Hydrolytic 
ring opening of glutarimide yields N-α-substituted glutamine and isoglutamine, 
which are further hydrolysed to N-substituted glutamic acid (Figure 12). This was 
confirmed  by subjecting the metabolites to reverse-phase HPLC and the retention 
times matched those of independently synthesised products. In order to produce a 
molecule that retains the biological activity of the acylaminoglutarimides, but is 
resistant to enzyme-catalysed degradation, a series of lactam derivatives were tested. 
The lactam derivatives are only structurally dissimilar by the replacement of a 
carbonyl group with CH2.
46
 
 
Figure 12 Hydrolytic ring opening of glutarimide ring  
1.2.5 Lactam BSCIs 
The 6-membered lactam equivalent of NR58, 4 (1.09) (Figure 13) was tested for 
stability. It was shown to be considerably more stable, with less than 10 % 
undergoing metabolism in 24 hours. This compound was not as potent as NR58, 4 
but showed that these types of compounds were viable alternatives, leading to the 
synthesis of more lactam analogues. The 5-membered (1.10), 6-membered (1.09) and 
7-membered (1.11) lactam equivalents of NR58, 4 were synthesised returning 
leukocyte migration inhibition ED50 values of  245 nM, 100 nM  and 40 nM 
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respectively .
46
 The 7-membered ring lactam (1.11) (Figure 13) was the most active, 
but still eight times less active than NR58, 4. By increasing the chain length the 
potency was increased, but solubility became a problem so unsaturated chains were 
produced. The result was BN83253 (1.12) (Figure 13) which has a potency similar to 
NR58, 4, 3 nM,  but is relatively resistant to metabolism in serum. This compound 
showed greater potency than NR58, 4 when administered orally, with an effective 
oral availability of roughly 10 %.
46
  A library of potential drug candidates was 
synthesised via the acylation of the lactams. The results showed that, like the 
aminoglutarimides, the (S)-enantiomer of the lactam was the more potent. The 
results also showed that the branching of the α-carbon of the side chains greatly 
increased their potency, which was retained even when administered orally. One of 
the most successful BSCI synthesised by the group (1.13), contains the caprolactam 
and a hydrophobic tertiary butyl group and has a potency of 40 pM (Figure 13).
47
 
 
Figure 13 ED50's of compounds 1.10-1.13 
1.2.6 Mechanism of Action of BSCIs 
The initial strategy in developing "Peptide 3" was to identify a receptor-binding 
antagonist, but the evidence suggests "Peptide 3" does not function through binding 
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to or modulating the properties of chemokine receptors. The binding of "Peptide 3" 
to different cell lines was studied. "Peptide 3" bound to cells expressing no 
chemokine receptors and when chemokine receptors were expressed at over 1 
million copies per cell no additional binding was detected. "Peptide 3" had no effect 
on the binding of chemokines to chemokine receptors, nor did they affect the level of 
chemokine receptors expressed. Modifications to "Peptide 3" gave similar changes in 
potency in assays involving all chemokines, suggesting the target is a single receptor 
as opposed to a number of chemokine receptors. BSCIs only affect the migratory 
response aspect of chemokine signalling. They do not affect intracellular calcium ion 
concentrations, or downregulate chemokine receptors on the cell surface. From this it 
seems likely that BSCIs target a component of the chemokine signalling pathway 
associated with the migratory response.
48
 
Through screening a large number of receptors it has been found that BSCIs in fact 
bind to SSTR2, a receptor classically thought of as a somatostatin receptor.
49-51
  
1.3 Somatostatin and SSTR2 
Somatostatin is a multi-functional peptide hormone; originally thought to be a 
growth hormone (GH) inhibitor. However, its functions have been found to be more 
diverse and can be divided into four key cellular processes such as glandular 
secretion, cell proliferation, smooth muscle contraction and neurotransmission.
52
 It is 
produced by neuroendocrine cells and is involved in the integration of the nervous 
and hormonal systems. 
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1.3.1 Discovery of Hypothalmic Releasing Factors 
Somatostatin was discovered by Roger Guillemin as part of his research into brain 
hormone function that was to win him a share in the 1977 Nobel Prize for 
Physiology and Medicine.
53
 
Somatostatin is one of a group of hormones known as hypothalamus releasing 
factors. These are hormones of hypothalmic origin and affect the release of pituitary 
hormones. The hypothalamus effectively links the nervous and endocrine system via 
the pituitary gland. The anatomical basis for the link between the hypothalamus and 
the pituitary was established by Harris and co-workers in the 1940s.
54
 The 
hypothalamus is roughly the size of an almond and is located just above the brain 
stem. Hypothalmic releasing factors are produced in neuroendocrine neurons, which 
are in the periventricular nucleus in the third ventricle of the hypothalamus. The 
pituitary is roughly the size of a pea and is located below the hypothalamus in a 
protective bony enclosure of the skull called the sella turcica. It is comprised of three 
lobes: the anterior, intermediate and posterior. It is the anterior lobe which secretes 
hypothalmic controlled hormones. The hypophyseal portal system is a system of 
blood vessels which connect the hypothalamus and the pituitary. The primary plexus 
is composed of small capillaries which flow down the stalk of the pituitary and are 
distributed throughout the anterior lobe by the secondary plexus.
55
 
Corticotropin-releasing factor (CRF) was the first hypothalmic hormone to be 
demonstrated. It stimulates the release of adrenocorticotropic hormone (ACTH) 
which causes the secretion of steroids by the adrenal cortex in the body's response to 
stress. However due to instability and difficulties with assays, not enough material 
was isolated to determine its structure.
55, 56
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Thyrotropin-releasing factor (TRF) (1.14) was the first hypothalmic releasing 
hormones to be isolated.
56
 Initial research into these hormones was hindered by the 
fact that only nanogram quantities of hormone were found in each brain meaning 
huge numbers of brains were necessary to obtain structural data. In separate 
laboratories Schally and co-workers worked with primarily porcine TRF and 
Guillemin and co-workers worked with primarily ovine TRF. In 1968 Guillemin and 
co-workers isolated one mg of TRF from 300,000 sheep hypothalami.
57
 The primary 
structure was established by mass spectrometry and it was identical to that isolated 
by Schally and co-workers of porcine origin.
58
 TRF is a three residue polypeptide 
which stimulates thyroid stimulating hormone TSH and prolactin.
59
 The structure 
(Figure 14) was determined
60
 and it was successfully synthesised.
61, 62
 
 
Figure 14 Thyrotropin-releasing factor (TRF)  
Luteninizing hormone releasing hormone (LH-RH) or gonadotropin-releasing factor 
(GnRF) affects luteninizing hormone (LH) and follicle stimulating hormone (FSH).
59
 
In 1949 Sawyer and co-workers demonstrated the involvement of the central  
nervous system in the control of gonadotropin secretion.
63
 The presence of LH-RH 
in hypothalamic extracts of rats was first detected in the early 1960s and at this point 
it was thought the LH releasing activity and FS releasing activity were due to two 
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different substances.
55
 LH-RH was purified, the structure determined,
64
 and it was 
shown to be active both in vivo and in vitro.
65
 
After the discovery and isolation of TRH and LH-RH it was generally accepted that 
the control of the pituitary secretion of GH would also be regulated by a hypothalmic 
releasing factor.
66
 The presence of somatostatin in the hypothalamus was first 
observed by Krulich and co-workers.
67
 Somatostatin was isolated from 500,000 
sheep hypothalami to yield 8.5 mg of somatostatin.
66
 Schally and co-workers 
isolated somatostatin from porcine hypothalami to prove the structures were identical 
over both species.
68
 
Somatostatin (1.15) (Figure 15) has the primary structure H-Ala-Gly-Cys-Lys-Asn-
Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH with a disulphide bond between the 
cysteine residues, making it a cyclic peptide. This structure was deduced by Edman 
degradation of the carboxymethylated peptide, the carboxymethylated tryptic digest 
and the chymotryptic digest.
69
 The proposed structure was synthesised on solid 
phase and was shown to have the same properties and activity of native 
somatostatin.
70
 
 
Figure 15  Somatostatin  
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1.3.2 Functions of Somatostatin 
Somatostatin's most striking feature is the number of physiological functions it is 
involved in.
71, 72
 As previously stated, somatostatin has been shown to not only affect 
GH regulation, but also glandular secretion, cell proliferation, smooth muscle 
contraction as well as acting as a neurotransmitter. 
73
 In terms of glandular secretion, 
somatostatin also regulates thyrotropin,
74
 glucagon, insulin
75
 and gastrin.
76
 Smooth 
muscle contractions are mediated through regulation of acetylcholine, which acts as 
an excitatory neurotransmitter at neuromuscular junctions.
77, 78
 Cells which contain 
somatostatin (typically neurons or endocrine-like cells) have been found in the 
central and peripheral nervous system, the pancreas, the gut
79
 and in small numbers 
in the thyroid, adrenals, submandibular glands, kidneys, prostate and the placenta.
66
 
Consequently somatostatin has been shown to act on the brain gut, pituitary, 
endocrine and exocrine pancreas, adrenals, thyroids and kidneys. 
1.3.4 Preprosomatostatin 
Differences were noticed in the chromatographic behaviour of synthetic somatostatin 
compared to immunoreactive somatostatin, obtained through purification from 
porcine intestinal extracts. Immunoreactive somatostatin was determined to contain 
an N-terminally extended form of somatostatin. Consequently there are two active 
forms of somatostatin: somatostatin-14 (Figure 16) and N-terminally extended 
somatostatin-28 (Figure 17).
80
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Figure 16 Somatostatin-14 
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Figure 17 Somatostatin-28 
Somatostatin is transcribed as inactive preprosomatostatin consisting of 116 amino 
acids.
81
 Like other secretory proteins somatostatin is synthesised as precursors on 
ribosomes, then translocated into the lumen of the endoplasmic reticulum. They are 
then transported through budding coated vesicles through the Golgi apparatus stacks 
to the trans-Golgi apparatus network. Once in the Golgi apparatus, prosomatostatin 
is sorted into clathrin-coated or non-clatharin-coated vesicles ready for processing. A 
24 amino acid sequence from the C-terminus is cleaved to yield a 92 amino acid 
prosomatostatin protein.
82-84
 Somatostatin-14 and somatostatin-28 are both generated 
by endoproteolytic processing of prosomatostatin.
85-87
 Processing is thought to occur 
by members of the subtilisin-related serine convertases family (SPCs) furin, PC1 and 
PC2.  Cleavage occurs at the dibasic Arg-Lys cleavage site to produce somatostatin-
14 and an 8 kDa peptide and is caused by the enzymes PC1 and PC2. Monobasic 
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cleavage at an Arg site produces somatostatin-28 and a 7 kDa peptide, this is caused 
by the enzyme furin.
80
 In addition there is a monobasic Lys cleavage site which 
produces the decapeptide antrin, or prosomatostatin[1-10], a molecule without any 
known biological activity (Figure 18).  
 
Figure 18 Schematic of mammalian prosomatostatin 
Fish and other lower invertebrates have two distinct genes for somatostatin-14 and 
somatostatin-28. Humans have a single prosomatostatin molecule which undergoes 
tissue specific processing to give somatostatin-14 or somatostatin-28. The 
hypothalamus and cerebral cortex synthesise somatostatin in a 4:1 ratio of -14 to -28. 
The stomach, pancreatic islets, enteric neuron and retina produce predominantly -14 
while the intestinal mucosal cells synthesise predominantly -28.
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1.3.5 Receptors 
There are five somatostatin receptor subtypes SSTR1-5 and like chemokine receptors 
they are all GPCRs.
88-91
 Each receptor is encoded for by separate genes on different 
chromosomes. Due to their similarities in structure and reactivity the receptors can 
be subdivided into two groups SSTR2,3 and 5  and SSTR1 and 4.
92
 SSTR2 is the 
only receptor in which the gene coding for it has an intron, therefore it gives rise to 
the spliced variants SSTR2A and SSTR2B which differ in the length of the 
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cytoplasmic tail at the C-terminus. There is 39 %- 57 % sequence identity over the 
various receptor family members with SSTR1 and SSTR4 showing the highest 
sequence identity, not surprising considering they belong to the same subfamily.
88
 
1.4 Somatostatin Analogues 
Due to its diverse biological functions somatostatin has attracted a great deal of 
pharmaceutical interest. The clinical use of somatostatin itself has mainly been 
hampered by a short half-life, which, when in circulation, is less than three minutes. 
The sites of enzymatic degradation of somatostatin are shown in Figure 19.
93
 A large 
number of analogues have been synthesised, initially to achieve greater metabolic 
stability than somatostatin-14. Another necessary aim is the improvement in receptor 
selectivity.
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Figure 19 Sites of somatostatin susceptible to enzymatic degradation 
Not long after its discovery, analogues of somatostatin were synthesised without the 
Ala-Gly side chain. These were shown to retain high biological activity leading to 
the conclusion that the cyclic structure contained the necessary binding 
information.
95
 Initial studies were carried out to determine the minimum requirement 
or critical motif for activity of a somatostatin analogue. This was achieved by:  
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 1) Systematic deletion of single residues,  
 2) Shortening of the C and N termini,  
 3) Replacing single amino acids with alanine to maintain the peptide back 
 bone but lose the functionality,  
 4) Replacement of each L-amino acid with the corresponding D-amino acid, 
 and finally, 
 5) Replacing residues with alternate residues.  
The most significant finding was that replacing tryptophan with D-tryptophan gave 
an analogue with a potency of eight times higher than that of native somatostatin. 
This could be credited to its greater resistance to degradation being a D-amino acid, 
however it may be due to its greater ability to stabilise the active conformation. 
Complete recovery of somatostatin from the assay indicated that degradation is not 
an issue.
96
 Another important finding was upon replacing residues Phe-(6), Phe-(7), 
Trp-(8), Lys-(9) or Phe-(11) with alanine, GH inhibiting potency was decreased by 
approximately 30-fold. The remaining residues were all expendable and replacing 
them with alanine had little biological effect. This study also showed the possibility 
of analogues which selectively inhibit one biological response over another. An 
analogue was synthesised with 1750 % increased inhibition of insulin over 
glucagon.
96
 
Veber and co-workers used these findings to synthesise a cyclic hexapeptide 
analogue c[Pro(6)-Phe-(7)-D-Trp-(8)-Lys-(9)-Thr-(10)-Phe-(11)] called L-363,301 
(1.16) (Figure 20), which showed a greater potency at inhibiting the release of 
insulin, glucagon and GH than native somatostatin.
97
 This molecule was shown to 
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contain a βII turn around the Trp-Lys and a βVI turn around the Phe-Pro which 
contained a cis-amide bond.
98
 Investigations were done into the importance of the 
lysine residue. Replacement with ornithine gave a 10-fold reduction in activity. 
Replacement with either histidine, arginine or p-NH2-Phe led to a complete loss of 
function. Replacement with the isosteric lysine analogues thialysine and γ- and δ-
fluorolysine gave comparable results to lysine. The most important factor is the  
precise distance of the primary amine from the peptide backbone, whilst small 
changes in the basicity of the residue is not important.
99
 A number of similar cyclic 
peptides were synthesised including MK678
100
 (1.17) (Figure 20), known as 
seglitide, which showed a 10-fold increase in potency. Although structurally similar, 
seglitide gains a hydroxyl group from the replacement of a phenylalanine with a 
tyrosine, yet loses a hydroxyl group in the replacement of threonine with valine. The 
proline is also replaced by an N-methylated alanine residue.  
 
Figure 20 L-363,301 (1.16) and MK678 or seglitide (1.17) 
Bauer and co-workers synthesised the most successful of the cyclic peptides - an 
octapeptide analogue named SMS 201-995 (1.18) (Figure 22). It was found to be 
three times more potent than native somatostatin in GH inhibition in vitro and more 
resistant to enzymatic degradation, making it 20 times more active than somatostatin 
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in vivo. The aim was to synthesise a compound that would inhibit GH in doses 
significantly less than those that would inhibit insulin. The compound must also be 
stable enough to inhibit GH over a therapeutically adequate time span. The starting 
point was a cyclic peptide Cys-Phe-D-Trp-Lys-Thr-Cys (Figure 21) cyclised by a 
disulphide bond between the two cysteine residues. However, this analogue had only 
1/1000 of the activity of somatostatin in vitro or in vivo. Substitutions were made 
onto the cysteine residues at either end of the molecule. As previously mentioned 
Phe
6 
was known to be an important residue for activity so a D-Phe residue was 
placed at the N-terminus, which also acted to hinder the disulphide bridge from 
enzymatic attack. The C-terminus was extended with a threoninol residue, which 
most likely mimics Thr
12
 of the native somatostatin. 
 
Figure 21 Cyclic hexapeptide starting point and SMS 201-995 (1.18) 
Metabolic stability was determined by mixing the compounds with ultrafiltrate of rat 
kidney homogenate, as it has been shown to degrade most endogenous peptides 
within minutes. SMS 201-995 showed remarkable stability compared to native 
somatostatin
101
 and with a half-life of approximately 117 minutes.
102
 The disulfide 
bridge stabilises the biologically active sequence of Phe-D-Trp-Lys-Thr, the 
important β-turn is kept in over the D-Trp and Lys residues. Any modifications 
which change this backbone structure render the peptide inactive.
103
 SMS 201-995 or 
octreotide, now branded as sandostatin, is sold by Novartis Pharmaceuticals as an 
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injectable drug used for the treatment of acromegaly as well as for the treatment of 
gastroenteropancreatic tumours and following pancreatic surgery. 
 
Figure 22 SMS 201-995, octreotide or sandostatin (1.18) 
Based on the structure of sandostatin, a series of analogues were synthesised in 
which the disulfide bridge was replaced by a monosulfide or lanthionine bridge, for 
example lanthionine-octreotide (1.19) (Figure 23). Lanthionine bridges are 
components in naturally occurring molecules such as nisin
104
 and epidermin.
105
 They 
were shown to give increased selectivity to receptors SSTR2 and SSTR5 
representing a good mimic for a β-turn.106 Weaker binding meant they were not as 
potent as their precursor. 
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Figure 23 Lanthionine-octreotide (1.19) 
Precise information regarding the structure of the cyclic peptides was obtained by the 
synthesis of α and β-methylated analogues of L-363,301 (Figure 20). The structure 
of α-methylated compounds was shown to be flat. These α-methylated compounds 
displayed poorer activity, indicating the folded conformation is the active one.
107
 The 
most active analogue (1.20) was one which contains a β-methylated tryptophan 
residue, the α-centre has (R)-stereochemistry as in D-Trp and the β-centre was (S)-
stereochemistry. This analogue showed improved activity compared to L-363,301 
(1.16) (Figure 24).
108
 In the active conformation the backbone amide of the 
tryptophan was shown to be anti while the lysine was gauche meaning the side 
chains were close in proximity. The phenylalanine was anti meaning it was also 
close (8-9 Å) to the tryptophan and lysine residues (Figure 25). It can be concluded 
that this conformation fits into the somatostatin receptor binding sites.
109
 The β-
methylated tryptophan residues were used later in the development of non-peptide 
analogues. 
29 
 
 
Figure 24 β-Methylated analogue of L-363,301 (1.20) 
 
Figure 25 Newman projection of (1.20) β-methylated analogue of L-363,301 
The synthesis of retro-inverse analogues indicated to Goodman and co-workers that 
the precise structure of the peptide backbone was not important - it merely held the 
residues in the correct orientation.
110
 This was an important finding as it led to the 
synthesis of  non-peptide and consequently small molecules analogues, more suitable 
for use as drugs. The challenge was to synthesise scaffolds which kept the β-turn 
motif found to be essential for binding, as is the case with many ligand receptor 
combinations.
111
 
Hirschmann and co-workers replaced the peptide backbone with a β-D-glucose 
scaffold. Their motivation was the well defined structure and readiness for 
functionality the sugar scaffold provided, along with the decrease in capability of 
forming hydrogen bonds. The replacement of the NH by the N-methylated version in 
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cyclic peptide cyclosporin, improves its oral activity, indicating the NH bond of the 
peptide backbone may contribute to the bioavailability problems.
112
 The β-turn was 
mimicked and amino acid side chains were attached through etherification 
reactions.
113
 The resulting compounds were glucosides (Figure 26) with the side 
chain at positions C1, C2 and C6 mimicking D-Trp-(8), Phe-(7) and Lys-(9). They 
synthesised a number of compounds, for example compound (1.21) which bound in 
a dose-dependent manner. They concluded hydrogen bonding to the backbone was 
not necessary, the β-D-glucose scaffold could be used as a β-turn mimic and that 
non-peptidal peptidomimetics could act as ligands.
114, 115
 A similar D-xylose mimic 
(1.22) was also synthesised (Figure 26).
116
 
 
Figure 26 β-D-glucose-based (1.21) and a D-xylose (1.22)  
Both these compounds showed low binding affinity which was attributed to high 
amounts of rotational freedom in the molecules. This led to the synthesis of the 
1,3,4-trisubstitued-1,4-benzodiazepin-2-one analogue 1.23 (Figure 27), being more 
conformationally restricted and having inherent increased bioavailability. Compared 
to the D-glucose and D-xylose based analogues it showed a two and three fold 
increase in binding respectively.
117
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Figure 27 1,3,4-trisubstitued-1,4-benzodiazepin-2-one (1.23) 
Other non-peptide scaffolds have been reported to show selectivity. Imidazole 1.24 
118
 and tetrahydro-β-carboline 1.25119 are known to be SSTR3 selective ligands 
(Figure 28). 3-Thio-1,2,4-triazoles were used as the scaffold of ligands selective for 
SSTR2 and SSTR5 such as the SSTR2 selective compound (1.26) (Figure 28).
120
 
 
Figure 28 Compounds 1.24, 1.25 and 1.26 
The most successful ligands were probably those based on a medium ring 
heterocyclic backbone, which acted to keep the functional groups in the correct 
conformation.
121
 A series of β-turn mimics were synthesised, retaining the side chain 
functionality and side chain 3D conformation to maintain activity.
122
 These were 
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based on a medium ring heterocyclic scaffold that used a covalently linked thioether 
to replace the hydrogen bond and maintain the constrained structure (Figure 29). 
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Figure 29 β-Turn motif and medium ring heterocyclic scaffold  
Ellman and co-workers used these in the synthesis of some small molecule 
somatostatin mimics. An SSTR5 selective ligand (1.27) was reported with a potency 
of 87 nM (Figure 30).
124
 Further studies to enhance its potency and selectivity were 
carried out. A bicyclic mimetic (1.28) with increased potency was synthesised 
(Figure 30), but it was not as selective as the parent compound for SSTR5.
125
 
 
Figure 30 Compounds 1.27 and 1.28 
Another notable example of a ligand selective to other receptors include Kessler and 
co-workers' SSTR5 selective analogue, synthesised by using backbone cyclisation.
126
 
PTR 3046 (1.29) (Figure 31) is conformationally restrained by a lactam bridge and 
two N-alkylated residues, and is stable to enzymatic degradation. 
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Figure 31 PTR 3046 (1.29) 
Ankersen and co-workers synthesised a series of compounds with the most potent, 
NNC 26-9100 (1.30) (Figure 32), binding to SSTR4 with a selectivity of 100-fold 
over other SSTR receptors. It was discovered through a screening program based on 
the Phe-Try-Lys-Thr motif,  a scaffold containing two aromatic groups and one basic 
group.
127
  
 
Figure 32 NNC 26-9100 (1.30) 
Gademann and co-workers used β-peptides as somatostatin mimics.94 They were 
attracted to β-peptides for two reasons: they fold into well-defined secondary 
structures (for example helices, pleated sheets and turns) both in solid state and 
solution, and they have excellent stability against degradation (compared to natural 
peptides). The example shown compound 1.31 (Figure 33), is a β-peptide version of 
the Phe-Try-Lys-Thr β-turn motif.128 It was shown to mimic somatostatin, albeit with 
a lower potency.
129
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Figure 33 β-Peptide analogue of Phe-Try-Lys-Thr motif (1.31) 
A group at Merck synthesised the first potent non-peptide agonist which selectively 
binded to the SSTR2 receptor. An integrated approach of combinatorial chemistry 
and high-throughput receptor-binding techniques was used to rapidly identify 
subtype selective compounds. Using the cyclic hexapeptide L-363,377 (1.32) (Figure 
34), was used as the basis for the probe. The chemical collection of Merck, 
consisting of 200,000 compounds, was searched and 75 compounds were selected 
for binding assays, from which a number were developed.
130
 
 
Figure 34 L-363,377 (1.32) 
The compounds synthesised all had small molecular weights (MW <550). L-054,264 
(1.33) (Figure 35) is a spiro[1H-indene-1, 4'-piperidine] derivative; the cyclic 
analogue of the lysine motif gives rigidity thought to hold the amine in the correct 
orientation for binding. It has selectivity for SSTR2 of over 1000-fold and inhibited 
the release of GH with an IC50 of 6 nM.
131
 L-054,522 (1.34) (Figure 35) is a 
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benzimidazolone derivative it contains the (2S,3R)-β-Me-D-Trp motif as described 
earlier and the tertiary butyl ester of lysine. It displayed increased potency and 
selectivity.
132
 L-779,976 (1.35) (Figure 35), a hybrid of the two former compounds, 
showed 600-fold selectivity for SSTR2 and inhibited GH with an IC50 of 0.025 
nM.
130
.  
 
Figure 35 L-054,264 1.33, L-054,522 1.34  and L-779,976 1.35 
The main limitation of these compounds is  their low oral bioavailability, so efforts 
were made to improve this by limiting their potential hydrogen bonding interactions. 
Analogues were synthesised in which the urea was N-methylated or replaced by a 
carbamate, but this led to a significant loss of potency. This was attributed to a 
change in conformation of the molecule which was detrimental to binding. Further 
analogues were synthesised with cyclisation of the urea backbone with the aim to 
keep it in the correct orientation for binding, but reduce its hydrogen bonding 
capacity. The most potent compound had a GH inhibiting IC50 value of 70 nM 
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which, although not as potent as the previous molecules, it had a much improved 
bioavailability.
133
 Through the urea cyclisation studies it was concluded that the NH 
of the urea was not necessary for binding . A series of iso-nipecotic and nipecotic 
acid amide structures were synthesised (1.36) and (1.37), the most potent being 
shown in Figure 36.
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Figure 36 Compounds 1.36 and 1.37  
The previous compounds are all somatostatin agonists with respect to GH regulation, 
therefore on binding they inhibit the release of GH. Previous to this, SSTR2 
antagonists have been much rarer,
135
 however some do exist. The first full SSTR2 
antagonist in respect to GH regulation showed binding equivalent to that of 
somatostatin, but without agonist qualities. In the presence of somatostatin however, 
it did not bind. It was a cyclic hexapeptide with the carboxy terminal cysteine a D-
Cys.
136
 A linear hexapeptide AC-178,335 (1.38) with the sequence (Ac-D-His-D-Phe-
D-Ile-D-Arg-D-Trp-D-Phe-NH2) was synthesised containing all D-amino acids and 
was shown to act as an antagonist in vivo (Figure 37).
137
 Hocart and co-workers also 
researched peptide antagonists, again highlighting the importance of the D-Cys 
residue.
138, 139
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Figure 37 AC-178,335 (1.38) 
The group at Pfizer synthesised the first small molecule SSTR2 antagonists in 
respect to GH regulation in the hope of upregulating GH in farm animals. It was 
discovered that the agonists and antagonists varied little in their structures. It is 
possible that small structural changes such as the sulfonamide (1.39) (Figure 38) 
might be responsible for causing the ligand to hit the antagonist binding pocket.
140
 
 
Figure 38 Pfizer's SSTR2 antagonists (1.39) 
1.5 The Structure of SSTR2  
As previously stated somatostatin has five known receptors, but it is to SSTR2 that 
BSCIs bind the structure of which is shown in Figure 39.
141
 Work has been carried 
out to determine the domains of the receptors for GH regulating ligands. MK678 
(1.17), the selective SSTR2 agonist, was used to map the binding site by site-directed 
mutagenesis. It was found that the second and third extracellular loop were crucial 
for high affinity binding.
142
 This was further investigated by the synthesis of SSTR1 
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and SSTR2 chimeras which showed that while the second extracellular loop was 
essential for SSTR1 selective binding, it was not necessary for SSTR2 selective 
binding. In contrast the third extracellular loop and the surrounding trans-membrane 
helices were essential for SSTR2 selective binding.
143
 The sequence Phe-(294)-Asp-
(295)-Phe-(296)-Val-(297) was shown to play an essential role for binding. In 
particular, residues Phe-(294) in trans-membrane helix 7 and Asn-(276) in trans-
membrane helix-6 have been reported as key residues for binding and these interact 
with the residues Phe-(7)-Trp-(8)-Lys-(9)-Thr-(10) in somatostatin.
144
 The folded 
structure of the receptor is shown in Figure 40, with the binding domain highlighted. 
 
Figure 39 Structure of SSTR2 (taken from Reisine et al)
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Figure 40 Folded structure of SSTR2 (taken from Lubbert et al)
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1.6 Functional Selectivity 
The binding of different ligands to SSTR2 exerting a different affect to the 
endogenous ligand is not a novel concept.
145
 It can be attributed to either functional 
selectivity or allosteric regulation. 
Functional selectivity is a relatively new concept which goes against classical 
receptor ligand theory. It contrasts with the traditionally held theory associated with 
the idea of 'intrinsic efficacy' - the property of each molecules at the target 
receptor.
146
 It was thought ligands could be one of the following:  
 1) Agonists, which bind and produce the same response as the endogenous 
 ligand,  
 2) Antagonists, which bind and act as a competitive inhibitor to the 
 endogenous ligand,  
 3) Inverse agonists, which bind and produce the inverse response to the 
 endogenous ligand, or finally,  
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 4) Partial agonists, which bind and produce a partial response of the 
 endogenous ligand.  
Each pathway that the ligand-receptor combination activates is activated in the same 
proportion.
147
 There is mounting evidence that receptors can form ligand-specific 
active conformations, introducing a new concept - biased agonists theory.
148-150
 
Different ligands can have different efficacies regarding the different functions being 
performed. Due to different receptor-ligand conformations, there are different 
protein-protein interactions within the cell and thus a different intracellular response 
to each ligand. 
147, 150, 151
 
Mailman and co-workers discovered the functional selectivity involved in the 
dopamine receptor.
152
 The dopamine receptor ligands dihydrexidine (DHX) and 
quinpirole both decrease the release from the pituitary gland of prolactin (a hormone 
involved in the regulation of lactation). These two ligands have different affects on 
striatal neurons, quinpirole being much more potent than DHX. Clarke and co-
workers discovered functional selectivity at the serotonin subtype 2C (5-HT2c) 
receptor. The three ligands for this receptor are 3-trifluoromethyl-piperazine 
(TFMPP), quipazine and (6)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
(DOI). TFMPP and quipazine both activate the inositol pathway with efficacy equal 
to that of the classical ligand 5-hydroxytryptamine (5-HT), but only a 60 % efficacy 
in activating the arachadonic acid pathway. Conversely DOI activates the 
arachadonic acid pathway with equal efficacy to that of 5-HT but only has 60 % 
efficacy in activating the inositol pathway.
147
 Pharmacological, biochemical and 
genetic evidence have all been cited for functional selectivity by Mark von Zastrow. 
Pharmacological evidence is shown by differing regulation of receptor endocytosis 
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via clathrin-coated pits by μ-opiate receptor ligands. [(D-Ala-(2), N-Me-Phe-(4), 
Gly-(5)-ol)-Enkephalin] (DAMGO) and morphine were both considered full 
agonists, but DAMGO reduces endocytosis to a greater extent than morphine, 
meaning they have different levels of efficacy.
153
 Biochemical studies have shown 
varying levels of phosphorylation of the β2-adrenergic receptor in relation to 
different ligands.
154
 Genetic evidence is shown by studies of active mutants of the 
human complement factor 5a, all of which exhibit different levels of efficacy. One 
mutant exhibits constant activation of G-protein mediated responses and constant 
endocytosis. Another mutant exhibits constant activation of G-protein responses but 
is only endocytosed in response to a ligand. A third mutant is activated only upon 
exposure to the ligand but exhibits constant endocytosis.
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Functional selectivity has been shown to occur at the somatostatin receptors SSTR2, 
SSTR4 and SSTR5.
145
 Eleven somatostatin analogues were tested for their ability to 
inhibit cyclic AMP production and their ability to stimulate receptor internalisation. 
Their relative potencies for the two activities varied 10-fold and the synthetic short 
peptides were 5-10 times more potent at signal generation. This gave rise to the 
conclusion that agonists stabilise different receptor conformations with varying 
abilities to activate down-stream signalling pathways.
156
 These findings highlighted 
the somatostatin receptor as a potential target for new drugs as: – the possibility of 
new drugs with different pharmacological profiles at specifically targeted receptor 
subtypes holds great promise”.145 More recent evidence of functional selectivity at 
the SSTR2 receptor is shown by somatostatin analogues SOM230
157, 158
 and 
KE108.
159
 Both, like somatostatin, also acted as agonists for the inhibition of cAMP. 
Unlike somatostatin, they also acted as antagonists for stimulation of intracellular 
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calcium accumulation and both were partial agonists/antagonists for ERK 
phosphorylation.
160
 Further to this, as well as showing functional selectivity in 
receptor signalling, they also show it in receptor regulation. Both were shown to be 
less able to induce receptor internalisation than somatostatin.
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1.6.1 Cortistatin and Functional Selectivity 
Cortistatin is a neuropeptide which binds to all five somatostatin receptors.
162
 It is 
closely related to somatostatin, yet functionally distinct, thereby displaying an 
example of functional selectivity. Cortistatin enhances slow wave sleep by the 
antagonism of the excitatory effects of acetylcholine on the cortex.
163
 Cortistatin-14 
has 11 of the same amino acids as somatostatin, including the motif FWKT which 
indicates its importance for binding. It also has two homologously placed cysteine 
residues responsible for the cyclic nature of the peptide. Cortistatin, like 
somatostatin, is coded for by a preprohormone gene, preprocortistatin a 112 amino 
acid length of protein. Cleavage occurs at two dibasic cleavage sites, KK and KR, to 
produce cortistatin-14 and cortistatin-29, analogous to somatostatin-14 and 
somatostatin-28. As for somatostatin, PC1 and PC2 are thought to be responsible for 
this cleavage as they are highly expressed in the cerebral cortex, a major site of 
cortistatin expression.
164
 
The binding site of SSTR2 may have different conformations when somatostatin 
binds compared to binding with BSCIs. It is also possible that there are distinct 
binding sites for the individual ligands. 
1.6.2 Allosteric Regulation 
GPCRs are known to possess topographically distinct allosteric binding sites 
recognised by molecules with disparate affinities and efficacies to the orthosteric 
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binding site and the endogenous ligand.
165, 166
 Although it is logical that the 
orthosteric site is the target for most drugs, it is likely this site is conserved across 
many subtypes, therefore the allosteric site might provide more selectivity.
167
 
Depending on the nature of the allosteric binding it can modulate the agonism or 
antagonism of the orthosteric ligand.
168
 It is stated that - "New insights into the 
intermolecular associability of GPCRs, with one another and with cellular accessory 
proteins, imply an unexpectedly broad spectrum of complexes that may presage the 
potential for orthosteric and allosteric ligands to attain signal pathway selectivity as 
a basis for new therapeutics".
167
 The concept of bitopic ligands is relatively new.
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A bitopic ligand is a molecule in which two topographically distinct ligand binding 
sites are connected together in the same molecule. Studies regarding bitopic ligand 
have been carried out by De Amici, Holzgrabe and colleagues on the M2 muscarinic 
acetylcholine receptor. Hybrid molecules were synthesised comprising of orthosteric 
agonists, based on oxotremorine and a phthalimidopropane or 1,8-naphthalimido-
2,2-dimethylpropane allosteric modulator. The resulting molecule displayed both 
allosteric and orthosteric binding properties.
169
  
1.7 Somatostatin and Inflammation 
As far we know, BSCIs bind to SSTR2 and exert an anti-inflammatory effect. 
Somatostatin, the endogenous ligand of SSTR2 has been linked with anti-
inflammatory activity, although it is not often considered to be one of its major 
functions. It was first reported to be expressed in human immune cells by Bhathena 
and co-workers,
170
 and subsequently it has been reported it can be synthesised and 
released at the site of inflammation by immune cells. Granuloma cells have been 
reported to express mRNA for preprosomatostatin and inflammatory mediators 
induce its synthesis.
171
 T-cells isolated from granulomas have also been reported to 
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express mRNA for the receptor SSTR2.
172
 Somatostatin is thought to be involved in 
a feedback loop regulating inflammation and T-cell function. Also involved is 
another neuropeptide, substance P (SP), which is associated with the processes of 
pain and inflammation. Somatostatin acts on T-cells to inhibit IFN-γ, a pro-
inflammatory cytokine.
173
 Substance P enhances INF-γ secretion174 and 
downregulates somatostatin mRNA production by macrophages. Levite and co-
workers reported that somatostatin controls adhesion of T-lympocytes to fibronectin, 
a molecule necessary for T-cell extravasation and migration.
175
 However, a 
mechanism for its anti-inflammatory action is as yet unknown. 
Somatostatin and its analogues have been reported to have anti-inflammatory effects 
in animal and humans. In mice treatment with somatostatin and octreotide resulted in 
a decreased INF-γ secretion.173 In rats, treatment with octreotide and BIM 23014 
resulted in decreased leukocyte concentration and decreased levels of local 
inflammatory mediators such as TNF-α and substance P.176 In rabbits, intraarticular 
somatostatin was reported to reduce inflammation of chronic arthritis.
177
 Reduced 
inflammation was reported to occur on a similar experiment with humans suffering 
from rheumatoid arthritis.
178-180
 Particular work has focussed on rheumatoid arthritis, 
and SSTR2 has been reported to be expressed in synovia of affected joints.
181
 Takeba 
and co-workers reported the inhibition of proliferation of affected synovial cells by 
somatostatin in vitro.
182
 Paran and co-workers reported the results of a clinical trial 
in which significant clinical improvements were found in patients on treatment with 
the somatostatin analogue octreotide.
183
 In summary, there is evidence associating 
somatostatin and inflammation, but little is known about the mechanism of action.  
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1.8 Research Hypothesis 
BSCIs bind to SSTR2 and block the action of chemokines. The link between 
somatostatin, chemokines and inflammation has also been shown in phylogenetic 
relationship studies - the study of evolutionary relatedness linked to functional 
relatedness. It has been shown that chemokines receptors and somatostatin receptors 
are closely related.
184
 This could potentially mean links between their intracellular 
signalling systems.   
Because somatostatin is thought of as the endogenous ligand for SSTR2, the site to 
which it binds is thought of as the orthosteric site.  The binding of somatostatin to 
this site is known to affect GH regulation.  There is evidence linking somatostatin 
and inflammation but no known mechanism for this. BSCIs show significantly more 
anti-inflammatory action. The aim of this thesis is to determine whether BSCIs also 
bind to this orthosteric site and, through functional selectivity, cause a different 
intracellular effect, or whether  they bind to an allosteric site, thereby changing the 
nature of SSTR2 agonism.  
To achieve this, a library of ligands, based on current SSTR2 ligands and hybrid 
ligands (which in addition contain the acylaminolactam BSCI structure), were 
synthesised (as shown in section 2.1). These were subsequently tested in two 
functional assays, an SSTR2 binding assay and a leukocyte migration assay.  
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Chapter 2 - SSTR2 Ligands, BSCIs and Hybrids 
2.1 Introduction 
The aims of this thesis are to determine by which mechanism BSCIs act at SSTR2 
whether it be through functional selectivity or allosteric  regulation. As a starting 
point a catalogue of molecules was synthesised in order to both probe the receptor 
SSTR2, and to gain information on the critical motifs responsible for activity for 
both SSTR2 binding and BSCI activity (see section 1.4 and 1.2.1). The molecules 
were based on current SSTR2 ligands such as compound 1.39, current BSCI 
compounds such as lactam 1.13 (Figure 41) and on hybrid structures of the two 
classes.  
 
Figure 41 Current SSTR2 ligand by Pfizer
140
 and current BSCI
47
 
Current SSTR2 ligands are based on the tripeptide sequence KWF, the critical motif 
of activity for somatostatin (Figure 42).
132
 In comparison, current BSCIs are based 
on the tripeptide WxQ, in which x is a hydrophobic amino acid. This sequence was 
derived from "Peptide 3", the initial compound shown to have BSCI activity, and is 
also present in NR58, 3.14.3, a second generation BSCI. The hydrophobic residue is 
valine in "Peptide 3" and isoleucine in NR58, 3.14.3, though activity is retained 
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when phenylalanine is substituted for these residues.
45
 In addition both "Peptide 3" 
and NR58, 3.14.3 contain a lysine residue preceding this tripeptide sequence. The 
similarities in these two sequences are apparent and indicate why they both bind the 
receptor SSTR2 (Figure 42). 
 
Figure 42 Critical motifs for activity for BSCI NR58, 3.14.3 and somatostatin  
Molecules based on the KWF sequence or the hybrid KWFQ sequence were 
synthesised with a lactam representing the glutamine residue (Figure 43). Molecules 
containing both 6-membered and 7-membered lactams have been synthesised, as 
have simplified molecules, replacing the lactam moiety with a methyl substituent in 
both the para and meta positions. The lysine and tryptophan components of the 
molecules have been gradually reduced and eventually removed altogether over the 
sequence. The molecules synthesised can be split into five groups represented by 
compounds 2.01-2.09 (Figure 43): 
1) lysine-tryptophan-phenylalanine (KWF analogues, e.g. compound 2.01-2.03) 
2) tryptophan-phenylalanine (WF analogues, e.g. compounds 2.04),  
3) lysine-tryptophan-phenylalanine-glutamine (KWFQ analogues, e.g. compounds 
2.05-2.07),  
4) tryptophan-phenylalanine-glutamine (WFQ analogues, e.g. compound 2.08), 
5) phenylalanine-glutamine (FQ analogues, e.g. compound 2.09). 
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Figure 43 Catalogue of molecules synthesised; K mimics (red), W (blue), F (black) and Q (pink) 
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2.2 Non-Lactam Containing Molecules 
The compounds based on current SSTR2 ligands were either KWF or WF mimics. 
Disconnections were made between the lysine and tryptophan motifs, and the 
tryptophan and phenylalanine motifs (Figure 44). Each amino acid motif was 
synthesised separately before being coupled together. This synthetic sequence is 
similar to that used by Merck in the synthesis of related SSTR2 ligands.
132
 
 
Figure 44 Disconnection of 2.01 used in the synthesis of SSTR2 like ligands 
2.2.1 Phenylalanine Mimics 
Three phenylalanine mimics, acids 2.10-2.12, were synthesised by coupling 
isonipecotic acid to commercially available acid chlorides, using either benzoyl 
chloride or the sulfonyl chlorides para-toluenesulfonyl chloride and meta-
toluenesulfonyl chloride (Scheme 1). These biphasic amide-forming reactions are 
examples of a Schotten-Baumann reaction.
185
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Scheme 1 Synthesis of compounds 2.10-2.12 
2.2.2 Phenylalanine-Tryptophan Mimics 
Compounds 2.10, 2.11 and 2.12 and 4-biphenyl carboxylic acid, another 
phenylalanine mimic, were coupled to the commercially available tryptamine. This 
furnished the smallest of the SSTR2 type ligands, the WF mimics (2.04 and 2.13-
2.15). The reaction was carried out in dichloromethane with 2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate 
methanaminium (HATU) as a coupling agent and triethylamine as a base (Scheme 
2). 
 
Scheme 2 Synthesis of compounds 2.04 and 2.13-2.15 
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2.2.3 The Use of HATU 
Formation of an amide requires activation of the carboxylic acid, usually by making 
it into an ester with a good leaving group. There are a number of peptide coupling 
reagents, including carbodiimides such as N,N'-dicyclohexylcarbodiimide (DCC) and 
uronium or phosphonium reagents such as benzotriazole-1-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP), benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and HATU.
186
 
Carbodiimides generate by-products that are difficult to remove from the product, for 
this reason HATU was the chosen peptide coupling reagent. Crystal structures and 
NMR data have shown that HATU exists in the guanidinium form (also known as 
the N-form), unlike the analogous structure of BOP and PyBOP which exist in the 
uronium form (also known as the O-form) due to the high stability of the P-O bond 
(Figure 45).
187
  
 
Figure 45 O-form and N-form of HATU and O-form of BOP 
In the N-form of HATU there is more double bond character between the nitrogen of 
the triazole ring and the carbon with the two N(CH3)2 groups, best represented by the 
right hand resonance form of Figure 46. This restricts rotation around this bond, 
meaning the N(CH3)2 protons are inequivalent and the 12 protons of the dimethyl 
groups appear as two singlets for six protons each at 3.00 and 3.40 ppm in the 
1
H 
NMR.
187
 In contrast, the O-form of HATU shows one singlet at 3.24 ppm that 
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integrates for all 12 protons.
187
 This is due to higher double bond character between 
the carbon with the two N(CH3)2 groups and the nitrogen of the N(CH3)2 group, best 
represented by the left hand resonance form of Figure 46. This leads to a greater 
degree of rotation around the oxygen bonds, so the twelve N(CH3)2 protons all 
appear equivalent, and hence appear as only one singlet in the 
1
H NMR. The reason 
the oxygen to carbon bond displays less double bond character compared to the 
carbon to nitrogen bond in the N-form is because oxygen is more electronegative, 
and hence an oxygen cation is less stable than a nitrogen cation. Experimentally, the 
1
H NMR of the HATU used showed two singlets corresponding to six protons at 
3.39 and 3.04 ppm, confirming it was the N-form. The N-form also shows a 
characteristic IR band at 1664-1675 cm
-1
 while the O-form shows a characteristic IR 
band at 1709-1711.
187
 The HATU used showed a band at 1664 cm
-1
, further 
confirming the structure as the N-form. 
 
Figure 46 Resonance structures of the N- and O-form of HATU, N-form favours the structure on the 
right, O-form favours the structure on the left  
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HATU reacts with the carboxylic acid to form an active ester and tetramethyl urea; 
on addition of the amine it reacts with the active ester to form the amide bond 
(Scheme 3). 
 
Scheme 3 Mechanism of HATU forming an active ester
186
 
2.2.5 Lysine-Tryptophan Mimics 
The second disconnection in the synthesis (Figure 44) is between the tryptophan and 
lysine motifs to create the KWF mimics. To allow the coupling of the carboxylic 
acid functionality of tryptophan to the lysine motif, the tryptophan amine was 
protected with di-tert-butyldicarbonate (Boc protected) to give acid 2.16 (Scheme 4). 
 
Scheme 4 Synthesis of compound 2.16 
Five different commercially available amines (2.17-2.21) were coupled to acid 2.16 
to give compounds 2.22-2.26. The amines were propylamine 2.17, N-Z,1,4-
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diaminobutane 2.18, N-Z,1,4-diaminopentane 2.19, N-Z,1,4-diaminohexane 2.20 and 
H-lysine(Z)-O
t
Bu 2.21. The last four of that list are mono-carboxybenzyl- (Cbz) 
protected diamines. These reactions were performed using HATU as a coupling 
agent and triethylamine as a base (Scheme 5). 
 
Figure 47 Amines or their hydrogen chloride salts 2.17-2.21 
 
Scheme 5 Synthesis of compounds 2.22-2.26 
2.2.6 Removal of the Boc Group 
The next stage was to deprotect the tryptophan amines by removal of the Boc groups 
to allow further coupling to the phenylalanine mimics. Boc groups are removed by 
acid hydrolysis. The reactions were performed by dissolving the compounds in 
methanol and adding three equivalents of methanesulfonic acid (Scheme 6). The free 
amines (2.27-2.31) were provided by addition of triethylamine and reacted without 
further purification.  
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Scheme 6 Compounds 2.27-2.31 
The presence of the tertiary butyl ester in 2.26 (Figure 49) posed a problem, as this 
must be left unaffected while the structurally similar tertiary butyl carbamate group 
is removed. This is possible because of the increased basicity of the Boc group, due 
to the conjugation of the lone pair from the nitrogen in the amide bond, which 
stabilises the protonated carbonyl oxygen. This stabilisation of the protonated amide, 
and subsequent stabilisation of the transition state, means the activation energy for 
Boc removal is lower than for the tertiary butyl ester removal (Figure 48). 
 
Figure 48 Energy diagram, protonation and breaking of the O-C bond in 
t
Bu amide and a 
t
Bu ester.  
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Methods using 4 M HCl in 1,4-dioxane, and para-toluenesulfonic acid in ethanol 
were unsuccessful - both the Boc group and the tertiary butyl ester group were 
removed. Finally methanesulfonic acid was used
132
 - the reaction was initially 
carried out in deuterated methanol and followed by 
1
H NMR spectroscopy. Figure 50 
shows the aliphatic region of the 
1
H NMR spectrum of the starting material. The Boc 
and tertiary butyl groups, as well as the peaks for the protons at the stereocentres of 
tryptophan and lysine can be clearly observed. Methanesulfonic acid was added and 
a 
1
H NMR spectrum was taken after 48 hours (Figure 51). The Boc group peak has 
disappeared while the tertiary butyl ester group remains. In addition the proton at the 
stereocentre of tryptophan has changed and the by-product from the tertiary butyl 
cation reacting with the solvent methanol is visible. The reaction was heated to 50 ºC 
overnight and another 
1
H NMR spectrum was taken (Figure 52). The 
1
H NMR 
spectrum shows the Boc group and the tertiary butyl ester groups have been 
removed. This study reveals that although the deprotection reaction is slow, only the 
Boc group is removed at room temperature. By heating the reaction the undesired 
effect of having the tertiary butyl ester group removed occurs.  
 
Figure 49 Synthesis of 2.31 from 2.26 
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Figure 50 Aliphatic region of 
1
H NMR spectrum of (1.26) taken before addition of MeSO2OH (t = 0), 
Boc and 
t
Bu ester peaks are labelled as are the two peaks for the protons at stereocentres  
 
 
Figure 51 Aliphatic region of 
1
H NMR spectrum taken after addition of MeSO2OH (t = 48 hours), 
Boc group peak has disappeared,  
t
Bu ester peak is present, 
t
BuOMe is the by-product  
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Figure 52 Aliphatic region of 
1
H NMR spectrum after being heated to 50 ºC (t = 48 hours), both Boc 
and 
t
Bu ester groups have gone, peak visible is the by-product 
t
BuOMe  
 
2.2.7 Lysine-Tryptophan-Phenylalanine Mimics  
Sulfonamide 2.32 was synthesised by coupling 4-toluenesulfonyl chloride to amine 
2.27 (Scheme 7). 
 
Scheme 7 Synthesis of compound 2.32  
Compound 2.33 was synthesised from amine 2.27 using HATU as the coupling 
reagent with triethylamine as a base (Scheme 8). 
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Scheme 8 Synthesis of compound 2.33  
Compound 2.34 was synthesised with amine 2.18 as the lysine motif, compounds 
2.35 and 2.36 (Scheme 9) were synthesised using amine 2.19 whilst compounds 
2.37-2.40 were synthesised using amine 2.21 (Scheme 10). 
 
Scheme 9 Synthesis of compounds 2.34-2.36  
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Scheme 10 Synthesis of compounds 2.37-2.40 
2.2.8 Removal of the Cbz Groups  
The final stage was to remove the Cbz group from carbamates 2.34-2.40 to release 
the amine functionality of the lysine mimics (Scheme 11). This was done by a 
hydrogenolysis reaction.
132
 In total six SSTR2 ligands were synthesised in this way, 
with four containing the tertiary butyl ester motif (Figure 53, 2.01 and 2.41-2.45). 
 
 
Scheme 11 Synthesis of compounds 2.01 and 2.41-2.45  
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Figure 53 Compounds 2.01 and 2.41-2.45 (isolated yields shown in brackets) 
2.2.10 Another KWF mimic  
One final urea-containing SSTR2 ligand was synthesised using a different method.
188
 
Disuccinimidyl carbonate was used as a coupling reagent. This provides a carbonyl 
for the commercially available 4-(2-keto-1-benzimidazolinyl)-piperidine to react 
with to form a urea link between the tryptophan and the phenylalanine motif 
(Scheme 12). D-Tryptophan methyl ester 2.46 was synthesised from D-tryptophan 
using thionyl chloride in methanol, and the free amine was reacted with 
disuccinimidyl carbonate and 4-(2-keto-1-benzimidazolinyl)piperidine. Two 
products were formed from this reaction - the desired product compound 2.47, and a 
symmetrical tryptophan methyl ester-containing urea 2.48. The two products were 
separated by flash column chromatography.  
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Scheme 12 Synthesis of compounds 2.46 and 2.47 and unwanted product 2.48  
Methyl ester 2.47 was hydrolysed with lithium hydroxide in tetrahydrofuran and 
D2O to give acid 2.49 (Scheme 13). D2O was used as a solvent so that if 
epimerisation of the stereocentre occurred it would be highlighted by a reduction in 
the integral of the stereocentre bound hydrogen in the 
1
H NMR spectrum. No 
reduction in the integral was observed, indicating epimerisation did not occur. Acid 
2.49 was coupled to amine 2.21 to give carbamate 2.50. The Cbz group was removed 
as for the previous compounds by hydrogenolysis to give the final SSTR2 like ligand 
compound 2.51. 
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Scheme 13 Synthesis of compounds 2.49-2.51 
2.3 Lactam Containing Molecules 
2.3.1 Glutamine Mimics - Lactam Synthesis 
6-Membered and 7-membered lactams were synthesised by cyclisation of L-ornithine 
and L-lysine (Scheme 14, 2.52-2.54).
189
 The 7-membered lactam 2.52 was isolated as 
a colourless oil which formed white crystals when left to stand, the 6-membered 
lactams 2.53 and 2.54 were not isolated. 
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Scheme 14 Synthesis of compounds 2.52-2.54 
After addition of the base, the 6-membered lactam is formed at a temperature under 
0 °C. In these mild conditions enolisation of the amino ester or amino lactam product 
does not occur and so the stereochemistry of the ester is maintained in the product 
lactam. The rate of cyclisation to give 7-membered rings is lower than that for 6-
membered rings therefore the 7-membered lactam only forms at a reasonable rate 
when the reaction is heated under reflux conditions.  These harsher conditions results 
in racemisation of the product. The racemic 7-membered ring was resolved using 
enantiomerically pure pyroglutamic acid. The free amine lactam dissolves in 
dimethoxyethane, and on addition of enantiomerically pure pyroglutamic acid the 
desired enantiomer of lactam precipitates out as the pyroglutamic acid salt whilst the 
other enantiomer remains in solution (Scheme 15, 2.55, 2.56).
190
 Washing with 2-
propanol ensured all free lactam was removed. 
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Scheme 15 Synthesis of compounds 2.55-2.56 
2.3.2 Using Mosher's Acid to determine e.e. 
To determine the enantiomeric excess of the resolved lactam it was coupled to an 
enantiomerically pure compound, α-methoxy-α-trifluoromethylphenylacetic acid 
(MTPA), known as Mosher's acid, to make diastereoisomers.
191
 This was done via 
the acid chlorides compounds 2.57 and 2.58. The enantiomeric excess of lactam 
2.55, calculated from the diastereomeric compounds 2.59 and 2.60, was 95 % (from 
compound 2.59) and 98 % (from compound 2.60). The compounds were washed in 
hot propan-2-ol before further optical testing. 
 
Scheme 16 Synthesis of compounds 2.59 and 2.60  
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2.3.3 Using Chiral HPLC to Determine the e.e. 
To ensure the optical purity of all the lactams a faster technique was required. Chiral 
high-performance liquid chromatography (HPLC) proved to be an appropriate, 
successful and faster method. Sufficient separation of the lactams required the amine 
functionality of the lactams to be Cbz protected
192
 - this was achieved by reacting the 
lactams with benzylchloroformate (Scheme 17, 2.61-2.64). 
 
Scheme 17 Synthesis of compounds 2.61-2.64  
Pre-resolution, the lactam ring was shown to be racemic following Cbz protection 
and chiral HPLC. The resolved lactams of each enantiomer, after a final wash with 
hot propan-2-ol, were shown to have an enantiomeric excess of ≥ 99 %. The 
hydrogen chloride salts of the 7-membered lactams were generated in an ion 
exchange reaction. Dissolving acetyl chloride in ethanol creates HCl in situ and 
adding the pyroglutamic acid lactam salt results in the hydrogen chloride salt of the 
lactam precipitating from solution (Scheme 18, 2.65, 2.66). 
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Scheme 18 Synthesis of compounds 2.65 and 2.66  
4-Carboxybenzaldehyde was benzylated (Scheme 19) with a yield of 80 % to give 
aldehyde 2.68. The reaction was performed in DMF with sodium hydride as the base 
and benzyl bromide as the electrophile.
193
 N, N, N', N'-Tetramethylethylenediamine 
(TMEDA) or 1,4-diazabicyclo[2.2.2]octane (DABCO) were used to wash out excess 
benzyl bromide. The amine is monoalkylated by benzyl bromide and the product can 
be washed into pH 2 buffer. Residual DMF can be removed by washing with 0.1 M 
aqueous HCl. Sodium chlorite and sulfamic acid are used to oxidise the aldehyde.
193
 
Sulfamic acid is a scavenger which reacts with the hypochlorous acid by-product to 
prevent this unwanted reaction.
194
 
 
Scheme 19 Synthesis of compounds 2.68 and 2.69 
Compound 2.69 was used to synthesise phenylalanine-glutamine mimics 2.71-2.74 
(Figure 54). Acid 2.69 was converted to its acid chloride with oxalyl chloride and 
catalytic DMF (Scheme 20). Acid chloride 2.70 was reacted with the 7-membered 
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lactam pyroglutamic acid salt 2.55 and the 6-membered lactam 2.53 in a Schotten-
Baumann reaction
185
 to give amides 2.71 and 2.73. The benzyl group in 2.71 was 
removed by hydrogenolysis to give acid 2.72. Finally, acid 2.72 was coupled to 
isonipecotic acid benzyl ester hydrogen chloride salt 2.77 (vide infra) to give tertiary 
amide 2.74. Because of the low yields involved in synthesising terephthalic acid 
monobenzylester 2.69 (18 % over two steps), another phenylalanine mimic was 
chosen in order to allow the efficient synthesis of a large number of compounds 
including this motif. 
 
Scheme 20 Synthesis of compounds 2.70-2.74 
77 
 
 
Figure 54 Compounds 2.71-2.74  
2.3.5 Sulfonamide Phenylalanine Mimics 
Isonipecotic acid was protected with di-tert-butyldicarbonate (Scheme 21, 2.75). The 
carboxylic acid 2.75 was then benzyl-protected using benzyl bromide to give 
compound 2.76. The Boc group was removed to give compound 2.77.  
 
Scheme 21 Synthesis of compounds 2.75-2.77  
Amine 2.77 was coupled to both 3-(chlorosulfonyl)benzoic acid and 4-
(chlorosulfonyl)benzoic acid under Schotten-Baumann conditions
185
 (Scheme 22). 
The sulfonamide products 2.78 and 2.79 were coupled to the lactams either using 
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HATU as a coupling reagent, or by making an acid chloride and coupled under 
Schotten-Baumann conditions
185
 (Scheme 23, 2.80-2.82). 
 
Scheme 22 Synthesis of compounds 2.78-2.79 
 
Scheme 23 Synthesis of compounds 2.80-2.82 
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The benzyl esters of compounds 2.80-2.82 were removed by hydrogenolysis to give 
compounds 2.09 and 2.83-2.84 (Scheme 24).  
 
Scheme 24 Synthesis of compounds 2.09 and 2.83-2.84 
The FQ mimics (Figure 55, 2.09 and 2.83-2.84) were coupled to the KW amines 
tryptamine and compounds 2.27-2.31, using HATU as a coupling reagent. 
 
Figure 55 Compounds 2.09 and 2.83-2.84  
Compounds 2.07, 2.08 and 2.85-2.87 were synthesised using tryptamine or amine 
2.27 using HATU as a coupling reagent (Figure 56).  
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Figure 56 Compounds 2.07-2.08 and 2.85-2.87 (isolated yields are shown in brackets) 
Compounds 2.88-2.92 were synthesised using amines 2.28-2.31 using HATU as a 
coupling reagent (Figure 57,). Finally the Cbz groups were removed through 
hydrogenolysis reactions to give the largest hybrid compounds, the KWFQ mimics 
compounds 2.93-2.96 (Figure 58). 
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Figure 57 Compounds 2.88-2.92 (isolated yields are shown in brackets) 
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Figure 58 Compounds 2.05-2.06 and 2.93-2.94 (isolated yields are shown in brackets) 
2.4 Biological Testing  
The compounds were subjected to two different biological assays, an SSTR2 binding 
assay and a leukocyte migration assay to determine BSCI activity. 
2.4.1 SSTR2 Binding   
SSTR2 binding data was obtained by Tilly Sharp at Total Scientific (Babraham 
Research Campus, Cambridge) using a technique called fluorescence polarisation 
(FP). This technique gives a measure of the amount each compound binds to SSTR2 
in comparison to fluorescently labelled somatostatin, the native ligand for SSTR2. 
FP is based on the theory initially described by Perrin in 1926 that small molecules, 
when excited by plane polarised light, can emit largely depolarised light as a result 
of rapid molecular tumbling in solution.
195
 Small molecules that are bound to a 
receptor have an effective increase in molecular volume and tumble much slower in 
solution. Therefore, when excited by plane polarised light, the emitted light remains 
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polarised to a greater extent.
196
 The FP of somatostatin bound to SSTR2 can be 
compared to the FP of somatostatin that has been displaced by the test compound. If 
the compound displaces somatostatin, the non-bound somatostatin will cause the 
emission of depolarised light. Conversely, if the compound does not displace 
somatostatin, the emitted light will remain polarised (Figure 59). The FP assay was 
run following a standard protocol. Emitted light is measured in the vertical and 
horizontal planes and the polarisation is calculated. 
 
Figure 59 Fast tumbling small molecules depolarise light, slow tumbling large molecules allows light 
to remain polarised 
The WF, KWF, KWFQ, WFQ and FQ mimics were tested for their SSTR2 binding 
activity at a concentration of 1 nM, the results are shown in Table 1. 
 The data is given as percentage inhibition of SS-14 FITC from SSTR2. The WF, 
WFQ and FQ compounds showed no significant binding. These compounds are 
lacking the lysine motif which is known to promote strong binding in these types of 
ligands.
197
 The KWF compounds (2.01, 2.45 and 2.51), based on the structure of 
current SSTR2 ligands, all show high activity as expected. The KWFQ compounds 
(2.05 and 2.94), based on the structure of current SSTR2 ligands with the addition of 
the lactam, showed equally high activity. The key findings of these results are that 
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the full lysine motif is required for SSTR2 binding and that the addition of the 
lactam is not significantly detrimental to binding. 
Family Compound % Inhibition Family Compound % Inhibition 
WF 
2.04 -2 
WFQ 
2.07 -17 
2.14 -7 2.08 -9 
2.15 0 2.85 -25 
2.32 -3 2.86 -6 
2.33 -18 2.87 -18 
KWF 
2.01 105 
FQ 
2.09 5 
2.45 96 2.71 -15 
2.51 97 2.72 6 
KWFQ 
2.05 
2.94 
98 
75 
2.73 3 
2.80 17 
2.81 8 
Table 1% inhibition of SS-14 FITC at SSTR2, compounds a 1 nM, values are given with an estimate 
error ± 20 % (data from Tilly Sharp at Total Scientific) 
The errors associated with measurement are about 20 % in this assay. The errors 
associated with the effective concentration of the test compound are due to 
distribution and solubility. Their significance depends on the position in the binding 
curve. The binding curve is sigmoidal, meaning the errors close to 0 and 100 % are 
less significant than the errors at 50 %. The majority of data from these assays is in 
the former regions. 
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Figure 60 % inhibition, minimal at 0  and 100 %,  greatest at 50 % inhibition 
The half maximal inhibitory concentration (IC50) and binding affinity (Ki) values 
were calculated for the five active compounds. The percentage inhibition of the 
compounds was measured at different concentrations and plotted against the log of 
these concentrations. A sigmoidal curve (Equation 1) was fitted to the data to 
determine the IC50 value and the hill slope. The hill slope is the number of substrates 
which bind each receptor and was approximately one for these compounds. 
)HillSlope)*IC((log 50101
100
x
y

   
Equation 1 
The Ki was calculated using the Cheng-Prusoff equation,
198
 Equation 2 where S is 
the concentration of test compound and Km is the concentration of SS-14 FITC at 
which binding is half maximal. 
m
i
K
[S]
1
IC
K 50

  
Equation 2 Cheng-Prusoff equation
198
 
 The Km of SS-14 FITC was determined by titrating it against unlabelled 
somatostatin, the Km of which was taken from the literature as 0.23 nM.
199
 This gave 
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a Ki value of 0.384 nM. This value of 0.384 nM was used as the Km to calculate the 
Ki values of the test compounds (Table 2, Figure 61). 
Family Compound IC50 (nM) Hill slope Ki (nM) 
KWF 
2.01 4.21 ± 1.24 1.15 ± 0.251 1.17 
2.45 32.2 ± 1.19 1.32 ± 0.251 8.93 
2.51 0.870 ± 1.18 1.89 ± 0.548 0.241 
KWFQ 
2.05 55.0 ± 1.15 1.36 ± 0.222 15.3 
2.94 110 ± 1.09 1.19 ± 0.115 30.5 
Table 2 SSTR2 binding IC50 and Ki values  
The data was than fitted to a slightly modified equation (Equation 3) taking into 
account that some of the maximal inhibition levels are above 100 % (Table 3, Figure 
62). 
y =
max.inhibition
1+10
((logIC50-x)*HillSlope)
 
Equation 3 
Family Compound IC50 (nM) Hill slope Max. Inhib. Ki (nM) 
KWF 
2.01 6.47 ± 1.20 0.965 ± 0.128 119 ± 4.57 1.80 
2.45 66.9 ± 1.19 0.858 ± 0.082 133 ± 6.61 18.6 
2.51 1.08 ± 1.08 1.45 ± 0.144 115 ± 1.81 0.300 
KWFQ 
2.05 93.4 ± 1.24 0.965 ± 0.18 125 ± 8.64 25.9 
2.94 140 ± 1.26 1.04 ± 0.151 110 ± 8.96 38.8 
Table 3 SSTR2 binding IC50 and Ki values using Equation 3  
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Figure 61 Titration curves, x-axis is log of the concentration of test compound, y-axis is % inhibition 
of SS-14 FITC 
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Figure 62 Titration curves using Equation 3, x-axis is log of the concentration of the test compound, 
y-axis % inhibition of SS-14 FITC  
These curves take into account the outlying values of the previous curves and 
consequently the fit is better, the errors are reasonably constant however. This data 
shows the three KWF compounds are in general more potent than the KWFQ 
compounds with compound 2.51 being the most potent.  
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2.4.2 Leukocyte Migration Assay 
Leukocyte migration data was determined by Dr Jill Reckless of The Department of 
Medicine at The University of Cambridge, using a multi-well filter migration assay 
system protocol (Figure 63).
200
 The migrated cells were quantified using the dye 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). In the presence 
of reductases, the tetrazolium ion was reduced to a formazan (Scheme 25). The 
concentration of reductases was related to the number of living cells, so measuring 
the amount of formazan is a way of determining this. Data was given as percentage 
inhibition of neutrophil migration at a given concentration. 
 
Figure 63 Cross-section of a single migration chamber 
 
Scheme 25 Reduction of a MTT to the corresponding formazan  
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The five compounds that showed the highest binding activity to SSTR2 - that is the 
KWF (2.01, 2.45 and 2.51) and KWFQ mimics (2.05 and 2.94) - were tested as to 
their BSCI activity. The ability of the compounds to prevent the chemokine induced 
migration of the neutrophils was measured at two different concentrations 1 µM and 
1 nM and the results are shown in Table 4. Data is given as a percentage inhibition of 
neutrophil migration. All the compounds show very high inhibition at 1 µM. At 1 
nM all the compounds still show high inhibition (over 90 %) apart from lactam 2.94. 
Lactam 2.94 inhibits 119 % at 1 µM however at 1 nM this drops down to 7 %. This 
correlates with the SSTR2 binding, as lactam 2.94 has lower binding activity and a 
lower IC50 value than the other compounds in this group. This study reveals that for 
these particular ligands high SSTR2 binding correlates to a certain extent with BSCI 
activity. All the compounds with high SSTR2 binding also have anti-inflammatory 
activity whether they contain the lactam or not. The position of the lactam is 
important and decreased SSTR2 binding results in lower BSCI activity. 
Family Compound 
% Inhibition  
± % error 
1 µM 1 nM 
KWF 
2.01 123 ± 25 118 ± 19 
2.45 126 ± 21 99 ± 16 
2.51 124 ± 15 94 ± 8 
KWFQ 
2.05 130 ± 15 115 ± 38 
2.94 119 ± 31 7 ± 15 
Table 4 % Inhibition of neutrophil migration, errors represent 1 SD (data from Dr Jill Reckless, The 
University of Cambridge) 
2.5 Conclusions 
The KWF mimic compounds display high inhibition of somatostatin at SSTR2 
which was expected as they were based on existing SSTR2 ligands. Likewise the 
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KWFQ mimics based on the existing SSTR2 ligands with the addition of the lactam 
also showed high binding, this shows the addition of the lactam does not have a 
negative effect on their SSTR2 binding ability. The IC50's show the KWF mimics are 
more potent however with compound 2.51 having an approximate 100-fold increase 
over compound 2.94. The IC50's for compounds 2.45, 2.51 and compounds very 
close in structure to 2.01 have been reported as 85, 0.26 and between 2.6-2.9 nM.
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These are close to the values reported herein. 
Both the KWF and KWFQ mimics show high inhibition of leukocyte migration at a 
concentration of 1 µM. At a concentration of 1 nM all of the compounds retain this 
high activity apart from compound 2.94. This correlates with the IC50 values to a 
certain extent as compound 2.94 has the highest value. This indicates that in these 
compounds the ability to displace somatostatin from SSTR2 is linked with the 
compounds BSCI ability.  
It is unexpected however that the KWF compounds act as BSCIs despite lacking the 
WxQ motif thought essential for BSCI activity. Previous studies have shown while 
cyclic peptides containing KWIQ act as BSCIs those containing KWI have no BSCI 
activity and in fact act as inhibitors. BIM58079D, BIM58092D and BIM58078D 
(compounds 2.95-2.97) all contain WIQ and have leukocyte migration inhibition 
potencies of 12, 20 and 80 nM respectively (Figure 64). BIM23454 (compound 2.98) 
is a cyclic peptide containing a KWx motif of lysine, (D)-tryptophan and pyridinyl 
alanine (Pal) (Cpa stands for p-chlorophenylalanine and NaI stands for 3-(2-
napthyl)alanine). Compound 2.98 has an IC50 value of 2.6 nM
139
 for the 
displacement of somatostatin from SSTR2, lacking the WxQ motif it is a potent 
antagonist against the action of compounds with BSCI activity. This evidence 
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supports the need the WxQ motif for a compound to have BSCI activity. However 
the fact that the peptide-like compounds we synthesised did not contain the 
glutamine residue but still retained BSCI activity suggests that conclusions based on 
the cyclic BSCIs do not necessarily hold true for the acyclic BSCIs.  
 
Figure 64 Compounds 2.95-2.98 
Hoyer and colleges have studied the ability of SSTR2 ligands to inhibit forskolin-
stimulated adenylate cyclase and thus the production of cyclic adenosine 
monophosphate (cAMP).
201
 The results for compound 2.51 and compounds 1.39 and 
2.100 (similar in structure to compound 2.01) gave inhibition values of 117.9, 117.5 
and 119.1 % respectively. These values correlate with the leukocyte migration 
inhibition data and could indicate cAMP inhibition correlates with leukocyte 
migration inhibition. To gain more information on this theory the data is required on 
the inhibition of cAMP for compound 2.45 as well as the KWFQ mimics 2.05 and 
2.94. As somatostatin is a growth hormone regulator the KWQ and KWFQ mimics 
could also be tested as to their ability to regulate growth hormone. 
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Figure 65 Compounds 1.39, 2.01 and 2.100 synthesised by Hay and colleges
140
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Chapter 3 - Lactams with Alkyl Side Chains 
Within this chapter, molecules based on the acylaminolactam BSCI structure 
were studied to determine whether they act though functional selectivity, like the 
SSTR2 and hybrid ligands of Chapter 2, or whether they exert their action 
through an allosteric site.  
3.1 Analysis of SSTR2 Binding Data of Existing BSCIs 
Despite the synthesis of a range of highly potent BSCIs such as lactam 1.13 (40 
pM in vitro) and the clinical candidate FX125L, information regarding the 
binding and mechanism of action of BSCIs is vital for future development and 
understanding of this type of drug. During the early investigations into BSCIs a 
large number of potential candidates were synthesised by Fox et al. These 
synthesised compounds, along with a number of natural products and natural 
product-derived compounds, were tested for their SSTR2 binding ability by Dr 
Jill Reckless of The Department of Medicine at The University of Cambridge. As 
part of this project, the author analysed this data so that additional conclusions 
could be drawn about the ligand structural requirements for SSTR2 binding and 
to highlight areas to be investigated further. The binding data is given as 
percentage inhibition of fluorescently labelled somatostatin (SS-14 FITC) from 
SSTR2. The data was also compared to previously reported leukocyte migration 
inhibition data to determine whether there was any correlation. The leukocyte 
migration data is reported as half maximal effective dose (ED50) concentrations 
values of the compounds inhibition of THP-1 leukocytes migration stimulated by 
chemoattractant MCP-1. 
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Nine of the tested compounds were natural products, derivatives or existing 
drugs with little relation to the traditional acylaminolactam BSCI structure. Six 
had a binding of less than 6 %; of the remaining three, the highest binding was 
obtained from phenytoin sodium (Figure 66, 3.01) with a binding of 29 %. 
Compound 3.01 has a five-membered succinimide ring, which in its protonated 
form has structural similarities to the glutarimide-containing BSCIs. Yohimbine 
(3.02) had an activity of 14 % (Figure 66), while yohimbine derivatives with an 
amide (3.03), methyl amide (3.04), dimethyl amide (3.05), carboxylic acid (3.06) 
and the stereoisomer raulwolscine (3.07) all had activities under 6 %. 
Oxymetazoline (3.08) (Figure 66) had an activity of 15 % and the glutarimide-
containing thalidomide (3.09) had an activity of 4 %. In conclusion none of the 
natural products or known drug molecules showed high levels of activity, 
however they do provide a useful standard for the comparison of other 
molecules. 
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Figure 66 Compounds 3.01-3.09 (somatostatin binding inhibition shown in brackets, data from 
Dr Jill Reckless, University of Cambridge) 
As previously mentioned, BSCIs are based on the tripeptide WxQ (x being any 
hydrophobic amino acid) and contain a hydrophobic tail group attached to a 
glutamine mimic. Modern BSCIs have a lactam as a glutamine mimic. A group 
of compounds were tested with open chain glutamine mimics. The most active of 
these compounds still have an activity under 17 %. As previously discussed, the 
errors for this assay are approximately 20 %, therefore these values may 
effectively be zero. The common structural similarity between these compounds 
is a linear eleven-carbon chain with a terminal olefin. Compound 3.10 has a 
dimethylated glutamic acid as the head group and shows an activity of 17 %; 
compound 3.11 has a glutamide head group and shows an activity of 14 % and 
compound 3.12 just has a methylated acid as the head group (lacking an amino 
acid side chain) and has an activity of 10 % (Figure 67). These compounds have 
98 
 
low BSCI activity, with compound 3.11 having a leukocyte migration inhibition 
value of 15000 nM.
45
 
 
Figure 67 Compounds 3.10-3.12 (somatostatin binding inhibition and leukocyte migration 
inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge) 
Of the glutarimide compounds, the most active was compound 3.13 (Figure 68) 
with an activity of 79 % and a leukocyte migration inhibition ED50 value of 66 
nM.
45
 Compound 1.08 (previously mentioned in Chapter 1), contains the linear 
eleven-carbon chain with a terminal olefin and displays similar activity to the 
compounds with open chain head groups with an activity of 12 %. Despite its 
low displacement of somatostatin from SSTR2, compound 1.08 is a more potent 
BSCI than glutarimide 3.13, with an ED50 of 5 nM.
45
  The more important 
compounds however were the lactams as previously stated. These retain the 
BSCI activity of glutarimides but with the benefit of improved metabolic 
stability.
46
 
 
Figure 68 Compounds 3.13 and 1.08 (somatostatin binding inhibition and leukocyte migration 
inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge) 
All of the compounds with the highest activity, regarding displacing somatostatin 
from SSTR2, have long carbon chain tail groups apart from one - a 6-membered 
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lactam with an unsubstituted phenyl ring (compound 3.14). The general 
conclusion drawn from this is that a lactam, substituted with a long carbon chain 
or an aromatic group of some fashion, is necessary to displace somatostatin from 
its SSTR2 binding site. The nature of the long chain remains unclear, however 
some form of substitution at the 2-position appears to be necessary. For example, 
compound 3.15, which contains a 2-gem-dimethyl group, and the mono-
substituted unsaturated compound 3.16 (Figure 69) have high somatostatin 
displacement values of 107 and 104 % respectively, but compound 3.15 is a 
significantly better BSCI with an ED50 of 0.09 nM compared to 10 nM for 
compound 3.16.
47
  
 
Figure 69 Compounds 3.15 and 3.16 (somatostatin binding inhibition and leukocyte migration 
inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge) 
Unfunctionalised or unbranched long chain substituted lactams, such as the 
sulfonamide compounds 3.17-3.21 and the carboxamide, compounds 3.22-3.26, 
all show much lower levels of somatostatin displacement. The 7-membered 
lactam sulfonamide with an 18-carbon chain, compound 3.17, shows the highest 
activity at 58 % and is the only example of these classes that shows any 
significant activity at all. The remaining compounds, 3.18-3.21, all had activities 
of less than 15 % (Figure 70).  
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Figure 70 Compounds 3.17-3.21 (somatostatin binding inhibition shown in brackets, data from 
Dr Jill Reckless, University of Cambridge) 
The 7-membered carboxamides all had activities of less than 18 % (Figure 71). 
These compounds do however show good BSCI activity. Compound 3.23 was 
the most potent inhibitor of leukocyte migration with an ED50 of 3 nM, with 
compounds 3.24, 3.25 and 3.26 having ED50s of 5, 15 and 50 nM respectively.
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This indicates the unsubstituted long chain in a conformation that does not 
displace somatostatin, yet still manages to bind and exert BSCI activity. 
 
 
Figure 71 Compounds 3.22-3.26 (somatostatin binding inhibition and leukocyte migration 
inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge)  
Of the compounds bearing aromatic systems the most active was compound 3.14 
with 56 % displacement of somatostatin from SSTR2; this compound is also a 
potent BSCI with an ED50 of 0.09 nM (Figure 72).
202
 However the errors are high 
at this level of inhibition. Replacing the phenyl ring with a pyridine ring, as in 
compound 3.27, removes the activity completely. The 7-membered equivalent of 
3.14, compound 3.28, has an activity of 23 % and an ED50 of 0.4 nM.
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Removing the aromaticity and replacing it with one double bond, as in 
compound 3.29, decreases the activity to 2 %, whilst removing the unsaturation 
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altogether, as in compound 3.30, abolishes any activity. Despite their low 
displacement of somatostatin from SSTR2 compounds 3.29 and 3.30 have high 
leukocyte migration inhibition ED50 of 0.8 and 0.5 nM respectively.
47
 This 
indicates that, due to the small nature of the compounds, they can bind to SSTR2 
and exert their BSCI function whilst not displacing somatostatin. Other examples 
include the very potent compounds 3.31, 1.13 (previously mentioned in Chapter 
1) and 3.32 with ED50 values of 90, 40 and 70 pM respectively (Figure 72).
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None of these inhibit somatostatin binding to SSTR2, with values of 21, 6 and 14 
% respectively. 
 
Figure 72 Compounds 3.14 and 3.27-3.30 (somatostatin binding inhibition and leukocyte 
migration inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge) 
Comparing the importance of the lactam ring size gives mixed findings. 
Compound 1.09 and the analogous 7-membered (1.11) and 5-membered (1.10) 
compounds (previously mentioned in Chapter 1) all have similar somatostatin 
displacement values of 12, 2 and 0 % respectively. However their BSCI potency 
decreases as ring size decreases, the compounds have ED50s of 40, 100 and 245 
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nM for compounds 1.11, 1.09 and 1.10 respectively (Figure 73). The most active 
aromatic compound has a 6-membered ring, 3.14, which displaces somatostatin 
from SSTR2 at 56 % compared to 23 % for the corresponding 7-membered 
compound 3.28; this shows a difference in the differing ring sizes, however again 
errors in this region are relatively high. Their ED50s are 0.4 and 0.09 nM 
respectively, again showing higher potency with the larger ring size of lactam. 
 
Figure 73 Compounds 1.09-1.11 (somatostatin binding inhibition and leukocyte migration 
inhibition shown in brackets, data from Dr Jill Reckless, University of Cambridge) 
Regarding the compounds ability to displace somatostatin from SSTR2 it can be 
concluded from this data that lactams with a long carbon side chain are the most 
potent. The nature of the chain is relevant however and substitution of the 2-
position as seen in compounds 3.15 and 3.16 appears to be necessary for the 
displacement of somatostatin from SSTR2. Those without this substitution such 
as the sulfonamides (3.17-3.21), carboxamides (3.22-3.26) and those with the 
terminal olefin (1.09-1.11) do not displace somatostatin from binding. A lactam 
with an aromatic substituent (3.14) has also shown reasonable high displacement 
of somatostatin. 
From comparing the ability of the compounds to displace somatostatin from 
SSTR2 with their leukocyte migration inhibition it can be seen the two do not 
correlate (Table 5). It is not necessary for a compound to displace somatostatin 
from binding in order to be a good BSCI; likewise those that displace 
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somatostatin are not necessarily good BSCIs. The most potent BSCIs are 
compounds 3.31, 3.32 and 1.13 with ED50 values of 90, 70 and 40 pM 
respectively however their displacement of somatostatin are all very low (21, 14 
and 6 % respectively). Seemingly these compounds lacking the long alkyl chain 
substituents are able to bind to SSTR2 and exert their BSCI function while not 
displacing somatostatin. Compound 3.15 with substitution at the 2-position 
displaces somatostatin at 107 % while having a leukocyte migration inhibition 
value of 90 pM. However the longer chain alkyl compounds lacking substitution 
at the 2-position may still possess good BSCI activity as seen in the 3 nM 
compound 3.23. This may be due to the nature of their side chain which allows 
them to fold away from the somatostatin binding domain of SSTR2.  
Compound Structure % somatostatin 
inhibition 
Leukocyte migration 
inhibition ED50 (nM) 
3.13 
 
79 66 
1.08 
 
12 5 
1.11 
 
2 40 
1.09 
 
12 100 
1.10 
 
0 245 
3.15 
 
107 0.09 
104 
 
1.13 
 
6 0.04 
3.32 
 
14 0.07 
3.31 
 
21 0.09 
3.23 
 
18 3 
3.24 
 
17 5 
3.25 
 
8 3 
3.26 
 
5 50 
3.29 
 
2 0.8 
3.30 
 
0 0.5 
Table 5 % somatostatin inhibition and leukocyte migration inhibition ED50 (data from Dr Jill 
Reckless, University of Cambridge) 
As a result of these findings the initial set of compounds to be investigated 
further will simply be acylaminolactams with an alkyl chain (ranging from a 
methyl group to a nonyl group), the aim of gaining more systematic information 
on the affect of chain length on activity, and the theory those with unsubstituted 
chains may be poorer at displacing somatostatin. Alkyl substituted benzoyl head 
groups will also be synthesised to give a hybrid of the most active compounds in 
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regards to displacing somatostatin from SSTR2, the long chains and the aromatic 
component (Chapter 4). 
3.2 Lactams with Alkyl Side Chains 
A series of acylamino tetrahydropyridin-2-one BSCIs compounds 3.33-3.40 
(Figure 74) were synthesised. The 6-membered lactam head group was 
synthesised as previously described in Chapter 2, and was coupled to a series of 
commercially available acid chlorides under Schotten-Baumann 
conditions
185
(Scheme 26). The yields are very low for the smaller compounds 
and gradually increase as the alkyl chain increases (Table 6). This is due to the 
compounds high solubility in water owing to their lack of hydrophobic groups. 
They are consequently washed into the aqueous layer in the work-up, reducing 
the isolated yield. Compounds synthesised ranged from decanoylamino- to 
butylanoylamino-tetrahydropyridin-2-one, all containing (S)-3-
aminotetrahydropyridin-2-one apart from compound 3.38 which contained (R)-3-
aminotetrahydropyridin-2-one.  
 
Figure 74 Compounds 3.33-3.40 
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Compound Yield (%) Compound Yield (%) 
3.33 30 3.37 13 
3.34 27 3.38 10 
3.35 26 3.39 7 
3.36 21 3.40 3 
Table 6 Compounds 3.33-3.40 and their respective yields 
 
 
Scheme 26 Synthesis of compounds 3.33-3.40 
3.3 6-Membered Exupéry Compounds 
Following on from the synthesis of the longer chain acylamino 
tetrahydropyridin-2-ones, a series of small molecules were synthesised as 
potential BSCIs. At present the smallest BSCIs comprise a 6-membered or 7-
membered lactam with a tertiary butyl side chain - for example the previously 
mentioned compound 1.13 (Figure 75). The idea was to make the smallest BSCIs 
possible to see how this affected their activity; an idea that was inspired by the 
inventor Antoine de Saint-Exupéry who said "a designer knows he has achieved 
perfection not when there is nothing left to add, but when there is nothing left to 
take away".
203
 Accordingly, 5-membered, 6-membered and 7-membered lactams 
were synthesised with tertiary butyl, isopropyl, ethyl and methyl groups. Larger 
adamantane compounds were also synthesised for comparison. 
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Figure 75 A current small BSCI
47
 
3.3.1 6-Membered Lactam via a Hydrophobic Precursor 
Due to difficulties associated with recovering the small alkanoylamino 
tetrahydropyridin-2-one compounds after an aqueous work-up the smallest 
compounds were synthesised via a different method. As an aqueous work-up is 
generally necessary the attachment of the small side chain to a more hydrophobic 
"masked lactam" was used as a lactam precursor. The selection of the Cbz group 
increases hydrophobicity and allows for a neutral residue-free deprotection that 
does not need an aqueous work-up. Formation of the lactam was achieved by a 
cyclisation reaction resulting from Cbz removal via hydrogenolysis, which was 
the last step in the synthesis (Figure 76).  
 
Figure 76 Lactam and “masked lactam” hydrophobic precursor 
N-(Z)-Orthinine methyl ester (3.41) was synthesised by acid catalysed ester 
formation using methanolic HCl (Scheme 27). The amide bond was then formed 
under Schotten-Bauman conditions.
185
 Isobutyryl chloride, propionyl chloride, 
acetyl chloride were the three acid chlorides used to give the products 
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compounds 3.42-3.44. The products were extracted with ethyl acetate and 
washed with pH 2 buffer to give higher yields then when coupled to the lactam. 
The yields were 83, 64 and 92 % respectively, considerably higher than the best 
yield of 30 % using the previous method in the synthesis of compound 3.33. 
 
Scheme 27 Synthesis of compound 3.41-3.44 
The target lactams was formed by a hydrogenolysis reaction which removed the 
Cbz group (Scheme 28). Once the Cbz group was removed, the free amine of the 
ornithine side chain is then able to react with the methyl ester as in the previous 
lactam synthesis.  
 
Scheme 28 Synthesis of compounds 3.45-3.47  
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3.4 5-Membered Exupéry Compounds 
The 6-membered and 7-membered ring lactams were synthesised using ornithine 
and lysine respectively. Diaminobutyric acid is the 5-membered lactam starting 
material, therefore the 5-membered lactam could be synthesised by making a 
methyl ester and base catalysed cyclisation.
204
 The Hofmann reaction was used to 
synthesis diaminobutyric acid from Boc protected glutamine. 
3.4.1 Hofmann Reaction  
The Hofmann reaction is a method of converting an amide to an amine.
205
 This 
method used iodobenzene diacetate to effect this transformation (Scheme 29).  
 
Scheme 29 Mechanism of Hofmann Reaction 
The presence of the acetic acid by-product ensures the amine, once formed, is 
protonated, preventing it from reacting with the isocyanate to form a urea 
molecule.
206
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3.4.2 5-Membered Lactam  via a Hydrophobic Precursor  
The resulting amines 3.48 and 3.49 were Cbz protected using benzyl 
chloroformate giving bis protected amino acids 3.50 and 3.51 (Scheme 30).
206
 
Methanolic acid then removed the Boc group and forms the methyl ester in one 
step to give compounds 3.52-3.53. 
 
Scheme 30 Synthesis of compounds 3.48-3.53 
Amines 3.52 and 3.53 were coupled to pivaloyl chloride and adamantane 
carbonyl chloride to give 3.55-3.57 (Scheme 31). Adamantane carbonyl chloride 
(3.54) was synthesised from adamantane carboxylic acid with oxalyl chloride 
and catalytic DMF.  
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Scheme 31 Synthesis of compounds 3.55-3.57 
Hydrogenolysis removed the Cbz group allowing cyclisation to occur (Scheme 
32). The rate of cyclisation was noticeably slower in one case, the open chain 
amine was recovered after hydrogenolysis. Cyclisation was induced by further 
stirring in methanol with gentle heating. Compounds 3.58-3.59 were successfully 
synthesised. 
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Scheme 32 Synthesis of compounds 3.58-3.59 
3.4.3 5-Membered Lactam via an Alternative Method 
The very small 5-membered ring BSCIs were synthesised using a different 
method. The 5-membered aminolactam was synthesised in the same fashion as 
the 6-membered aminolactams (from the methyl ester under basic conditions) 
(Scheme 33). The reaction did not go to completion however the mixture of 
cyclised, compound 3.60 and the open chain products was carried on to the next 
step. Isobutyryl chloride, propionyl chloride and acetyl chloride were coupled to 
the mixture of products under Schotten-Baumann conditions.
185
 On completion, 
products 3.61-3.63 were purified by flash column chromatography without 
exposure to an aqueous work-up (Scheme 33). 
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Scheme 33 Synthesis of compounds 3.60-3.63 
3.5 ‘Reverse’ 5-Membered Lactams 
Further 5-membered lactams with tertiary butyl and adamantane groups were 
synthesised, with the two amide bonds reversed (Figure 77). This gave 
compounds with the same chemical formula and molecular weights to see the 
affect of the amide bond orientation. 
 
Figure 77 5-Membered lactams and 'reverse' compounds 
3.5.1 Reverse Molecules from Pyroglutamic Acid 
The 'reverse' lactams were synthesised by coupling pyroglutamic acid to 
adamantamine and tertiary butylamine using HATU as a coupling reagent. The 
compounds from adamantamine (3.64-3.65) were synthesised successfully, 
however the yields were quite low. This is most likely again due to loss of a 
certain amount of the product during the aqueous work-up.  
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Scheme 34 Synthesis of compounds 3.64 and 3.65 
3.5.2 ‘Reverse’ Molecules via a Hydrophobic Precursor 
This method was not successful for the 'reverse' lactams with a tertiary butyl 
group due to their increased solubility in water. A hydrophobic lactam precursor 
was therefore synthesised for the 'reverse' lactams. Glutamic acid methyl ester 
was synthesised from glutamic acid using methanolic HCl (Scheme 35, 3.66, 
3.67).
206
 The amine was Cbz protected with benzyl chloroformate to give acids 
3.68 and 3.69. The acid was then coupled to tertiary butyl amine with HATU to 
give compounds 3.70 and 3.71. The lactam was formed by removing the Cbz in 
another hydrogenolysis reaction to give lactams 3.72 and 3.73. Compound 3.74, 
the isopropyl lactam precursor equivalent, was synthesised in the same fashion. 
Isopropylamine was coupled to acid 3.68, deprotection via hydrogenolysis and 
subsequent cyclisation gave the 'reverse' lactam 3.75. 
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Scheme 35 Synthesis of compounds 3.66-3.73 
3.6 7-Membered Exupéry Compounds 
The tertiary butyl and adamantane 7-membered lactams (compounds 1.13 and 
3.31) had been previously synthesised by the Fox group.
47
 To complete the 
series, the isopropyl, ethyl and methyl lactams were synthesised. These could not 
be synthesised via a hydrophobic precursor due to the difficulty in cyclisation of 
7-membered lactams. The necessary heating under reflux conditions would cause 
epimerisation of the sterocentre as shown in Chapter 2. 
3.6.1 Different Rates of Lactam Cyclisation 
6-Membered lactams cyclise at the fastest rate, followed by 5-membered and 
finally 7-membered. This may explain the absence of diaminobutryic acid and 
ornithine as amino acids coded for by t-RNA. Both could undergo spontaneous 
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lactamisation (Scheme 36). In addition to this, diaminobutyric acid can undergo 
reversible acyl transfer reactions.
207, 208
  
 
Scheme 36 Ornithine may undergo spontaneous lactamisation in a peptide chain 
The rate of lactam cyclisation differs to that of saturated heterocycles, where 5-
membered rings form faster than 6-membered rings. The smaller rings form 
faster on entropic grounds, as there are fewer bonds to align. The transition state 
for the tetrahedral intermediates of the 6-membered lactam is close in structure to 
a stable chair conformations. They result in a lactam in a half chair conformation 
with the amide bond lying flat. The transition state for the tetrahedral 
intermediate of the 5-membered lactam is less stable not being able to resemble a 
chair conformation. The 5-membered ring forms slower in this case due to 
enthalpic reasons explaining the slower rate of cyclisation seen. The 5-membered 
lactam ring is more strained, but by allowing the amide to lie flat strain is 
partially relieved by slight puckering of the ring. The 7-membered lactams close 
via a pseudo-chair conformation transition state. On deprotection of the Cbz 
protected hydrophobic lactam precursors the 6-membered lactams form 
immediately. The 5-membered lactams do not always form without further 
heating. On synthesis of the free lactams the 6-membered cyclises in 2 hours at 0 
°C. The 5-membered lactam was kept at 0 °C to prevent epimerisation under the 
basic conditions. The reaction however only proceeded to 50 % completion even 
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after 48 hours. The 7-membered lactam required heating under reflux conditions 
for at least 48 hours for complete ring closure to happen. 
3.6.2 7-Membered Lactam Synthesis 
 The synthesis of the 7-membered Exupéry compounds therefore started with (S)-
3-amino-azepan-2-one.HCl 2.65. Isobutyryl chloride, propionyl chloride and 
acetyl chloride were all coupled to lactam 2.65. Two equivalents of triethylamine 
were used to neutralise the salt and neutralise the HCl produced (Scheme 37). 
The addition of diethyl ether to the reaction caused this triethylamine hydrogen 
chloride to precipitate. The filtrate was reduced in vacuo and purified by flash 
column chromatography to give lactams 3.76-3.78.
209
 
 
Scheme 37 Synthesis of compounds 3.76-3.78 
3.7 Biological Results 
3.7.1 SSTR2 Binding Data 
BSCIs bind to SSTR2, as shown by their displacement of somatostatin from the 
receptor. The exact location of the binding site is however unknown. It could be 
the same binding site as somatostatin or an allosteric binding site. The SSTR2 
binding data was again determined by Tilly Sharp at Total Scientific (Babraham 
Research Campus, Cambridge) using FP by exactly the same method as for the 
compounds in Chapter Two. The data is given as percentage inhibition of SS-14 
FITC from SSTR2. None of the compounds tested (Figure 78) showed any 
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significant displacement of somatostatin from SSTR2 at a concentration of 100 
µM (Table 7). These results correlate to those of the 7-membered lactams (3.22-
3.26). The data for the Exupéry compounds correlates with the smaller 
compounds seen at the start of the chapter (3.29-3.32) (Table 8) - none of the six 
ring compounds with a methyl, ethyl or isopropyl group or the 'reverse' 
compounds show any displacement of somatostatin.  
 
Figure 78 Compounds tested for SSTR2 binding 
Compound % Somatostatin Inhibition Compound % Somatostatin Inhibition 
3.33  2 3.37 -20 
3.34  5 3.38  -2 
3.35  10 3.39 1 
3.36  -12 3.40  -3 
Table 7 % at 1 nM of SS-14 FITC from SSTR2 (data from Tilly Sharp at Total Scientific) 
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Compound % Somatostatin Inhibition Compound (reverse) % Somatostatin Inhibition 
3.45 0 3.64  -1 
3.46  0 3.65  -1 
3.47  3 3.72  -1 
  3.73  -8 
  3.75  -8 
Table 8 % inhibition at 1 nM of SS-14 FITC from SSTR2 (data from Tilly Sharp at Total 
Scientific) 
As previously discussed the errors associated with the measurement in this assay 
are about 20 %. The errors associated with the concentration are lowest around 0 
and 100 %. All the data is around 0 % with the highest being only 10 % so 
therefore the errors are minimal. 
3.7.2 Leukocyte Migration Assay 
Leukocyte migration data was again determined by Dr Jill Reckless of The 
Department of Medicine, The University of Cambridge. The data is given as 
percentage inhibition of neutrophil migration at given concentrations. The results 
for the Exupéry compounds (Figure 79) are shown in Table 9 and Table 10. They 
include the eleven synthesised compounds and four compounds previously 
synthesised by the group (labelled with an asterisk, compounds 1.13, 3.31 and 
3.79-3.80).
47
 They were tested at concentrations of 1 µM and 1 nM. Figure 75 
shows the 1 µM results in red and 1 nM results in blue. The results show that of 
the fifteen compounds tested (Figure 79), the majority had excellent activity 
(over 98 %). The least active compounds were the three with the methyl group 
sidechain - even at a concentration of 1 µM, the percentage inhibition is as low 
as 47 % for the 5-membered compound (3.61) and approximately 75 % for the 6-
membered and 7-membered compounds (3.47 and 3.76). These values drop to 25 
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% for 3.61 at a concentration of 1 nM and approximately 50 % for the 3.47 and 
3.76. Continuing the trend, the next least active compounds were the next 
smallest - the three compounds with the ethyl group (3.62, 3.46 and 3.77). These 
compounds showed high activity at a concentration of 1 µM, all over 98 %. 
However at a concentration of 1 nM the activity dropped significantly to 72, 86 
and 92 % for the 7-memberd, 6-membered and 5-membered compounds 
respectively. The remaining compounds with the isopropyl, tertiarybutyl and 
adamantane groups all have activity over 98 % at both concentrations. These 
findings indicate that for highest BSCI activity the lactams require a branched 
side chain. The ring size seems to be optimal at either a 6-membered or 7-
membered lactam. They show there are number of potential structures for 
successful BSCIs. Pharmacokinetic studies have shown the adamantane structure 
is easily metabolised.
47
 
 
Figure 79 Exupéry compounds  
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5 Ring 
Compound 
% Inhibition 
± Error 
6 Ring 
Compound 
% Inhibition 
± Error 
7 Ring 
Compound 
% Inhibition 
± Error 
3.61 47 ± 3 3.47 74 ± 7 3.76 75 ± 6 
3.62 104 ± 17 3.46 105 ± 4 3.77 98 ± 37 
3.63 102 ± 5 3.45 102 ± 6 3.78 104 ± 21 
3.59 110 ± 11 3.79* 101 ± 30 1.13* 106 ± 19 
3.58 103 ± 13 3.80* 99 ± 23 3.31* 111 ± 31 
Table 9 % inhibition of neutrophil migration a 1 µM, errors represent 1 SD (data from Dr Jill 
Reckless, University of Cambridge) 
5 Ring 
Compound 
% Inhibition 
± Error 
6 Ring 
Compound 
% Inhibition 
± Error 
7 Ring 
Compound 
% Inhibition 
± Error 
3.61 25 ±6 3.47 52 ±7 3.76 55 ±8 
3.62 92 ±23 3.46 86 ±13 3.77 72 ±10 
3.63 100 ±21 3.45 110 ±20 3.78 109 ±16 
3.59 104 ±9 3.79* 104 ±30 1.13* 107 ±12 
3.58 109 ±30 3.80* 107 ±22 3.31* 108 ±21 
Table 10 % inhibition of neutrophil migration a 1 nM, errors represent 1 SD (data from Dr Jill 
Reckless, University of Cambridge) 
 
Figure 80 % inhibition of neutrophil migration, at 1 µM red and 1 nM blue 
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The five 'reverse' compounds (Figure 81) were all tested at a concentration of 1 
µM (Table 11). All showed inhibition over 60 %, however this is relatively low 
compared to the non-'reverse' compounds at 1 µM. The most potent compound 
was the isopropyl substituted (S)-lactam, followed by the tertiary butyl 
substituted (S)-lactam and the adamantane substituted (S)-lactam. The 
compounds with (R)-stereochemistry were the least potent, again following the 
same pattern with the tertiary butyl substituted compound being more potent than 
the adamantane substituted compound. The 'reverse' isopropyl, tertiary butyl and 
adamantane substituted (S)-lactams have potencies of 90, 81 and 78 % 
respectively, compared to the analogous Exupéry isopropyl, tertiary butyl and 
adamantane substituted 5-membered (S)-lactams with potencies of 102, 110 and 
103 %. These findings show reversing the amide bonds in the lactams does not 
reduce BSCI activity completely however it does significantly decrease it. 
 
Figure 81 Reverse compounds 3.64-3.65, 3.72-3.73 and 3.75 
Compound 
% Inhibition  
± error 
3.64 78 ± 17  
3.65 64 ± 9 
3.72 81 ± 31  
3.73 76 ± 23  
3.75 90 ± 29  
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Table 11 % inhibition of neutrophil migration at 1 µM, errors represent 1 SD (data from Dr Jill 
Reckless, University of Cambridge) 
3.8 Conclusions 
The SSTR2 binding data of the compounds synthesised in this chapter correlates 
with the results seen from the data analysed at the start of the chapter. 
Compounds 3.33-3.40, the 6-membered acylaminolactams with the linear alkyl 
substituents showed no inhibition of the binding of somatostatin at SSTR2. This 
was seen in the analogous 7-membered carboxamides (3.22-3.26), the 
sulfonamides (3.17-3.21) and those with a terminal olefin (1.09-1.11). The nature 
of the long chain means the conformation does not block the binding of 
somatostatin. 
The Exupéry and 'reverse' compounds show no displacement of somatostatin 
which again correlates with the results seen from the smaller compounds at the 
start of this chapter (compounds 3.29-3.32). Some of these compounds are potent 
BSCIs, showing it is not necessary for the compound to displace somatostatin to 
act as potent BSCIs. Preventing the binding of somatostatin could have 
detrimental biological effects due to the fact it has a number of functions within 
the body including growth hormone regulation. The Exupéry and 'reverse' BSCIs 
do not prevent somatostatin binding which is a desirable property as they will not 
act as somatostatin regulators thus yielding unwanted side effects. 
The BSCI data shows that there are a number of Exupéry compounds which are 
potent inhibitors of leukocyte migration, presenting a number of potential clinical 
candidates. Modifying the compounds by reversing the amide bonds do not 
improve their potency therefore compounds based on the Exupéry model are the 
best. Other biological data being similar then factors to consider in choosing a 
124 
 
clinical candidate would be the ease of synthesis. The 6-membered lactams are at 
present the easiest to synthesise due to the fact they cyclise under mild conditions 
and retain their stereochemical integrity. 
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Chapter 4 - Lactams with Alkyl Substituted Aromatic 
Side Chains 
4.1 Introduction 
The initial analysis of previously synthesised compounds in Chapter 3 highlighted 
that long chain or benzoyl BSCIs display high binding to the receptor SSTR2. To 
include both of these motifs, a series of benzoyl and benzenesulfonyl lactams were 
synthesised with different lengths of alkyl chains in the para, meta and ortho 
position. 
4.2 4-Carboxy Compounds 
Twenty 4-alkylbenzoyl lactams were synthesised, comprising of 6-membered and 7-
membered lactams of both (S)- and (R)-stereochemistry and one of five alkyl 
substituents (ethyl, butyl, tert-butyl, hexyl and octyl). Five commercially available 
acids, 4-ethylbenzoic acid, 4-
n
butylbenzoic acid, 4-
t
butylbenzoic acid, 4-
n
hexylbenzoic acid and 4-
n
octylbenzoic acid, were made into the corresponding acid 
chlorides 4.01-4.05. They were synthesised using oxalyl chloride in dichloromethane 
with catalytic DMF as described in Chapter 2 (Scheme 38). 
 
Scheme 38 Synthesis of compounds 4.01-4.05 
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The acid chlorides were coupled to the lactams under Schotten-Baumann
185
 
conditions (Scheme 39, 4.06-4.25).  
 
Scheme 39 Synthesis of compounds 4.06-4.25 
4.3 4-Sulfonyl Compounds 
A series of 4-alkylbenzenesulfonyl lactams were synthesised, again comprising of 
the 6-membered and 7-membered lactams of both (S)- and (R)-stereochemistry, with 
the same five alkyl substituents as used for the 4-carboxy compounds and (ethyl, 
butyl, tert-butyl, hexyl and octyl). 4-tert-Butylbenzenesulfonylchloride (4.27) was 
commercially available, whilst 4-ethylbenzenesulfonic acid and 4-
octylbenzenesodiumsulfonate were converted into the corresponding sulfonyl 
chlorides, compounds 4.26 and 4.28. (Scheme 40).  
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Scheme 40 Synthesis of compounds 4.26 and 4.28 
The sulfonylchlorides 4.26-4.28 were coupled to the lactams in a Schotten-
Baumann
185
 reaction, this time the acid chloride is a sulfonyl chloride (Scheme 41).  
 
Scheme 41 4-Sulfonyl compounds 4.29-4.37 
For the 4-butyl and 4-hexylbenzenesulfonyl chlorides, the corresponding acids were 
not commercially available. These were instead synthesised from 4-
chlorobenzenesulfonic acid. This required a reaction involving the formation of a 
carbon-carbon bond. 
4.3.1 Methods of C-C Bond Formation 
In organic synthesis carbon-carbon bond forming is one of the most important 
reactions. Catalytic amounts of transition metals salts were shown to induce 
reactions of Grignard reagents and organic halides by Kharasch as far back as the 
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1940s.
210
 In 1972 Corriu
211
 (Scheme 42) and Kumada
212
 (Scheme 43) independently 
reported the nickel catalysed cross-coupling of Grignard reagents and aryl or alkenyl 
halides. This led the way into a huge amount of research into metal catalysed cross-
coupling reactions, resulting in a number of commonly used reactions, valued for 
their mild reaction conditions and tolerance of functional groups. 
 
Scheme 42 Corriu's nickel catalysed coupling 
211
 
 
Scheme 43 A Kumada cross-coupling
212
 
After his discovery in 1972 Kumada developed the Kumada cross-coupling reaction, 
in which palladium or nickel-phosphine complexes catalyse the reaction of Grignard 
or organolithium compounds with aryl chlorides, bromides or iodides. Due to the 
electropositive nature of magnesium or lithium, base sensitive groups are not 
tolerated.
213
 The Negishi cross-coupling uses organozinc compounds as a less 
electropositive metal version of the Kumada. In 1976 Negishi reported the first 
nickel catalysed reaction of organoaluminium compounds (Scheme 44) and aryl or 
alkenylhalides.
214
 The most successful however proved to be organozinc compounds 
with catalytic palladium (Scheme 45).
215
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Scheme 44 A Negishi cross-coupling using an organoaluminium compound 
214
 
 
Scheme 45 A Negishi cross-coupling using an organozinc compound
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The Stille cross-coupling is the palladium catalysed reaction of organostannane 
compounds with aryl halides. The first of these was published by Eaborn in 1976
216
 
(Scheme 46), in which organostannanes (formed in situ from distanannes) coupled 
with aryl halides. Stille realised that organostannane compounds and aryl halides 
could be coupled and pioneered the use of this method (Scheme 47).
217
 Advantages 
include their tolerance to a high number of functional groups and that they are easily 
prepared and stored, due to their stability to moisture and oxygen. They are, 
however, toxic and traces of tin are difficult to remove from the product. 
 
Scheme 46 Eaborn's use of organostannanes  
 
Scheme 47 A Stille cross-coupling 
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Suzuki and Miyaura reported the first example of what came to be known as the 
Suzuki reaction in 1979 (Scheme 48). They showed that aryl halides would react 
with alkenylboranes in the presence of catalytic palladium and base to give the 
coupled product.
218
 Advantages include the non-toxic boron by-products, which are 
easily separated from the product. Aryl chlorides however are much less reactive 
than the corresponding aryl iodides and bromides.
219
 In 1986 Suzuki and Miyaura 
reported the successful cross-coupling of aryl or alkenyl halides with alkyl boranes - 
the β-alkyl Suzuki-Miyaura reaction (Scheme 49). Previously these reactions had 
been unsuccessful due to problems associated with β-hydride elimination. By 
optimising the palladium catalyst with a bis(diphenylphosphino)ferrocene (dppf)  
ligand, PdCl2(dppf) proved to be efficient enough to react at a faster rate than 
unwanted side reactions could occur.
220
  
 
Scheme 48 A Suzuki cross-coupling
218
 
 
Scheme 49 A Suzuki-Miyaura cross-coupling
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In 1984 Hayashi reported the use of the same catalyst PdCl2(dppf) for the successful 
cross-coupling of primary or secondary alkyl Grignard and alkylzinc reagents with 
aryl halides (Scheme 50).
221
 In 1988 Hiyama reported the use of organosilicon 
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compounds, which reacted with aryl, allyl or alkenyl halides with a palladium 
catalyst (Scheme 51). Previously it had been thought the carbon-silicon bond was too 
strong to be broken in a reductive elimination and these reactions had not been 
successful. Hiyama uses tris(diethylamino)sulfonium difluorotrimethylsilicate 
(TSAF) as a source of fluoride anions to cleave the carbon silicon bond and facilitate 
transmetallation.
222
 More recently, fluoride free couplings have been achieved. 
Disiloxanes, which are in equilibrium with the active silanolate species, cross-couple 
with arylhalides catalysed by palladium in the presence of base.
223
  
 
Scheme 50 A Hayashi cross-coupling
221
 
 
Scheme 51 A Hiyama cross-coupling
222
 
Furstner has reported the use of iron as the catalyst in the cross coupling of aryl 
halides and Grignard reagents. Iron boasts a number of advantages - it is both 
cheaper and less toxic than metals such as tin, nickel and palladium. Iron catalysts 
have been successful without the need for ancillary ligands to render them 
sufficiently active like other metals. Finally, iron catalysts have been shown to be 
more successful in reactions with aryl chlorides, which are cheaper alternatives to 
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aryl bromides or iodides in which palladium and nickel are not. Iron was first 
reported as a cross coupling catalyst by Kochi in 1971 (Scheme 52).
224, 225
  
 
Scheme 52 Kochi's use of  an iron catalyst
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Little follow up work has been carried out; however what was done focused on 
alkenyl halides.
227
 The first reported heteroaryl bromide and Grignard iron catalysed 
coupling was reported by Figadere.
228
 Furstner however reported the first aryl 
chloride and Grignard reagent coupling. Furstner has shown that iron catalyses the 
reaction of aryl halides with Grignard reagents and, in contrast to other cross-
coupling reactions, aryl chlorides react most successfully - another advantage owing 
to the relatively low cost of aryl chlorides compared to aryl bromides and iodides. 
These studies showed that alkyl Grignard reagents were much more successful than 
aryl, allyl or alkenyl reagents. FeCl2 reacts with four equivalents of Grignard reagent 
to give [Fe(MgCl)2] as shown in Scheme 53.
229
 This gives an Fe
-II 
complex which, 
due to its high nucleophilic character, can oxidatively insert into an aryl halide bond 
to give an Fe
0
 complex. Another equivalent of the Grignard reagent reacts with the 
iron and reductive elimination yields the product (Scheme 54). 
 
Scheme 53 Reaction of FeCl2 with 4 equivalents of Grignard reagent 
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Scheme 54 Mechanism for Fe catalysed cross-coupling 
4.3.2 Use of Fe Cross-Coupling Reaction 
The reaction used to synthesise the target 4-alkylbenzenesulfonic acids and 3- and 2-
alkylbenzoic acids was Furstner's iron cross-coupling reaction. Conventionally 
reacting methyl-4-chlorobenzoate with a Grignard reagent such as EtMgCl would 
give a tertiary alcohol. The ethyl anion acts as a nucleophile and attacks the ester 
resulting in the loss of the methyl ester. Another equivalent of Grignard attacks again 
resulting in the tertiary alcohol. During this reaction tetrahydrofuran as the solvent 
and the ester can both chelate with the magnesium - this aids in the nucleophilic 
attack of the ester by polarising the carbonyl. In the presence of N-methylpyrrolidone 
(NMP) and tris(acetylacetonato)iron(III) (Fe(acac)3) the chloride undergoes a 
substitution reaction with the Grignard reagent (Scheme 55). 
 
Scheme 55 Grignard reactions with and without NMP and Fe(acac)3 
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NMP probably chelates to the magnesium and, due to conjugation from the lone pair 
on the nitrogen, this chelation is stronger than chelation by an ester. This has the 
affect of not polarising the ester carbonyl group thus not enhancing the likelihood of 
nucleophilic attack. Fe(acac)3 is an Fe(III) complex and is only the pre-catalyst, the 
form in which iron is added to the reaction. The active species, believed to be an Fe(-
II) complex, is formed from the reaction of five equivalents of Grignard reagent 
(Scheme 56) with Fe(acac)3. The iron then inserts into the carbon-chlorine bond in 
an oxidative addition reaction. The alkyl anion attacks the iron, causing the chloride 
to leave, in a transmetallation reaction. Finally reductive elimination occurs, causing 
the loss of the iron to give the alkyl substituted product (Scheme 57).  
 
Scheme 56 Formation of Fe(MgCl)2  
 
Scheme 57 Reaction of Fe(MgCl)2 with methyl-4-chlorobenzoate 
The target compounds were 4-butylbenzenesulfonic acid and 4-
hexylbenzenesulfonic acid. 4-Chlorobenzenesulfonylchloride was converted to the 
isopropylsulfonate ester (4.38), using propan-2-ol and DMAP as a nucleophilic 
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catalyst.
230
 The iron cross-coupling reaction was then carried out to give compounds 
4.39-4.40 (Scheme 58).  
 
Scheme 58 Synthesis of compounds 4.38-4.40 
The sulfonate ester was removed using NaI (Scheme 59, 4.41, 4.43).
230
 The sodium 
salt was converted into the sulfonyl chloride using the previously used method to 
give compounds (4.43) and (4.44) which were not isolated and coupled to the 
lactams under Schotten-Baumann conditions
185
 (Scheme 60, 4.45-4.48). 
 
 
Scheme 59 Synthesis of compounds 4.41-4.44 
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Scheme 60 Synthesis of compounds 4.45-4.48 
4.4 3-Carboxy and 2-Carboxy Compounds 
This reaction had previously been reported for 4-chloro substituted compounds but 
not so successfully for 3- or 2-chloro substituted compounds. The next target 
compounds were 3- or 2-alkyl substituted benzoyl lactams so methyl-3-
chlorobenzoate (4.49) and methyl-2-chlorobenzoate (4.50) were synthesised from 
their corresponding acids using methanolic HCl (Scheme 61). The iron cross-
coupling reaction was carried out as described above. Reaction times of 5 minutes, 
15 minutes and 15 hours and all led to similar results. Some product was formed, 
(4.51-4.53) however some starting material remained. The unreacted starting 
material was inseparable from the product. After basic hydrolysis of the ester it was 
possible to separate the unreacted starting materials from the products. The starting 
material hydrolyses preferentially to the product so, on extraction, the hydrolysed 
starting materials remained in the aqueous layer allowing clean ester to be obtained. 
The clean ester was then subjected to another hydrolysis reaction to yield the acids 
(4.54-4.56). The acid chlorides, compounds (4.57-4.59), were synthesised as 
previously described and coupled to the lactam to give the following: 3-
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butylbenzoyl-(S)-3-amino-azepan-2-one (4.60), 3-hexylbenzoyl-(S)-3-amino-azepan-
2-one (4.61) and 2-butylbenzoyl-(S)-3-amino-azepan-2-one (4.62). 
 
Scheme 61Synthesis of compounds 4.49-4.62 
4.5 Fe Cross-Coupling on Amides 
Because of the success of these reactions, the coupling was attempted with a tertiary 
amide instead of an ester. This involved the synthesis of 4-
chlorobenzoyldimethylamide (4.63) from 4-chlorobenzoylchloride (Scheme 62). The 
iron cross-coupling reaction was carried under the same conditions, yielding the 
product, 4-hexylbenzoyldimethylamide (4.64), which was purified by flash column 
chromatography to remove excess NMP. The reaction was carried out using a meta-
chloride, which as with the esters was not as clean although some product was 
formed. The reaction using an ortho-chloride was unsuccessful. Potential 
applications for this reaction would be to synthesise chlorobenzoyl lactams and 
perform iron cross coupling substitution reactions on these.  
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Scheme 62 Synthesis of compounds 4.63-4.64 
4-Chlorobenzoyl and 4-chlorobenzenesulfonyl lactams were synthesised from 4-
chlorobenzoylchloride or 4-chlorobenzenesulfonylchloride and the 6-membered and 
7-membered lactams 2.53 and 2.65 (Scheme 63). The resulting compounds 4.65-4.68 
were all subjected to the iron cross-coupling reaction however no desired product 
was recovered. 
 
Scheme 63 Synthesis of compounds 4.65-4.68 
4.6 SSTR2 Binding Results 
The SSTR2 binding data was determined by Glenda Chandler at Total Scientific 
(Babraham Research Campus, Cambridge) using FP by exactly the same method as 
for the compounds in Chapter Two. Data is given as percentage inhibition as SS-14 
FITC from SSTR2. As expected, the compounds with the longer alkyl chains show 
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greater ability to displace somatostatin from binding to SSTR2. None of the 
compounds with an alkyl group in the para or meta position smaller than a hexyl 
group showed any activity. The results for the larger compounds (Figure 81) are 
shown in Table 12.  
 
Figure 82 Compounds tested for SSTR2 binding 
Compounds 4.36 and 4.37 showed the greatest activity at 100 % comparable to the 
SSTR2 ligands of Chapter 2. These were the 6-membered sulfonamides with the 
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octyl group substituent. The next best compound was 4.35, the analogous 7-
membered compound, but the activity has dropped down to 46 %. The hexyl 
sulfonamides 4.47 and 4.48 have similar activities of 28 and 27 % respectively, 
being the next most active compounds. From this data it can be concluded that the 
sulfonamides show greater activity than the carboxamides, with the most active 
being the octyl compounds. The 6-membered lactams are more active than the 7-
membered, however the stereochemistry of the lactam does not seem to matter. This 
correlates with the previously synthesised alkyl sulfonamides of Chapter 3 in which 
the sulfonamide compound 3.17 showed greater activity of 58 % over the 
corresponding carboxamide compounds. The only other compounds that showed 
notable activity were 4.21 and 4.25, the 6-membered hexyl and octyl carboxy 
compounds with (R)-stereochemistry. From this it can be concluded that again the 6-
membered lactams are more active than the 7-membered lactam compounds. The 
stereochemistry does seem to have an effect as the corresponding (S)-compounds 
have lower activities. Although some strongly binding compounds have been 
synthesised the overall results seem varied and this may be explained by their 
solubility in the assay. The compounds showing lower than expected activity did not 
stay in solution when in 4 % aqueous DMSO. They were tested up to 10 % aqueous 
DMSO and still did not stay in solution, they could not be dissolved in any higher 
concentrations of DMSO as this would affect the assay. It has been shown that, in 
the case of the sulfonamides, high binding can be achieved by using the long chain 
and aromatic motifs on the lactam. It is possible that all the hexyl and octyl 
compounds would show high binding but are hindered by their poor solubility. As 
previously discussed the errors associated with the measurement in this assay are 
about 20 %.  
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Compound 
(7-membered) 
% Somatostatin 
 Inhibition 
Compound 
(6-membered) 
% Somatostatin 
 Inhibition 
4.18 11 4.20 9 
4.19 10 4.21 25 
4.22 1 4.24 -2 
4.23 4 4.25 31 
4.35 46 4.36 101 
4.47 28 4.37 100 
  4.48 27 
Table 12 % inhibition of SS-14 FITC from SSTR2 (data from Glenda Chandler at Total Scientific) 
Rough IC50 values were calculated for compounds 4.36 and 4.37 by performing a 
titration by the same method as those in Chapter 2. The values obtained were 50 and 
49 μM for compounds 4.36 and 4.37 respectively. The values are 100-fold less 
potent than the compounds in Chapter 2, however they were not designed as SSTR2 
ligands so this is not surprising. 
4.7 Conclusions 
These results indicate compounds with the longer chain substituents are required to 
displace somatostatin from binding. The substituent on the aromatic ring is required 
to be at least a hexyl group for this to occur. Not all the compounds with a hexyl or 
octyl substituent gave high inhibition values however this can possibly be attributed 
to their poor solubility as previously discussed. The unsubstituted 6-membered 
(3.14) and 7-membered (3.28) benzoylamino lactams from the data analysed at the 
start of Chapter 3 display inhibition values of 56 and 23 % respectively. It appears 
that these are better at displacing somatostatin than those with ethyl, butyl or tertiary 
butyl substituents which all have values of 0 % inhibition. It was the relatively high 
inhibition value of compound 3.14 compared to other BSCIs lacking long chain 
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substituents that prompted the synthesis of these alkyl benzoyl substituted lactams. It 
was thought that perhaps the presence of the aromatic ring enhanced the ability of 
the compound to inhibit the binding of somatostatin, and indeed does increase 
binding in relation to the unsubstituted compounds of Chapter 3. It has been shown 
that the ability to displace somatostatin from binding to SSTR2 does not necessarily 
translate into high BSCI activity. Leukocyte migration data is available for the non-
substituted benzoyl lactams, compounds 3.14 and 3.28 of 400 and 90 pM 
respectively, the methyl substituted benzoyl lactams, compounds 4.69 and 4.70 of 60 
and 90 pM respectively, and of the tosyl substituted lactams, compounds 4.71 and 
4.72 of 10 and 200 pM respectively (Figure 83).
202
 These show high levels of 
leukocyte migration inhibition, therefore for comparison leukocyte migration data is 
required for the compounds synthesised herein. However the insolubility of these 
compounds as shown in particular by the hexyl and octyl compounds may pose a 
problem in the leukocyte migration assay and suggest these compounds would not be 
suitable drug candidates.  
 
Figure 83 Compounds 3.14, 3.28 and 4.69-4.72 (leukocyte migration inhibition shown in brackets, 
data from Dr Jill Reckless, University of Cambridge) 
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Chapter 5 - Conclusions 
The results obtained indicate a split binding site model for SSTR2. It has been 
concluded that BSCIs exert their action through SSTR2 because a large number of 
them have been shown to displace somatostatin, the endogenous ligand, from 
binding.
51
 Likewise a large number of BSCIs do not displace somatostatin but 
strongly inhibit leukocyte migration.
46-48
 It is therefore evident that to be good BSCIs 
the compounds do not need to displace somatostatin from its binding site on SSTR2, 
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and therefore they may not bind in exactly the same binding site as somatostatin. 
BSCIs with long chains substituted at the 2-position are more potent competitive 
ligands for SSTR2. BSCIs with long unsubstituted chains do not displace 
somatostatin which means the side chains of certain compounds are in such a 
conformation that they do not block somatostatin binding. From this it can be 
concluded that the binding site for the lactam is close and perhaps partially 
overlapping to the binding site of somatostatin. In a similar fashion BSCIs lacking a 
large side chain are too able to bind without blocking somatostatin. The compounds 
in Chapter 2 displayed a correlation between high somatostatin displacement and 
high BSCI activity. These were  the compounds structurally based on known SSTR2 
ligands therefore high SSTR2 binding was expected, evidently the tight binding of 
those compounds allowed the BSCI activity to be stimulated also. 
It was initially thought that, like somatostatin, the KWF mimic ligands bound to the 
orthosteric binding site of SSTR2 resulting in affects such as cAMP and growth 
hormone regulation (Figure 84). Somatostatin shows only approximately 50 % 
maximal effect in the leukocyte migration inhibition assay. It is was expected the 
KWF mimics would also show low BSCI activity. It was expected likewise that 
BSCIs bound to an adjacent allosteric site have the potential to block the orthosteric 
site preventing somatostatin from binding. 
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Figure 84 The predicted binding patterns different ligands at SSTR2, a) KWF ligands bind at an 
orthosteric site, b) lactams at an adjacent allosteric site and either displace somatostatin, or c) bind 
alongside somatostatin. 
 
This study has revealed that an anti-inflammatory affect can be exerted through both 
the orthosteric and allosteric binding site. The KWF mimic compound 2.51 binds 
with a similar affinity to SSTR2 as somatostatin, however like the other KWF 
mimics is a much more potent BSCI, which is exerted though the orthosteric site. 
Somatostatin is a weak BSCI. Therefore it is concluded that although the binding 
patterns seems to be the same as shown in Figure 84 certain ligands are able to exert 
an anti-inflammatory response through the orthosteric site. SSTR2 is functionally 
selectivity as the KWF mimics, somatostatin and acylaminolactams are producing 
different cellular responses. The allosteric part of the binding site is the area in which 
the lactams bind which again causes an anti-inflammatory response, which, in the 
case of a number of molecules, is much more potent than somatostatin (Figure 85). 
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Figure 85 Split binding site model for SSTR2 
 
Intracellular effects are caused by the protein-protein interactions of the receptor-
ligand complex and intracellular proteins. Different ligands result in different 
receptor-ligand conformations, thus different intracellular protein-protein 
interactions therefore different intracellular responses. It is possible that the anti-
inflammatory affect exerted by small acylaminolactams and KWF mimics require a 
more sterically crowded receptor-ligand complex. The much larger size of 
somatostatin may preclude this "BSCI" conformation inhibiting full anti-
inflammatory activity. 
The most important aspect regarding the future work of BSCIs would be to prove 
that they bind to SSTR2 by the synthesis of a fluorescently or radio labelled ligand. 
This would enable information to be directly gained on the binding affinity of the 
compounds and information on inhibitors, as well as giving a clearer picture of the 
mechanism of which they act through. Due to the selection of a clinical candidate 
FX125L which has performed well on Phase I clinical trials, new small molecules 
are not required for drug development. The compounds synthesised herein have 
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shown similar BSCI activity to the current clinical candidate and other factors such 
as metabolic stability and ease of synthesis have supported its choice. 
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Chapter 6 - Experimental  
6.1 General Experimental 
All experiments were carried out in fume hoods, adhering to general laboratory 
safety protocols and risk assessments (COSHH). Reagents and chemicals were 
purchased from Sigma Aldrich, Lancaster, TCI, Alfa Aesar or Bachem and used 
without further purification. pH 2 buffer was made with a 0.75 M solution of NaSO4 
and a 0.25 M solution of H2SO4. 
1
H-NMR and 
13
C-NMR spectra were recorded on a Bruker Avance DRX 400 MHz 
fourier transform machine at room temperature (298 K) unless otherwise stated. 
Chemical shifts are quoted in parts per million downfield of tetramethylsilane. 
Solvents were used as an internal standard when assigning NMR spectra (δH: CDCl3 
7.26 ppm, CD3OD 3.31 ppm, d
6
-DMSO 2.50 ppm, D2O 4.79 ppm; δC: CDCl3 77.1 
ppm, CD3OD 49.0 ppm, d
6
-DMSO 39.5 ppm. Coupling constants, J, are given in Hz 
to the nearest 0.5. 
13
C-NMR spectra were recorded with broadband proton 
decoupling and spectra assigned on the basis of pendant, 3D COSY and HMQC 
spectra. Infra-red spectra were recorded on a Avatar 320. [α]D values were recorded 
on an optical activity AA 1000 polarimeter set at 598 nm (sodium D line) and units 
are 10
-1 
deg cm
2
 g
-1
. The samples were made to C = 1 ≡ 10 mg/mL using 
spectroscopic grade MeOH or chloroform. ESI mass spectra were obtained on a 
Bruker Esquire 2000 mass spectrometer coupled with an Agilent 1100 HPLC 
(without a column) as the delivery system. Accurate mass spectra were obtained 
using a Bruker micro-TOF ESI attached to a time of flight (TOF) analyser, CHN 
elemental analyses were carried out by Warwick Analytical Services. Thin Layer 
Chromatography (TLC) was performed using silica (0.25 mm) coated alumina 
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plates. Melting points were determined using a Stuart SMP10 melting point machine. 
The optical purity was measured by HPLC analysis using a Varian Prostar 335 
Photodiode Array Detector, using a Varian Prostar Solvent Delivery Module and a 
Varian Prostar 420 Autosampler. The e.e.s were determined using a CHIRALPAK 
AS column (4.6 mm × 250 mm) (n-hexane/propan-2-ol = 1:1; flow rate, 0.5 mL/min, 
λ = 207 nm). 
6.2 Chapter 2 Experimental 
6.2.1 Potential SSTR2 ligands - Non-Lactam Containing Compounds 
2.10, N-meta-Toluenesulfonyl isonipecotic acid 
Isonipecotic acid (1.30 g, 10.1 mmol) was dissolved in H2O (30 mL) and THF (30 
mL). meta-Toluenesulfonylchloride (1.45 mL, 10.0 mmol) and triethylamine (4.2 
mL, 30 mmol) were added and the reaction was stirred on ice overnight. The organic 
solvents were removed in vacuo and the reaction acidified with 4M H2SO4 to pH 2. 
The product was extracted with ethyl acetate, dried over Na2CO3 and reduced in 
vacuo. The product was purified by recrystallisation from hot ethyl acetate to give 
compound 2.10 as a white solid (2.16 g, 76 %); mp 146-147 °C; υmax/cm
-1
: 2882 
(saturated C-H), 1697 (C=O) and 1333, 1151 (SO2); Anal. (C13H17NO4S requires: C; 
55.11, H; 6.05, N; 4.94) found: C; 54.39, H; 6.05, N; 4.94; δH (300 MHz, CDCl3) 
10.30 (br.s, 1H, OH), 7.55-7.51 (m, 2H, CH-CH-CCH3 and CH-C-CH3,), 7.40-7.38 
(m, 2H, CH-CSO2), 3.65 (td, 2H, J 12, 3.5, equatorial CH2-N), 2.43 (qd, 2H, J 11.5, 
3, axial CH2-N), 2.42 (s, 3H, CH3), 2.27 (tt, 1H, J 10.5, 4, CH-COOH), 1.98 (dd, 2H, 
J 13, 3.5, equatorial CH2-CH2N) and 1.80 (qd, 2H, J 12, 4, axial CH2-CH2-N); δC (75 
MHz, CDCl3) 179.3 (C=O), 138.7 (C-CH3), 135.2 (C-SO2), 133.1 (CH-C-CH3), 
128.3 (CH-CHCCH3), 127.3 (CH-SO2), 124.2 (CH-CHCHCCH3), 45.8 (CH2-N), 
150 
 
39.2 (CH-COOH), 26.6 (CH2-CH2N) and 20.8 (CH3); ESI m/z 100 %, 284.1 (MH
+
) 
and 24 %, 306.2 (MNa
+
). 
 2.11, N-para-Toluenesulfonyl isonipecotic acid 
Isonipecotic acid (0.71 g, 5.5 mmol) was dissolved in H2O (25 mL) and THF (25 
mL). para-Toluenesulfonylchloride (0.99 g, 5.2 mmol) and triethylamine (2.1 mL, 
15 mmol) were added and the reaction was stirred on ice overnight. The THF was 
removed in vacuo and the reaction acidified with 4M H2SO4 to pH 2. The product 
was extracted with ethyl acetate, dried over Na2CO3 and reduced in vacuo to give 
compound 2.11 as a white solid (1.19 g, 84 %); mp 165-167 ºC (Lit. 169-170 °); 
υmax/cm
-1
: 2871 (saturated C-H) 1696 (C=O) and 1331, 1157 (SO2); Anal. 
(C13H17NO4S requires: C; 55.11, H; 6.05, N; 4.94) found: C; 55.12, H; 6.04, N; 5.02; 
δH (400 MHz, CDCl3) 7.63 (d, 2H, J 8, CH-CSO2), 7.32 (d, 2H, J 8, CH-CCH3), 3.64 
(dt, 2H, J 12, 3, equatorial CH2-N), 2.05 (s, 3H, CH3), 2.14-2.01 (m, 2H, axial CH2-
N), 1.89 (tt, 1H, J 4, 2.5, CH-COOH), 1.56 (dq, 2H, J 12, 3, equatorial CH2-CH-
COOH) and 1.42 (qd, 2H, J 11, 4, axial CH2-CH-COOH); δC (100 MHz, CDCl3) 
180.2 (C=O), 143.9 (C-CH3), 133.3(C-SO2), 129.9 (CH-CCH3), 127.9 (CH-CSO2), 
45.6 (CH2-N), 40.1 (CH-COOH), 27.5 (CH2-CH-COOH) and 21.8 (CH3); HR ESI 
m/z (C13H17NO4SNa
+
 requires 306.0770) found 306.0761. Data is consistent with 
previously reported data for this compound.
231
  
2.12, N-Benzoyl isonipecotic acid 
Isonipecotic acid (1.29 g, 9.99 mmol) was dissolved in H2O (50 mL) and THF (50 
mL). Benzoyl chloride (1.2 mL, 10 mmol) and triethylamine (4.2 mL, 30 mmol) 
were added and the reaction was stirred on ice overnight. The THF was removed in 
vacuo and the reaction acidified with 4M H2SO4 to pH 2. The product was extracted 
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with ethyl acetate, and dried over Na2SO4 and reduced in vacuo to give compound 
2.12 as a white solid (1.57 g, 67 %); mp 129-130 ºC; υmax/cm
-1
: 2923 (saturated C-
H), 2858 (O-H), 1730 (acid C=O) and 1612 (amide C=O); Anal. (Calcd for 
C13H15NO3.1/17 H2O: C, 66.63; H, 6.50; N, 5.98) Found: C, 66.61; H, 6.50; N, 5.90; 
δH (400 MHz, CDCl3) 11.06 (s, 1H, OH), 7.28-7.16 (m, 5H, phenyl), 4.48 (br.s, 1H, 
equatorial CH2-NCO), 3.71 (br.s, 1H, equatorial CH2-NCO), 3.16 (br.t, 2H, axial 
CH2-NCO), 2.58 (tt, 1H, J 4, 2.5, CH-COOH) and 1.88-1.37 (m, 4H, axial and 
equatorial CH2-CH-COOH); δC (100 MHz, CDCl3) 178.5 (C=O acid), 170.9 (C=O-
amide), 135.5 (i-phenyl CH), 129.8 (p-phenyl CH), 128.5 (m-phenyl CH), 126.9 (o-
phenyl), 47.6 (CH2-NCO), 41.6 (CH2-NCO), 40.6 (CH-COOH), 28.5 (CH2-CH-
COOH) and 27.5 (CH2-CH-COOH); HR ESI m/z (C13H15NO3Na
+
 requires 256.0944) 
found 256.0946. Data is consistent with previously reported data for this 
compound.
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2.04, N-(2-(1H-Indol-3-yl)ethyl)-1-(meta-tolylsulfonyl)piperidine-4-carboxamide 
Acid 2.10 (1.81 g, 3.39 mmol) was dissolved in dichloromethane (40 mL) and 
cooled to 0° C. HATU (2.53 g, 6.65 mmol) was added and the mixture was stirred 
for 10 minutes. Tryptamine (1.05 g, 6.55 mmol) and triethylamine (2.7 mL, 19 
mmol) were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo, the product was dissolved in ethyl acetate and washed with a pH 
2 buffer (3 × 10 mL) and ½ saturated NaHCO3 (3 × 10 mL). The organic layer was 
dried over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:70:30) to give 
compound 2.04 as a white solid (0.87 g, 32 %); mp 142-143 º C; υmax/cm
-1
: 3390 (N-
H), 2924 (saturated C-H), 1655 (C=O amide), 1556 (aromatic) and 1330, 1156 
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(SO2); δH (400 MHz, CDCl3) 8.19 (br.s, 1H, indole NH), 7.57-7.50 (m, 3H, indole 
CH-C-C, CH-CSO2 and CH-CHCHCCH3), 7.40-7.34 (m, 3H, indole CH-C-NH, CH-
CHCCH3 and CH-CCH3), 7.19 (t, 1H, J 7.5, indole CH-CH-C), 7.09 (t, 1H, J 7.5, 
indole CH-CH-C-C), 6.97 (d, 1H, J 2, indole CH-NH), 5.54 (t, 1H, J 5.5, NH-CH2), 
3.71 (dt, 2H, J 12, 3.5, equatorial CH2-N), 3.55 (q, 2H, J 6.5, CH2-CH2-indole), 2.93 
(t, 2H, J 6.5, CH2-indole), 2.41 (s, 3H, CH3), 2.30 (td, 2H, J 11.5, 3.5, axial CH2-N), 
1.91 (tt, 1H, J 11.5, 4, CH-CO) and 1.81 (m, 4H, CH2-CH2N); δC (100 MHz, CDCl3) 
173.9 (C=O), 139.4 (C-CH3), 136.5 (indole C-NH), 135.9 (C-SO2), 133.72 (CH-
CCH3), 129.0 (CH-CHCCH3), 127.9 (CH-CHCHCCH3), 127.3 (indole C-CNH), 
124.8 (CH-CSO2), 122.2 (indole CH-NH), 122.1 (indole CH-CH-C-C), 119.4 (indole 
CH-CH-C), 118.6 (indole CH-C-C), 112.6 (indole C-CH2), 111.4 (indole CH-C-
NH), 45.6 (CH2-N), 42.0 (CH-CONH), 39.8 (CH2-NH), 28.1 (CH2-CH2N), 25.1 
(CH2-indole), and 21.4 (CH3); ESI m/z 100 %, 448.1 (MNa
+
).  
2.13, N-(2-(1H-Indol-3-yl)ethyl)-1-tosylpiperidine-4-carboxamide 
Acid 2.11 (0.60 g, 2.1 mmol) was dissolved in dichloromethane (20 mL) and cooled 
to 0° C. HATU (0.76 g, 2.0 mmol) was added and the mixture was stirred for 10 
minutes. Tryptamine (0.33 g, 2.1 mmol) and triethylamine (0.8 mL, 6 mmol) were 
added and the reaction was stirred over night. The dichloromethane was removed in 
vacuo, the product was dissolved in ethyl acetate and washed with a pH 2 buffer (3 × 
10 mL) and ½ saturated NaHCO3 (3 × 10 mL). The organic layer was dried over 
Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:70:30) to give 
compound 2.13 as a white solid (0.42 g, 48 %); mp 186-188 º C; υmax/cm
-1
: 3384 (N-
H), 2928 (saturated C-H), 1633 (C=O amide), 1559 (aromatic), and 1329, 1160 
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(SO2); δH (400 MHz, d
6
-DMSO) 10.77 (s, 1H, NH indole), 7.80 (t, 1H, J 6, NH-
CH2), 7.62 (d, 2H, J 8, CH-C-SO2), 7.50 (d, 1H, J 7.5, indole CH-C-C), 7.44 (d, 2H, 
J 8, CH-C-CH3), 7.32 (d, 1H, J 8, indole CH-C-NH), 7.10 (d, 1H, J 2, indole CH-
NH), 7.05 (t, 1H, J 7.5, indole CH-CH-C), 6.96 (t, 1H, J 7.5, indole CH-CH-C-C), 
3.56 (br.d, 2H, J 12, equatorial CH2-N), 3.28 (q, 2H, J 7, CH2-CH2-indole), 2.77 (t, 
2H, J 7.5, CH2-indole), 2.40 (s, 3H, CH3), 2.24 (td, 2H, J 11.5, 2.5, axial CH2-N), 
2.05 (tt, 1H, J 11.5, 4, CH-CCO), 1.72 (dd, 2H, J 14, 3, equatorial CH2-CH2N), and 
1.55 (qd, 2H, J 12.5, 4, axial CH2-CH2N); δC (100 MHz, d
6
-DMSO) 173.3 (C=O), 
143.4 (C-CH3), 136.2 (C-NH), 132.6 (C-SO2), 129.8 (CH-C-CH3), 127.4 (CH-C-
SO2), 127.2 (indole C-C-NH), 122.6 (CH-NH), 120.9 (CH-CH-C-C), 118.2 (CH-C-
C), 118.2 (CH-CH-C), 111.7 (C-CH2), 111.3 (CH-C-NH), 45.3 (CH2-N), 40.4 (CH-
CONH), 39.4 (CH2-NH), 27.7 (CH2-CH2N), 25.1 (CH2-indole) and 21.5 (CH3); ESI 
m/z 100 %, 448.2 (MNa
+
) and 5 %, 426.2 (MH
+
); HR ESI m/z (C23H27N3O3SNa
+
 
requires 448.1665) found 448.1677. 
2.14, N-(2-(1H-Indol-3-yl)ethyl)-1-benzoylpiperidine-4-carboxamide 
Acid 2.12 (0.93 g, 3.4 mmol) was dissolved in dichloromethane (30 mL) and cooled 
to 0° C. HATU (1.57 g, 4.13 mmol) was added and the mixture was stirred for 30 
minutes. Tryptamine (0.64 g, 3.4 mmol) and triethylamine (1.7 mL, 12 mmol) were 
added and the reaction was stirred for 48 hours. The dichloromethane was removed 
in vacuo, the product was dissolved in ethyl acetate and washed with a pH 2 buffer 
(3 × 10 mL) and ½ saturated NaHCO3 (3 × 10 mL). The organic layer was dried over 
Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (ethyl acetate:MeOH 100:0 to 70:30) to give compound 2.14 as a 
white solid (0.72 g, 48 %); mp 183-185 °C; υmax/cm
-1
: 3278 (N-H), 2919 (saturated 
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C-H), 1652 (C=O amide) and 1599 (aromatic); δH (400 MHz, d
6
-DMSO) 10.42 (s, 
1H, NH indole), 7.54 (d, 1H, J 8, indole CH-C-C), 7.45-7.41 (m, 3H, phenyl m-CH 
and p-CH), 7.38-7.33 (m, 3H, indole CH-C-NH and phenyl o-CH), 7.09 (s, 1H, 
indole CH-NH), 7.06 (t, 1H, J 8, indole CH-CH-C), 6.98 (t, 1H, J 7.5, indole CH-
CH-C-C), 3.99 (br.d, 2H, J 11, equatorial CH2-N), 3.41 (q, 2H, J 6.5, CH2-NH), 2.98 
(td, 2H, J 12, 3, axial CH2-N), 2.88 (t, 2H, J 7, CH2-indole), 2.41 (tt, 1H, J 13.5, 4, 
CH-CO), 1.73 (dd, 2H, J 13, 3, equatorial CH2-CH2N) and 1.57 (qd, 2H, J 11.5, 4, 
axial CH2-CH2N); δC (100 MHz, d-DMSO) 173.6, 169.0 (C=O), 136.3 & 136.2 (C6 
& C12), 129.3 (C11), 128.4 (C10), 127.3 (C7), 126.6 (C9), 122.6 (C1), 120.8 (C4), 
118.2 (C5), 118.16 (C3), 111.8 (C8), 111.3 (C2), 41.8 (CH pip), 40.1 (CH2-N), 39.1 
(CH2-NH), 30.0, 28.3 (CH2-CH2-N) and 25.2 (CH2-indole); ESI m/z 100 %, 398.2 
(MNa
+
) and 9 %, 376.3 MH
+
); HR ESI m/z (C23H25N3O2Na
+
 requires 398.1839) 
found 398.1836. 
2.15, N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide 
4-Biphenyl carboxylic acid (0.93 g, 4.7 mmol) was dissolved in dichloromethane (40 
mL) and cooled to 0° C. HATU (1.83 g, 4.81 mmol) was added and the mixture was 
stirred for 4 hours. Tryptamine (0.68 g, 4.2 mmol) and triethylamine (2 mL, 14 
mmol) were added and the reaction was stirred for 48 hours. The dichloromethane 
was removed in vacuo, the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 mL). The organic layer 
was dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:70:30) to 
give compound 2.15 as a beige solid (0.88 g, 55 %); mp 171-173 °C; υmax/cm
-1
: 3422 
(N-H), 1618 (C=O amide) and 1538 (aromatic); δH (400 MHz, d
6
-DMSO) 10.82 (s, 
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1H, NH indole), 8.67 (t, 1H, J 6, NH-CH2), 7.97 (d, 2H, J 8.5, biphenyl CH-C-CO), 
7.76 (d, 2H, J 8.5, biphenyl CH-C-phenyl), 7.73 (d, 2H, J 8, biphenyl CH-C-aryl), 
7.61 (d, 1H, J 8, indole CH-C-C), 7.49 (t, 1H, J 8, biphenyl CH-CH-C-aryl), 7.40 (t, 
1H, J 7.5, biphenyl CH-CH-CH-C-aryl), 7.36 (d, 1H, J 8, indole CH-C-NH), 7.20 (d, 
1H, J 2, indole CH-NH), 7.08 (t, 1H, J 7.5, indole CH-CH-C), 6.99 (t, 1H, J 7.5, 
indole CH-CH-C-C), 3.59 (q, 2H, J 7, CH2-CH2-indole) and 2.99 (t, 2H, J 7.5, CH2-
indole); δC (100 MHz, d-DMSO) 165.8 (C=O), 142.6, 139.2 (biphenyl C-aryl), 136.3 
(indole C-NH), 133.5 (biphenyl C-CO), 129.0 (biphenyl CH-CH-C-aryl), 128.0 
(biphenyl CH-C-CO), 127.8 (biphenyl CH-C-phenyl), 127.3 (indole C-C-NH), 126.8 
(biphenyl CH-C-aryl), 126.4 (biphenyl CH-CH-CH-C-aryl), 122.6 (indole CH-NH), 
120.9 (indole CH-CH-C-C), 118.3 (indole CH-C-C), 118.2 (indole CH-CH-C), 111.9 
(indole C-CH2), 111.4 (indole CH-C-NH), 40.2 (CH2-NH), 25.2 (CH2-indole); ESI 
m/z 100 %, 340.3 (MH
+
) and 17 %, 363.1 (MNa
+
); HR ESI m/z (C23H20N2ONa
+ 
requires 363.1468) found 363.1465. NMR data is consistent with previously reported 
data for this compound.
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2.16, Boc-D-tryptophan 
D-Tryptophan (2.04 g, 9.99 mmol) was dissolved in THF (20 mL), H2O (20 mL) and 
cooled to 0 ºC. Di-tert-butyl-dicarbonate (2.18 g, 9.99 mmol) and triethylamine (2.8 
mL, 20 mmol) were added and the reaction was stirred for 12 hours. The THF was 
removed in vacuo; ethyl acetate (30 mL) was added and the organic layer was 
separated and washed with pH 2 buffer (3 × 25 mL). The organic layer was then 
dried over Na2SO4 and reduced in vacuo, purified by re-crystallisation with ethyl 
acetate and petroleum ether to give compound 2.16 as a white solid (0.39 g, 13 %); 
mp 133-135 ºC (Lit. 135-136 °); [α]25D  (c = 1.08, acetic acid) + 19.12 (Lit. -18.2 for 
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L enantiomer); υmax/cm
-1
: 3373 (N-H), 2979 (O-H), 1719, 1702 (C=O), 1702 and 
1246 (C-O); δH (400 MHz, d6-DMSO) 12.53 (1H, br.s, OH), 10.82 (s, 1H, NH 
indole), 7.50 (d, 1H, J 8, indole CH-C-C), 7.34 (d, 1H, J 8, indole CH-C-NH), 7.15 
(d, 1H, J 4, NH-COO), 7.06 (t, 1H, J 7.5, indole CH-CH-C-NH), 6.98 (t, 1H, J 7.5, 
indole CH-CH-C-C), 6.95 (s, 1H, indole CH-NH), 4.15 (td, 1H, J 9, 4, CH-CH2-
indole), 3.13 (dd, 1H, J 14, 4 CH2-indole), 2.98 (dd, 1H, J 14, 10, CH2-indole) and 
1.33 (s, 9H, C(CH3)3); δC (100 MHz, d6-DMSO) 173.9 (C=O acid), 155.4 (C=O 
carbamate), 136.0 (indole C-NH), 127.2 (indole C-C-NH), 123.6 (indole CH-NH), 
120.9 (indole CH-CH-C), 118.3 (indole CH-C-C), 118.1 (indole CH-CH-C-C), 111.4 
(indole CH-C-NH), 110.2 (indole C-CH2), 78.0 (C(CH3)3), 54.5 (CH-CH2-indole), 
28.2 (C(CH3)3) and 26.8(CH2-indole); ESI m/z 100 %, 327.1 (MNa
+
).  Data is 
consistent with previously reported data for this compound.
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2.22, (R)-tert-Butyl-3-(1H-indol-3-yl)-1-oxo-1-(propylamino)propan-                   
2-ylcarbamate 
Acid 2.16 (3.40 g, 11.2 mmol) was dissolved in dichloromethane (100 mL) and 
cooled to 0°C. HATU (4.10 g, 10.8 mmol) was added and the mixture was stirred for 
4 hours. Proplyamine (0.90 mL, 11 mmol) and triethylamine (4.70 mL, 33.6 mmol) 
were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo, the product dissolved in ethyl acetate and washed with a pH 2 
buffer (3 × 25 mL), 0.1 M HCl (3 × 25 mL) and ½ saturated NaHCO3 (3 × 25 mL). 
The organic solvents were removed in vacuo. The product was purified by 
recrystallisation from ethyl acetate and petroleum ether to give compound 2.22 as a 
white solid (3.04 g, 79 %); mp 133-135 º C; [α]29D (c = 0.256, MeOH) -2.73; υmax/cm
-
1
: 3329 (N-H), 2934 (saturated C-H), 1687, 1646 (C=O), and 1246 (C-O); Anal. 
Calcd for C19H27N3O3: C, 66.06; H, 7.88; N, 12.16. Found: C, 65.80; H, 7.88; N, 
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12.07; δH (600 MHz, CDCl3) 8.34 (s, 1H, indole NH), 7.66 (d, 1H, J 8, indole CH-C-
C), 7.35 (d, 1H, J 8.5, indole CH-C-NH), 7.19 (t, 1H, J 8, indole CH-CH-C), 7.12 (t, 
1H, J 7.5, indole CH-CH-C-C), 7.02 (s, 1H, indole CH-NH), 5.75 (s, 1H, NH-
CH2CH2CH3), 5.22 (s, 1H, NH-COO), 4.40 (br.s, 1H, CH-CH2-indole), 3.30 (br.d, 
1H, J 12, CH2-indole), 3.19-2.99  (m, 3H, CH2-indole and CH2-CH2-CH3), 1.42 (s, 
9H, C(CH3)3), 1.34-1.22 (m, 2H, CH2-CH3) and 0.72 (br.t, 3H, J 6.5, CH3-CH2); δC 
(150 MHz, CDCl3) 171.6 (C=O amide), 155.5 (C=O carbamate), 136.4 (indole C-
NH), 127.4 (indole C-C-NH), 123.2 (indole CH-NH), 122.5 (indole CH-CH-C-C), 
119.7 (indole CH-C-C), 118.9 (indole CH-CH-C), 111.2 (indole CH-C-NH), 110.8 
(indole C-CH2), 80.0 (C(CH3)), 55.3 (CH-CH2-indole), 41.2 (CH2-NHCO), 30.9 
(CH2-indole), 29.7 (C(CH3)) 22.5 (CH2-CH3) and 11.1 (CH3-CH2); ESI m/z 100 %, 
368.1 (MNa
+
).  
2.23, (R)-O-Benzyl N-(4-(2-tertbutylcarbonylamino)-3-(1H-indol-3-
yl)propanamido)butylcarbamate 
Acid 2.16 (0.57 g, 1.8 mmol) was dissolved in dichloromethane (20 mL) and cooled 
to 0°C. HATU (0.82 g, 2.2 mmol) was added and the mixture was stirred for 10 
minutes. N-Z,1,4-Diaminobutane.HCl (0.51 g, 1.9 mmol) and triethylamine (0.80 
mL, 5.7 mmol) were added and the reaction was stirred over night. The 
dichloromethane was removed in vacuo, the product dissolved in ethyl acetate and 
washed with a pH 2 buffer (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). The 
organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (petroleum ether:ethyl acetate, 70:30 to 50:50) to 
give compound 2.23 as a white solid (0.65 g, 67 %); mp 134-135 º C; [α]27D (c = 
0.259, MeOH) -6.11; υmax/cm
-1
: 3344 (N-H), 2978 (saturated C-H), 1680 (amide 
C=O), 1519 (aromatic) and 1239 (C-O); δH (500 MHz, CDCl3) 8.75 (s, 1H, indole 
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NH), 7.65 (d, 1H, J 7.5, indole CH-C-C), 7.38-7.28 (m, 6H, phenyl and indole CH-
C-NH), 7.16 (t, 1H, J 7.5, indole CH-CH-C-NH), 7.10 (t, 1H, J 7.5, indole CH-CH-
C-C), 6.96 (s, 1H, indole CH-NH), 5.73 (br.s, 1H, NHCbz or NHCO-CH), 5.31 (br.s, 
1H, NH-COO), 5.12 (s, 2H, CH2-phenyl),  4.96 (br.t, 1H, J 5.5, NHCbz or NHCO-
CH), 4.40 (br.s, 1H, CH-CH2- indole),  3.29 (dd, 1H, J 14, 4, CH2-indole), 3.20-2.86 
(m, 5H, CH2-indole, CH2-NH-CO and CH2-NHCbz), 1.43 (s, 9H, C(CH3)3) and 
1.22-1.08 (m, 4H, CH2-CH2-NHCbz and CH2-CH2-NHCO);  δC (125 MHz, CDCl3) 
171.7 (C=O amide), 156.7, 155.5 (C=O carbamate), 136.6 (indole C-NH), 136.3 
(phenyl C), 128.6, 128.2, 128.1 (phenyl CH), 127.3 (indole C-C-NH), 123.5 (indole 
CH-NH), 122.1 (indole CH-CH-C-C), 119.6 (indole CH-C-C), 118.8 (indole CH-
CH-C-NH), 111.4 (indole CH-C-NH), 110.4 (indole C-CH2), 80.0 (C(CH3)3), 66.8 
(CH2-phenyl), 55.4 (CH-CH2-indole), 40.7, 39.0 (CH2-NHCbz and CH2-NH-CO), 
28.9, 27.3, 26.5 (CH2-indole, CH2-CH2-NHCbz and CH2-CH2-NHCO) and 28.4 
(C(CH3)3); ESI m/z 100 %, 531.3 (MNa
+
). 
2.24, (R)-O-Benzyl N-(4-(2-tertbutylcarbonylamino)-3-(1H-indol-3-
yl)propanamido)pentylcarbamate 
Acid 2.16 (0.56 g, 1.8 mmol) was dissolved in dichloromethane (20 mL) and cooled 
to 0°C. HATU (0.69 g, 1.8 mmol) was added and the mixture was stirred for 10 
minutes. N-Z,1,5-Diaminopentane.HCl (0.50 g, 1.8 mmol) and triethylamine (0.80 
mL, 5.7 mmol) were added and the reaction was stirred over night. The 
dichloromethane was removed in vacuo, the product dissolved in ethyl acetate and 
washed with a pH 2 buffer (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). The 
organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (petroleum ether:ethyl acetate, 70:30 to 50:50) to 
give compound 2.24 as a white solid (0.56 g, 59 %); mp 114-115º C; [α]28D (c = 0.26, 
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MeOH) -7.88; υmax/cm
-1
: 3346 (N-H), 2936 (saturated C-H), 1678 (amide C=O), 
1519 (aromatic) and 1246 (C-O); Anal. Calcd for C29H38N4O5: C, 66.64; H, 7.33; N, 
10.72. Found: C, 66.35; H, 7.34; N, 10.62; δH (500 MHz, CDCl3) 9.11 (br.s, 1H, 
indole NH), 7.67 (d, 1H, J 8, indole CH-C-C), 7.39-7.29 (m, 6H, phenyl & indole 
CH-C-NH), 7.17 (t, 1H, J 7.5, indole CH-CH-C), 7.11 (t, 1H, J 7.5, indole CH-CH-
C-C), 6.98 (d, 1H, J 2, indole CH-NH), 5.62 (br.s, 1H, NHCbz or NH-CH2), 5.31 
(br.s, 1H, NH-CH), 5.13 (s, 2H, CH2-phenyl), 5.00 (br.t, 1H, J 5, NHCbz or NH-
CH2), 4.42 (br.s, 1H, CH-CH2- indole), 3.31 (dd, 1H, J 14, 4, CH2-indole), 3.17-3.02 
(m, 4H, CH2-indole, CH2-NHCO and CH2-NHCbz), 2.99-2.88 (m, 1H, CH2-NHCO 
or CH2-NHCbz), 1.44 (s, 9H, C(CH3)3) 3.35 (quin., 2H, J 7, CH2-CH2-NH or CH2-
CH2-NHCbz), 1.22-1.11 (m, 2H, CH2-CH2-NH or CH2-CH2-NHCbz) and 1.00-0.83 
(m, 2H, CH2-CH2CH2NHCbz); δC (125 MHz, CDCl3) 171.7 (C=O amide), 156.8, 
155.5 (C=O carbamate), 136.6 (indole C-NH), 136.4 (phenyl C), 128.6, 128.2, 
128.16 (phenyl CH), 127.3 (indole C-C-NH), 123.5 (indole CH-NH), 122.0 (indole 
CH-CH-C-C), 119.6 (indole CH-C-C), 118.8 (indole CH-CH-C), 111.5 (indole CH-
C-NH), 110.3 (indole C-CH2), 80.0 (C(CH3)3), 66.8 (CH2-phenyl), 55.3 (CH-CH2-
indole), 40.9, 39.0 (CH2-NHCO and CH2-NHCbz), 29.7, 29.0, 28.8, 23.5 (CH2-
indole, CH2-CH2-NH, CH2-CH2-NHCbz and CH2-CH2CH2NHCbz) and 28.4 
(C(CH3)3); ESI m/z 100 %, 545.3 (MNa
+
). 
2.25, (R)-O-Benzyl N-(4-(2-tertbutylcarbonylamino)-3-(1H-indol-3-
yl)propanamido)hexylcarbamate 
Acid 2.16 (0.53 g, 1.7 mmol) was dissolved in dichloromethane (15 mL) and cooled 
to 0°C. HATU (0.66 g, 1.7 mmol) was added and the mixture was stirred for 10 
minutes. N-Z,1,6-Diaminohexane.HCl (0.50 g, 1.7 mmol) and triethylamine (0.7 mL, 
5 mmol) were added and the reaction was stirred over night. The dichloromethane 
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was removed in vacuo, the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). The organic layer 
was dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate, 70:30 to 40:60) to give 
compound 2.25 as a white solid (0.09 g, 10 %); mp 54-57 º C; [α]27D (c = 0.502, 
MeOH) -2.59; υmax/cm
-1
: 3308 (N-H), 2932 (saturated C-H), 1694 (amide C=O), 
1657 (aromatic) and 1247 (C-O); δH (500 MHz, CDCl3) 8.92 (br.s, 1H, NH), 7.66 (d, 
1H, J 7.5, indole CH-C-C), 7.38-7.29 (m, 6H, indole CH-C-NH and phenyl), 7.17 (t, 
1H, J 7, indole CH-CH-C), 7.10 (t, 1H, J 7.5, indole CH-CH-C-C), 7.01 (s, 1H, 
indole CH-NH), 5.64 (br.s, 1H, NH-Cbz or NH-CO), 5.30 (br.s, 1H, NH-CH), 5.13 
(s, 2H, CH2-phenyl), 4.97 (br.s, 1H, NH-Cbz or NH-CO), 4.42 (br.s, 1H, CH-CH2- 
indole),  3.31 (br.d, 1H, J 14, CH2-indole), 3.17-3.05 (m, 3H, CH2-indole, CH2-NH-
CO and CH2-NHCbz), 3.03-2.95 (m, 1H, CH2-NH-CO or CH2-NHCbz), 1.89 (br.d, 
1H, J 12, CH2-NH-CO or CH2-NHCbz), 1.44 (s, 9H, C(CH3)3) 1.48-1.36 (m, 3H, 
CH2-CH2NHCO, CH2-CH2CH2NHCbz or CH2-CH2NHCbz), 1.22-1.12 (m, 3H, CH2-
CH2NHCO, CH2-CH2CH2NHCbz or CH2-CH2NHCbz) and 1.04-0.93 (m, 2H, CH2-
CH2CH2NHCO); δC (125 MHz, CDCl3) 171.6 (C=O amide), 156.7, 155.5 (C=O 
carbamate), 136.6 (indole C-NH), 136.4 (phenyl C), 128.6, 128.2, 128.1 (phenyl), 
127.4 (indole C-C-NH), 123.3 (indole CH-NH), 122.1 (indole CH-CH-C-C), 119.6 
(indole CH-C-C), 118.8 (indole CH-CH-C), 111.4 (indole CH-C-NH), 110.4 (indole 
C-CH2), 80.0 (C(CH3)3), 66.8 (CH2-phenyl), 55.4 (CH-CH2-indole), 40.9, 39.1 (CH2-
NH-CO or CH2-NHCbz), 29.7, 28.9, 28.8, 26.0, (CH2-indole, CH2-CH2NHCO, CH2-
CH2CH2NHCbz and CH2-CH2NHCbz), 25.8 (CH2-CH2CH2NHCO) and 28.4 
(C(CH3)3); ESI m/z 100 %, 559.3 (MNa
+
).  
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2.26, (S)-tert-Butyl-6-(benzyloxycarbonylamino)-2-((R)-2-(tert-
butoxycarbonylamino)-3-(1H-indol-3-yl)propanamido)hexanoate 
Acid 2.16 (0.30 g, 0.99 mmol) was dissolved in dichloromethane (10 mL) and 
cooled to 0°C. HATU (0.38 g, 0.99 mmol) was added and the mixture was stirred for 
10 minutes. H-Lysine(Z)-O
t
Bu.HCl (0.37 g, 1.0 mmol) and triethylamine (0.4 mL, 3 
mmol) were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo, the product was dissolved in ethyl acetate and washed with a pH 
2 buffer (3 × 25 mL) and ½ saturated NaHCO3 (3 × 25 mL). The organic layer was 
dried over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate, 90:10 to 50:50) to give compound 
2.26 as a white solid (0.33 g, 52 %). The reaction was repeated on a scale of 5 mmol 
(2.61 g, 91 %); mp 131-132 °C; [α]27D (c = 0.0503, MeOH) -12.97; Anal. Calcd for 
C34H46N4O7: C, 65.57; H, 7.45; N, 9.00. Found: C, 65.51; H, 7.47; N, 8.93; υmax/cm
-
1
: 3310 (N-H), 2948 (saturated C-H), 1700 (C=O) and 1661 (amide C=O); δH (400 
MHz, d6-DMSO) 10.79 (s, 1H, indole NH), 8.11 (d, 1H, J 7.5, NH-CH-COO
t
Bu), 
7.59 (d, 1H, J 8, indole CH-C-C), 7.37-7.31 (m, 6H, phenyl & indole CH-C-NH), 
7.21 (t, 1H, J 5, NH-Cbz), 7.13 (s, 1H, indole CH-NH), 7.05 (t, 1H, J 7, indole CH-
CH-C), 6.96 (t, 1H, J 7.5, indole CH-CH-C-C), 6.71 (d, 1H, J 8, NH-CH-CH2), 4.98 
(s, 2H, CH2-phenyl), 4.26 (td, 1H, J 8, 5, CH-CH2- indole), 4.02 (q, 1H, J 8, CH-
COO
t
Bu), 3.04 (dd, 1H, J 9, 4, CH2-indole), 2.98-2.91 (m, 2H, CH2-NHCbz), 2.89 
(dd, 1H, J 8.5, 4, CH2-indole), 1.57-1.64 (m,1H, CH2 in (CH2)4 chain), 1.56-1.50 (m, 
1H, CH2 in (CH2)4 chain), 1.49-1.24 (m, 4H, CH2 in (CH2)4 chain), 1.39 (s, 9H, 
CHCOOC(CH3)3) and 1.31 (s, 9H, NHCOOC(CH3)3); δC (100 MHz, d6-DMSO) 
172.0, 171.2 (C=O ester and amide) 156.0, 155.0 (C=O carbamate), 137.2 (indole C-
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NH), 136.0 (phenyl C), 128.3, 127.7 (phenyl CH), 127.4 (indole C-C-NH), 123.6 
(indole CH-NH), 120.8 (indole CH-CH-C-C), 118.5 (indole CH-C-C), 118.0 (indole 
CH-CH-C), 111.2 (indole CH-C-NH), 110.1 (indole C-CH2), 80.5, 
(CHCOOC(CH3)3), 77.9 (NHCOOC(CH3)3), 65.1 (CH2-phenyl), 54.9 (CH-
NHCOO), 52.6 (CH-COO
t
Bu), 40.1 (CH2–indole), 38.9 (CH2-NHCbz), 30.8, 28.9, 
22.3 (CH2 from CH2)4 chain), 28.1 (NHCOOC(CH3)3) and 27.4 (CHCOOC(CH3)3); 
HR ESI m/z (C34H46N4O7H
+ 
requires 623.3439) found 623.3457. 
2.27, (R)-2-Amino-3-(1H-indol-3-yl)-N-propylpropanamide 
Compound 2.22 (3.04 g, 8.80 mmol) was dissolved in MeOH (50 mL), methane 
sulfonic acid (1.70 mL, 26.4 mmol) was added and the reaction was stirred for 20 
hours and determined to be completed by TLC. The reaction was quenched with 
triethylamine (6.1 mL, 44 mmol) and reduced in vacuo to give compound 2.27 as a 
colourless oil which was not isolated. This compound has previously been reported 
but with no characterisation data.
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2.28, (R)-O-Benzyl N-(4-(2-amino)-3-(1H-indol-3-yl)propanamido) 
butylcarbamate 
Carbamate 2.23 (0.31 g, 0.61 mmol) was dissolved in MeOH (15 mL), methane 
sulfonic acid (145 μL, 1.83 mmol) was added and the reaction was stirred for 48 
hours and determined to be completed by TLC. The reaction was quenched with 
triethylamine (0.5 mL, 3 mmol) and reduced in vacuo to give compound compound 
2.28 as a colourless oil which was not isolated. 
2.29, (R)-O-Benzyl N-(5-(2-amino)-3-(1H-indol-3-yl)propanamido) 
pentylcarbamate 
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Carbamate 2.24 (0.3 g, 0.5 mmol) was dissolved in MeOH (3 mL), methane sulfonic 
acid (97 μL, 1.5 mmol) was added and the reaction was stirred for 24 hours and 
determined to be completed by TLC. The reaction was quenched with triethylamine 
(0.35 mL, 2.5 mmol) and reduced in vacuo to give compound 2.29 as a colourless oil 
which was not isolated. 
2.30, (R)-O-Benzyl N-(6-(2-amino)-3-(1H-indol-3-yl)propanamido) 
hexylcarbamate 
Carbamate 2.25 (0.09 g, 0.2 mmol) was dissolved in MeOH (3 mL), methane 
sulfonic acid (42 μL, 0.75 mmol) was added and the reaction was stirred for 24 hours 
and determined to be completed by TLC. The reaction was quenched with 
triethylamine (0.18 mL, 1.3 mmol) and reduced in vacuo to give compound 2.30 as a 
colourless oil which was not isolated. 
2.31, (S)-tert-Butyl 2-((R)-2-amino-3-(1H-indol-3-yl)propanamido)-6-
(benzyloxycarbonylamino)hexanoate 
Carbamate 2.26 (4.35 g, 6.99 mmol) was dissolved in MeOH (150 mL), methane 
sulfonic acid (1.36 mL, 21.0 mmol) was added, the reaction was stirred for 72 hours 
at room temperature. The reaction was quenched with triethylamine (4.9 mL, 35 
mmol) and reduced in vacuo to give compound 2.31 as a brown oil, by 
1
H NMR 
yield was determined as 100 % as product was pure; δH (400 MHz, d6-DMSO) 10.99 
(s, 1H, NH indole), 8.55 (1H, d, J 7.5, NH-CHCOO), 7.63 (d, 1H, J 8, indole CH-C-
C), 7.40-7.27 (m, 6H, indole CH-C-NH & phenyl), 7.23 (s, 1H, indole CH-NH), 7.08 
(t, 1H, J 7.5, indole CH-CH-C), 6.99 (t, 1H, J 7.5, indole CH-CH-C-C), 4.99 (s, 2H, 
CH2-phenyl), 4.08 (q, 1H, J 8, CH-COO), 3.91 (t, 1H, J 6.5, CH-NH2), 3.19 (dd, 1H, 
J 14.5, 6.5, CH2-indole), 2.98 (dd, 1H, J 14.5, 6.5, CH2-indole), 1.41 (s, 9H, 
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C(CH3)3), 1.64-1.22 (m, 6H, CH2 of (CH2)4 chain) and 1.05-0.98 (m, 2H, CH2 of 
(CH2)4 chain); δC (100 MHz, d6-DMSO) 170.9 and 170.4 (ester and amide C=O), 
156.1 (carbamate C=O), 137.2 (indole C-NH), 136.2 (phenyl C), 128.3, 127.6 
(phenyl CH), 127.5 (indole C-C-NH), 124.6 (indole CH-NH), 120.9 (indole CH-C-
C), 118.4, 118.3 (indole CH-CH-C and CH-CH-C-C), 111.4 (indole CH-CNH), 
107.9 (indole C-CH2), 80.8 (C(CH3)3), 65.1 (CH2-phenyl), 52.5 (CH-NH2), 52.0 
(CH-COO), 45.7 (CH2-indole), 39.7 (C(CH3)3), 28.9, 28.7 (CH2-CH and CH2-
NHCbz) and 22.6, 22.25 (CH2-CH2CH and CH2-CH2NHCbz); HR ESI m/z 
(C29H38N4O5H
+
 requires 523.2915) found 523.2916. 
2.32, (R)-3-(1H-Indol-3-yl)-2-(4-methylphenylsulfonamido)-N-propyl 
propanamide 
Amine 2.27 (7 mmol) was dissolved in dichloromethane, para-toluenesulfonyl 
chloride (1.42 g, 7.45 mmol) and triethylamine (2.9 mL, 21 mmol,) were added, the 
reaction was stirred for 15 hours. The dichloromethane was removed in vacuo, the 
product dissolved in ethyl acetate and washed with a pH 2 buffer (3 × 25 mL). The 
organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (petroleum ether:ethyl acetate:MeOH, 62.5:37.5:0 
to 0:80:20) to give compound 2.32 as a white solid (0.59 g, 21 %); mp 69-71º C; 
[α]20D (c = 0.244, MeOH) 50.11; υmax/cm
-1
: 3389 (N-H), 2965 (saturated C-H), 1648 
(amide C=O) and 1322, 1156 (SO2); δH (500 MHz, CDCl3) 8.40 (s, 1H, NH indole), 
7.43 (d, 2H, J 7, CH-CSO2), 7.28 (t, 2H,  J 8, indole CH-C-NH and CH-C-C), 7.15 
(t, 1H, J 7.5, indole CH-CH-C), 7.04-7.95 (m, 3H, CH-C-CH3 and indole CH-CH-C-
C), 6.91 (s, 1H, indole CH-NH), 6.40 (t, 1H, J 5, NH-CH2CH2), 5.19 (d, 1H, J 6, 
NH-CH), 3.89 (q, 1H, J 6, CH-CH2-indole), 3.18-3.01 (m, 4H, CH2-indole and CH2-
CH2CH3), 2.31 (s, 3H, CH3-aryl), 1.36 (sextet, 1H, J 7.5, CH2-CH3) and 0.79 (t, 1H, 
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J 7.5, CH3-CH2); δC (125 MHz, CDCl3) 170.8 (C=O), 143.8 (C-CH3),  136.4 (indole 
C-NH), 135.2 (C-SO2), 129.6 (C-CCH3), 126.9 (C-CSO2), 126.8 (indole C-C-NH), 
123.4 (indole CH-NH), 122.4 (indole CH-CH-C-C), 119.8 (indole CH-C-C), 118.5 
(indole CH-CH-C), 111.3 (indole CH-C-NH), 109.3 (indole C-CH2), 57.0 (CH-CH2-
indole), 41.4 (CH2-NH), 28.6 (CH2-indole), 22.5 (CH2-CH3), 21.6 (CH3-aryl) and 
11.23 (CH3-CH2); ESI m/z 100 %, 422.2 (MNa
+
) and 50 %, 821.2 (M2Na
+
). 
2.33, (R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(propylamino)propan-2-yl)biphenyl-4-
carboxamide 
4-Biphenylcarboxylic acid (1.29 g, 6.51 mmol) was dissolved in dichloromethane 
and cooled to 0 °C. HATU (2.35 g, 6.18 mmol) was added and the reaction stirred 
for 10 minutes. Amine 2.27 (5.7 mmol) was dissolved dichloromethane and 
triethylamine (2.4 mL, 17 mmol) were added to the reaction which was stirred for 48 
hours. The dichloromethane was removed in vacuo, and the product was dissolved in 
ethyl acetate and washed with a pH 2 buffer (3 × 15 mL), 0.1 M HCl (3 × 15 mL) 
and sodium bicarbonate (3 × 15 mL). The organic layer was dried over Na2SO4 and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate:MeOH, 60:40:0 to 0:80:20) to give compound 2.33 as 
a brown solid (1.00 g, 63 %); mp 188-189 º C; υmax/cm
-1
: 3435, 3316 (N-H), 2932 
(saturated C-H), 1625 (C=O amide) and 1529 (aromatic); δH (500 MHz, CDCl3) 8.26 
(s, 1H, indole NH), 7.82 (d, 1H, J 8, indole CH-C-C), 7.81 (d, 2H, J 8, biphenyl CH-
C-CO), 7.62 (d, 2H, J 9, biphenyl CH-CH-C-CO and CH-C-aryl), 7.60 (d, 2H, J 7.5, 
biphenyl CH-CH-C-CO and CH-C-aryl),  7.46 (t, 2H, J 7.5, biphenyl CH-CH-C-
aryl), 7.40-7.36 (m, 2H, indole CH-C-NH and biphenyl CH-CH-CH-C-aryl), 7.23-
7.14 (m, 3H, indole CH-CH-C, CH-CH-C-C and NH-CO-biphenyl), 7.11 (s, 1H, 
indole CH-NH), 5.83 (s, 1H, NH-CH2), 4.94 (dt, 1H, J 13, 5, CH-CH2-indole), 3.50 
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(dd, 1H, J 9, 5, CH2-indole), 3.24 (dd, 1H, J 13, 9, CH2-indole), 3.11 (quin., 1H, J 7, 
CH2-Et), 3.05 (quin., 1H, J 7, CH2-CH2-CH3), 1.33-1.24 (m, 2H, CH2-CH3) and 0.73 
(t, 3H, J 7, CH3); δC (125 MHz, CDCl3) 171.2 (C=O), 166.9 (C=O), 144.6 (biphenyl 
C-phenyl), 140.0 (biphenyl C-aryl), 136.3 (indole C-NH), 132.4 (biphenyl C-CO), 
128.9 (biphenyl CH-CHC-aryl), 128.1 (biphenyl CH-C), 127.7 (biphenyl CH-C-
aryl), 127.4 (biphenyl CH-C-phenyl), 127.1 (biphenyl CH-CHCH-C-aryl), 127.2 
(indole C-C-NH), 123.2 (indole CH-NH), 122.4 (indole CH-CH-C-C), 119.9 (indole 
CH-C-C), 119.1 (indole CH-CH-C), 111.3 (indole CH-C-NH), 111.0 (indole C-
CH2), 54.5 (CH-CH2-indole), 41.3 (CH2-NHCO), 28.7 (CH2-indole), 22.5 (CH2-
CH3) and 11.2 (CH3); ESI m/z 100 %, 448.2 (MNa
+
) and 30 %, 873.3 (M2Na
+
). 
2.34, (R)-O-Benzyl N-(4-(3-(1H-Indol-3-yl)-2-(1-tosylpiperidine-4-
carboxamido)propanamido)butylcarbamate) 
Acid 2.11 (0.34 g, 1.2 mmol) was dissolved in dichloromethane (10 mL) and cooled 
to 0°C. HATU (0.46 g, 1.2 mmol) was added and the mixture was stirred for 10 
minutes. Amine 2.28 (1.2 mmol) in dichloromethane and triethylamine (0.50 mL, 3.6 
mmol) were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo, the product was dissolved in ethyl acetate and washed with a pH 
2 buffer (3 × 10 mL) and ½ saturated NaHCO3 (3 × 10 mL). The organic layer was 
dried over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate, 95:5 to 0:100) to give compound 
2.34 as a colourless oil (0.36 g, 47 %); υmax/cm
-1
: 3302 (N-H), 2939 (saturated C-H), 
1698, 1644 (C=O), 1644, 1328, 1160 (SO2) and 1251 (C-O); δH (400 MHz, CDCl3) 
8.92 (br.s, 1H, indole NH), 7.58 (d, 3H, J 7, indole CH-C-C and CH-CSO2), 7.38-
7.24 (m, 8H, indole CH-C-NH, CH-CCH3 and phenyl), 7.10 (t, 1H, J 7.5, indole CH-
CH-C), 7.02 (t, 1H, J 7.5, indole CH-CH-C-C), 6.93 (s, 1H, indole CH-NH), 6.71 (d, 
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1H, J 6, NH-CH), 6.29 (br.t, 1H, J 5, NHCbz or NH-CO), 5.20 (br.t, 1H, J 5, NHCbz 
or NH-CO), 5.09 (s, 2H, CH2-phenyl), 4.70 (br. q, 1H, J 7, CH-CH2-indole), 3.66 
(br.t, 2H, J 11, equatorial CH2-NSO2), 3.18 (dd, 2H, J 14, 5, CH2-indole), 3.12-2.92 
(m, 3H, CH2-NHCbz & CH2-NHCO), 2.89-2.77 (m, 1H, CH2-NHCO),  2.41 (s, 3H, 
CH3-aryl), 2.22-2.12 (m, 2H, J 11, axial CH2-NSO2), 1.98-1.88 (m, 1H, CH-
CH2CH2N), 1.76-1.37 (m, 4H, CH2-CH2NSO2) and 1.21-1.05 (m, 4H, CH2-CH2-
NHCO and CH2-CH2-NHCbz); δC (100 MHz, CDCl3) 173.8, 171.5 (C=O amide), 
156.9 (C=O carbamate), 143.8 (C-CH3), 136.6 (indole C-NH), 136.3 (phenyl C), 
133.0 (C-SO2), 129.8 (CH-CCH3), 128.6, 128.2 (phenyl CH), 128.1 (CH-CSO2), 
127.7 (phenyl CH), 127.3 (indole C-C-NH), 123.4 (indole CH-NH), 122.1 (indole 
CH-CH-C-C), 119.5 (indole CH-C-C), 118.8 (indole CH-CH-C), 111.5 (indole CH-
C-NH), 110.3 (indole C-CH2), 66.7 (CH2-phenyl), 53.9 (CH-CH2-indole), 45.5 
(CH2-N), 41.8 (CH-CH2CH2N), 40.7 (CH2-NHCbz), 39.1 (CH2-NHCO), 29.0, 28.0, 
(CH2-indole and CH2-CH2N), 27.5, 26.4 (CH2-CH2NHCbz, CH2-CH2NHCO) and 
21.6 (CH3); ESI m/z 100 %, 696.3 (MNa+) and 35 %, 674.5 (MH
+
). 
2.35, (R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(5-(2-phenoxyacetamido)pentylamino) 
propan-2-yl)-1-(meta-tolylsulfonyl)piperidine-4-carboxamide 
Acid 2.10 (0.20 g, 0.71 mmol) was dissolved in dichloromethane (4 mL) and cooled 
to 0° C. HATU (0.19 g, 0.51 mmol) was added and the mixture was stirred for 1 
hour. Amine 2.29 (0.5 mmol) in dichloromethane and triethylamine (0.20 mL, 1.4 
mmol) were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo, the product was dissolved in ethyl acetate and washed with a pH 
2 buffer (3 × 5 mL), 0.1 M HCl (3 × 5 mL) and ½ saturated NaHCO3 (3 × 5 mL). 
The organic layer was dried over Na2SO4 and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate, 50:50 to 
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0:100) to give compound 2.35 as a white solid (0.17 g, 49 %) mp 69-70 °C; υmax/cm
-
1
: 3289 (N-H), 2928 (saturated C-H), 1697, 1639 (C=O), 1526 (aromatic), 1329, 154 
(SO2) and 1248 (C-O); δH (400 MHz, CDCl3) 9.21 (indole NH), 7.61 (d, 1H, J 7.5, 
indole CH-C-C), 7.54 (s, 1H, CH-CSO2), 7.51 (t, 1H, J 5, CH-CHCCH3), 7.40 (d, 
2H, J 5, CH-CCH3 and CH-CHCHCCH3), 7.35-7.28 (m, 6H, indole CH-C-NH and 
phenyl), 7.13 (t, 1H, J 7.5, indole CH-CH-C), 7.03 (t, 1H, J 7.5, indole CH-CH-C-
C), 6.94 (d, 1H, J 2, indole CH-NH), 6.72 (d, 1H, J 7.5, NH-CH), 6.11 (br.t, 1H, J 
5.5, NH-COCH or NHCbz), 5.24 (br.t, 1H, J 5.5, NH-COCH or NHCbz), 5.10 (s, 
2H, CH2-phenyl), 4.72 (q, 1H, J 7, CH-CH2-indole), 3.72-3.65 (m, 2H, equatorial 
CH2-N), 3.20 (dd, 1H, J 15.4, 6, CH2-indole), 3.15-3.00 (m, 4H, CH2-NHCbz, CH2-
NHCO and CH2-indole), 2.89-2.78 (m, 1H, CH2-NHCO), 2.42 (s, 3H, CH3), 2.25-
2.17 (m, 2H, axial CH2-N), 1.98-1.91 (m, 1H, CH-CCO), 1.70 (d, 4H, J 11, CH2-
CH2N), 1.34 (br.t, 2H, J 7, CH2-CH2NHCbz), 1.16 (quin, 2H, J 7, CH2-CH2NHCO) 
and 1.00-0.84 (m, 2H, CH2-(CH2)2NHCbz); δC (100 MHz, CDCl3) 173.7, 171.4 
(C=O), 156.9 (C=O carbamate), 139.3 (C-CH3), 136.6 (C-SO2), 136.4 (indole C-
NH), 135.8 (phenyl C), 133.7 (CH-CCH3), 129.0 (CH-CH-CCH3), 128.6, 128.1 
(phenyl CH), 127.9 (CH-CSO2), 127.3 (indole C-C-NH), 124.8 (CH-CH-CHCCH3), 
123.4 (indole CH-NH), 122.0 (indole CH-CH-C-C), 119.4 (indole CH-C-C), 118.7 
(indole CH-CH-C), 111.6 (indole CH-C-NH), 110.2 (indole C-CH2), 66.7 (CH2-
phenyl), 53.9 (CH-CH2-indole), 45.5 (CH2-N), 41.8 (CH-CH2-CH2-N), 40.9 (CH2-
NH-Cbz), 39.2 (CH2-NH-CO), 29.7, 29.1, 28.7, 28.1 (CH2-indole, CH2-CH2N, CH2-
CH2NHCbz & CH2-CH2NHCO), 23.6 (CH2-(CH2)2-NH-Cbz) and 21.4 (CH3); ESI 
m/z 100 %, 710.2 (MNa
+
) and 39 %, 423.3 (MH
+
-C13H16NO3S); HR ESI m/z 
(C37H45N5O6SNa
+ 
requires 710.2983) found 710.2975. 
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2.36, (R)-O-Benzyl 5-(3-(1H-indol-3-yl)-2-(1-tosylpiperidine-4-carboxamido) 
propanamido)pentylcarbamate 
Acid 2.11 (0.20 g, 0.71 mmol) was dissolved in dichloromethane (10 mL) and 
cooled to 0° C. HATU (0.26 g, 0.69 mmol) was added and the mixture was stirred 
for 10 minutes. Amine 2.29 (0.7 mmol) in dichloromethane and triethylamine (2.1 
mmol, 0.29 mL) were added and the reaction was stirred over night. The 
dichloromethane was removed in vacuo, the product was dissolved in ethyl acetate 
was washed with a pH 2 buffer (3 × 10 mL) and ½ saturated NaHCO3 (3 × 10 mL). 
The organic layer was dried over Na2SO4 and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate, 95:5 to 
20:80) to give compound 2.36 as a white-yellow solid (0.12 g, 25 %); mp 115-117 º 
C; [α]30D (c = 0.25, MeOH) -0.1; υmax/cm
-1
: 3293 (N-H), 2927 (saturated C-H), 1698, 
1633 (C=O), 1326, 1152 (SO2) and 1246 (C-O); Anal. Calcd for C37H45N5O6S: C, 
64.61; H, 6.59; N, 10.18. Found: C, 64.01; H, 6.59; N, 10.18; δH (400 MHz, CDCl3) 
9.27 (s, 1H, indole NH), 7.56 (d, 2H, J 8, indole CH-C-C and CH-CSO2), 7.33-7.23 
(m, 8H, indole CH-C-NH, CH-CCH3 and phenyl), 7.11 (1H, t, J 7.5, indole CH-CH-
C), 6.99 (t, 1H, J 7.5, indole CH-CH-C-C), 6.90 (s, 1H, indole CH-NH), 6.79 (d, 1H, 
J 7.5, NH-CH), 6.27 (br.t, 1H, J 4.5, NHCbz or NH-CO), 5.34 (br.t, 1H, J 5, NHCbz 
or NH-CO), 5.07 (s, 2H, CH2-phenyl), 4.71 (q, 1H, J 7, CH-CH2-indole), 3.62 (br.t, 
2H, J 10, equatorial CH2-N), 3.22-2.94 (m, 5H, CH2-indole, CH2-NHCbz and CH2-
NHCO), 2.85-2.73 (m, 1H, CH2-NHCbz or CH2-NHCO), 2.38 (s, 3H, CH3), 2.17-
2.06 (m, 2H, axial CH2-N), 1.94-1.84 (m, 1H, CH-CH2CH2N), 1.64 (m, 4H, CH2-
CH2-N), 1.35-1.26 (br.t, 2H, CH2-CH2-NHCO), 1.13 (td, 2H, J  7.5, 1.5, CH2-
CH2CH2-NHCO or CH2-CH2CH2NHCbz) and 0.96-0.79 (m, 2H, CH2-CH2CH2-
NHCO or CH2-CH2CH2NHCbz); δC (100 MHz, CDCl3) 173.8, 171.5 (C=O amide), 
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156.9 (carbamate C=O), 143.8 (C-CH3), 136.6 (indole C-NH), 136.4 (phenyl C), 
132.8 (C-SO2), 129.8 (CH-CCH3), 128.6, 128.1 (phenyl CH), 128.0 (CH-CSO2), 
127.7 (phenyl CH), 127.3 (indole C-C-NH), 123.4 (indole CH-NH), 121.9 (indole 
CH-CH-C-C), 119.3 (indole CH-C-C), 118.7 (C3), 111.6 (indole CH-C-NH), 110.1 
(indole C-CH2), 66.6 (CH2-phenyl), 53.9 (CH-CH2-indole), 45.5 (CH2-NSO2), 41.7 
(CH-CH2CH2N), 40.9, 39.2 (CH2-NHCbz and CH2-NHCO), 29.7, 29.1, 28.7, 28.6 
(CH2-indole, CH2-CH2N, CH2-CH2NHCbz and CH2-CH2NHCO), 23.7 (CH2-
CH2CH2NHCbz) and 21.6 (CH3);  ESI m/z 100 %, 710.4 (MNa
+
) and 62 %, 688.3 
(MH
+
).  
2.37, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-(meta-tolylsulfonyl)piperidine-
4-carboxamido)propanamido)-6-(benzyloxycarbonylamino)hexanoate 
Acid 2.10 (1.13 g, 3.99 mmol) was dissolved in dichloromethane (30 mL) and 
cooled to 0 ºC. HATU (1.70 g, 4.47 mmol) was added and the reaction was stirred 
for 4 hours. Amine 2.31 (4 mmol) in dichloromethane (20 mL) and with 
triethylamine (1.7 mL, 12 mmol) were added and the reaction was stirred for 48 
hours. The dichloromethane was removed in vacuo, and the product was dissolved in 
ethyl acetate was washed with a pH 2 buffer (3 × 20 mL), 0.1 M HCl (3 × 20 mL), 
and ½ saturated NaHCO3 (3 × 20 mL). The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 80:20:0 to 0:70:30) to give 
compound 2.37 as a white solid (1.61g, 51 %); mp 76-78 ºC; [α]24D  (c = 0.505, 
MeOH) - 11.19; υmax/cm
-1
: 3298 (N-H), 2932 (saturated C-H), 1705 (C=O ester), 
1644 (C=O amide), 1520 (aromatic), 1332, 1155 (SO2) and 1249 (C-O); δH (400 
MHz, CDCl3) 9.28 (br.s, 1H, NH indole), 7.67 (d, 1H, J 8, indole CH-C-C), 7.54 (s, 
1H, CH-CSO2), 7.52 (d, 1H, J 6.5, CH-CHCH-CCH3),7.4-7.37 (m, 2H, CH-CCH3 
and CH-CHCCH3), 7.35-7.30 (m, 5H, phenyl), 7.14 (t, 1H, J 8, indole CH-CH-C), 
171 
 
7.07 (t, 1H, J 7.5, indole CH-CH-C-C), 6.94 (d, 1H, J 1.5, indole CH-NH ), 6.39 (d, 
1H, J 7, NH-CH), 6.0 (d, 1H, J 7.5, NH-CH), 5.12 (dd, 1H, J 14, 12, CH2-phenyl), 
5.05 (t, 1H, J 6, NH-Cbz), 4.74 (br.q, 1H, J 7, CH-CH2-indole), 4.26 (q, 1H, J 6.5, 
CH-COO
t
Bu), 3.73 (d, 1H, J 14, CH2-N equatorial), 3.69 (d, 1H, J 14, CH2-N 
equatorial), 3.24 (dd, 1H, J 14, 4.5, CH2-indole), 3.15-2.93 (m, 3H, CH2-indole & 
CH2-NH-Cbz), 2.42 (s, 3H, CH3), 2.29 (td, 2H, J 11.5, 3, CH2-N axial), 2.00-1.95 
(m, 2H, CH2-CH-COO
t
Bu), 1.85-1.69 (m, 4H, CH2-CH2-N), 1.51-1.39 (m, 1H, CH2-
CH2-NH-Cbz),  1.35 (s, 9H, C(CH3)3), 1.36-1.28 (m, 1H, CH2-CH2-NH-Cbz), 0.86-
0.75 (m, 1H, CH2-CH2-CH-COO
t
Bu) and 0.72-0.65 75 (m, 1H, CH2-CH2-CH-
COO
tBu); δC (100 MHz, CDCl3) 173.6, 170.9, 170.7 (C=O ester and amide), 156.9 
(C=O carbamate), 139.3 (C-CH3), 136.5 (C-SO2), 136.0 (indole C-NH), 133.7 (C-
CH3), 129.0 (CH-CCH3), 128.2, 128.1 (phenyl CH), 127.9 (CH-CSO2), 127.1 (indole 
C-C-NH), 124.8 (CH-CHCHCCH3), 123.2 (indole CH-NH), 122.1 (indole CH-C-C), 
119.6 (indole CH-CH-C), 118.7 (indole CH-CH-C-C), 111.6 (indole CH-C-NH), 
110.0 (indole C-CH2), 82.8 (C(CH3)3), 53.9 (CH-CH2-indole), 52.6 (CH-COO
t
Bu), 
45.5 (CH2-N), 41.9 (CH-CH2CH2N), 40.8 (CH2-NHCbz), 31.7, 29.8, 29.2, 27.98, 
27.92 (CH2-indole, CH2-CH2-N, CH2-CH2NHCbz, CH2-CHCOO
t
Bu) and 21.6 (CH2-
CH2CHCOO
t
Bu); ESI m/z 100 %, 810.3 (MNa
+
).  
2.38, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-tosylpiperidine-4-carboxamido) 
propanamido)-6-(benzyloxycarbonylamino)hexanoate 
Acid 2.11 (0.10 g, 3.5 mmol) was dissolved in dichloromethane (30 mL) and cooled 
to 0 ºC. HATU (1.39 g, 3.66 mmol) was added and the reaction was stirred for 10 
minutes. Amine 2.31 (3.5 mmol) in dichloromethane (20 mL) and triethylamine (1.5 
mL, 10.7 mmol) were added and the reaction was stirred for 48 hours. The 
dichloromethane was removed in vacuo, the product dissolved in ethyl acetate was 
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washed with a pH 2 buffer (3 × 50 mL) and ½ saturated NaHCO3 (3 × 50 mL). The 
organic layer was dried over Na2CO3 and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate:MeOH 
80:20:0 to 0:90:10) to give compound 2.38 (1.75g, 63 %); mp 155-157 ºC; [α]25D  (c 
= 1, chloroform) -3.70; υmax/cm
-1
: 3333 (N-H), 2957 (saturated C-H), 1704 
(ester/carbamate C=O), 1663 (amide C=O), 1527 (aromatic) and 1338, 1151 (SO2) 
and 1250 (ester C-O); δH (400 MHz, CDCl3) 9.36 (s, 1H, indole NH), 7.65 (d, 1H, J 
7.5, indole CH-C-C), 7.60 (d, 2H, J 8, CH-CSO2), 7.36-7.28 (m, 8H, phenyl, indole 
CH-C-NH and CH-C-CH3), 7.13 (t, 1H, J 7.5, indole CH-CH-C), 7.06 (t, 1H, J 7, 
indole CH-CH-C-C), 6.95 (s, 1H, indole CH-NH), 6.40 (d, 1H, J 7.5, NH-CHCH2-
indole), 6.01 (d, 1H, J 7.5, NH-CH-COO), 5.14 (d, 1H, J 12, CH2-phenyl), 5.11 (d, 
1H, J 12, CH2-phenyl), 5.11 (t, 1H, J 5, NHCbz), 4.75 (br.q, 1H, J 5, CH-CH2-
indole), 4.31 (br.q, 1H, J  CH-COO), 3.70 (br.t, 2H, J 11 equatorial CH-NSO2), 3.22 
(dd, 1H, J 14, 4.5, CH2-indole), 3.17-2.91 (m, 3H, CH2-NHCbz & CH2-indole), 2.42 
(s, 3H, CH3-aryl), 2.31-2.18 (m, 2H, axial CH2-NSO2), 2.00-1.94 (m, 1H, piperidine 
CH-CONH), 1.85-1.80 (m, 2H, CH2-CH2-NSO2), 1.79-1.67 (m, 2H, CH2-CH2-NSO2 
and CH2-CH), 1.47-1.40 (m, 1H, CH2-CH), 1.36-1.22 (m, 2H, CH2-CH2-NHCbz), 
1.35 (s, 9H, (CH3)3), 0.84-0.76 (m, 1H, CH2-CH2-CH) and 0.72-0.64 (m, 1H, CH2-
CH2-CH); δC (100 MHz, CDCl3) 173.0 (C=O ester), 170.6, 170.2 (C=O amide), 
156.3 (C=O carbamate), 143.6 (C-CH3), 136.5 (indole C-NH), 133.1(C-SO2), 129.7 
(CH-C-CH3), 128.6, 128.2 (phenyl CH), 128.1 (CH-SO2), 127.9 (phenyl C), 127.7 
(phenyl CH), 127.1 (indole C-C-NH), 123.2 (indole CH-NH), 122.1 (indole CH-CH-
C-C), 119.6 (indole CH-C-C), 118.7 (indole CH-CH-C), 111.6 (indole CH-C-NH), 
109.9 (indole C-CH2), 82.3 (C(CH3)3), 66.8 (CH2-phenyl), 53.9 (CH-CH2-indole), 
52.5 (CH-COO), 45.5 (CH2-NSO2), 41.8 (CH-CONH), 40.8 (CH2-CH2-NSO2), 31.7 
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(CH2-NHCbz), 29.8, 28.9, 27.8 (CH2-CH, CH2-CH2-NHCbz and CH2-indole), 27.9 
(C(CH3)3), 21.5 (CH2-CH2-CH) and 21.0 (phenyl-CH3); HR ESI m/z 
(C42H53N5NaO8S requires 810.3493) found 810.3507.  
2.39, (S)-tert-Butyl 2-((R)-2-(1-benzoylpiperidine-4-carboxamido)-3-(1H-indol-
3-yl)propanamido)-6-(benzyloxycarbonylamino)hexanoate 
Acid 2.12 (1.16 g, 4.98 mmol) was dissolved in dichloromethane (30 mL) and 
cooled to 0 ºC. HATU (1.93 g, 5.06 mmol) was added and the reaction was stirred 
for 10 minutes. Amine 2.31 (5 mmol) in dichloromethane (20 mL) and triethylamine 
(2.1 mL, 15 mmol) were added and the reaction stirred for 48 hours. The 
dichloromethane was removed in vacuo, the product dissolved in ethyl acetate was 
washed with a pH 2 buffer (3 × 50 mL) and ½ saturated NaHCO3 (3 × 50 mL). The 
organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (petroleum ether:ethyl acetate:MeOH 80:20:0 to 
0:90:10)  to give compound 2.39 as a beige solid (1.67 g, 55 %); mp 132-150 ºC 
(decomposed); υmax/cm
-1 
3285 (N-H), 2933 (saturated C-H), 1703 (ester C=O) and 
1644 (amide C=O); δH (400 MHz, CDCl3) 9.36 (br.s, 1H, NH indole), 7.74 (d, 1H, J 
7.5, CH-C-C), 7.39-7.29 (m, 5H, phenyl), 7.15 (t, 1H, J 7.5, CH-CH-C), 7.10 (t, 1H, 
J 7.5, CH-CH-C-C), 6.96 (d, 1H, J 2, CH-NH), 6.57-6.51 (m, 1H, NH), 6.13, 6.00 
(d, 1H, J 8, NH rotamers), 5.13 (s, 2H, CH2-phenyl), 5.07 (t, 1H, J 6, NHCbz), 4.83-
4.78 (m, 1H, CH-CH2-indole), 4.63 (br.s, 1H, CH2-N equatorial), 4.40, 4.30 (q, 1H, J 
5, CH-COO), 3.74 (br.s, 1H, CH2-N equatorial), 3.30 (dd, 1H, J 4.5, 11.5, CH2-
indole), 3.13-3.02 (m,  2H, CH2-N axial), 3.00-2.79 (m, 3H, CH2-indole and CH2-
NHCbz), 2.34 (tt, 1H, J 1, 4.5, CH-CONH), 1.87-1.60 (m, 4H, CH2-CH2-N and CH2-
CH), 1.51-1.42 (m, 1H, CH2-CH2-NH), 1.36-1.29 (m, 1H, CH2-CH2-NH), 1.35 (s, 
9H, C(CH3)3), 0.85-0.78 (m, 1H, CH2-CH2-CH) and 0.74-0.67 (m, 1H, CH2-CH2-
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CH); δC (400 MHz, CDCl3) 173.4 (C=O ester), 171.6, 171.2, 168.2 (C=O amide), 
156.1 (C=O carbamate), 137.2 (indole C-NH), 136.3 (phenyl C), 135.9 (C), 129.3 
(phenyl CH), 128.4 (phenyl CH), 128.3 (phenyl CH), 127.7 (phenyl CH), 127.4 
(indole C-C-NH), 126.6 (phenyl CH), 123.6 (indole CH-NH), 120.7 (indole CH-CH-
C), 118.5 (indole CH-CH-C-C), 118.1 (indole CH-C-C), 111.2 (indole CH-C-NH) 
and 109.9 (indole C-CH2), 80.5 (C(CH3)3), 65.1 (CH2-phenyl), 52.9 (CH-CH2-
indole), 52.6 (CH-COO), 41.3 (CH-CONH), 40.1 (CH2-NCO), 39.9 (CH2-CH2-
NCO), 30.7 (CH2-NHCbz), 28.9, 28.4, 28.3 (CH2-CH2-NHCbz, CH2-CH and CH2-
indole), 27.6 (C(CH3)3) and 22.4 (CH2-CH2-CH); ESI m/z 100 %, 760.6 (MNa
+
). 
2.40, (S)-tert-Butyl 6-(benzyloxycarbonylamino)-2-((R)-2-biphenyl-4-
ylcarboxamido-3-(1H-indol-3-yl)propanamido)hexanoate 
4-Biphenylcarboxylic acid (0.72 g, 3.6 mmol) was dissolved in dichloromethane (80 
mL) and cooled to 0 ºC. HATU (1.39 g, 3.66 mmol) was added and the reaction was 
stirred for 10 minutes. Amine 2.31 (3.5 mmol) in dichloromethane and triethylamine 
(1.50 mL, 10.7 mmol) were added to the reaction. The reaction was stirred for 48 
hours. The dichloromethane was removed in vacuo, the product dissolved in ethyl 
acetate was washed with a pH 2 buffer (3 × 50 mL) and ½ saturated NaHCO3 (3 × 50 
mL). The organic layer was dried over Na2CO3 and reduced in vacuo. The product 
was purified by silica column chromatography petroleum ether:ethyl acetate:MeOH 
(80:20:0 to 0:90:10) to give compound 2.40 as a beige solid (0.31g, 12 %); mp 172-
174 ºC (decomposed); [α]25D (c = 0.5, MeOH) -11.54; υmax/cm
-1
: 3325 (N-H), 1708 
(C=O ester/carbamate), 1665 (C=O amide) and 1530 (aromatic); δH (400 MHz, d6-
DMSO) 10.79 (d, 1H, NH indole), 8.55 (d, 1H, J 9.5, NH-CO-biphenyl), 8.39 (d, 
1H, J 7, NH-CH-COO), 7.94 (d, 2H,  J 8,biphenyl CH-C-CO), 7.74 (t, 5H, J 8.5, 
indole CH-C-C, biphenyl CH-C-phenyl, CH-C-aryl), 7.50 (t, 2H, J 8, biphenyl CH-
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CH-C-aryl), 7.42 (d, 1H, J 7, biphenyl CH-CHCH-C-aryl), 7.37-7.30 (m, 6H, indole 
CH-C-NH and phenyl), 7.27-7.30 (m, 2H, NHCbz & indole CH-NH), 7.07 (t, 1H, J 
7.5, indole CH-CH-C), 6.99 (t, 1H, J 7.5, indole CH-CH-C-C), 5.00 (s, 2H, CH2-
phenyl),  4.84 (td, 1H, J 10, 5, CH-CH2-indole), 4.16-4.10 (m, 1H, CH-COO), 3.27-
3.13 (m, 2H, CH2-indole), 2.98 (q, 2H, J 7, CH2-NHCbz), 1.74-1.53 (m, 2H, CH2-
CH), 1.41 (s, 9H, C(CH3)3), 1.45-1.32 (m, 2H, CH2-CH2-NH) and 1.30-1.20 (m, 2H, 
(CH2-CH2-CH); δC (100 MHz, d6-DMSO) 171.8 and 171.2 (ester and amide C=O), 
165.6 (C=O biphenyl), 156.1 (C=O carbamate), 142.3 (biphenyl C-phenyl), 139.1 
(biphenyl C-aryl), 137.2 (biphenyl C-CO), 136.1 (indole C-NH), 132.9 (phenyl C), 
129.0 (biphenyl CH-CH-C-aryl), 128.3 (biphenyl CH-C-CO), 128.1, 128.0 (phenyl 
CH), 127.7 (indole C-C-NH), 127.3 (biphenyl CH-C-aryl), 127.0 (aryl CH-C-
phenyl), 126.8 (biphenyl CH-CH-CH-C-aryl), 126.3 (phenyl CH), 123.7 (indole CH-
NH), 120.8 (indole CH-CH-C-C), 118.6 (indole CH-C-C), 118.1 (indole CH-CH-C), 
111.2 (indole CH-C-NH), 110.4 (indole C-CH2), 80.5 (C(CH3)3), 65.1 (CH2-phenyl), 
54.0 (CH-CH2-indole), 52.6 (CH-COO), 40.1 (CH2-NHCbz), 30.8 (CH2-CH), 28.9 
(CH2-indole), 27.9 (CH2-CH2-NHCbz), 27.6 (C(CH3)) and 22.5 (CH2-CH2-CH); HR 
ESI m/z (C42H46N4NaO6 requires 725.3363) found 725.3319. 
2.41, (R)-N-(1-(4-Aminobutylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-
tosylpiperidine-4-carboxamide 
Carbamate 2.34 (0.21 g, 0.31 mmol) was dissolved in MeOH (2 mL). Charcoal 
activated palladium (0.08 g, catalytic) was added and the reaction was stirred under 
hydrogen for 24 hours. The reaction was filtered through celite and the MeOH 
removed in vacuo to give compound 2.41 as a colourless oil (0.14 g, 84 %); δH (400 
MHz, CDCl3) 9.10 (br.s, 1H, NH indole), 7.60 (d, 1H, J 8.5, indole CH-C-C), 7.58 
(d, 2H, J 8.5, H), 7.35-7.27 (m, 3H, indole CH-C-NH and CH-CCH3), 7.12 (t, 1H, J 
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8, indole CH-CH-C), 7.03 (t, 1H, J 7.5, indole CH-CH-C-C), 6.98 (s, 1H, indole CH-
NH), 6.90 (br.s, 1H, NH-CH2), 6.71 (br.d, 1H, J 7, NH-CH), 4.64 (q, 1H, J 7, CH-
CH2-indole), 3.72-3.62 (m, 2H, equatorial CH2-N), 3.18 (dd, 1H, J 14, 5, CH2-
indole), 3.12-2.87 (m, 4H, CH2-indole, CH2-NHCO and CH2-NH2), 2.54-2.46 (m, 
1H, CH2-NHCO or CH2-NH2), 2.41 (s, 3H, CH3), 2.20 (br.t, 2H, J 10, CH2-N axial), 
2.02-1.90 (m, 1H, CH-CCO), 1.81-1.60 (m, 4H, CH2-CH2N) and 1.29-1.11 (m, 4H, 
CH2-CH2-NH and CH2-CH2-NH2); δC (100 MHz, CDCl3) 173.7, 171.3 (C=O), 143.7 
(C-CH3), 136.3 (indole C-NH), 133.0 (C-SO2), 129.7 (CH-CCH3), 127.7 (CH-
CSO2), 127.5 (indole C-C-NH), 123.3 (indole CH-NH), 122.1 (indole CH-CH-C-C), 
119.5 (indole CH-C-C), 118.8 (indole CH-CH-C), 111.4 (indole CH-C-NH), 110.6 
(indole C-CH2), 54.1 (CH-CH2-indole), 45.5 (CH2-NSO2), 41.8 (CH-CH2CH2N), 
40.9,  39.1 (CH2-NH2 and CH2-NHCO), 29.0, 28.1, 27.9 (CH2-CH2NH2, CH2-CH2N 
and CH2-indole), 26.5 (CH2-CH2NH) and 21.5 (CH3); ESI m/z 100 %, 540.30 
(MH
+
). 
2.42, (R)-N-(1-(5-Aminopentylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-
tosylpiperidine-4-carboxamide 
Carbamate 2.36 (0.10 g, 0.15 mmol) was dissolved in MeOH (1 mL) and THF (1 
mL). Palladium activated charcoal (0.02 g, catalytic) was added and the reaction 
stirred under hydrogen for 24 hours. The reaction was filtered through celite and the 
organic solvent was removed in vacuo to give the product compound 2.42 as a 
colourless oil (0.069 g, 83 %); δH (400 MHz, MeOD) 7.65 (d, 2H, J 8, CH-CH3), 
7.60 (d, 1H, J 7.5, indole CH-C-C), 7.44 (d, 2H, J 8, CH-CSO2), 7.35 (d, 1H, J 7.5, 
indole CH-C-NH), 7.11 (t, 1H, J 8, indole CH-CH-C), 7.08 (s, 1H, indole CH-NH), 
7.02 (t, 1H, J 8, indole CH-CH-C-C), 4.60 (t, 1H, J 7.5, CH-CH2-indole), 3.62 (br.d, 
1H, J 11.5, equatorial CH2-N), 3.61 (br.d, 1H, J 11.5, equatorial CH2-N), 3.21 (dd, 
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1H, J 15, 7, CH2-indole), 3.17-2.98 (m, 3H, CH2-indole, CH2-NHCO), 2.56 (t, 1H, J 
7, CH2-NH2), 2.46 (s, 4H, CH3 and CH2-NH2), 2.30 (qd, 2H, J 11, 2, CH2-CH2N) 
2.16 (tt, 1H, J 11, 4, CH-CH2CH2N), 1.79 (br.d, 1H, J 15, CH2-CH2N), 1.74-1.50 (m, 
3H, CH2-CH2N), 1.45-1.25 (m, 4H, CH2-CH2NHCO and CH2-CH2NH2) and 1.19-
1.10 (m, 2H, CH2-CH2CH2NH2). 
2.01, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-(meta-tolylsulfonyl)piperidine-
4-carboxamido)propanamido)-6-aminohexanoate 
Carbamate 2.37 (1.6 g, 2.0 mmol) was dissolved in MeOH (10 mL). Palladium 
activated charcoal (0.1 g, catalytic) was added and the reaction stirred under 
hydrogen for 48 hours. The reaction was filtered through celite and the organic 
solvents removed in vacuo to give the product compound 2.01 as a beige solid (0.33 
g, 13 %); mp; 103-104 °C; [α]24D (c = 0.245, CHCl3) -5.41; ; υmax/cm
-1
: 3302 (N-H), 
2955 (saturated C-H), 1702 (ester C=O), 1664 (amide C=O), 1337, 1153 (SO2) and 
1251 (ester C-O); δH (400 MHz, MeOD) 7.62-7.55 (m, 3H, CH-CH-CHCCH3, CH-
CHCCH3, CHCCH3), 7.54-7.52 (m, 2H, indole CH-C-C and CH-CSO2), 7.36 (d, 1H, 
J 8, indole CH-C-NH), 7.50 (t, 1H, J 7.5, indole CH-CH-C), 7.11 (s, 1H, indole CH-
NH), 7.04 (t, 1H, J 7.5, indole CH-CH-C-C), 4.73 (t, 1H, J 7.5, CH-CH2-indole), 
4.10 (dd, 1H, J 9, 5, CH-COO), 3.34 (d, 1H, J 12, equatorial CH2-N), 3.68 (d, 1H, J 
12, equatorial CH2-N), 3.23 (dd, 1H, J 14, 8, CH2-indole), 3.09 (dd, 1H, J 14, 7, 
CH2-indole), 2.56 (t, 2H, J 7.5, CH2-NH2),  2.45 (s, 3H, CH3), 2.34 (qd, 2H, J 11.5, 
3.5, axial CH2-N), 2.20 (tt, 1H, J 11.5, 4, CH-CH2CH2), 1.83 (d, 1H, J 14, CH2-
CH2N), 1.78-1.55 (m, 5H, CH2-CH2N and CH2-CH-COO
t
Bu), 1.46 (s, 9H, C(CH3)3), 
1.36 (quin., 2H, CH2-CH2NH2) and 1.00 (quin., 2H, CH2-CH2CH); δC (100 MHz, 
MeOD) 176.6, 173.8, 172.7 (C=O ester and amide), 140.9 (C-CH3), 138.0 (C-SO2), 
137.2 (indole C-NH), 135.0 (CH-CCH3), 130.3 (CH-CHCCH3), 129.1 (CH-CSO2), 
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129.0 (indole C-C-NH), 126.0 (CH-CHCHCCH3), 124.8 (indole CH-NH), 122.6 
(indole CH-CH-C-C), 120.0 (indole CH-C-C), 119.6 (indole CH-CH-C), 112.5 
(indole CH-C-NH), 111.1 (indole C-CH2), 82.8 (C(CH3)3), 55.5 (CH-CH2-indole), 
54.6 (CH-COO), 46.9 (CH2-N), 42.6 (CH-CH2CH2N), 42.1 (CH2-NH2), 32.8, 32.2, 
31.4, 29.2 (CH2-indole, CH2-CH2N, CH2-CH2NH2, CH2-CHCOO), 28.4 (CH3-aryl), 
23.8 (CH2-CH2-CH-COO) and 21.6 (C(CH3)3); ESI m/z 100 %, 654.3 (MH
+
), 7 %, 
676.2 (MNa
+
); HR ESI m/z (C34H48N5O6SH
+ 
requires 654.3320) found 654.3329.  
2.43, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-tosylpiperidine-4-carboxamido) 
propanamido)-6-aminohexanoate 
Carbamate 2.38 (1.55 g, 1.96 mmol) was dissolved in MeOH (10 mL) and THF (5 
mL). Palladium activated charcoal (0.08 g, catalytic) was added and the reaction was 
stirred under hydrogen for 24 hours. The reaction was filtered through celite and 
reduced in vacuo to give compound 2.43 (0.11g, 99 %); mp 127-131 ºC 
(decomposed); υmax/cm
-1
: 3385 (N-H), 2926 (saturated C-H), 172 (ester C=O), 1634 
(amide C=O), 1538 (NH2) and 1331, 1145 (SO2); δH (400 MHz, CDCl3) 9.26 (s, 1H, 
NH indole), 7.58 (d, 3H, J 8, indole CH-C-C CH-CSO2), 7.30 (t, 3H, J 8, indole CH-
C-NH and CH-CCH3), 7.11 (t, 1H, J 7, indole CH-CH-C), 7.03 (t, 1H, J 7.5, indole 
CH-CH-C-C), 6.99 (s, 1H, indole CH-NH), 6.53 (d, 1H, J 8, NH-CHCH2-indole), 
6.49 (d, 1H, J 7 NH-CHCOO), 4.69 (q, 1H, J  8, CH-CH2-indole), 4.24 (br.q, 1H, J 
7, CH-COO), 3.62-3.73 (m, 2H, equatorial CH2-N), 3.20 (dd, 1H, J 15, 7, CH2-
indole), 3.10 (dd, 1H, J 14, 8, CH2-indole), 2.68-2.78 (br.s, 2H, CH2-NH2), 2.50-2.62 
(br.d, 2H, axial CH2-N), 2.40 (s, 3H, CH3), 2.15-2.26 (br.t, 2H, equatorial CH2-
CH2N), 1.89-1.99 (m, 1H, CH-CH2CH2N), 1.61-1.79 (m, 4H, axial CH2-CH2N and 
CH2-CHCOO), 1.37 (s, 9H, C(CH3)3), 1.41-1.34 (m, 2H, CH2-CH2NH2) and 0.87-
0.99 (m, 2H, CH2-CH2CHCOO); δC  (100 MHz, CDCl3) 173.9, 171.2, 171.1 (C=O 
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ester and amide), 143.7 (C-CH3), 136.4 (indole C-NH), 133.0 (C-SO2), 129.7 (CH-
CCH3), 127.7 (CH-CSO2), 127.4 (indole C-C-NH), 123.4 (indole CH-NH), 122.1 
(indole CH-CH-C), 119.5 (indole CH-CH-C-C), 118.6 (indole CH-C-C), 111.5 
(indole CH-C-NH), 110.1 (indole C-CH2), 82.2 (C(CH3)3), 54.1 (CH-CH2-indole), 
52.8 (CH-COO), 45.5 (CH2-NSO2), 41.8 (CH-CH2CH2N) 41.0 (CH2-CH2N), 31.5 
(CH2-NH2), 31.1, 28.0, 27.85, (CH2-CH2NH2, CH2-CHCOO and CH2-indole), 27.7 
(CH2-CH2CHCOO), 27.9 ((C(CH3)3) and 21.5 (CH3); ESI m/z 100 %, 654.5 (MH
+
). 
2.44, (S)-tert-Butyl 6-amino-2-((R)-2-(1-benzoylpiperidine-4-carboxamido)-3-
(1H-indol-3-yl)propanamido)hexanoate 
Carbamate 2.39 (1.57 g, 2.13 mmol) was dissolved in MeOH (20 mL). Palladium 
activated charcol (0.08 g, catalytic) was added and the reaction was stirred under 
hydrogen for 24 hours. The reaction was filtered through celite and the organic 
solvents removed in vacuo to give compound 2.44 as a white solid (0.95 g, 63 %); 
mp 103-105 ºC; υmax/cm
-1
: 3279 (N-H), 2927 (saturated C-H), 1732 (ester C=O), 
1645 (amide C=O) and 1615 (NH2); HR ESI m/z (C34H45N5O5 require 604.3493) 
found 604.3500.  
2.45, (S)-tert-Butyl 6-amino-2-((R)-2-biphenyl-4-ylcarboxamido-3-(1H-indol-3-
yl)propanamido)hexanoate 
Carbamate 2.40 (0.52 g, 0.74 mmol) was dissolved in THF (15 mL). Palladium 
activated charcoal (0.3 g, catalytic) was added and the reaction stirred under 
hydrogen for 24 hours. The palladium was removed through filtration and the 
organic solvent was removed in vacuo to give compound 2.45 as a brown oil (0.19 g, 
46 %); υmax/cm
-1
: 3272 (N-H), 2929 (saturated C-H), 1724 (C=O ester), 1638 (C=O 
amide) and 1528 (aromatic); δH (400 MHz, MeOD) 7.87 (d, 2H,  J 8.5, CH-CCO), 
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7.70 (d, 1H, J 8, indole CH-C-C), 7.63 (d, 2H, J 8.5, CH-C-aryl or CH-C-phenyl), 
7.60 (d, 2H, J 8.5, CH-C-aryl or CH-C-phenyl), 7.43 (t, 2H, J 7.5, CH-CH-C-aryl), 
7.40-7.33 (m, 4H, indole CH-C-NH and CH-CHCHC-aryl), 7.22 (s, 1H, indole CH-
NH), 7.13 (t, 1H, J 7.5, indole CH-CH-C), 7.06 (t, 1H, J 7.5, indole CH-CH-C-C), 
5.02 (t, 1H, J 7.5, CH-CH2-indole), 4.19 (dd, 1H, J 5, 9, CH-COO), 3.45 (dd, 1H, J 
14, 8, CH2-indole), 3.38-3.31 (m, 1H, CH2-indole obscured by MeOD),  2.60 (t, 2H, 
J 7, CH2-NH2), 1.67-1.57 (m, 1H, (CH2-CH), 1.53-1.34 (m, 3H, CH2-CH & CH2-
CH2NH2), 1.42 (s, 9H, C(CH3)3) and 1.00 (quin., 2H, (CH2-CH2CH); δC (100 MHz, 
MeOD) 174.1, 172.7, 169.5 (C=O ester and amide), 145.8, 139.1, 137.2 (C-aryl), 
133.9 (indole C-NH), 130.1 (CH-CH-C-aryl), 128.3 (CH-C-CO), 129.0 (indole C-C-
NH), 128.2 (CH-C-aryl), 127.80 (CH-C-phenyl), 126.2 (CH-CHCHC-aryl), 124.8 
(indole CH-NH), 122.6 (indole CH-CH-C-C), 120.0 (indole CH-C-C), 119.6 (indole 
CH-CH-C), 112.5 (indole CH-C-NH), 111.1 (indole C-CH2), 82.9 (C(CH3)3), 56.5 
(CH-CH2-indole), 54.6 (CH-COO), 41.4 (CH2-NH2), 32.0 (CH2-CH-COO), 31.1 
(CH2-indole), 29.4 (CH2-CH2NH2), 28.3 (C(CH3)) and 23.7 (CH2-CH2CH); ESI m/z 
100 %, 569.2 (MH
+
) and 11 %, 489.3 (M-C5H8O2); HR ESI m/z (C34H40N4O4H
+
 
requires 569.3122) found 569.3147. 
2.46, (D)-Tryptophan methyl ester hydrogen chloride 
D-Tryptophan (10 g, 49 mmol) was added to MeOH (100 mL) to form a suspension. 
Thionyl chloride (5.0 mL, 69 mmol) was slowly added to MeOH (50 mL) which was 
added to the suspension. The reaction was heated under reflux conditions, under 
nitrogen. After 3 hours the reaction was cooled and reduced in vacuo to 75 mL, 
dichloromethane was added and the reaction cooled to 0-5 ºC and stirred for 30 
minutes. The resulting precipitate was filtered and washed with dichloromethane to 
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give compound 2.46 as a white solid (4.91 g, 46 %); δH (400 MHz, D2O) 7.56 (d, 
1H, J 8, indole CH-C-C), 7.48 (d, 1H, J 7.5, indole CH-C-NH), 7.25 (s, 1H, indole 
CH-NH), 7.22 (t, 1H, J 8, indole CH-CH-C), 7.14 (t, 1H, J 8, indole CH-CH-C-C), 
4.40 (t, 1H, J 6.5, CH-CH2-indole), 3.75 (s, 3H, CH3), 3.45 (dd, 1H, J 14, 7, CH2-
indole) and 3.39 (dd, 1H, J 14, 7, CH2-indole); δC (100 MHz, D2O) 170.4 (C=O), 
136.2 (indole C-NH), 126.3 (indole C-C-NH), 125.4 (indole CH-NH), 122.2 (indole 
CH-CH-C-C), 119.6 (indole CH-C-C), 118.0 (indole CH-CH-C), 112.0 (indole CH-
C-NH), 105.9 (indole C-CH2), 53.3 (CH-CH2-indole and CH3) and 25.6 (CH2-
indole). 
2.47, 4-(2-Keto-1-benzimidazolinyl)piperidine-(D)-Trp-OMe 
Amine 2.46 (2.55 g, 10.0 mmol), N,N-diisopropylethylamine (5.0 mL, 30 mmol) and 
disuccinidyl carbonate (2.56 g, 10.0 mmol) were dissolved in dichloromethane (50 
mL) and stirred for 30 minutes. 4-(2-Keto-1-benzimidazolinyl) piperidine (2.17 g, 
9.98 mmol) was added to the reaction which was stirred overnight. The 
dichloromethane was removed in vacuo, the product dissolved in ethyl acetate and 
washed with a pH 2 buffer (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 mL). The 
organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (ethyl acetate:MeOH, 100:0 to 80:20) to give 
compound 2.47 as a white solid (0.83 g, 39 %); mp 134-136 º C; [α]20D (c = 0.526, 
MeOH) 12.45; υmax/cm
-1
: 3269 (N-H), 2949 (saturated C-H), 1688, 1622 (C=O) and 
1366 (C-O); δH (500 MHz, CDCl3) 9.37 (s, 1H, NH-indole), 8.31 (br.s, 1H, NH-C-
CH), 7.59 (d, 1H, J 8, indole CH-C-C), 7.35 (d, 1H, J 8.5, indole CH-C-NH), 7.17 (t, 
1H, J 7.5, indole CH-CH-C), 7.13-7.00 (m, 6H, indole CH-NH, indole CH-CH-C-C 
and aryl), 5.1 (d, 1H, J 7, NH-CHCH2-indole), 4.88 (q, 1H, J 6, CH-CH2-indole), 
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4.43 (tt, 1H,  J 12.5, 4, CH-NCO) 4.06 (br.d, 1H, J 13.5, equatorial CH2-N), 4.00 
(br.d, 1H, J 13.5, equatorial CH2-N), 3.74 (s, 3H, CH3), 3.39 (dd, 1H, J 15, 5, CH2-
indole), 3.33 (dd, 1H,  J  14.5, 5, CH2-indole), 2.87 (td, 1H, J 13,2, axial CH2-N), 
2.82 (td, 1H, J 13,2, axial CH2-N), 2.32 (qd, 1H, J 12.5, 4.5, CH2-CH2N), 2.27 (qd, 
1H, J 12.5, 4.5, CH2-CH2N) and 1.76 (br.d, 2H, J 13, equatorial CH2-CH2N); δC (125 
MHz, CDCl3) 173.8 (C=O ester), 156.9, 155.1 (C=O urea), 136.4 (indole C-NH), 
128.2, 127.7 (C-NCO and C-NHCO), 127.5 (indole C-C-NH), 123.2 (indole CH-
NH), 122.1 (CH-CHCN or CH-CH-C-NHCO), 121.8 (CH-CHCN or CH-CH-C-
NHCO), 121.5 (indole CH-CH-C-C), 119.5 (indole CH-C-C), 118.4 (indole CH-CH-
C), 111.6 (indole CH-C-NH), 109.9 (CH-CN or CH-CNHCO), 109.8 (C8) 109.4 
(CH-CN or CH-CNHCO), 54.8 (CH-CH2-indole), 52.3 (O-CH3), 50.6 (CH-N-CO), 
44.5 (CH2-N), 29.0 (CH2-CH2N) and 27.8 (CH2-indole); ESI m/z 100 %, 484.2 
(MNa
+
) and 31 % (MH
+
). 
2.48, (2R,2'R)-dimethyl 2,2'-carbonylbis(azanediyl)bis(3-(1H-indol-3-
yl)propanoate) 
The other product isolated in the synthesis of compound 2.47 was compound 2.48; 
δH (400 MHz, CDCl3) 8.46 (br.s, 2H, indole NH), 7.42 (d, 2H, J 8, indole CH-C-C), 
7.25 (d, 2H, J 8, indole CH-C-NH), 7.12 (t, 2H, J 8, indole CH-CH-C-NH), 7.04 (t, 
2H, J 8, indole CH-CH-C-C), 6.70 (s, 2H, indole CH-NH), 5.86 (d, 2H, NH-CO), 
4.82 (dt, 2H, J 8, 5.5, CH-CH2-indole), 3.39 (s, 6H, O-CH3) and 2.97 (d, 4H, CH2-
indole); δC (100 MHz, CDCl3) 174.1 (C=O ester), 157.3 (C=O urea), 136.0 (indole 
C-NH), 127.4 (indole C-C-NH), 123.5 (indole CH-NH), 121.9 (indole CH-CH-C-C), 
119.4 (indole CH-CH-C-NH), 118.4 (indole CH-C-C), 111.4 (indole CH-CH-NH), 
109.3 (indole C-CH2), 53.1, 52.3 (CH-CH2-indole) and 28.1 (CH2-indole). 
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2.49, 4-(2-Keto-1-benzimidazolinyl)piperidine-(D)-Trp-OH  
Ester 2.47 (0.60 g, 1.3 mmol) was dissolved in THF (20 mL). LiOH (0.13 g, 5.4 
mmol) was dissolved in D2O (20 mL), ethanol (5 mL) and added to the THF and 
stirred for 4 hours at room temperature. The reaction was acidified with HCl to pH 2, 
extracted with ethyl acetate and washed with NaCl (3 × 15 mL).  The organic layer 
was dried over Na2SO4 and reduced in vacuo to give compound 2.49 as a beige solid 
(0.52 g, 93 %) mp 187-188 °C; [α]22D (c = 1, MeOH) 0.7; δH; υmax/cm
-1
: 3316 (N-H), 
3060 (O-H carboxylic acid), 2932 (saturated C-H) and 1656, 1625 (C=O urea); δH 
(400 MHz, MeOD) 7.66 (d, 1H, J 8, indole CH-C-C), 7.35 (d, 1H, J 8, indole CH-C-
NH), 7.18 (s, 1H, indole CH-NH), 7.16-7.03 (m, 6H, CH-NH, indole CH-CH-C-C 
and aryl), 4.68 (dd, 1H, J 8, 5, CH-CH2-indole), 4.46 (tt, 1H, J 12.5, 4, CH-NCO) 
4.18-4.08 (m, 2H, equatorial CH2-N), 3.44 (dd, 1H, J 14.5, 5, CH2-indole), 3.27 (dd, 
1H,  J  14.5, 8, CH2-indole), 2.91 (qd, 2H, J 13.5, 2, axial CH2-N), 2.35 (qd, 1H, J 
12.5 ,4.5, axiaCH2-CHN l), 2.22 (qd, 1H, J 12.5, 4.5, axial CH2-CHN), and 1.72 (tt, 
2H, J 10, 2.5, equatorial CH2-CH2N); δC (100 MHz, MeOD) 176.6 (C=O acid), 
159.6 (C=O urea), 156.2 (C=O urea), 138.1 (indole C-NH), 130.2, 129.6 (C-NCO 
and C-NHCO), 129.0 (indole C-C-NH), 124.5 (indole CH-NH), 122.5 (CH-CHCN 
or CH-CH-C-NHCO), 122.48 (CH-CHCN or CH-CH-C-NHCO), 122.4 (indole CH-
CH-C-C), 119.9 (indole CH-C-C), 119.3 (indole CH-CH-C), 112.4 (indole CH-C-
NH), 111.6 (indole C-CH2), 110.6 (CH-CN or CH-CNHCO), 110.56 (CH-CN or 
CH-CNHCO), 56.5 (CH-CH2-indole), 52.1 (CH-NCO), 45.0, 44.9 (CH2-N), 30.9 
(CH2-CH2N) and 30.0 (CH2-indole); ESI m/z 100 %, 448.2 (MH
+
) and 17 %, 470.1 
(MNa
+
). 
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2.50, 4-(2-Keto-1-benzimidazolinyl)piperidine-(D)-Trp-(L)-Lys(Z)-O
t
Bu  
Acid 2.49 (0.51 g, 1.1 mmol,) was dissolved in dichloromethane (20 mL) and cooled 
to 0 °C. HATU (0.44 g, 1.2 mmol) was added and the reaction was stirred for 10 
minutes. Amine 2.21 (0.43 g, 1.2 mmol) and triethylamine (0.50 mL, 3.4 mmol) 
were added and the reaction was stirred for 24 hours. The dichloromethane was 
removed in vacuo, the product dissolved in ethyl acetate was washed with a pH 2 
buffer (3 × 15 mL), 0.1 M HCl (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). 
The organic layer was dried over Na2SO4 and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate:MeOH 
25:75:0 to 0:90:10)  to give compound 2.50 as a white solid (0.22 g, 25 %); δH (400 
MHz, MeOD) 7.67 (d, 1H, J 7.5, indole CH-C-C), 7.38-7.24 (m, 6H, indole CH-C-
NH and phenyl), 7.16 (s, 1H, indole CH-NH), 7.12-7.00 (m, 6H, indole CH-CH-C, 
indole CH-CH-C-C and aryl), 5.06 (s, 2H, CH2-phenyl), 4.70 (t, 1H, J 7.5, CH-CH2-
indole), 4.40 (tt, 1H,  J 12.5, 4, CH-NCO), 4.23 (dd, 1H, J 8, 5, CH-COO), 4.17 
(br.d, 1H, J 14, equatorial CH2-N), 4.12-4.07 (m, 1H, equatorial CH2-N), 3.34 (dd, 
1H, J 14, 7, CH2-indole), 3.21 (dd, 1H,  J  14, 7.5, CH2-indole), 3.07 (t, 2H, J 7, 
CH2-NHCbz), 2.87 (br.t, 1H, J 13, axial CH2-N), 2.82 (br.t, 1H, J 13, axial CH2-N), 
2.29 (qd, 1H, J 12.5 ,4.5, axial CH2-CH-N), 2.15 (qd, 1H, J 12.5, 4, axial CH2-CH-
N), 1.72-1.91 (m, 3H, CH2-CH2NHCbz and CH2-CHCOO), 1.59-1.50 (m, 1H, CH2-
CH2NHCbz and CH2-CH-COO), 1.47-1.36 (m, 2H, axial CH2-CH-N), 1.45 (s, 9H, 
C(CH3)3) and 1.19-1.07 (m, 2H, CH2-CH2CHCOO); δC (100 MHz, MeOD) 175.1, 
172.8 (C=O ester and amide), 159.0, 158.9, 156.2 (C=O urea and carbamate), 138.4 
(indole C-NH), 138.0 (phenyl C), 130.3, 129.7 (C-NCO and C-NHCO), 129.5 
(phenyl CH), 129.0 (indole C-C-NH), 128.99, 128.90 (phenyl CH), 124.7 (indole 
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CH-NH), 122.6, 122.4 (CH-CHCN and CH-CH-C-NHCO), 120.0, 119.9, 119.5 
(indole CH-CH-C, CH-CH-C-C and CH-C-C), 112.5 (indole CH-C-NH), 111.4 
(indole C-CH2), 110.6, 110.5 (CH-CN and CH-CNHCO), 82.9 (C(CH3)3), 67.4 
(CH2-phenyl), 57.3 (CH-CH2-indole), 54.5 (CH-COO), 52.1 (CH-NCO), 45.0, 44.9 
(CH2-N), 41.6 (CH2-NHCbz), 32.3 (CH2-CH-COO), 30.5 (CH2-CH2N), 29.5 (CH2-
indole), 28.4 (CH2-CH2NHCbz), 23.7 (C(CH3)3) and 21.0 (CH2-CH2CHCOO); ESI 
m/z 100 %, 766.4 (MH
+
). 
2.51, 4-(2-Keto-1-benzimidazolinyl)piperidine-(D)-Trp-(L)-Lys-O
t
Bu 
Carbamate 2.50 (0.22 g, 0.29 mmol) was dissolved in MeOH (5 mL). Palladium 
activated charcoal (0.02 g, catalytic) was added and the reaction stirred under 
hydrogen for 24 hours. The palladium was removed through filtration, and the 
MeOH was removed in vacuo to give compound 2.51 as a white solid (0.1 g, 55 %); 
δH (400 MHz, MeOD) 7.66 (d, 1H, J 8, indole CH-C-C), 7.35 (d, 1H, indole CH-C-
NH), 7.17 (s, 1H, indole CH-NH), 7.11-7.01 (m, 6H, indole CH-CH-C, indole CH-
CH-C-C and aryl), 4.68 (t, 1H, J 7, CH-CH2-indole), 4.42 (tt, 1H,  J 12.5, 4, CH-
NCO), 4.21 (m, 1H,CH-COO), 4.12 (d, 1H, J 12.5, equatorial CH2-N), 4.16 (d, 1H, J 
12.5, equatorial CH2-N), 3.38-3.30 (m, 1H, CH2-indole - obscured by MeOD), 3.24-
3.13 (m, 1H, CH2-indole), 2.91 (t, 1H, J 10, axial CH2-N), 2.86 (t, 1H, J 10, axial 
CH2-N), 2.55 (t, 2H, J 7.5, CH2-NH2), 2.31 (qd, 1H, J 12.5 ,4.5, axial CH2-CH-N), 
2.17 (qd, 1H, J 12.5, 4, axial CH2-CH-N), 1.75-1.62 (br.t, 3H, J 12.5, CH2-CHCOO 
and equatorial CH2-CH2N), 1.60-1.50 (m, 1H, CH2-CHCOO), 1.48-1.36 (m, 2H, 
CH2-CH2NH2), 1.46 (s, 9H, C(CH3)3) and 1.15-1.07 (m, 2H, CH2-CH2CHCOO); δC 
(100 MHz, MeOD) 175.2, 172.8 (C=O ester and amide), 159.0, 156.2 (C=O urea), 
138.1 (indole C-NH), 130.3, 129.7 (C-NCO and C-NHCO), 129.0 (indole C-C-NH), 
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126.2 (indole CH-NH), 124.7, 122.6 (CH-CHCN and CH-CH-C-NHCO), 122.4, 
120.0, 119.5 (indole CH-CH-C, CH-CH-C-C and CH-C-C), 112.5 (indole CH-C-
NH), 111.4 (indole C-CH2), 110.6, 110.5 (CH-CN and CH-CNHCO), 82.9 
(C(CH3)3), 57.4 (CH-CH2-indole), 54.6 (CH-COO), 52.1 (CH-NCO), 45.0, 44.9 
(CH2-N), 42.2 (CH2-NH2), 33.2 (CH2-CH-COO), 32.3 (CH2-CH2N), 30.08 (CH2-
indole), 29.5 (CH2-CH2NH2), 28.3 (C(CH3)3) and 23.8 (CH2-CH2-CH-COO); ESI 
m/z 100 %, 632.3 (MH
+
); HR m/z (C34H45N7O5H
+
 requires 632.555) found 
632.3578. 
6.2.2 Potential BSCIs - lactam containing compounds 
2.52, 3-Amino-azepan-2-one 
Acetyl chloride (118 mL, 1.65 mol) was carefully dissolved in MeOH (2 L). (L)-
Lysine.HCl (200 g, 1.10 mol) was added and the reaction heated under reflux 
conditions over night. The organic solvents were removed in vacuo to give (L)-lys-
methyl ester (239.6 g, 1.028 moles) as a white solid which was dissolved in MeOH 
(2 L). Sodium methoxide (470 mL, 2.06 mol) was added and the reaction was heated 
under reflux conditions and under nitrogen for 48 hours, then allowed to slowly cool 
for a further 48 hours. The NaCl precipitate was removed by filtration, 
dimethoxyethane was added and the resulting precipitate was removed by filtration. 
The organic solvents were then removed in vacuo to give compound 2.52 an oil 
which crystallised to a white solid when left to stand (60.60 g, 46 %); δH (400 MHz, 
D2O) 4.24 (dd, 1H, J 10, 1.5, CH-CO), 3.27-3.11 (m, 2H, lactam CH2-NH), 2.07-
1.90 (m, 2H, CH2-CH), 1.82 (dd, 1H, J 14, 4, equatorial lactam CH2-CH2NH), 1.75-
1.63 (m, 2H, lactam CH2-CH2CH) and 1.36 (ddt, 1H, J 15, 11, 3, axial lactam CH2-
CH2NH); δC (100 MHz, D2O) 173.9 (C=O), 52.9 (CH), 41.2 (lactam CH2-NH), 28.3 
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(lactam CH2-CH), 27.4 (lactam CH2-CH2CH) and 26.9 (lactam CH2-CH2NH); ESI 
mz 100 % (129.1). 
2.53, (S)-3-Amino-tetrahydropyridin-2-one 
Acetyl chloride (32.0 mL, 448 mmol) was dissolved in MeOH (150 mL). (L)-
Ornithine.HCl (30.0 g, 178 mmol) was added and the reaction heated under reflux 
conditions for 3 hours. The reaction was then cooled to 0 °C and sodium methoxide 
(120 mL) was added until pH 9-10 was reached, the reaction was stirred for 2.5 
hours. Diethyl ether (75 mL) was added and the precipitate removed by filtration, the 
organic solvents were then removed in vacuo to give compound 2.53 as a white oily 
solid which was not isolated and immediately dissolved in H2O and reacted. 
2.54, (R)-3-Amino-tetrahydropyridin-2-one 
Acetyl chloride (0.70 mL, 9.8 mmol) was dissolved in MeOH (20 mL). (D)-
Ornithine.HCl (0.720 g, 4.26 mmol) was added and the reaction heated under reflux 
conditions for 3 hours. The reaction was then cooled to 0 °C and sodium methoxide 
(1.5 mL) was added until pH 9-10 was reached, the reaction was stirred for 2.5 
hours. On completion of the reaction the organic solvents were then removed in 
vacuo to give compound 2.54 as a white oily solid which was not isolated  
immediately dissolved in H2O and reacted. 
2.55, (S)-3-Amino-azepan-2-one hydropyroglutamate 
Amine 2.52 (20.9 g, 163 mmol) was dissolved in dimethoxyethane (500 mL) and 
heated to 70 °C. (S)-(−)-2-Pyrrolidone-5-carboxylic acid (21.70 g, 168.10 mmol) 
was added slowly and the reaction was heated for 3 hours. The resulting precipitate 
was removed by filtration, washed with propan-2-ol and dried in vacuo to give 
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compound 2.55 as a white solid (28.35 g, 67 %); δH (400 MHz, D2O) 4.20 (dd, 1H, J 
11, 1.5, lactam CH), 4.07 (dd, 1H, J 9, 6, pyroglutamic acid CH), 3.26-3.12 (m, 2H, 
lactam CH2-NH), 2.46-2.37 (m, 1H, pyroglutamic acid CH2-CO), 2.30 (t, 2H, J 8, 
pyroglutamic acid CH2-CCOO), 2.01-1.90 (m, 2H, lactam CH2-CH, lactam CH2-
CH2CH and pyroglutamic acid CH2-CO), 1.77 (br.d, 1H, J 14, equatorial lactam 
CH2-CH2NH), 1.71-1.61 (m, 2H, lactam CH2-CH2CH and lactam CH2-CH) and 1.31 
(br.q, 1H, J 12.5, axial lactam CH2-CH2NH); δC (100 MHz, D2O) 181.7, 180.2, 
173.8 (C=O), 58.3 (pyroglutamic acid CH), 52.9 (lactam CH), 41.2 (lactam CH2-
NH), 29.9 (pyroglutamic acid CH2-CO), 28.2, 27.4, 26.9 (lactam CH2-CH, CH2-
CH2CH, CH2-CH2NH) and 25.3 (CH2-COO pyroglutamic acid). 
2.56, (R)-3-Amino-azepan-2-one hydropyroglutamate 
Amine 2.52 (38.7 g, 302 mmol) was dissolved in dimethoxyethane (500 mL) and 
heated to 70 °C. (R)-(+)-2-Pyrrolidone-5-carboxylic acid (39.0 g, 302 mmol) was 
added slowly and the reaction was heated for 3 hours. The resulting precipitate was 
removed by filtration, washed with propan-2-ol and dried in vacuo to give compound 
2.56 as a white solid (71.38 g, 91 %); δH (400 MHz, D2O) 4.18 (dd, 1H, J 7.5, 2, 
lactam CH), 4.07 (dd, 1H, J 10, 6, pyroglutamic acid CH), 3.25-3.01 (m, 2H, lactam 
CH2-NH), 2.45-2.35 (m, 1H, pyroglutamic acid CH2-CO), 2.30 (t, 2H, J 8.5, 
pyroglutamic acid CH2-CCOO), 2.00-1.89 (m, 2H, lactam CH2-CH, lactam CH2-
CH2CH and pyroglutamic acid CH2-CO), 1.80 (br.d, 1H, J 13.5, equatorial lactam 
CH2-CH2NH), 1.70-1.57 (m, 2H, lactam CH2-CH2CH and lactam CH2-CH) and 1.31 
(br.q, 1H, J 12.5, axial lactam CH2-CH2NH); δC (100 MHz, D2O) 181.7, 180.2, 
173.8 (C=O), 58.3 (pyroglutamic acid CH), 52.9 (lactam CH), 41.2 (lactam CH2-
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NH), 29.7 (pyroglutamic acid CH2-CO), 28.2, 27.4, 26.9 (lactam CH2-CH, CH2-
CH2CH, CH2-CH2NH) and 25.3 (CH2-COO pyroglutamic acid). 
2.59, (S)-3,3,3-Trifluoro-2-methoxy-N-((S)-2-oxoazepan-3-yl)-2-
phenylpropanamide 
(S)-(-)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid (0.05 g, 0.21 mmol) was 
dissolved in dichloromethane (1 mL), oxalyl chloride (27 µL, 0.32 mmol) and DMF 
(1 drop, catalytic) were added and the reaction stirred for 2 hours. The organic 
solvents were removed in vacuo and the product compound 2.57 was dissolved in 
THF (4 mL) and cooled to 0°C. Pyroglutamic acid salt 2.55 (0.26 g, 0.98 mmol) in 
H2O (4 mL) and K2CO3 (0.44 g, 3.2 mmol) were added and the reaction was stirred 
over night. The THF was removed in vacuo, ethyl acetate added and was washed 
with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo to give 
compound 2.59 as a white solid (0.046 g, 63 %); δH (400 MHz, CDCl3) 8.00 (d, 1H, 
J 6, NH-CH), 7.56-7.53 (m, 2H, phenyl CH), 7.40-7.36 (m, 3H, phenyl CH), 6.05 
(br.t, 1H, J 4, NH-CH2), 4.59 (ddd, 1H, J 11, 6, 1.5, lactam CH), 3.47, 3.39 (br.q, 
3H, J 1.5, OCH3), 3.34-3.20 (m, 2H, lactam CH2-NH), 2.05-1.96 (m, 2H, equatorial 
lactam CH2-CH and equatorial lactam CH2-CH2NH), 1.89-1.75 (m, 2H, lactam CH2-
CH2CH), 1.51-1.32 (m, 2H, axial lactam CH2-CH and CH2-CH2NH). 
2.60, (R)-3,3,3-Trifluoro-2-methoxy-N-((S)-2-oxoazepan-3-yl)-2-
phenylpropanamide 
(R)-(+)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid (0.19 g, 0.82 mmol) was 
dissolved in dichloromethane (4 mL), oxalyl chloride (0.10 mL, 0.15 mmol) and 
DMF (1 drop, catalytic) were added and the reaction stirred for 2 hours. The organic 
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solvents were removed in vacuo and the product compound 2.58 was dissolved in 
THF (15 mL) and cooled to 0°C. Pyroglutamic acid salt 2.55 (1.01 g, 3.93 mmol) in 
H2O (15 mL) and K2CO3 (1.67 g, 12.1 mmol) were added and the reaction was 
stirred over night. The THF was removed in vacuo, ethyl acetate added and was 
washed with a pH 2 buffer (3 × 25 mL), dried over Na2SO4 and reduced in vacuo to 
give compound 2.60 as a colourless oil (0.16 g, 58 %); δH (400 MHz, CDCl3) 8.10 
(d, 1H, J 6, NH-CH), 7.49-7.45 (m, 2H, phenyl CH), 7.32-7.29 (m, 3H, phenyl CH), 
7.07 (br.t, 1H, J 6, NH-CH2), 4.47 (br.dd, 1H, J 11, 7.5, lactam CH), 3.46, 3.32 (br.q, 
3H,  J 1.5, OCH3), 3.18-3.12 (m, 2H, lactam CH2-NH), 2.05 (br.d, 1H, J 12.5, 
equatorial lactam CH2-CH), 1.97-1.90 (m, 1H, equatorial lactam CH2-CH2NH), 1.79-
1.67 (m, 2H, lactam CH2-CH2CH), 1.47 (q, 1H, J 12.5, axial lactam CH2-CH) and 
1.34-1.22 (m, 1H, CH2-CH2NH). 
2.61, (S)-Benzyl -2-oxopiperidin-3-ylcarbamate 
Amine 2.53 (5.71 g, 50.0 mmol) was dissolved in H2O (30 mL) and cooled to 0 °C. 
Benzyl chloroformate (11 mL, 75 mmol) was added. The pH was with Na2CO3 until 
pH 10 was reached and THF (30 mL) was added, the reaction stirred overnight. The 
THF was removed in vacuo and the aqueous layer was extracted with ethyl acetate (3 
× 25 mL), diethyl ether (3 × 25 mL), washed with NaCl (3 × 15 mL) and dried over 
Na2SO3. The product was purified by recrystallisation from ethyl acetate and 
petroleum ether to give compound 2.61 as a white solid (0.91 g, 68 % over 2 steps); 
The e.e. was determined to be > 99 % by chiral HPLC; mp 64-65 °C; [α]24D  (c = 1, 
CHCl3) +35.2; υmax/cm
-1
: 3323 (N-H), 2950 (saturated C-H), 1749 (C=O ester), 1684 
(C=O amide), 1523 (aromatic) and 1259 (C-O); δH (400 MHz, CDCl3) 7.37-7.28 (m, 
5H, phenyl), 6.85 (br.s, 1H, NH-CH2), 6.03 (d, 1H, J 6, CH-NH), 5.11 (s, 2H, CH2-
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phenyl), 4.38-31 (m, 1H, lactam CH), 3.22-3.12 (m, 2H, lactam CH2-NH), 2.42-2.35 
(m, 1H, CH2CH), 1.89-1.78 (m, 1H, lactam CH2CH) and 1.73-1.53 (m, 2H, lactam 
CH2CH2NH); δC (100 MHz, CDCl3) 171.7 (C=O amide), 155.4 (C=O carbamate), 
136.5 (phenyl C), 128.5, 128.1 (phenyl CH), 67.1 (CH2-phenyl), 51.1 (lactam CH), 
41.7 (lactam CH2-NH), 27.0 (lactam CH2-CH) and 21.1 (lactam CH2-CH2NH). HR 
ESI (C13H16N2O3Na requires 271.1052) found 271.1063.  
2.62, (R)-Benzyl -2-oxopiperidin-3-ylcarbamate  
Amine 2.54 (5.70 g, 50.0 mmol) was dissolved in H2O (30 mL) and cooled to 0 °C. 
Benzyl chloroformate (11 mL, 75 mmol) was added. The pH was with Na2CO3 until 
pH 10 was reached and THF (30 mL) was added, the reaction stirred overnight. The 
THF was removed in vacuo and the aqueous layer was extracted with ethyl acetate (3 
× 25 mL), diethyl ether (3 × 25 mL), washed with NaCl (3 × 15 mL) and dried over 
Na2SO3. The product was purified by recrystallisation from ethyl acetate and 
petroleum ether to give compound 2.62 as a white solid (0.91 g, 88 % over 2 steps); 
The e.e. was determined to be > 99 % by chiral HPLC; δH (400 MHz, CDCl3) 7.37-
7.25 (m, 5H, phenyl), 6.77 (br.s, 1H, NH-CH2), 5.91 (d, 1H, J 6, NH-CH), 5.09 (s, 
2H, CH2-phenyl), 4.05 (dt, 1H, J 10.5, 6.5, CH-CO), 3.25-3.19 (m, 2H, lactam CH2-
NH), 2.45-2.37 (m, 1H, equatorial lactam CH2-CH), 1.89-1.78 (m, 2H, lactam CH2-
CH2NH) and 1.59 (qd, 1H, J 12, 5, axial lactam CH2-CH); δC (100 MHz, CDCl3) 
171.7 (lactam C=O), 156.2 (carbamate C=O), 141.2 (phenyl C), 128.6, 127.5 (phenyl 
CH), 66.8 (CH2-phenyl), 51.6 (lactam CH), 41.7 (lactam CH2-NH), 27.6 (lactam 
CH2-CH) and 21.0 (lactam CH2-CH2NH); ESI m/z 80 %, 271.1 (MNa
+
) and 80 %, 
518.8 (M2Na
+
). 
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2.63, (S)-Benzyl- 2-oxoazepan-3-ylcarbamate 
Pyroglutamic acid salt 2.55 (5.25 g, 20.4 mmol) was dissolved in H2O  (20 mL) and 
cooled to 0 °C. Benzylchloromate (1.4 mL, 10 mmol) was added. The pH  was 
adjusted to pH 10 by the addition of Na2CO3 and THF was added, the reaction was 
stirred for 15 hours. The THF was removed and the aqueous layer extracted with 
ethyl acetate, washed with NaHCO3, dried over Na2SO4 and reduced in vacuo to give 
compound 2.63 as a white solid (2.01 g, 75 %). The e.e. was determined to be > 99 
% by chiral HPLC; mp 121-122 °C; [α]28D (c = 0.652, MeOH) -0.71; υmax/cm
-1
: 3239 
(N-H), 2914 (saturated C-H), 1723 (C=O carbamate), 1663 (C=O amide) and 1254 
(C-O) ester; δH (400 MHz, CDCl3) 7.37-7.27 (m, 5H, phenyl CH), 6.73 (s, 1H, NH-
CH2), 6.21 (d, 1H, J 5, NH-COO), 5.12 (d, 1H, J 12.5, CH2-phenyl), 5.08 (d, 1H, J 
12, CH2-benzyl), 4.33 (dd, 1H, J 11, 5, CH-CO), 3.25-3.17 (m, 2H, lactam CH2-
NH), 2.09 (br.d, 1H, J 13, CH2-CH2CH), 2.03-1.95 (m, 1H, lactam equatorial CH2-
CH), 1.86-1.70 (m, 2H, lactam CH2-CH2NH and CH2-CH2CH), 1.52 (qd, 1H, J 12.5, 
3, lactam axial CH2-CH) and 1.43-1.30 (m, 1H, CH2-CH2NH); δC (100 MHz, CDCl3) 
175.6 (C=O amide), 155.6 (C=O carbamate), 136.6 (phenyl C), 128.5, 128.1, 128.0 
(phenyl CH), 66.7 (CH2-phenyl), 53.7 (CH), 42.1 (CH2-NH), 32.0 (CH2-CH), 28.9, 
28.0 (CH2-CH2NH and CH2-CH2CH); ESI m/z 100 %, 285.1 (MNa
+
). Data is 
consistent with previously reported data for this compound.
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2.64, Cbz (R)-3-Amino-azepan-2-one 
Pyroglutamic acid salt 2.56 (0.36 g, 1.4 mmol) was dissolved in H2O  (10 mL) and 
cooled to 0 °C. Benzylchloromate (0.2 mL, 1 mmol) was added. The pH was 
adjusted to pH 10 by the addition of Na2CO3 and THF was added, the reaction was 
stirred for 15 hours. The reaction was separated and the aqueous layer was extracted 
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with ethyl acetate and all the organic layers combined. The organic layers were then 
washed with NaHCO3, dried over Na2SO4 and reduced in vacuo to give compound 
2.64 as a white solid (0.22 g, 79 %); The e.e. was determined to be > 99 % by chiral 
HPLC; mp 120-121 °C; [α]31D (c = 0.63, MeOH) +0.97; υmax/cm
-1
: 3245 (N-H), 2929 
(saturated C-H), 1729 (C=O carbamate), 1664 (C=O amide) and 1249 (C-O) ester; 
δH (400 MHz, CDCl3) 7.36-7.27 (m, 5H, phenyl CH), 6.29 (br.t, 1H, NH-CH2), 6.16 
(d, 1H, J 4, NH-CH), 5.11 (d, 1H, J 12, CH2-phenyl), 5.07 (d, 1H, J 12, CH2-
benzyl), 4.33 (ddd, 1H, J 11.5, 6, 1.5, lactam CH), 3.30-3.17 (m, 2H, lactam CH2-
NH), 2.10 (br.d, 1H, J 14, equatorial lactam CH2-CH), 2.00 (br.d, 1H, equatorial 
lactam CH2-CH2NH), 1.86-1.70 (m, 2H, lactam CH2-CH2CH), 1.52 (br.q, 1H, J 11.5, 
axial lactam CH2-CH) and 1.43-1.32 (m, 1H, CH2-CH2NH); δC (100 MHz, CDCl3) 
175.5 (C=O amide), 155.6 (C=O carbamate), 136.6 (phenyl C), 128.5, 128.1, 128.0 
(phenyl CH), 66.7 (CH2-phenyl), 53.7 (CH), 42.2 (lactam CH2-NH), 32.1 (lactam 
CH2-CH), 28.9, 28.0 (lactam CH2-CH2NH and lactam CH2-CH2CH); ESI m/z 100 
%, 285.1 (MNa
+
) and 34 %, 546.7 (M2Na
+
).  
2.65, (S)-3-Amino-azepan-2-one hydrogen chloride  
Acetyl chloride (37.0 mL, 520 mmol) was dissolved in ethanol (700 mL) and to it 
pyroglutamic acid salt 2.55 (121.5 g, 472.9 mmol) was added. The reaction was 
stirred for 2 hours and then filtered to give the HCl salt 2.65 as a white solid (72.14 
g, 93 %). 
2.66, (R)-3-Amino-azepan-2-one hydrogen chloride 
Acetyl chloride (24.0 mL, 334 mmol) was dissolved in ethanol (500 mL) and to it 
pyroglutamic acid salt 2.56 (78.0 g, 303 mmol) was added. The reaction was stirred 
for 2 hours and then filtered to give the HCl salt 2.66 as a white solid (49.2 g, 99 %). 
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2.67, Benzyl 4-carboxy benzoate - alternative method of synthesis 
Terephthalic acid (15 g, 90 mmol) was dissolved in aqueous KOH (12.0 g, 214 
mmol) in 150 ml H2O. The pH was adjusted to pH 9 by adding HCl drop wise.  
Ethanol (100 mL) and benzyl chloride (10.5 mL, 100 mmol) were added and the 
reaction was heated under reflux conditions for 2 hours. After cooling NaHCO3 (10.0 
g, 119 mmol) was added and the oily layer was removed by filtration. The filtrate 
was acidified with concentrated HCl and shaken with ethyl acetate (500 mL). The 
precipitated terephthalic acid was removed by filtration. The filtrate was separated 
and the organic layer was washed with NaCl (aq) (3 × 150 mL), dried over Na2CO3 
and reduced in vacuo, the product was then purified by re-crystallisation with hot 
ethyl acetate and petroleum ether to give compound 2.67 (2.76 g, 10 %); mp 175-177 
ºC (decomposed); υmax/cm
-1
; 2983 (O-H), 1707 (C=O), 1683 (aromatic) and 1259 
(ester C-O); δH (400 MHz, CDCl3) 8.16 (s, 4H, CH-COOH and CH-COO), 7.49-7.32 
(m, 5H, phenyl) and 5.39 (s, 2H, CH2-phenyl); δC (100 MHz, CDCl3) 176.2 
(COOH), 174.9 (COO-benzyl), 138.6 (C aryl), 135.8 (C-CH2O), 133.0 (C aryl), 
129.9, 129.0, 128.3 (phenyl CH), 128.1 (CH-COOH), 127.1 (CH-COO) and 67.9 
(CH2-phenyl); HR ESI m/z (C15H12O4 requires 255.0663) found 255.0659. Data is 
consistent with previously reported data for this compound.
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2.68, 4-Carboxybenzoate benzaldehyde  
4-Carboxybenzaldehyde (0.76 g, 5.1 mmol) was dissolved in DMF (12 mL), this was 
added to a solution of NaH (0.21 g, 5.3 mmol) in DMF (10 mL) and stirred under 
nitrogen for 45 minutes. Benzyl bromide (0.7 mL, 5 mmol) was added and the 
reaction stirred overnight. On completion H2O was added to the reaction and HCl 
until pH2 was reached. The product was extracted with ethyl acetate (3 × 15 mL), 
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the organic layer washed with NaCl and NaCO3H (3 × 15 mL) then reduced in 
vacuo. The product was stirred in DABCO (15 mL) for 48 hours, pH 2 buffer was 
added and the product was extracted with ethyl acetate (3 × 15 mL), dried over 
Na2CO3 and reduced in vacuo to give compound 2.68 as a yellow oil (0.98 g, 80 %); 
δH (400 MHz, CDCl3) 10.05 (s, 1H, aldehyde H), 8.19 (d, 2H, J 8, CH-CCHO), 7.89 
(d, 2H, J 8, CH-CCOO), 7.48-7.25 (m, 5H, phenyl) and 5.39 (s, 2H, CH2-phenyl). 
Data is consistent with previously reported data for this compound.
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2.69, Benzyl 4-carboxy benzoate  
Sodium chlorite (0.34 g, 3.0 mmol) was dissolved in H2O  (10 mL), this was added 
dropwise to a solution of aldehyde 2.68 (0.7 g, 3 mmol) and sulfamic acid (0.25 g, 
2.6 mmol) in acetonitrile (50 mL) and H2O  (50 mL), the reaction was stirred for one 
hour. The reaction was quenched with pH 2 buffer (50 mL), extracted with ethyl 
acetate (3 × 25 mL), washed with NaCl (3 × 15 mL), dried over Na2SO4 and reduced 
in vacuo. The product was purified by recrystallisation from hot ethyl acetate and 
petroleum ether to give compound 2.69 as a white solid (0.17 g, 22 %). See 
alternative method of synthesis for characterisation data. 
2.70, 4-Benzyloxycarbonyl benzoyl chloride 
Acid 2.69 (2.56 g, 9.99 mmol) was dissolved in dichloromethane (10 mL). Oxalyl 
chloride (1.3 mL, 15 mmol) and DMF (1 drop, catalytic) was added and the reaction 
was stirred at room temperature for 24 hours. The oxalyl chloride was removed in 
vacuo. The product compound 2.70 was not isolated and reacted on. 
2.71, (S)-3-(4'-Benzyloxycarbonyl benzoylamino)-3-amino-azepan-2-one 
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Acid chloride 2.70 (9.99 mmol) in dichloromethane was cooled on ice and added to 
pyroglutamic acid salt 2.55 (2.57, 10.0 mmol) in H2O, the reaction was stirred for 12 
hours. The organic layer was separated, the aqueous layer extracted with ethyl 
acetate (3 × 10 mL) and all the organic layers were combined. The organic layers 
were washed with pH 2 buffer (3 × 10 mL), dried over Na2CO3 and reduced in 
vacuo, the product was purified by re-crystallisation with hot ethyl acetate to give 
compound 2.71 (0.37 g, 10%); mp 160 ºC (decomposed); [α]25D (c = 0.58, MeOH) 
+26.03; υmax/cm
-1
: 2937 (saturated C-H), 1718 (ester C=O), 1666 (amide C=O), 1533 
(aromatic) and 1270 (ester C-O); δH (400 MHz, CDCl3) 8.11 (d, 2H, J 8.5, CH-
COO), 7.88 (d, 2H, J 8.5, CH-CONH), 7.77 (d, 1H, J 10, NH-CH), 7.39-7.54 (m, 
5H, phenyl), 6.62 (t, 1H, J 5, NH-CH2), 5.36 (s, 2H, CH2-phenyl), 4.69 (q, 1H, J 5, 
lactam CH), 3.24-3.48 (m, 2H, lactam CH2-NH), 2.22 (d, 1H, J 13, equatorial lactam 
CH2-CH), 2.00-2.19 (m, 1H, equatorial lactam CH2-CH2NH), 1.79-1.95 (m, 2H, 
lactam CH2-CH2CH), 1.55 (q, J 12.5, axial lactam CH2-CH) and 1.41 (q, 1H,  J 13, 
axial lactam CH2-CH2NH); δC (100 MHz, CDCl3) 175.6 (C=O ester), 165.7, 165.33 
(C=O amide), 138.2, 132.8 (C aryl), 135.8 (phenyl C), 129.9 (CH-CCOO), 128.7, 
128.4, 128.2 (phenyl CH), 127.2 (CH-CCONH), 67.1 (CH2-phenyl), 52.8 (lactam 
CH), 42.2 (lactam CH2-NH), 31.5 (lactam CH2-CH), 28.9 (lactam CH2-CH2CH) and 
28.0 (CH2-CH2NH); HR ESI m/z (C21H22N2O4 requires  367.1652) found 367.1666.  
2.72, (S)-3-(4'-Carboxy benzoylamino)- 3-amino-azepan-2-one  
Ester 2.71 (0.37 g, 1.0 mmol) was dissolved in THF (20 mL). Palladium activated 
charcoal (0.04 g, catalytic) was added and the reaction was stirred under hydrogen 
for 24 hours. The reaction was filtered and the THF was reduced in vacuo, the 
product was purified by re-crystallisation in THF and petroleum ether to give 
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compound 2.72 as a white solid (0.26 g, 95 %); mp 253-257°C (decomposed); [α]26D 
(c = 0.62, MeOH) +19.64.υmax/cm
-1
: 2924 (O-H), 1688 (acid C=O) and 1627 
(aromatic); δH (400 MHz, d6-DMSO) 13.19 (s, 1H, OH), 8.41 (d, 1H, J 7, NH-CH), 
8.02 (d, 2H, J 8, CH-CCOOH), 7.95 (d, 2H, J 8, CH-CCONH), 7.86 (t, 1H, J 6, NH-
CH2), 4.63 (dd, 1H, J 11, 8, lactam CH), 3.24 (td, 1H, J 8.5, 5 axial lactam CH2-NH) 
3.10 (m, 1H, equatorial lactam CH2-NH), 1.91 (t, 2H, J 11, equatorial lactam CH2-
CH and equatorial lactam CH2-CH2NH), 1.75 (m, 2H, lactam CH2-CH2CH), 1.57 (q, 
1H, J 11, axial lactam CH2-CH) and 1.25 (q, 1H, J 12, axial lactam CH2-CH2NH); δC 
(100 MHz, d6-DMSO) 174.1 (C=O acid), 166.8, 164.5 (C=O), 138.0, 133.1 (C aryl), 
129.3 (CH-CCOOH), 127.4 (CH-CCONH),), 52.0 (lactam CH), 40.6 (lactam CH2-
NH), 30.6 (lactam CH2-CH), 28.9 (lactam CH2-CH2CH) and 27.7 (lactam CH2-
CH2NH); ESI m/z 100 %,  299.1 (MNa
+
). 
2.73, (S)- 4'-Benzyloxycarbonyl benzoylamino)-3-amino-tetrahydropyridin-2-
one 
Acid chloride 2.70 (15 mmol) in dichloromethane was cooled on ice and added to 
amine 2.53 (15 mmol) in H2O, the reaction was stirred for 12 hours. The organic 
layer was separated, the aqueous layer washed with ethyl acetate (3 × 10 mL), the 
organic layers were washed with pH 2 buffer (3 × 10 mL), dried over Na2CO3 and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate:MeOH 75:25:0 to 0:90:10) to give compound 2.73 
(0.93 g, 18 %); mp 139-140 °C;[α]24D (c = 0.27, CHCl3) +60.09; υmax/cm
-1
: 3240 (N-
H), 2945 (saturated C-H), 1724 (ester C=O), 1673 (amide C=O), 1548 (aromatic) 
and 1278 (ester C-O); δH (400 MHz, CDCl3) 8.03 (d, 2H, J 7.5, CH-CCOO), 7.83 (d, 
2H, J 7.5, CH-CCONH), 7.70 (d, 1H, J 6, NH-CH), 7.24-7.29 (m, 5H, phenyl), 6.85 
(br.s, 1H, NH-CH2), 5.33 (s, 2H, CH2-phenyl), 4.39 (dt, 1H, J 11.5, 5.5, lactam CH), 
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3.31-3.26 (m, 2H, lactam CH2-NH), 2.50 (ddt, 1H, J 4.5, 5, 13, lactam CH2-CH), 
1.2-1.84 (m, 2H, lactam CH2-CH2CH) and 1.73-1.62 (m, 1H, lactam CH2-CH), δC 
(100 MHz, CDCl3) 172.0 (C=O ester), 166.6, 165.7 (C=O amide), 138.0 (C phenyl), 
135.7, 132.7 (C aryl), 129.8 (CH-CCOO), 128.7, 128.4, 128.3 (phenyl CH), 127.3 
(CH-CCONH), 67.1 (CH2-phenyl), 50.9 (lactam CH), 41.7 (lactam CH2-NH), 27.1 
(lactam CH2-CH) and 21.2 (lactam CH2-CH2NH); ESI m/z 100 %, 375.1 (MNa
+
) and 
29 %, 353.1 (MH
+
); HR ESI m/z (C20H20N2O4Na
+
 requires  375.1315) found 
375.1313. 
2.74, (S)-Benzyl 1-(4-(2-oxoazepan-3-ylcarbamoyl)benzoyl)piperidine-4-
carboxylate 
Acid 2.72 (0.13 g, 0.45 mmol) was dissolved in dichloromethane (5 mL) and cooled 
to 0 ºC. HATU (0.17 g, 0.45 mmol) was added and the reaction stirred for 10 
minutes. Amine 2.77 (0.5 mmol) and triethylamine (0.30 mL, 1.4 mmol) were added 
and the reaction stirred for 15 hours. The dichloromethane was removed in vacuo, 
the product dissolved in ethyl acetate (20 mL), washed with pH 2 buffer (3 × 15 mL) 
and ½ saturated sodium bicarbonate (3 × 15 mL), dried over Na2CO3 and reduced in 
vacuo. The product was purified silica column chromatography petroleum 
ether:ethyl acetate:MeOH (60:40:0 to 0:90:10) to give compound 2.74 as a 
colourless oil ( 0.10 g, 47 %); δH (400 MHz, CDCl3) 7.85 (d, 2H, J 7.5, aryl CH), 
7.69 (d, 1H, J 5.5, NH-CH), 7.42 (d, 2H, J 8, aryl CH), 7.37-7.27 (m, 5H, phenyl), 
6.80 (br.t, 1H, J 5, NH-CH2), 5.11 (s, 2H, CH2-phenyl), 4.68 (q, 1H, J 5, lactam CH), 
4.55-4.40 (m, 1H, equatorial CH2-N), 3.70-3.52 (m, 1H, equatorial CH2-N), 3.34-
3.19 (m, 2H, lactam CH2-NH), 3.12-2.93 (m, 2H, axial CH2-N), 2.61 (tt, 1H, J 10, 4, 
CH-CH2CH2N), 2.19 (d, 1H, J 14, equatorial lactam CH2-CH), 2.11-1.96 (m, 2H, 
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lactam CH2-CH2CH), 1.94-1.60 (m, 5H, equatorial lactam CH2-CH2NH and CH2-
CH2N), 1.53 (q, 1H, J 12, axial lactam CH2-CH) and 1.39 (q, 1H, J 12, axial lactam 
CH2-CH2NH); δC (100 MHz, CDCl3) 175.7 (C=O ester), 173.8, 169.5, 165.4 (C=O), 
138.9 (CH-CON), 135.8 (C-CH2O), 135.3 (C-CONH), 128.6, 128.4, 128.1 (phenyl 
CH), 127.4, 127.0 (aryl CH), 66.5 (CH2-phenyl), 52.7 (lactam CH), 46.9 (CH2-NH), 
42.1 (lactam CH2-N), 41.5 (CH2-N), 40.9 (CH-COO-benzyl), 31.5 (lactam CH2-CH), 
28.9 (lactam CH2-CH2CH), 28.6 (CH2-CH2N) and 28.0 (lactam CH2-CH2NH). 
2.75, 1-(tert-Butoxycarbonyl)piperidine-4-carboxylic acid 
Isonipecotic acid (15.5 g, 120 mmol) was dissolved in H2O with Na2CO3 (21.16 g, 
199.6 mmol) and dioxane (50 mL). Di-tert-butyl-dicarbonate (26.0 g, 119 mmol) 
was added and the reaction was stirred for 24 hours. The organic solvents were 
reduced in vacuo and the reaction acidified to pH 2 with HCl. Diethyl ether (80 mL) 
was added and the resulting precipitate was removed through filtration. The aqueous 
layer was extracted with ethyl acetate (3 × 25 mL), the organic layers were then 
combined and dried over NaSO4 and reduced in vacuo to give compound 2.75 as a 
white solid (19.11 g, 69 %); mp 145-147 ºC; υmax/cm
-1
: 3192 (O-H), 2973 (saturated 
C-H), 1732 (carbamate C=O), 1655 (amide C=O) and 1154 (ester C-O); δH (500 
MHz, CDCl3) 9.65 (OH), 3.99 (br.s, 2H, equatorial CH2-N), 2.84 (t, 2H, J 11.5, axial 
CH2-N), 2.46 (tt, 1H, J 11, 4, CH-COOH), 1.88 (2H, d, J 12.5, equatorial CH2-
CH2N), 1.62 (qd, 2H, J 10.5, 4.5, axial CH2-CH2N) and 1.43 (s, 9H, C(CH3)3); δC 
(125 MHz, CDCl3) 180.1 (C=O acid), 154.8 (C=O carbamate), 79.9 (C(CH3)3, 43.3 
(CH2-N), 40.8 (CH-COOH), 28.7 (C(CH3)3 and 28.2 (CH2-CH2N). Data is consistent 
with previously reported data for this compound.
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2.76, 4-Benzyl-1-tert-butyl piperidine-1,4-dicarboxylate 
Acid 2.75 (18.0 g, 78.5 mmol) was dissolved in DMSO (50 mL) and to this KOH 
(4.84 g, 86.4 mmol) was H2O (10 mL) were added. Benzyl bromide (9.30 mL, 78.5 
mmol) was added and the reaction stirred for 15 hours. H2O (100 mL) was added and 
the product was extracted with ethyl acetate (3 × 50 mL), washed with ½ saturated 
sodium bicarbonate (3 × 50 mL) to give compound 2.76 as a colourless oil (16.6 g, 
66 %); υmax/cm
-1
:  2975 (saturated C-H), 1732 (ester C=O), 1688 (carbamate C=O) 
and 1154 (ester C-O); δH (400 MHz, CDCl3) 7.38-7.28 (m, 5H, phenyl), 5.11 (s, 2H, 
CH2-phenyl), 4.01 (br.d, 2H, J 10, equatorial CH2-N), 2.81 (br.t, 2H, J 12, axial 
CH2-N), 2.49 (tt, 1H, J 11, 4, CH-CO), 1.89 (dd, 2H, J 13, 3, equatorial CH2-CH2-
N), 1.64 (dtd, 2H, J 14, 12, 5, axial CH2-CH2N) and 1.46 (s, 9H, C(CH3)3); δC (100 
MHz, CDCl3) 174.3 (ester C=O), 154.7 (carbamate C=O), 136.0 (phenyl C ), 128.6, 
128.3, 128.1 (phenyl CH), 79.6 (C(CH3)3), 66.3 (CH2-phenyl), 42.8 (CH2-N), 41.2 
(CH-CO), 28.4 (C(CH3)3) and 28.0 (CH2-CH2-N); ESI mz 100 %, 342.2 (MNa
+
). 
Data is consistent with previously reported data for this compound.
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2.77, 4-Benzyl-piperidine-4-carboxylate hydrogen chloride 
Carbamate 2.76 (50 mmol) was dissolved in 4M HCl in dioxane (10 mL) and stirred 
for 4 hours. The organic solvents were removed in vacuo to give compound, 2.77 as 
a white solid (12.7 g, 99 %); mp 146-147 °C; υmax/cm
-1
:  2938 (saturated C-H), 1737 
(ester C=O), 1596 (aromatic) and 1199 (ester C-O); δH (d
6
-DMSO) 9.60 (br.s, 1H, 
NH2Cl), 9.44 (br.s, 1H, NH2Cl), 7.36-7.29 (m, 5H, phenyl), 5.12 (s, 2H, CH2-
phenyl), 3.35 (br.s, 2H, equatorial CH2-N), 3.02 (br.s, 2H, axial CH2-N), 2.54 
(quintet, 1H, J 4.5, CH-COO-benzyl) and 2.25-2.07 (m, 4H, CH2-CH2-N). Data is 
consistent with previously reported data for this compound.
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2.78, 3-(4-(Benzyloxycarbonyl)piperidin-1-ylsulfonyl)benzoic acid 
Amine 2.77 (2.63 g, 10.3 mmol) was dissolved in dichloromethane (40 mL) and 
triethylamine (5.6 mL, 40 mmol), the reaction was cooled on ice. 3-
(Chlorosulfonyl)benzoic acid (2.21 g, 10.0 mmol) was added and the reaction was 
stirred for 48 hours. Further dichloromethane (40 mL) was and the reaction which 
was washed with pH 2 buffer (3 × 25 mL), dried over NaSO4 and reduced in vacuo. 
The product was purified by recrystallisation from hot ethyl acetate to give 
compound 2.78 as a white solid (1.74 g, 43 %); mp 166-167 °C; υmax/cm
-1
:  2926 (O-
H), 1729, 1677 (acid C=O), 1336, 1134 (SO2), 1160 and 1115 (C-O); Anal. Calcd for 
C20H21NO6S: C, 59.54; H, 5.25; N, 3.47. Found: C, 59.62; H, 5.19; N, 3.51; δH (400 
MHz, d
6
-DMSO) 8.28 (d, 2H, J 7.5, CH-CCOO), 8.22 (s, 1H, OCC-CH-SO2), 8.01 
(d, 1H, J 8, CH-CSO2), 7.82 (t, 1H, J 7.5, CH-CH-CSO2), 7.40-7.30 (m, 5H, phenyl), 
5.09 (s, 2H, CH2-phenyl, 3.55 (br.d, 2H, J 11.5, equatorial CH2-N), 2.55-2.46 (m, 
3H, axial CH2-N and CH-CH2), 1.96 (dd, 2H, J 12.5, 3, equatorial CH2-CH2N) and 
1.62 (qd, 2H, J 12, 4, axial CH2-CH2N); δc (100 MHz, d
6
-DMSO) 173.31 (C=O 
acid), 166.0 (C=O ester), 136.2, 136.1, 132.0 (C-SO2, C-COOH and C-CH2O), 133.6 
(CH-CCOOH), 131.4 (CH-CSO2), 130.2 (CH-CH-CSO2), 128.4 ( OCC-CH-SO2), 
128.0, 127.7 (phenyl), 65.5 (CH2-phenyl), 44.9 (CH2-N), 38.7 (CH-COO-benzyl) 
and 27.0 (CH2-CH2N); ESI m/z 100 %, 426.1 (MNa
+
) and 7 %, 404.1 (MH
+
). 
2.79, 4-(4-(Benzyloxycarbonyl)piperidin-1-ylsulfonyl)benzoic acid 
Amine 2.77 (3.99 g, 15.6 mmol) was dissolved in dichloromethane and triethylamine 
(7.8 mL, 56 mmol). The reaction was cooled on ice, 4-(chlorosulfonyl) benzoic acid 
(3.10 g, 14.1 mmol) was added and the reaction stirred overnight. The reaction was 
acidified and the resulting precipitate was removed by filtration, the remaining 
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organic solvents were removed in vacuo to give compound 2.79 as a white solid (5.0 
g, 88 %); υmax/cm
-1
: 2965 (saturated C-H), 1727 (ester C=O), 1687 (amide C=O), 
1653 (aromatic), 1336, 1166 (SO2) and 1280 (C-O); δH (400 MHz, d
6
-DMSO) 8.17 
(d, 2H, J 8, CH-CCOOH), 7.86 (d, 2H, J 8.5, CH-CSO2), 7.39-7.28 (m, 5H, phenyl), 
5.07 (s, 2H, CH2-phenyl), 3.52 (dt, 2H, J 12, 4, equatorial CH2-N), 2.55-2.43 (m, 3H, 
axial CH2-N and CH-CH2CH2N), 1.93 (dd, 2H, J 14, 3, equatorial CH2-CH2N) and 
1.60 (qd, 2H, J 11,4, axial CH2-CH2N); δc (100 MHz, d
6
-DMSO) 173.3 (C=O acid), 
166.2 (C=O ester), 139.3, 136.1, 134.7 ( C-SO2, C-COOH and phenyl C), 130.2 (C-
COOH or C-CSO2), 128.4 (phenyl CH), 128.0 (C-COOH or C-CSO2), 127.7, 127.6 
(phenyl CH), 65.5 (CH2-phenyl), 45.0 (CH2-N), 38.7 (CH-CH2-CH2N) and 27.0 
(CH2-CH2N); ESI m/z 100 %, 426.0 (MNa
+
). 
2.80, (S)-Benzyl 1-(3-(2-oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-
carboxylate 
Acid 2.78 (3.01 g, 7.46 mmol) was dissolved in dichloromethane and cooled to 0 °C. 
HATU (2.80 g, 7.36 mmol) was added and the reaction stirred for 1 hour. Lactam 
2.65 (2.05 g, 7.97 mmol) in H2O and triethylamine (3.1 mL, 22 mmol) and the 
reaction was stirred overnight. Ethyl acetate was added, the organic layer was 
washed with pH 2 buffer (3 × 25 mL) and ½ saturated sodium bicarbonate, dried 
over Na2CO3 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:70:30 to give 
compound 2.80 as a white solid  (2.88 g, 75 %) mp  78-80 º C; υmax/cm
-1
: 3273 (N-
H), 2930 (saturated C-H), 1726 (C=O ester), 1644 (C=O amide), 1333, 1150 (SO2) 
and 1287 (C-O); δH (400 MHz, CDCl3) 8.21 (s, 1H, OCC-CH-SO2), 8.06 (d, 2H, J 8, 
CH-CCO or CH-CSO2), 7.88-7.84 (m, 2H, CH-CCO or CH-CSO2 and NH-CH), 
7.61 (t, 1H, J 8, CH-CH-CSO2), 7.37-7.27 (m, 5H, phenyl), 6.70 (t, 1H, J 6, NH-
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CH2), 5.09 (s, 2H, CH2-phenyl), 4.72 (dd, 1H, J 11, 6, lactam CH-CO), 3.66 (br.d, 
2H, J 12, equatorial CH2-N), 3.35-3.30 (m, 2H, lactam CH2-NH), 2.50 (dt, 2H, J 
11.5, 2.5, axial CH2-N), 2.32 (tt, 1H, J 10.5, 4, CH-CH2-CH2N), 2.19 (br.d, 1H, J 
12.5, equatorial CH2-CH), 2.10-1.97 (m, axial CH2-CH2N and equatorial lactam 
CH2-CH2NH), 1.92-2.77 (m, 4H, axial CH2-CH2N and lactam CH2-CH2CH), 1.59 (q, 
1H, J 12.5, equatorial lactam CH2-CH) and 1.43 (br.q, 1H, J 11.5, axial lactam CH2-
CH2NH); δc (100 MHz, CDCl3) 175.5, 173.5 (C=O ester and amide), 164.6 (C=O 
lactam), 136.9, 135.7, 135.5 (C-COO, C-SO2, C-CH2-O), 131.3 (CH-CSO2 and CH-
COO), 130.2 (CH-CSO2 and CH-COO), 129.5 (CH-CH-CSO2), 128.6 (phenyl m-
CH), 128.3 (phenyl p-CH), 128.0 (phenyl o-CH), 126.3 (OCC-CH-SO2), 66.5 (CH2-
phenyl), 52.8 (lactam CH ), 47.4 (lactam CH2-NH), 45.4 (CH2-N), 39.9 (CH-
CH2CH2N), 31.4 (lactam CH2-CH), 28.8 (lactam CH2-CH2CH), 28.0 (CH2-CH2N) 
and 27.4 (lactam CH2-CH2NH); ESI m/z 100 %, 536.3 (MNa
+
). 
2.81, (S)-Benzyl 1-(4-(2-oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-
carboxylate 
Acid 2.79 (6.00 g, 14.9 mmol) was dissolved in dichloromethane and cooled to 0 °C. 
HATU (5.38 g, 14.2 mmol) was added and the reaction stirred for 1 hour. Amine 
2.65 (3.00 g, 18.3 mmol) and triethylamine (5.8 mL, 21 mmol) were added and the 
reaction stirred overnight. The reaction was washed with H2O, and dried over 
Na2CO3 and reduced in vacuo to give a white solid. The product was purified by 
silica column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 
0:70:30) to compound 2.81 as a white solid (4.35 g, 57 %) mp 187-188 º C; [α]22D  (c 
= 0.352, chloroform) -37.43; υmax/cm
-1
:  3300 (N-H), 1725 (C=O ester), 1644 (C=O 
amide) and 1333, 1161 (SO2); δH (400 MHz, d6- DMSO) 8.54 (d, 1H, J 7, NH-CH), 
8.10 (d, 2H, J 8.5, CH-CCO), 7.88 (t, 1H, J 6, NH-CH2), 7.84 (d, 2H, J 8, CH-
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CSO2), 7.38-7.28 (m, 5H, phenyl), 5.07 (s, 2H, CH2-phenyl), 4.66 (dd, 1H, J 11,7, 
lactam CH), 3.52 (br.d, 2H, J 12, equatorial CH2-N), 3.26 (td, 1H, J 10.5,5, lactam 
axial CH2-NH), 3.16-3.04 (m, 1H, lactam equatorial  CH2-NH), 2.52-2.42 (m, 3H, 
axial CH2-N and CH-CH2CH2N), 1.97-1.84 (m, 4H, CH2-CH2N), 1.83-1.53 (m, 5H, 
lactam CH2-CH2NH, CH2-CH2CH and equatorial CH2-CH) and 1.26 (q, 1H, J 12, 
axial lactam CH2-CH); δC (100 MHz,d
6
-DMSO) 174.0, 173.3 (C=O ester and 
amide), 164.0 (C=O lactam), 138.2, 137.8, 136.1 (aryl C), 128.4 (CH-CCO), 128.3 
(CH-CSO2), 128.0, 127.7, 127.5 (phenyl CH), 66.5 (CH2-phenyl), 52.2 (lactam CH), 
45.0 (lactam CH2-NH), 40.6 (CH2-N), 39.9 (CH-CH2CH2N), 30.5 (lactam CH2-CH), 
28.9 (lactam CH2-CH2CH), 27.7 (CH2-CH2N) and 27.1 (lactam CH2-CH2NH); ESI 
m/z 100 %, 536.2 (MNa
+
). 
2.82, (S)-Benzyl 1-(3-(2-oxopiperidin-3-ylcarbamoyl)phenylsulfonyl)piperidine-
4-carboxylate 
Lactam 2.53 (1.71 g, 15.0 mmol) and K2CO3 (4.31 g, 31.2 mmol) was dissolved in 
H2O (25 mL) and cooled to 0 °C. Acid 2.78 (8 mmol) in dichloromethane, oxalyl 
chloride (1.4 mL, 16 mmol) and DMF (1 drop, catalytic) were added. The reaction 
was stirred for 2 hours, reduced in vacuo, the acid chloride re-dissolved in 
dichloromethane and slowly added to the lactam solution. The reaction was stirred 
overnight, the dichloromethane removed in vacuo. The reaction was extracted with 
ethyl acetate and washed with pH 2 buffer (3 × 15 mL) and ½ saturated NaHCO3 (3 
× 15 mL), dried over Na2SO3 and reduced in vacuo. The product was purified by 
silica column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 
0:70:30) to give compound 2.82 as a white solid (3.76 g, 50 %); δH (300 MHz, 
CDCl3) 8.18 (s, 1H, OCC-CH-SO2), 8.06 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.96 
(d, 1H, J 6.5, NH-CH), 7.83 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.57 (t, 1H, J 8, 
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CH-CH-CSO2), 7.36-7.27 (m, 5H, phenyl), 6.52 (br.s, 1H, NH-CH2), 5.09 (s, 2H, 
CH2-phenyl), 4.50 (q, 1H, J 6.5, lactam CH), 3.65 (br.dd, 2H, J 11.5, 3.5, equatorial 
CH2-N), 3.34 (br.td, 2H, J 6.5, 2, lactam CH2-NH), 2.47 (br.t, 2H, J 11.5, axial CH2-
N), 2.33 (tt, 1H, J 12.5, 4, CH-CH2-CH2N), 2.04-1.90 (m, 4H, CH2-CH2N) and 1.89-
1.72 (m, 4H, lactam CH2-CH and CH2-CH2NH); m/z (C25H29N3O6SNa
+
 requires 
522.1675) found 522.2. 
2.09, (S)-1-(3-(2-Oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-
carboxylic acid 
Ester 2.80 (1.64, 3.19 mmol) was dissolved in MeOH (20 mL). Palladium activated 
charcoal (0.2 g, catalytic) was added and the reaction stirred under hydrogen for 48 
hours. The reaction was filtered through celite and reduced in vacuo to give 
compound 2.09 as a white solid (0.83 g, 61%); mp 170-175 °C (decomposed); 
υmax/cm
-1
: 3267 (N-H), 2937 (saturated C-H), 1724 (C=O acid), 1627 (C=O amide), 
1539 (aromatic), 1335, 1172 (SO2) and 1272 (C-O acid); δH (400 MHz, CDCl3) 8.16 
(s, 1H, OCC-CH-SO2), 8.04 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.87 (d, 1H, J 8, 
CH-CCO or CH-CSO2), 7.81 (d, 1H, J 6, NH-CH), 7.60 (t, 1H, J 8, CH-CH-CSO2), 
7.39 (d, 1H, J 6, NH-CH2), 4.74 (dd, 1H, J 10.5, 6, lactam CH), 3.66 (br.d, 2H, J 10, 
equatorial CH2-N), 3.31 (br.s, 2H, lactam CH2-NH),  2.46 (q, 2H, J 9, axial CH2-N), 
2.23 (br.t, 1H, J 10.5, CH-CH2CH2N), 2.16 (d, 2H, J 13, equatorial lactam CH2-CH), 
2.08-1.71 (m, 7H,lactam CH2-CH2NH, CH2CH2CH and CH2-CH2N), 1.57 (q, 1H, J 
12, axial lactam CH2-CH) and 1.47-1.34 (1H, m, CH2-CH2NH);  δC (100 MHz, 
CDCl3) 178.0 (C=O acid), 176.5 (C=O amide), 164.9 (C=O lactam), 137.0, 135.4 
(CSO2 and CCO), 131.5, 130.4 (CH-CCO and CH-CSO2), 129.6 (CH-CH-CSO2), 
126.1 (OCC-CH-SO2), 52.7 (lactam CH), 45.5 (CH2-N), 42.2 (lactam CH2-NH), 39.8 
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(CH-CH2CH2N), 31.3 (lactam CH2-CH), 28.5 (lactam CH2-CH2CH), 27.9 (CH2-
CH2N), and 27.4 (lactam CH2-CH2NH). 
2.83, (S)-1-(4-(2-Oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-
carboxylic acid 
Ester 2.81 (2.05 g, 4.00 mmol) was dissolved in THF (10 mL) and MeOH (10 mL). 
Palladium activated charcoal (0.2 g, catalytic) was added and the reaction stirred 
under hydrogen for 48 hours. The reaction was filtered through celite and reduced in 
vacuo to give compound 2.83 as a white solid (1.58 g, 93%); δH (400 MHz, d6- 
DMSO) 8.53 (d, 1H, J 7, NH-CH), 8.08 (d, 2H, J 8, CH-CCO), 7.87-7.81 (m, 3H, 
CH-CSO2 and NH-CH2), 4.63 (dd, 1H, J 10.5, 7, lactam CH), 3.62-3.78 (m, 2H, 
equatorial CH2-N), 3.51-3.44 (m, 2H, lactam axial CH2-NH), 2.45 (br.t, 2H, J 11, 
CH2-N axial), 2.27 (tt, 1H, J 10, 2, CH-CH2CH2N), 1.96-1.83 (m, 4H, CH2-CH2N), 
1.81-1.67 (m, 2H, lactam CH2-CH2CH), 1.50-1.04 (m, 3H, CH2-CH2NH and 
equatorial CH2-CH) and 1.25 (q, 1H, J 13.5, axial lactam CH2-CH); ESI m/z 
(C19H25N3O6SNa
+
 requires 446.14) found 446.1. 
2.84, (S)-1-(3-(2-Oxopiperidin-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-
carboxylic acid 
Ester 2.82 (3.76 g, 7.50 mmol) was dissolved in MeOH (50 mL), palladium activated 
charcoal (0.4 g, catalytic) was added and the reaction was stirred under hydrogen for 
48 hours. The reaction was filtered through celite and reduced in vacuo to give 
compound 2.84 as a white solid (2.21 g, 72 %); δH (300 MHz, d
6
- DMSO) 9.00 (d, 
1H, J 8, NH-CH), 8.20 (s, 1H, OCC-CH-SO2), 8.19 (d, 1H, J 8, CH-CCO or CH-
CSO2), 7.89 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.76 (t, 1H, J 8, CH-CH-CSO2), 
7.72 (br.s, 1H, NH-CH2), 4.40 (br.q, 1H, J 7.5, lactam CH), 3.50 (br.d, 2H, J 10.5, 
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equatorial CH2-N), 3.31-3.32 (m, 2H, lactam CH2-NH), 2.43 (br.t, 2H, J 10.5, axial 
CH2-N), 2.28 (tt, 1H, J 10.5, 3.5, CH-CH2CH2N), 2.04-1.96 (m, 1H,  lactam CH2-
CH2NH and CH2-CH2N), 1.92-1.77 (m, 5H, lactam CH2-CH2NH and CH2-CH2N) 
and 1.55 (br. q, 2H, J 13, lactam CH2-CH2CH). 
2.08, (S)-N-(2-(1H-indol-3-yl)ethyl)-1-(3-(2-oxoazepan-3-ylcarbamoyl) 
phenylsulfonyl)piperidine-4-carboxamide 
Acid 2.09 (0.83 g, 2.0 mmol) was dissolved in dichloromethane (15 mL) and cooled 
to 0° C. HATU (0.78 g, 2.1 mmol) was added and the mixture was stirred for 4 
hours. Tryptamine (0.34 g, 2.1 mmol) and triethylamine (0.90 mL, 6.4 mmol) were 
added and the reaction was stirred for 48 hours. The dichloromethane was removed 
in vacuo and the product was dissolved in ethyl acetate and was washed with a pH 2 
buffer (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). The organic layer was 
reduced in vacuo and the product was purified by silica column chromatography 
(petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:70:30) to give compound 2.08 as 
a white solid (0.23 g, 20 %) mp 127-129 °C; [α]24D  (c = 0.117, MeOH) + 10.68; 
υmax/cm
-1
: 3384 (N-H), 2929 (saturated C-H), 1639 (C=O amide), 1517 (aromatic) 
and 1334, 1149 (SO2); δH (300 MHz, CDCl3) 8.63 (br.s, 1H, NH-indole), 8.19 (s, 
1H, OCC-CH-SO2), 8.03 (d, 1H, J 7.5, CH-CCO or CH-CSO2), 7.86 (d, 1H, NH-
CH), 7.83 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.57 (t, 1H, J 8, CH-CH-CSO2), 7.51 
(d, 1H, J 8, indole CH-C-C), 7.34 (d, 1H, J 8, indole CH-C-NH), 7.14 (t, 1H, J 8, 
indole CH-CH-C), 7.05 (t, 1H, J 8, indole CH-CH-C-C), 6.91 (s, 1H, indole CH-
NH), 6.41 (t, 1H, J 5.5, lactam NH-CH2), 5.68 (t, 1H, J 5, NH-CH2), 4.71 (dd, 1H, J 
11, 5, lactam CH), 3.62 (br.t, 2H, J  10.5, equatorial CH2-N), 3.52 (q, 2H, J 6, CH2-
CH2-indole), 3.31-3.22 (m, 2H, lactam CH2-NH), 2.90 (t, 2H, J 6.5, CH2-indole), 
2.31 (br. t, 2H, J 10.5, axial CH2-N), 2.14 (d, 1H, J 14, equatorial lactam CH2-CH) 
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2.05-1.99 (m, 2H, lactam CH2-CH2CH), 1.93-1.79 (m, 3H, CH-CH2CH2N and 
lactam CH2-CH2NH),), 1.75-1.61 (m, 4H, CH2-CH2N), 1.56 (q, 1H, J 12, axial 
lactam CH2-CH) and 1.38 (q, 1H, J 12.5, equatorial lactam CH2-CH2NH); δC (100 
MHz, CDCl3) 175.5, 173.6, 164.8 (C=O), 137.1, 136.5 (C-CO and C-SO2), 135.4 
(indole C-NH), 131.3 (CH-CCO or CH-CSO2), 130.4 (CH-CCO or CH-CSO2), 
129.5 (CH-CH-CSO2), 127.3 (indole C-C-NH), 126.2 (OCC-CH-SO2), 122.2 (indole 
CH-NH), 122.1 (indole CH-C-C), 119.4 (indole CH-CH-C), 118.6 (indole CH-CH-
C-C), 112.6 (indole C-CH2), 111.5 (indole CH-C-NH), 52.8 (lactam CH), 45.4 (CH2-
N), 42.2 (lactam CH2-NH), 41.4 (CH-CH2-CH2N), 39.6 (CH2-CH2-indole), 31.4 
(lactam CH2-CH), 28.8, 28.0 (lactam CH2-CH2NH and CH2-CH2N), 27.9   (CH2-
indole) and 25.1 (lactam CH2-CH2CH); ESI m/z 100 %,  588.1 (MNa
+
); HR ESI m/z 
(C29H35N5O5SNa
+
 requires 588.2251) found 588.2264. 
2.85, (S)-N-(2-(1H-indol-3-yl)ethyl)-1-(4-(2-oxoazepan-3-ylcarbamoyl) 
phenylsulfonyl)piperidine-4-carboxamide 
Acid 2.83 (2.88 g, 6.80 mmol) was dissolved in dichloromethane (50 mL) and 
cooled to 0° C. HATU (2.51 g, 6.60 mmol) was added and the mixture was stirred 
for 4 hours. Tryptamine (1.09 g, 6.80 mmol) and triethylamine (2.9 mL, 20 mmol) 
were added and the reaction was stirred for 48 hours. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and MeOH and was 
washed with a pH 2 buffer (3 × 25 mL) and ½ saturated NaHCO3 (3 × 25 mL). The 
organic layer was reduced in vacuo and the product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:90:10) to give 
compound 2.85 as a white solid (2.69 g, 70 %); mp 135-136 °C; [α]29D  (c = 0.104, 
MeOH) + 11.06.υmax/cm
-1
: 3248 (N-H), 2930 (saturated C-H), 1644 (C=O amide), 
1544 (aromatic), 1338, 1154 (SO2); δH (300 MHz, CDCl3) 10.77 (br.s, 1H, NH 
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indole), 8.54 (d, 1H, J 7, NH-CH), 8.10 (d, 1H, J 8.5,  CH-CO), 7.89-7.80 (m, 4H, 
CH-CSO2, lactam NH-CH2 and NH-CH2), 7.50 (d, 1H, J 8, indole CH-C-C), 7.32 (d, 
1H, J 8, indole CH-C-NH), 7.10 (d, 1H, J 2, indole CH-NH), 7.05 (t, 1H, J 7.5, 
indole CH-CH-C), 6.96 (t, 1H, J 7.5, indole CH-CH-C-C), 4.71 (dd, 1H, J 10, 7.5, 
lactam CH), 3.62 (d, 2H, J 11.5, equatorial CH2-N), 3.32-3.20 (m, 3H, lactam CH2-
NH and CH2-CH2-indole), 3.14-3.06 (m, 1H, lactam CH2-NH), 2.77 (t, 2H, J 7.5, 
CH2-indole), 2.31 (br.t, 2H, J 11.5, axial CH2-N), 2.10 (tt, 1H, J 11, 4, CH-
CH2CH2N), 1.92 (t, 2H, J 11.5, equatorial lactam CH2-CH and CH2-CH2CH), 1.82-
1.68 (m, 4H, equatorial CH2-CH2N, equatorial lactam CH2-CH2NH and axial CH2-
CH2CH), 1.57 (br.t, 3H, J 11.5, axial CH2-CH2N and axial lactam CH2-CH) and 1.25 
(q, 1H, J 12, axial lactam CH2-CH2NH); δC (100 MHz, CDCl3) 174.0, 173.2, 164.1 
(C=O), 138.2, 137.8, 136.2 (C-SO2, C-CO, indole C-NH), 128.3 (CH-CCO), 127.5 
(CH-CSO2), 127.2 (indole C-C-NH), 122.6 (indole CH-NH), 120.9 (indole CH-C-
C), 118.2 (indole CH-CH-C), 118.1 (indole CH-CH-C-C), 111.7 (indole C-CH2), 
111.3 (indole CH-C-NH), 52.2 (lactam CH), 45.3 (CH2-N), 40.6 (lactam CH2-NH), 
40.3 (CH-CH2CH2N), 40.1 (CH2-CH2-indole), 30.5 (lactam CH2-CH), 28.9, 27.8 
(lactam CH2-CH2NH and CH2-CH2N), 27.7 (CH2-indole) and 25.1 (lactam CH2-
CH2CH); ESI m/z 100 %, 588.2 (MNa
+
) and 13 %, 565.1 (MH
+
); HR ESI m/z 
(C29H35N5O5SNa
+
 requires 588.2251) found 588.2263. 
2.07, N-((R)-3-(1H-indol-3-yl)-1-oxo-1-(propylamino)propan-2-yl)-1-(3-((S)-2-
oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamide 
Acid 2.09 (1.27 g, 3.00 mmol) was dissolved in dichloromethane (30 mL) and 
cooled to 0° C. HATU (1.10 g, 2.89 mmol) was added and the mixture was stirred 
for 4 hours. Amine 2.27 (2.80 mmol) and triethylamine (1.2 mL, 2.9 mmol) were 
added and the reaction was stirred for 48 hours. The dichloromethane was removed 
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in vacuo and the product was dissolved in ethyl acetate and washed with a pH 2 
buffer (3 × 15 mL), 0.1 M HCl (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). 
The organic layer was reduced in vacuo and the product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 40:60:0 to 0:70:30) to 
give compound 2.07 as a white solid (1.04 g, 57 %) mp 147-149 °C; [α]24D  (c = 
0.099, MeOH) + 9.34; υmax/cm
-1
: 3272 (N-H), 2929 (saturated C-H), 1639 (C=O 
amide), 1515 (aromatic) and 1334, 1129 (SO2); δH (400 MHz, CDCl3) 8.86 (br.s, 1H, 
NH-indole), 8.19 (s, 1H, OCC-CH-SO2), 8.02 (d, 1H, J 8, CH-CCO or CH-CSO2), 
7.94 (d, 1H, J 6.5, lactam NH-CH), 7.83 (d, 1H, J 8, CH-CCO or CH-CSO2), 7.57 (t, 
1H, J 8, CH-CH-CSO2), 7.53 (d, 1H, J 8, indole CH-C-C), 7.29 (d, 1H, J 8, indole 
CH-C-NH), 7.10 (t, 1H, J 7.5, indole CH-CH-C), 7.00 (t, 1H, J 7.5, indole CH-CH-
C-C), 6.92 (br.s, 2H, indole CH-NH and lactam NH-CH2), 6.84 (d, 1H, J 8, NH-CH-
CH2-indole), 6.37 (t, 1H, J 6, NH-
n
Pr), 4.74 (dd, 1H, J 11.5, 6, lactam CH), 4.68 (q, 
1H, J 7.5, CH-CH2-indole), 3.61 (d, 1H, J 11.5, CH2-N), 3.48 (d, 1H, J 11.5, CH2-
N),  3.33-3.25 (m, 2H, lactam CH2-NH), 3.17-2.97 (m, 4H , CH2-indole and CH2-
NH), 2.32-2.14 (m, 2H, CH2-N and equatorial lactam CH2-CH), 2.15-1.98 (m, 2H, 
axial lactam CH2-CH2NH  and CH2-CH2CH), 1.92-1.78 (m, CH-CH-CH2N and 
equatorial lactam CH2-CH2CH), 1.68-1.61 (m, 2H, CH2-CH2N), 1.58-1.50 (m, 3H, 
CH2-CH2N and axial lactam CH2-CH), 1.40 (br.q, 1H, equatorial lactam CH2-
CH2NH), 1.29 (sextet, 2H, J 7.5, CH2-CH3) and 0.72 (t, 2H, J 7.5, CH3); δC (100 
MHz, CDCl3) 175.5, 173.8, 171.6, 164.8 (C=O), 137.1 ,136.2, 135.4 (C-SO2, C-CO 
and indole C-NH), 131.3 (CH-CCO), 130.3 (CH-CSO2), 129.5 (CH-CH-CSO2), 
127.4 (indole C-C-NH), 126.2 (OCC-CH-SO2), 123.1 (indole CH-NH), 122.1 
(indole CH-C-C), 119.5 (indole CH-CH-C), 118.7 (indole CH-CH-C-C), 111.4 
(indole CH-C-NH), 110.6 (indole C-CH2), 53.9 (CH-CH2-indole), 52.9 (lactam CH), 
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45.3 (CH2-N), 42.1 (lactam CH2-NH), 41.4 (CH-CH2CH2N), 41.2 (CH2-CH2CH3), 
31.3 (lactam CH2-CH), 28.8 (CH2-indole), 28.4, 28.0 (CH2-CH2N and lactam CH2-
CH2NH), 27.6 (lactam CH2-CH2CH),  22.5 (CH2-CH3), 11.2 (CH3); ESI m/z 100 %, 
673.2 (MNa
+
); HR ESI m/z (C33H42N6O6SNa
+
 requires 673.2779) found 673.2774. 
2.86, N-((R)-3-(1H-indol-3-yl)-1-oxo-1-(propylamino)propan-2-yl)-1-(4-((S)-2-
oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamide 
Acid 2.83 (4.00 mmol) was dissolved in dichloromethane (60 mL) and cooled to 0° 
C. HATU (1.67 g, 4.39 mmol) was added and the mixture was stirred for 4 hours. 
Amine 2.27 (7 mmol) and triethylamine (1.7 mL, 4.0 mmol) were added and the 
reaction was stirred for 48 hours. The dichloromethane was removed in vacuo and 
the product was dissolved in ethyl acetate and washed with a pH 2 buffer (3 × 15 
mL) and ½ saturated NaHCO3 (3 × 15 mL). The organic layer was reduced in vacuo 
and the product was purified by silica column chromatography (petroleum 
ether:ethyl acetate:MeOH 25:75:0 to 0:70:30) and then by recrystallisation from 
ethyl acetate and petroleum ether to give compound 2.86 as a white solid (1.23 g, 47 
%); mp 143-144 °C; [α]28D  (c = 0.2, MeOH) + 12.31; υmax/cm
-1
: 3287 (N-H), 2926 
(saturated C-H), 1640 (C=O amide), 1516 (aromatic) and 1335, 1166 (SO2); δH (500 
MHz, d
6-
DMSO) 10.75 (d, 1H, J 1.5, NH-indole), 8.54 (d, 1H, J 7, lactam NH-CH), 
8.07 (d, 2H, J 8, CH-CCO), 7.88 (t, 1H, J 6, lactam NH-CH2 or NH-
n
Pr), 7.87-7.84 
(m, 2H, NH-CHCH2-indole and lactam NH-CH2 or NH-
n
Pr), 7.80 (d, 2H, J 8, CH-
CSO2), 7.55 (d, 1H, J 8, indole CH-C-C), 7.31 (d, 1H, J 8.5, indole CH-C-NH), 7.05 
(s, 1H, indole CH-NH), 7.04 (t, 1H, J 8, indole CH-CH-C), 6.94 (t, 1H, J 8, indole 
CH-CH-C-C), 4.65 (dd, 1H, J 10, 7.5, lactam CH), 4.45 (q, 1H, J 7.5, CH-CH2-
indole), 3.53 (d, 1H, J 11.5, equatorial CH2-N), 3.47-3.40 (m, 1H, equatorial CH2-
N), 3.25 (td, 1H, J 13, 5, axial lactam CH2-NH), 3.14-3.07 (m, 1H, equatorial lactam 
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CH2-NH), 3.03 (dd, 1H, J 14.5, 5, CH2-indole), 3.01-2.90 (m, 2H, CH2-Et), 2.87 (dd, 
1H, J 14.5, 8.5, CH2-indole), 2.32 (t, 1H, J 10.5, axial CH2-N), 2.28 (t, 1H, J 10.5, 
axial CH2-N), 2.15 (tt, 1H, J 10.5, 4, CH-CH2CH2N,), 1.91 (br.t, 2H, J 14, lactam 
CH2-CH and CH2-CH2CH), 1.80-1.76 (m, 1H, equatorial lactam CH2-CH2NH), 1.70 
(br.t, 2H, J 13, lactam CH2-CH and CH2-CH2CH),   1.63-1.55 (m, 2H, equatorial 
CH2-CH2N), 1.50 (q, 1H, J 12.5, axial CH2-CH2N), 1.48-1.39 (m, 1H, axial CH2-
CH2N), 1.32 (sextet, 2H, J 7.5, CH2-CH3), 1.25 (br.q, 1H, J 12.5, axial lactam CH2-
CH2NH), and 0.75 (t, 2H, J 7.5, CH3); δC (125 MHz, d
6-
DMSO) 174.5, 173.6, 
171.8,164.6 (C=O), 138.7, 138.3, 136.5 (C-SO2, C-CO and indole C-NH), 128.7 
(CH-CCO), 127.9 (CH-CSO2), 127.8 (indole C-C-NH), 124.0 (indole CH-NH), 
121.3 (indole CH-CH-C), 119.0 (indole CH-C-C), 118.6 (indole CH-CH-C-C), 111.7 
(indole CH-C-NH), 110.6 (indole C-CH2), 53.7 (CH-CH2-indole), 52.7 (indole CH), 
45.6 (CH2-N), 41.3 (lactam CH2-NH), 41.2 (CH2-CH2CH3), 40.1 (CH-CH2CH2N), 
31.0 (lactam CH2-CH), 29.4 (CH2-indole), 28.6, 28.2 (CH2-CH2N and lactam CH2-
CH2NH), 28.2 (lactam CH2-CH2CH), 22.6 (CH2-CH3), 11.7 (CH3); ESI m/z 100 %, 
673.2 (MNa
+
); HR ESI m/z (C33H42N6O6SH
+
 requires 651.2959) found 651.2965. 
2.87, N-((R)-3-(1H-indol-3-yl)-1-oxo-1-(propylamino)propan-2-yl)-1-(3-((S)-2-
oxopiperidin-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamide 
Acid 2.84 (2.21 g, 5.40 mmol) was dissolved in dichloromethane (50 mL) and 
cooled to 0° C. HATU (2.01 g, 5.29 mmol) was added and the mixture was stirred 
for 4 hours. Amine 2.27 (7 mmol) and triethylamine (2.3 mL, 5.4 mmol) were added 
and the reaction was stirred for 48 hours. The dichloromethane was removed in 
vacuo and the product was dissolved in ethyl acetate and MeOH and washed with a 
pH 2 buffer (3 × 15 mL). The organic layer was reduced in vacuo and the product 
was purified by silica column chromatography (petroleum ether:ethyl acetate:MeOH 
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50:50:0 to 0:70:30) and then by washing with ethyl acetate to give compound 2.87 as 
a white solid (0.82 g, 24 %); mp 167-168 °C; [α]20D  (c = 0.52, MeOH) -1.49; 
υmax/cm
-1
: 3280 (N-H), 2935 (saturated C-H), 1634 (C=O amide), 1543 (aromatic) 
1328, 1147 (SO2); δH (500 MHz, d
6
-DMSO) 10.74 (d, 1H, J 2, NH indole), 8.99 (d, 
1H, J 8.5, lactam NH-CH), 8.20-8.18 (m, 2H, OCC-CH-SO2 and CH-CCO or CH-
CSO2), 7.88-7.86 (m, 2H, NH-CH2-CH2-indole and NH-Pr), 7.84 (d, 1H, J 8, CH-
CCO or CH-CSO2), 7.75 (t, 1H, J 8, CH-CH-CSO2), 7.69 (br.s, 1H, lactam NH-
CH2), 7.55 (d, 1H, J 8, indole CH-C-C), 7.30 (d, 1H, J 8.5, indole CH-C-NH). 7.05 
(s, 1H, indole CH-NH), 7.04 (t, 1H, J 7.5, indole CH-CH-C-C), 6.94 (t, 1H, J 7.5, 
indole CH-CH-C), 4.44 (dd, 1H, J 14, 8.5, CH-CH2-indole), 4.42 (m, 1H, lactam 
CH), 3.58 (d, 1H, J 12, equatorial CH2-N), 3.47 (d, 1H, J 12, equatorial CH2-N), 
3.21-3.17 (m, 2H, lactam CH2-NH), 3.04 (dd, 1H, J 14, 6, CH2-indole), 3.01-2.91 
(m, 2H, CH2-Et), 2.87 (dd, 1H, J 14, 8.5, CH2-indole), 2.29 (td, 1H,J 12, 3.5, axial 
CH2-N), 2.24 (td, 1H, J 12, 3.5, axial CH2-N), 2.15 (tt, 1H, J 11.5, 4, CH-
CH2CH2N), 2.04-1.99 (m, 1H, lactam CH2-CH), 1.87-1.78 (m, 3H, lactam CH2-CH 
and CH2-CH2NH), 1.70 (br.d, 1H, J 12.5, equatorial CH2-CH2-N),  1.58 (br.d, 1H, J 
12.5, equatorial CH2-CH2-N), 1.50 (qd, 1H, J 12.5, 4.5, axial CH2-CH2N), 1.38 (qd, 
1H, J 12.5, 4.5, axial CH2-CH2N), 1.28 (sextet, 2H, J 7.5, CH2-CH3) and  0.76 (t, 
3H, J 7.5, CH3); δC (125 MHz, d
6
-DMSO) 173.7, 171.8,170.0, 164.7 (C=O), 136.5, 
136.3, 135.6 (C-SO2, C-CO and indole C-NH), 132.3, 130.5 (CH-CCO and CH-
CSO2), 130.2 (CH-CH-CSO2), 127.8 (indole C-C-NH), 126.4 (OCC-CH-SO2), 124.0 
(indole CH-NH), 121.3 (indole CH-CH-C-C), 119.0 (indole CH-C-C), 118.9 (indole 
CH-CH-C), 111.9 (indole CH-C-NH), 110.6 (indole C-CH2), 53.7 (CH-CH2-indole), 
50.1 (lactam CH), 45.7 (CH2-N), 41.7 (lactam CH2-NH), 40.8 (CH2-Et), 40.3 (CH-
CH2CH2N), 28.6 (lactam CH2-CH), 28.2 (CH2-indole), 28.1 (CH2-CH2N), 27.8 
214 
 
(lactam CH2-CH2NH), 22.8 (CH2-CH3) and 11.9 (CH3); ESI m/z 100 %, 659.2 
(MNa
+
) and 20 %, 636.5 (MH
+
); HR ESI m/z (C32H40N6O6SNa
+
 requires 659.2622) 
found 659.2635. 
2.88, O-Benzyl 4-((R)-3-(1H-indol-3-yl)-2-(1-(3-((S)-2-oxoazepan-3-ylcarbamoyl) 
phenylsulfonyl)piperidine-4-carboxamido)propanamido)butylcarbamate 
Acid 2.09 (0.26 g, 0.61 mmol) was dissolved in dichloromethane (10 mL) and 
cooled to 0° C. HATU (0.33 g, 0.87 mmol) was added and the mixture was stirred 
for 4 hours. Amine 2.28 (0.75 mmol) and triethylamine (0.30 mL, 2.3 mmol) were 
added and the reaction was stirred for 48 hours. The dichloromethane was removed 
in vacuo and the product was dissolved in ethyl acetate and was washed with a pH 2 
buffer (3 × 10 mL), 0.1 M HCl (3 × 10 mL) and ½ saturated NaHCO3 (3 × 10 mL). 
The organic layer was reduced in vacuo and the product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:90:10) to 
give compound 2.88 as a light yellow solid (0.39 g, 79 %); mp 110-111° C; [α]29D  (c 
= 0.2, MeOH) + 5.13; δH (700 MHz, DMSO) 10.73 (s, 1H, NH indole), 8.69 (d, 1H, 
J 7, lactam NH-CH), 8.20 (d, 1H, J 8, CH-CCO or CH-CSO2), 8.18 (s, 1H, OCC-
CH-SO2), 7.89 (t, 1H, J 5.5, NH-CHCH2-indole), 7.85-7.83 (m, 3H, CH-CCO or 
CH-CSO2, NH-Cbz and lactam NH-CH2), 7.75 (t, 1H, J 8, CH-CH-CSO2), 7.55 (d, 
1H, J 8, indole CH-C-C), 7.36-7.28 (m, 6H, indole CH-C-NH and phenyl), 7.20 (t, 
1H, J 5.5, NH-CH2CH2), 7.05 (s, 1H, indole CH-NH), 7.04 (t, 1H, J 7.5, indole CH-
CH-C), 6.94 (t, 1H, J 7.5, indole CH-CH-C-C), 4.99 (s, 2H, CH2-phenyl), 4.67 (dd, 
1H, J 11, 8, lactam CH), 4.44 (q, 1H, J 7.5, CH-CH2-indole), 3.56 (d, 1H, J 12, 
equatorial CH2-N), 3.47 (d, 1H, J 12, equatorial CH2-N), 3.24 (td, 1H, J 13.5, 5, 
CH2-NHCO), 3.10 (m, 1H, CH2-NHCO), 3.03 (dd, 1H, J 14.5, 5.5, CH2-indole), 
2.99-2.92 (m, 4H, lactam CH2-NH and CH2-NHCbz), 2.86 (dd, 1H, J 14.5, 8, CH2-
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indole), 2.28 (t, 1H, J 11, axial CH2-N ), 2.24 (t, 1H, J 11, axial CH2-N), 2.14 (tt, 1H, 
J 10.5, 3.5, CH-CH2CH2N), 1.93 (br.d, 1H J 14, equatorial lactam CH2-CH), 1.88 
(br.d, 1H, J 13.5, equatorial lactam CH2-CH2NH), 1.71-1.66 (m, 2H, lactam CH2-
CH2CH), 1.67 (t, 1H, J 12.5, axial lactam CH2-CH), 1.57 (br.d, 2H, J 12, equatorial 
CH2-CH2N), 1.45 (br.q, 1H, J 12, axial CH2-CH2N) 1.37 (br.q, 1H, J 12, axial CH2-
CH2N) and 1.25 (br.q, 1H, J 12.5, axial lactam CH2-CH2NH); δC (100 MHz, d
6
 
DMSO) 169.1, 168.2, 166.1, 158.7, (C=O amide), 150.9 (C=O carbamate), 131.4, 
130.6, 130.5, 129.5 (C-SO2, C-CONH, indole and C-NH, C phenyl), 125.9, 124.4 
(CH-CCO and CH-CSO2), 124.0 (CH-CH-CSO2), 122.7 (OCC-CH-SO2), 122.1, 
122.1 (phenyl CH), 121.7 (indole C-C-NH), 120.6 (indole CH-NH), 117.9 (indole 
CH-CH-C-C), 115.3 (indole CH-C-C), 112.8 (indole CH-CH-C), 105.7 (indole CH-
C-NH), 104.3 (indole C-CH2), 59.9 (CH2-phenyl), 48.1 (CH-CH2-indole), 46.8 
(lactam CH), 39.7 (CH2-N), 35.5 (lactam CH2-NH), 34.8 (CH-CH2CH2N), 34.5, 
33.0, 32.9, 25.1 (lactam CH2-CH, CH2-indole, CH2-NHCbz and CH2-NHCO), 23.1, 
22.3, 22.2 (lactam CH2-CH2CH lactam CH2-CH2NH and CH2-CH2-N) and 21.8, 21.1 
(CH2-CH2-NHCbz and CH2-CH2NHCO); ESI m/z (C42H51N7O8SNa
+
 requires 
836.3418) found 836.2.  
2.89, O-Benzyl 5-((R)-3-(1H-indol-3-yl)-2-(1-(3-((S)-2-oxoazepan-3-ylcarbamoyl) 
phenylsulfonyl) piperidine-4-carboxamido)propanamido)pentylcarbamate 
Acid 2.09 (1.47 g, 3.48 mmol) was dissolved in dichloromethane (40 mL) and 
cooled to 0° C. HATU (1.29 g, 3.39 mmol) was added and the mixture was stirred 
for 4 hours. Amine 2.29 (3.4 mmol) and triethylamine (1.40 mL, 10.2 mmol) were 
added and the reaction was stirred over night. The dichloromethane was removed in 
vacuo and the product was dissolved in ethyl acetate and washed with a pH 2 buffer 
(3 × 15 mL), 0.1 M HCl (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 mL). The 
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organic layer was dried over Na2SO4 and reduced in vacuo. The product was purified 
by silica column chromatography (petroleum ether:ethyl acetate:MeOH , 50:50:0 to 
0:10:90) to give compound 2.89 as a white-yellow solid (0.36 g, 13 %); mp 118-120 
º C; [α]22D =  53.35 MeOH; υmax/cm
-1
: 3299 (N-H), 2930 (saturated C-H), 1641 (C=O 
amide), 1516 (aromatic), 1335, 1149 (SO2) and 1249 (C-O); δH (700 MHz, d
6
-
DMSO) 10.72 (d, 1H, J 2.5, NH indole), 8.69 (d, 1H, J 7.5, lactam NH-CH), 8.19 (t, 
1H, J 8, CH-CH-CSO2), 8.18 (s, 1H, OCC-CH-CSO2), 7.88-7.82 (m, 4H, CH-CCO, 
CH-CSO2, lactam NH-CH2 and NH-CH-CH2-indole), 7.75 (t, 1H, J 7.5, NHCbz or 
NH-pentyl), 7.55 (d, 1H, J 7.5, indole CH-C-C), 7.37-7.28 (m, 6H, indole CH-C-C 
and phenyl), 7.20 (t, 1H, J 5.5, , NHCbz or NH-pentyl), 7.05 (d, 1H, J 2.5, indole 
CH-NH), 7.03 (d, 1H, J 7.5, indole CH-CH-C-C), 6.94 (t, 1H, J 7.5, indole CH-CH-
C), 4.99 (s, 2H, CH2-phenyl), 4.66 (ddd, 1H, H 11.5, 8, 1.5, lactam CH), 4.44 (q, 1H, 
J 8.5, CH-CH2-indole), 3.59 (d, 1H, J 10.5, equatorial CH2-N), 3.48 (d, 1H, J 10.5, 
equatorial CH2-N), 3.24 (td, 1H, J 13, 5, axial lactam CH2-NH), 3.13-3.08 (m, 1H, 
equatorial lactam CH2-NH), 3.03 (dd, 1H, J 14.5, 5, CH2-indole), 2.99 (t, 1H, J 6.5, 
CH2-NHCbz) and 2.97-2.92 (m, 3H, CH2-NHCbz and CH2-butyl), 2.86 (dd, 1H, J 
14.5, 8.5, CH2-indole), 2.29 (td, 1H, J 11.5, 2.5, axial CH2-N), 2.24 (td, 1H, J 11.5, 
2.5, axial CH2-N), 2.14 (tt, 1H, J 11, 4, CH-CH2CH2N), 1.93 (d, 1H, J 14, equatorial 
lactam CH2-CH), 1.88 (d, 1H, J 14, lactam CH2-CH2NH), 1.81-1.77 (m, 2H, CH2-
CH2NHCbz), 1.72-1.66 (m, 2H, lactam CH2-CH2NH and CH2-propyl), 1.62 (td, 1H, 
J 12, 2, CH2-CH2CH), 1.58 (dd, 1H, J 16, 2.5, lactam CH2-CH2CH), 1.50 (qd, 1H, J 
12, 3.5, axial lactam CH2-CH), 1.42-1.22 (m, 4H, CH2-CH2N), 1.18-1.12 (m, 2H, 
CH2-CH2CH2NHCbz); δC (175 MHz, d
6
-DMSO) 174.6, 173.6, 171.7, 164.3 (C=O), 
156.5 (C=O carbamate), 137.7, 136.4, 136.39, 135.7 (C-SO2, C-CONH, phenyl C 
and indole C-NH), 132.2 , 130.4 (CH-CCO and CH-CSO2), 130.1 (CH-CH-CSO2), 
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128.8 (OCC-CH-CSO2), 128.2 ,126.5 (phenyl), 127.8 (indole C-C-NH), 123.9 
(indole CH-NH), 121.2 (indole CH-CH-C-C), 118.9 (indole CH-C-C), 118.5 (indole 
CH-CH-C), 111.6 (indole CH-C-NH), 110.6 (indole C-CH2), 65.5 (CH2-phenyl), 
53.7 (CH-CH2-indole), 52.7 (lactam CH), 45.5 (CH2-NSO2), 41.2 (lactam CH2-NH), 
40.7, 39.6 (CH2-butyl and CH2-NHCbz), 40.0 (CH-CH2CH2N), 31.0 (CH2-CH2N), 
29.5, 29.4, 29.0, 28.5, 28.2, 27.9 (CH2-indole, lactam CH2-CH, CH2-CH2NH, CH2-
CH2CH and CH2-CH2NHCbz, CH2-propyl) and 24.0 (CH2-CH2CH2NHCbz); ESI 
m/z (100 %, 850.5 (MNa
+
).  
2.90, O-Benzyl 6-((R)-3-(1H-indol-3-yl)-2-(1-(4-((S)-2-oxoazepan-3-ylcarbamoyl) 
phenylsulfonyl)piperidine-4-carboxamido)propanamido)hexylcarbamate 
Acid 2.84 (0.061 g, 0.160 mmol) was dissolved in dichloromethane (5 mL) and 
cooled to 0°C. HATU (0.08 g, 0.21 mmol) was added and the mixture was stirred for 
4 hours. Amine 2.30 (0.16 mmol) and triethylamine (67 μL, 0.48 mmol) were added 
and the reaction was stirred over night. The dichloromethane was removed in vacuo 
and the product was dissolved in ethyl acetate and washed with a pH 2 buffer (3 × 5 
mL) and ½ saturated NaHCO3 (3 × 5 mL). The organic layer was dried over Na2SO4 
and reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate:MeOH, 50:50:0 to 0:90:10) to give compound 2.90 as 
a white solid (0.047 g, 36 %); mp 54-57 º C; δH (700 MHz, CDCl3) 8.07 (d, 2H, J 
8.5, CH-CCO), 7.83 (d, 2H, J 8.5, CH-CSO2), 7.57 (d, 1H, J 8.5, indole CH-C-C), 
7.36-7.27 (m, 6H, indole CH-C-NH and phenyl), 7.09 (1H, t, J 7.5, indole CH-CH-
C), 7.06 (s, 1H, indole CH-NH), 6.99 (t, 1H, J 7.5, indole CH-CH-C-C), 5.08 (s, 2H, 
CH2-phenyl), 4.81 (dd, 1H, J 10, 1.5, lactam CH), 4.60 (t, 1H, J 7.5, CH-CH2-
indole), 3.69 (d, 1H, J 11.5, equatorial CH2-N), 3.60 (d, 1H, J 11.5, equatorial CH2-
N), 3.38 (dd, 1H, J 15, 11.5, axial lactam CH2-NH), 3.28 (dd, 1H, J 14.5, 5, 
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equatorial lactam CH2-NH), 3.20 (dd, 1H, J 14.5, 7, CH2-indole), 3.13-3.04 (m, 4H, 
CH2-NHCbz and CH2-pentyl),  3.00 (dd, 1H, J 14.5, 7, CH2-indole), 2.34 (td, 1H, J 
12, 3, axial CH2-N), 2.30 (td, 1H, J 12, 3, axial CH2-N), 2.14 (tt, 1H, J 1H, CH-
CH2CH2N), 2.10-2.04 (m, 2H, CH2-CH and CH2-CH2NH), 1.92-1.84 (m, 2H, CH2-
CH2CH), 1.78-1.67 (m, 2H, CH2-CH2NHCbz), 1.63-1.59 (m, 1H, lactam CH2-CH), 
1.58-1.52 (m, 1H, lactam CH2-CH2NH), 1.45-1.39 (m, 4H, CH2-CH2CH2N), 1.31-
1.27 (m, 2H, CH2-butyl), 1.25-1.21 (m, 2H, CH2-CH2CH2CH2NHCbz) and 1.14-1.09 
(m, 2H, CH2-CH2CH2NHCbz); δC (175 MHz, CDCl3) 175.6, 175.1, 172.4, 166.0 
(C=O), 157.5 (C=O carbamate), 138.8, 138.1, 137.1, 136.6 (C-SO2, C-CO, indole C-
NH and phenyl C), 128.1 (CH-CCO), 128.0 (CH-CSO2), 127.5, 127.4 (phenyl), 
127.3 (indole C-C-NH), 123,1 (indole CH-NH), 121.0 (indole CH-CH-C), 118.5 
(indole CH-CH-C-C), 118.4 (indole CH-C-C), 111.1 (indole CH-C-NH), 109.6 
(indole C-CH2), 65.9 (CH2-phenyl), 54.5 (CH-CH2-indole), 52.7 (lactam CH), 45.4 
(CH2-N), 41.2 (lactam CH2-NH), 41.1 (CH-CH2CH2N), 38.9, 38.8 (CH2-NHCbz and 
CH2-pentyl), 30.7 (lactam CH2-CH), 29.4, 29.3, 28.6, 28.56, 28.53, 27.9, 27.8, 27.5 
8 (lactam CH2-CH2CH, lactam CH2-CH2NH, CH2-CH2-CH2-CH2-CH2NHCbz, CH2-
indole and CH2-CH2N. 
2.91, (S)-tert-butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-(3-((S)-2-oxoazepan-3-
ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamido)propanamido)-6-
(benzyloxycarbonylamino)hexanoate 
Acid 2.09 (2.0 g, 4.7 mmol) was dissolved in dichloromethane (35 mL) and cooled 
to 0° C. HATU (1.52 g, 4.00 mmol) was added and the mixture was stirred for 4 
hours. Amine 2.31 (4 mmol) and triethylamine (1.7 mL, 4.0 mmol) were added and 
the reaction was stirred for 48 hours. The dichloromethane was removed in vacuo 
and the product was dissolved in ethyl acetate and washed with a pH 2 buffer (3 × 20 
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mL), 0.1 M HCl (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 mL). The organic 
layer was reduced in vacuo and the product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:90:10) to give 
compound 2.91 as a white solid (1.32 g, 71 %); mp 127-128 °C; [α]22D = -7.08 
MeOH; υmax/cm
-1
: 3284 (N-H), 2932 (saturated C-H), 1705 (C=O ester), 1643 (C=O 
amide), 1513 (aromatic), 1334, 1150 (SO2) and 1250 (C-O); δH (700 MHz, CDCl3) 
9.33 (d, 1H, NH indole), 8.17 (s, 1H, OCC-CH-CSO2), 8.00 (d, 1H, J 7.5, CH-CCO 
or CH-CSO2), 7.83 (d, 1H, J 7.5, CH-CCO or CH-CSO2), 7.80 (d, 1H, J 5.5, lactam 
NH-CH), 7.63 (d, 1H, J 8, indole CH-C-C), 7.55 (t, 1H, J 8, CH-CH-CSO2), 7.33-
7.27 (m, 5H, indole CH-C-NH and phenyl), 7.10 (t, 1H, J 8, indole CH-CH-C ), 7.04 
(t, 1H, J 7.5, indole CH-CH-C-C), 6.90 (s, 1H, indole CH-NH), 6.60 (br.t, 1H, J 5, 
lactam NH-CH2), 6.50 (d, 1H, J 7, NH-CHCH2-indole), 6.20 (d, 1H, J 7.5, NH-
CHCOO), 5.10 (d, 1H, J 12, CH2-phenyl) 5.09 (d, 1H, J 5.5, CH2-phenyl), 5.06 (t, 
1H, J 6, NHCbz), 4.75 (q, 1H, J 7, CH-CH2-indole), 4.69 (dd, 1H, J 11, 5, lactam 
CH), 4.25 (q, 1H, J 6.5, CH-COO), 3.65 (d, 1H, J 11.5, equatorial CH2-N), 3.59-3.56 
(m, 1H, equatorial), CH2-N 3.29 (td, 1H, J 11, 5, axial lactam CH2-NH), 3.25-3.20 
(m, 1H, CH2-indole), 3.18 (dd, 1H, J 13.5, 5,5, equatorial lactam CH2-NH), 3.10-
3.01 (m, 2H, CH2-indole and CH2-NHCbz), 2.96 (qu, 1H, J  6, CH2-NHCbz), 2.36-
2.28 (m, 2H, axial CH2-N), 2.18 (d, 1H, J 13.5, axial CH2-N), 2.05-2.00 (m, 2H, 
lactam CH2-CH and CH2-CH2NH), 1.98-1.92 (m, 1H, CH-CH2CH2NSO2), 1.84 
(br.d, 2H, J 11.5, CH2-CHCOO), 1.77-1.65 (m, 4H, CH2-CH2N), 1.55 (q, 1H, J 11.5, 
axial lactam CH2-CH), 1.47-1.41 (m, 1H, lactam CH2-CH2CH), 1.39 (d, 1H, J 13, 
lactam CH2-CH2CH), 1.36-1.30 (m, 2H, lactam CH2-CH2NH and CH2-CH2NHCbz), 
1.33 (s, 9H, C(CH3)3), 1.29-1.24 (m, 1H, CH2-CH2NHCbz), 0.84-0.77 (m, 1H, CH2-
CH2CHCOO) and 0.75-0.69 (m, 1H, CH2-CH2CHCOO); δC (700 MHz, CDCl3) 
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175.4 (C=O ester), 173.4, 170.9, 170.7, 164.7 (C=O), 156.8 (C=O carbamate), 137.2, 
136.5, 136.4, 135.4 (C-SO2, C-CONH, indole C-NH and phenyl C), 131.2, 130.3 
(CH-CCO and CH-CSO2), 129.4 (CH-CH-CSO2), 128.6 (OCC-CH-SO2), 128.2 
(phenyl m-CH), 128.1 (phenyl p-CH), 127.2 (indole C-C-NH), 126.2 (phenyl o-CH), 
123.1 (indole CH-NH), 122.1 (indole CH-CH-C), 119.6 (indole CH-CH-C-C), 118.7 
(indole CH-C-C), 111.5 (indole CH-C-NH), 110.1 (indole C-CH2), 82.2 (C(CH3)3), 
66.8 (CH2-phenyl), 53.8 (C-CH2-indole), 52.8 (C-COO), 52.4 (lactam CH), 45.4 
(CH2-N), 42.2 (lactam CH2-NH), 41.6 (CH-CH2CH2N), 40.8 (CH2-NHCbz), 31.8 
(CH2-CH2N), 31.4, 29.8, 29.0, 28.8, 27.9, 27.8, (CH2-indole, lactam CH2-CH, lactam 
CH2-CH2NH, lactam CH2-CH2CH, CH2-CHCOO and CH2CH2NHCbz), 28.0 
(C(CH3)3) and 21.6 (CH2-CH2CHCOO); HR ESI m/z (C48H61N7O10SH
+
 requires 
928.4273) found 928.4284.  
2.92, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-(4-((S)-2-oxoazepan-3-
ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamido)propanamido)-6-
(benzyloxycarbonylamino)hexanoate 
Acid 2.84 (0.81 g, 1.9 mmol) was dissolved in dichloromethane and the reaction was 
cooled to 0 °C. HATU (0.79 g, 2.1 mmol) was added and the reaction was stirred for 
10 minutes. Amine 2.31 (2 mmol) in dichloromethane and triethylamine (0.9 mL, 6 
mmol) were added and the reaction stirred overnight. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 mL). The organic layer 
was dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 60:40:0 to 0:70:30)  
to give compound 2.92 as a white powder (1.36 g, 76 %); δH (700 MHz, MeOD) 
8.08 (d, 2H, J 8, CH-CCO), 7.85 (d, 2H, J 8, CH-CSO2), 7.59 (d, 1H, J 7.5, indole 
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CH-C-C), 7.38-7.31 (m, 5H,  phenyl), 7.11 (t, 1H, J 8, indole CH-CH-C), 7.08 (s, 
1H, indole CH-NH), 7.02 (t, 1H, J 7.5, indole CH-CH-C-C), 5.08 (s, 2H, CH2-
phenyl), 4.83 (d, 1H, J 11.5 lactam CH), 4.75 (t, 1H, J 7.5, CH-CH2-indole), 4.11 
(dd, 1H, J 8, 5, CH-COO), 3.72 (d, 1H, J 12.5, equatorial CH2-N), 3.64 (d, 1H, J 
12.5, equatorial CH2-N), 3.39 (t, 1H, J 13.5 axial lactam CH2-NH), 3.29 (dd, 1H, J 
14, 4, equatorial lactam CH2-NH), 3.22 (dd, 1H, J 14, 7.5, CH2-indole), 3.09 (dd, 
1H, J 14, 7, CH2-indole), 3.06-3.02 (m, 2H, CH2-NHCbz), 2.36 (t, 1H, J 11.5,  axial 
CH2-N), 2.32 (t, 1H, J 11.5,  axial CH2-N), 2.16 (tt, 1H, J 11, 2.5, CH-CH2CH2N), 
2.08 (br.d, 2H, J 11.5, lactam CH2-CH and lactam CH2-CH2NH), 1.93-1.85 (m, 2H, 
lactam CH2-CH2CH), 1.80-1.68 (m, 4H, CH2-CH2N and CH2CHCOO), 1.65-1.56 
(m, 2H, lactam CH2-CH and lactam CH2-CH2NH), 1.47-1.43 (m, 2H, CH2-CH2N), 
1.44 (s, 9H, C(CH3)3), 1.40-1.34 (m, 2H, CH2-CH2NHCbz) and 1.05-0.99 (m, 2H, 
CH2-CH2CH-COO); δC (175 MHz, MeOD) 175.6 (C=O ester), 175.0, 172.3, 171.2, 
166.1 (C=O amide), 157.5 (C=O carbamate), 138.9, 138.1, 137, 136.5 (C-SO2, C-
CONH, indole C-NH and phenyl C), 128.1 (CH-CCO), 127.5 (CH-CSO2), 127.9, 
127.6 (phenyl), 127.3 (indole C-C-NH), 123.2 (indole CH-NH), 121.2 (indole CH-
CH-C-C), 118.5 (indole CH-C-C), 118.1 (indole CH-CH-C), 111.1 (indole CH-C-
NH), 109.6 (indole C-CH2), 81.5 (C(CH3)3), 65.9 (CH2-phenyl), 55.0 (C-CH2-
indole), 54.0 (C-COO
t
Bu), 53.0 (lactam CH), 45.4 (CH2-N), 41.3 (lactam CH2-NH), 
41.2 (CH-CH2CH2N), 41.1 (CH2-NHCbz), 30.8 (CH2-CH2N), 30.0, 29.2, 29.1, 29.0, 
28.9, 28.6 (CH2-indole, lactam CH2-CH, lactam CH2-CH2NH, lactam CH2CH2CH, 
CH2-CH-COO
t
Bu and CH2-CH2-NH-Cbz), 27.0 (C(CH3)3) and 22.5 (CH2-
CH2CHCOO); HR ESI m/z (C48H60N7O10SH
+
 requires 927.4201) found 928.4273 
and (C48H61N7O10SNa
+
 requires 950.4098) found 950.4093. 
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2.06, N-((R)-1-(5-Aminopentylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-(3-
((S)-2-oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamide 
Carbamate 2.89 (0.23 g, 0.27 mmol) was dissolved in MeOH (8 mL) and THF (2 
mL). Palladium activated charcoal (0.5 g, catalytic) was added and the reaction 
stirred under hydrogen for 24 hours. The palladium was removed through filtration 
and the organic solvent was removed in vacuo to give compound 2.06 as a brown 
solid (0.16 g, 81 %); [α]24D (c = 0.0858, MeOH) +4.56; δH (400 MHz, MeOD) 8.53 
(s, 1H, OCC-CH-CSO2), 8.18 (d, 1H, J 7.5, CH-CCO or CH-CSO2), 7.93 (d, 1H, J 8, 
CH-CCO or CH-CSO2), 7.74 (t, 1H, J 8, CH-CH-CSO2), 7.59 (d, 1H, J 8, indole 
CH-C-C), 7.37 (d, 1H, J 8.5, indole CH-C-NH), 7.12 (s, 1H, indole CH-NH), 7.11 (t, 
1H, J 7.5, indole CH-CH-C), 7.02 (t, 1H, J 7.5, indole CH-CH-C-C), 4.84 (d, 1H, J 
9, lactam CH), 4.58 (t, 1H, J 8.5, CH-CH2-indole), 3.74 (d, 1H, J 11.5, equatorial 
CH2-N), 3.65 (d, 1H, J 11.5, equatorial CH2-N), 3.39-3.31 (m, 2H, lactam CH2-NH), 
3.25 (dd, 1H, J 14.5, 7.5, CH2-indole), 3.16-3.00 (m, 3H, CH2-indole and CH2-
NHCO), 2.87 (dd, 1H, J 8, 8.5, CH2-NH2), 2.37 (td, 1H, J 12, 3, axial CH2-N), 2.32 
(td, 1H, J 12, 3, axial CH2-N), 2.13 (m, 1H, CH-CH2CH2N), 2.08 (br.d, 2H, J 11, 
lactam CH2-CH), 1.90 (td, 2H, J 12, 4, CH2-CH2N), 1.84-1.58 (m, 6H, lactam CH2-
CH2CH, lactam CH2-CH2NH and CH2-CH2N), 1.43-1.34 (m, 4H, CH2-CH2NH2 and 
CH2-CH2NHCO) and 1.27-1.20 (m, 2H, CH2-CH2CH2NH2); δC (175 MHz, MeOD) 
175.7, 175.4, 172.7, 165.9 (C=O), 136.8, 136.6, 135.2 (C-SO2, C-CONH and indole 
C-NH), 131.3 (CH-CCO or CH-CSO2), 130.3 (CH-CCO or CH-CSO2), 129.4 (CH-
CH-CSO2), 127.4 (indole C-C-NH), 126.4 (OCC-CH-CSO2), 123.2 (indole CH-NH), 
121.1 (indole CH-CH-C-C), 118.4 (indole CH-C-C), 118.0 (indole CH-CH-C), 110.9 
(indole CH-C-NH), 109.6 (indole C-CH2), 54.5 (CH-CH2-indole), 52.8 (lactam CH), 
45.4 (CH2-N), 41.1 (lactam CH2-NH), 41.0 (CH-CH2-CH2N), 39.2 (CH2-NH2), 38.5 
223 
 
(CH2-NHCO), 30.5 (CH2-CH2N), 28.6, 28.3, 28.1, 28.0, 27.9, 27.7 (CH2-indole, 
lactam CH2-CH, lactam CH2-CH2NH, lactam CH2-CH2CH and CH2-CH2-
CH2CH2NH2), 23.0 (CH2-CH2CH2NH2); HR ESI m/z (C35H48N7O6SH
+
 requires 
694.3381) found 694.3398. 
2.93, N-((R)-1-(6-Aminohexylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-(4-
((S)-2-oxoazepan-3-ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamide 
Carbamate 2.90 (0.047 g, 0.056 mmol) was dissolved in MeOH (4 mL), palladium 
activated charcoal (0.01 g, catalytic) was added and the reaction stirred under 
hydrogen over night. The palladium was removed through filtration and the organic 
solvents removed in vacuo to give compound 2.93 as a light brown solid (0.02 g, 50 
%); δH (400 MHz, MeOD) 8.10 (d, 2H, J 8.5, CH-CCO), 7.87 (d, 2H, J 8.5, CH-
CSO2), 7.60 (d, 1H, J 7.5, indole CH-C-C), 7.36 (d, 1H, J 8, indole CH-C-NH), 7.12 
(1H, t, J 7.5, indole CH-CH-C), 7.09 (s, 1H, indole CH-NH), 7.03 (t, 1H, J 7.5, 
indole CH-CH-C-C), 4.87 (d, 1H, J 11, lactam CH), 4.60 (t, 1H, J 7, CH-CH2-
indole), 3.74 (d, 1H, J 12, equatorial CH2-N), 3.64 (d, 1H, J 12, equatorial CH2-N), 
3.45-3.36 (m, 2H, lactam CH2-NH), 3.22 (dd, 1H, J 14, 7, CH2-indole), 3.17-3.03 
(m, 3H, CH2-indole and CH2-pentyl), 2.72 (t, 2H, J 8, CH2-NH2),  2.39 (td, 1H, J 10, 
3, axial CH2-N), 2.34 (td, 1H, J 10, 3, axial CH2-N), 2.22-2.15 (m, 1H, J 1H, CH-
CH2CH2N), 2.09 (br.d, 1H, J 10.5, equatorial CH2-CH2N), 1.97-1.887 (m, 2H, CH2-
CH2NH2), 1.85-1.45 (m, 8H, axial CH2-CH2N, lactam CH2-CH2NH, lactam CH2-
CH2CH, lactam CH2-CH), 1.40-1.27 (4H, CH2-CH2-CH2NHCO) and 1.23-1.15 (m, 
2H, CH2-CH2CH2NH2); HR ESI (C36H50N7O6S requires 708.3538) found 708.3536.  
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2.05, (S)-tert-Butyl-2-((R)-3-(1H-indol-3-yl)-2-(1-(3-((S)-2-oxoazepan-3-
ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamido)propanamido)-6-
aminohexanoate 
Carbamte 2.91 (0.5 g, 0.5 mmol) was dissolved in MeOH (4 mL) and THF (2 mL). 
Palladium activated charcoal (0.2 g, catalytic) was added and the reaction stirred 
under hydrogen for 24 hours. The palladium activated charcoal was removed through 
filtration and the organic solvent was removed in vacuo to give compound 2.05 as a 
white solid (0.18 g, 45 %); mp 140-145 °C (decomposed); [α]24D (c = 0.244, CHCl3) 
+0.61; υmax/cm
-1
: 3254 (N-H), 2928 (saturated C-H), 1723 (C=O ester), 1638 (C=O 
amide), 1544 (aromatic), 1331 (SO2), 1274 (C-O) and 1150 (SO2); δH (400 MHz, 
MeOD) 8.25 (s, 1H, OCC-CH-CSO2), 8.15 (d, 1H, J 7.5, CH-CCO or CH-CSO2), 
7.90 (d, 1H, J 8.5, CH-CCO or CH-CSO2), 7.69 (t, 1H, J 7.5, CH-CH-CSO2), 7.58 
(d, 1H, J 8, indole CH-C-C), 7.34 (d, 1H, J 8.5, indole CH-C-NH), 7.10 (s, 1H, 
indole CH-NH), 7.09 (t, 1H, J 7.5, indole CH-CH-C), 7.0 (t, 1H, J 7.5, indole CH-
CHC-C), 4.85-4.81 (m, 1H, CH-COO
t
Bu), 4.74 (t, 1H, J 7.5, CH-CH2-indole), 4.10 
(dd, 1H, J 9.5, 5, lactam CH), 3.72 (d, 1H, J 12.5, quatorialCH2-N e), 3.64 (d, 1H, J 
12.5, equatorial CH2-N), 3.35-3.32 (m, 2H, lactam CH2-NH), 3.19 (dd, 1H, J 14, 7.5, 
CH2-indole), 3.05 (dd, 1H, J 14, 7.5, CH2-indole), 2.65 (t, 2H, J 8, CH2-NH2), 2.44-
2.33 (m, 2H, axial CH2-N), 2.13 (tt, 1H, J 11, 3.5, CH-CH2CH2N), 2.03 (br.d, 2H, J 
11.5, lactam CH2-CH and CH2-CH2NH), 1.88-1.80 (m, 2H, CH2-CH2N), 1.77-1.65 
(m, 2H, CH2-CH2N), 1.62-1.52 (m, 4H, lactam CH2-CH2CH and CH2-CH-COO), 
1.49-1.45 (m, 2H, lactam CH2-CH), 1.43 (s, 9H, C(CH3)3), 1.31 (quintet, 2H, CH2-
CH2NH2) and 0.98 (quintet, 2H, J 7.5, CH2-CH2CH and CH2-CH2NH); δC (175 
MHz, MeOD) 175.8, 175.1, 172.4, 171.3, 165.8 (C=O), 136.8 136.6 135.2 (C-SO2, 
C-CONH and indole C-NH), 131.3, 130.2 (CH-CCO or CH-CSO2), 129.4 (CH-CH-
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CSO2), 127.5 (indole C-C-NH), 126.4 (OCC-CH-CSO2), 123.2 (indole CH-NH), 
121.1 (indole CH-CH-C-C), 118.4 (indole CH-C-C), 118.1 (indole CH-CH-C), 111.0 
(indole CH-C-NH), 109.6 (indole C-CH2), 81.3 (C(CH3)3), 54.0 (CH-CH2-indole), 
53.2 (CH-COO), 52.7 (lactam CH), 45.4 (CH2-N), 41.1 (lactam CH2-NH), 41.08 
(CH-CH2-CH2N), 40.8 (CH2-NH2), 31.8 (CH2-CH2N), 30.6 (CH2-CH-COO), 28.69, 
28.1, 27.9, 27.8, 27.7 (lactam CH2-CH, CH2CH2CH and CH2CH2NH, CH2-indole, 
CH2-CH2NH2), 26.9 (C(CH3)3), 22.4 (CH2-CH2CHCOO); HR ESI (C40H55N7O8SH
+
 
requires 794.3906) found 794.3915. 
2.94, (S)-tert-Butyl 2-((R)-3-(1H-indol-3-yl)-2-(1-(4-((S)-2-oxoazepan-3-
ylcarbamoyl)phenylsulfonyl)piperidine-4-carboxamido)propanamido)-6-
aminohexanoate 
Carbamate 2.92 (0.70 g, 0.75 mmol) was dissolved in MeOH (8 mL). Palladium 
activated charcoal (0.3 g, catalytic) was added and the reaction stirred under 
hydrogen for 24 hours. The palladium was removed through filtration and the 
organic solvent was removed in vacuo to give compound 2.94 as a beige oil (0.40 g, 
67 %); υmax/cm
-1
: 3273 (N-H), 2931 (saturated C-H), 1725 (C=O ester), 1638 (C=O 
amide), 1535 (aromatic), 1332 (SO2), 1250 (C-O) and 1154 (SO2);  δH (700 MHz, 
MeOD) 8.09 (d, 2H, J 8.5, CH-CCO), 7.87 (d, 2H, J 8.5, CH-CSO2), 7.59 (d, 1H, J 
8, indole CH-C-C), 7.35 (d, 1H, J 8, indole CH-C-NH), 7.11 (t, 1H, J 7.5, indole 
CH-CH-C), 7.10 (s, 1H, indole CH-NH), 7.02 (t, 1H, J 7.5, indole CH-CH-C-C), 
4.83 (d, 1H, J 11, CH-COO), 4.71 (t, 1H, J 7.5, CH-CH2-indole), 4.24 (dd, 1H, J 8.5, 
5, lactam CH), 3.74 (d, 1H, J 12, equatorial CH2-N), 3.66 (d, 1H, J 12, equatorial 
CH2-N), 3.41-3.27 (m, 2H, lactam CH2-NH), 3.22 (dd, 1H, J 14, 7.5, CH2-indole), 
3.08 (dd, 1H, J 14, 7.5, CH2-indole), 2.57 (t, 2H, J 7.5, CH2-NH2), 2.44-2.33 (m, 2H, 
axial CH2-N), 2.20 (tt, 1H, J 10.5, 4, CH-CH2CH2N), 2.14-20.5 (br.d, 2H, equatorial 
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CH2-CH2N), 1.99-1.79 (m, 3H, lactam CH2-CH2NH, lactam CH2-CH, lactam CH2-
CH2CH), 1.74 (q, 2H, J 14, axial CH2-CH2-N), 1.67-1.56 (m, 4H, lactam CH2-
CH2NH, lactam CH2-CH, lactam CH2-CH2CH and CH2-CH-COO), 1.44 (m, 10H, 
CH2-CHCOO and C(CH3)3), 1.40-1.31 (m, 2H, CH2-CH2NH2), 1.00 (quin., 2H, J 
7.5, CH2-CH2CHCOO); δC (175 MHz, MeOD) 175.6 (C=O ester), 175.0, 172.4, 
171.3, 165.8 (C=O), 138.8, 138.2, 136.5 (C-SO2, C-CO and indole C-NH), 128.1 
(CH-CCO), 127.6 (CH-CSO2), 127.5 (indole C-C-NH), 123.4 (indole CH-NH), 
121.2 (indole CH-CH-C-C), 118.5 (indole CH-C-C), 118.2 (indole CH-CH-C), 111.1 
(indole CH-C-NH), 109.7 (indole C-CH2), 81.4 (C(CH3)3), 54.0 (CH-CH2-indole), 
53.2 (CH-COO), 52.7 (lactam CH), 45.3 (CH2-N), 41.2 (lactam CH2-NH), 41.0 (CH-
CH2CH2N), 40.7 (CH2-NH2), 31.7 (CH2-CH2N), 30.7, 28.6, 27.9, 27.7, 27.3, 27.0, 
(CH2-indole, lactam CH2-CH, lactam CH2-CH2NH, lactam CH2-CH2CH,  CH2-
CH2NH2 and CH2-CHCOO), 27.0 (C(CH3)3) and 22.4 (CH2-CH2CHCOO); HR ESI 
m/z (C40H55N7O8SH
+
 requires 794.3906) found 794.3921.  
6.3 Chapter 3 Experimental 
6.3.1 Lactams with long Alkyl Chains 
3.33, Decanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (40 mL) and cooled to 0°C. Decanoyl 
chloride (3.1 mL, 15 mmol) in dichloromethane (40 mL) and triethylamine (6.3 mL, 
45 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.33 as a white solid 1.22 g (30 %); mp 109-110 º C; [α]27D (c = 0.26, 
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CHCl3) +75.05; υmax/cm
-1
: 3202 (N-H), 2922 (saturated C-H) and 1656, 1638 (C=O); 
Anal. (C15H28N2O2 requires: C; 67.13, H; 10.52, N; 10.44) found: C; 66.87, H; 10.41, 
N; 10.26; δH (400 MHz, CDCl3) 7.21 (s, 1H, NH-CH2), 6.91 (d, 1H, J 6.5, NH-CH), 
4.11 (dt, 1H, J 6, 11.5, CH), 3.18-3.12 (m, 2H, lactam CH2-NH), 2.29-2.12 (m, 1H, 
lactam CH2-CH), 2.05 (t, 2H, J 7.5, CH2-CO), 1.76-1.70 (m, 2H, lactam CH2-
CH2NH), 1.51-1.41 (m, 3H, lactam CH2-CH and CH2-CH2CO), 1.17-1.08 (m, 10H, 
CH2-CH2-CH2-CH2-CH2-CH3) and 0.71 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 
173.5, 172.2 (C=O), 50.1 (CH), 41.4 (lactam CH2-NH), 36.3 (CH2-CO), 31.8 (lactam 
CH2-CH), 29.3 (CH2-CH2CO), 29.2 (CH2-CH2CH2CO), 29.1 (CH2-
CH2CH2CH2CO), 29.0 (CH2-CH2CH2CH2CH3), 27.2 (CH2-CH2CH2CH3), 25.6 
(CH2-CH2CH3), 22.5 (CH2-CH3), 21.0 (lactam CH2-CH2NH) and 14.0 (CH3); ESI 
m/z 100 %, 559.3 (M2Na
+
) and 15 %, 269.1 (MH
+
); HR ESI m/z (C15H28N2O2H
+
 
requires 291.2043) found 291.2040. 
3.34, Nonanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (40 mL) and cooled to 0°C. Nonanoyl 
chloride (2.8 mL, 15 mmol) in dichloromethane (40 mL) and triethylamine (6.7 mL, 
48 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.34 as a white solid 1.04 g (27 %); mp 102-103 º C; [α]27D (c = 0.244, 
CHCl3) +86.01; υmax/cm
-1
: 3304 (N-H), 2922 (saturated C-H) and 1637, 1620 (C=O); 
Anal. (C14H26N2O2 requires: C; 66.10, H; 10.30, N; 11.01) found: C; 65.96, H; 10.23, 
N; 10.95; δH (400 MHz, CDCl3) 7.14 (s, 1H, NH-CH2), 6.84 (d, 1H, J 6, NH-CH), 
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4.13 (dt, 1H, J 11.5, 6, CH), 3.20-3.14 (m, 2H, lactam CH2-NH), 2.30 (ddt, 1H, J 
5.5, 5, 13, lactam CH2-NH), 2.07 (t, 2H, J 7.5, CH2-CO), 1.79-1.71 (m, 2H, lactam 
CH2-CH2NH), 1.52-1.41 (m, 3H, CH2-CH and CH2-CH2CO), 1.20-1.07 (CH2-CH2-
CH2-CH2-CH2-CH3) and 0.73 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 173.5 
(C=O), 172.2 (C=O), 50.1 (CH), 41.4 (lactam CH2-NH), 36.4 (CH2-CO), 31.7 
(lactam CH2-CH), 29.3 (CH2-CH2CO), 29.2 (CH2-CH2CH2CO), 29.1 (CH2-
CH2CH2CH2CO), 27.2 (CH2-CH2CH2CH3), 25.7 (CH2-CH2CH3), 22.6 (CH2-CH3), 
21.0 (lactam CH2-CH2NH) and 14.0 (CH3); ESI m/z 100 %, 531.3 (M2Na
+
) and 30 
%, 277.1 (MNa
+
); HR ESI m/z (C14H26N2O2Na requires 277.1826) found 277.1884. 
3.35, Octanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (100 mL) and cooled to 0°C. Octanoyl 
chloride (2.6 mL, 15 mmol) in dichloromethane (40 mL) and triethylamine (6.7 mL, 
48 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.35 as a white solid 0.95 g (26 %); mp 106-107 º C; [α]27D (c = 0.3, 
CHCl3) +81.89; υmax/cm
-1
: 3302, 3201 (N-H), 2924 (saturated C-H), 1670, 1704 
(C=O) and 1530 (aromatic); Anal. (C13H24N2O2 requires: C; 64.97, H; 10.07, N; 
11.66) found: C; 64.89, H; 10.00, N; 11.47; δH (400 MHz, CDCl3) 7.0 (s, 1H, NH-
CH2), 6.75 (d, 1H, J 5.5, NH-CH), 4.18 (dt, 1H, J 11.5, 5.5, CH), 3.25-3.20 (m, 2H, 
lactam CH2-NH), 2.38 (ddt, 1H, J 4.5, 6, 13, lactam CH2-CH), 2.11 (t, 2H, J 8, CH2-
CO), 1.84-1.76 (m, 2H, lactam CH2-CH2NH), 1.56-1.44 (m, 3H, lactam CH2-CH and 
CH2-CH2CO), 1.24-1.14 (m, 8H, CH2-CH2-CH2-CH2-CH3) and 0.77 (t, 3H, J 7.5, 
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CH3); δC (100 MHz, CDCl3) 173.5, 172.2 (C=O), 50.2 (CH), 41.5 (lactam CH2-NH), 
36.4 (CH2-CO), 31.6 (lactam CH2-CH), 29.2 (CH2-CH2CO), 29.0 (CH2-
CH2CH2CO), 25.7 (CH2-CH2CH2CH3), 25.6 (CH2-CH2CH3), 24.9 (CH2-CH3), 21.0 
(lactam CH2-CH2CH) and 14.0 (CH3); ESI m/z 100 %, 503.0 (M2Na
+
) and 24 %, 
263.2 (MNa
+
); HR ESI m/z (C13H24N2O2Na
+
 requires 263.1730) found 263.1730. 
3.36, Heptanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. Heptanoyl 
chloride (2.3 mL, 15 mmol) in dichloromethane (25 mL) and triethylamine (6.3 mL, 
45 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 25 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.36 as a white solid 0.73 g (21 %); mp 101-102 º C; [α]27D (c = 0.23, 
CHCl3) +111.52; υmax/cm
-1
: 3298 (N-H), 2924 (saturated C-H) and 1625 (C=O); 
Anal. (C12H22N2O2 requires: C; 63.68, H; 9.80, N; 12.38) found: C; 63.38, H; 9.73, 
N; 12.15; δH (400 MHz, CDCl3) 6.66 (br.s, 1H, NH-CH2), 6.60 (d, 1H, J 6.5, NH-
CH), 4.22 (dt, 1H, J 12, 5.5, CH), 3.30-3.26 (m, 2H, lactam CH2-NH), 2.49 (dt, 1H, 
J 12, 5.5, 4.5, lactam equatorial CH2-CH), 2.17 (t, 1H, J 8, CH2-CO), 2.16 (t, 1H, J 
8, CH2-CO), 1.90-1.83 (m, 2H, lactam axial CH2-CH2NH and CH2-CH), 1.61-1.44 
(m, 3H, lactam axial CH2-CH2NH and CH2-CH2CO), 1.29-1.20 (m, 6H, CH2-CH2-
CH2-CH3) and 0.82 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 173.5, 172.1 (C=O), 
50.4 (CH), 41.6 (lactam CH2-NH), 36.6 (CH2-CO), 31.5 (lactam CH2-CH), 28.9 
(CH2-CH2CO), 27.2 (CH2-CH2CH2CO), 25.6 (CH2-CH2CH3), 22.5 (CH2-CH3), 21.0 
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(lactam CH2-CH2NH) and 14.0 (CH3); ESI m/z 100 %, 475.2 (M2Na
+
) and 26 %, 
249.0 (MNa
+
); HR ESI m/z (C12H22N2O2Na
+
 requires 249.1573) found 249.1573. 
3.37, Hexanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (80 mL) and cooled to 0°C. Hexanoyl 
chloride (2.1 mL, 16 mmol) in dichloromethane (25 mL) and triethylamine (6.3 mL, 
48 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.37 as a white solid 0.415 g (13 %); mp 101-102 º C; [α]30D (c = 0.46, 
CHCl3) +97.39; υmax/cm
-1
: 3215 (N-H), 2924 (saturated C-H) and 1666 (C=O); Anal. 
(C11H20N2O2 requires: C; 62.23, H; 9.50, N; 13.20) found: C; 62.08, H; 9.43, N; 
12.90; δH (400 MHz, CDCl3) 6.52 (d, 1H, J 5, NH-CH2), 6.34 (br.s, 1H, NH-CH), 
4.24 (dt, 1H, J 11, 5.5, CH), 3.33-3.28 (m, 2H, lactam CH2-NH), 2.53 (ddt, 1H, J 13, 
6, 5,  lactam equatorial CH2-CH), 2.19 (t, 1H, J 8, CH2-CO), 2.18 (t, 1H, J 8, CH2-
CO), 1.92-1.86 (m, 2H, lactam CH2-CH2NH), 1.61 (quintet, 2H, J 7.5, CH2-CH2CO), 
1.32-1.23 (m, 4H, CH2-CH2-CH3) and 0.86 (t, 3H, J 7.5, CH3); δC (100 MHz, 
CDCl3) 173.5, 172.0 (C=O), 50.5 (CH), 41.7 (lactam CH2-NH), 36.6 (CH2-CO), 31.4 
(CH2-CH2CO), 27.2 (lactam CH2-CH), 25.3 (CH2-CH2CH3), 22.4 (CH2-CH3), 21.0 
(lactam CH2-CH2NH) and 14.0 (CH3); ESI m/z 100 %, 447.0 (M2Na
+
) and 33 %, 
235.2 (MNa
+
); HR ESI m/z (C11H20N2O2Na
+
 requires 235.1417) found 235.1419.  
3.38, Pentanoylamino-(R)-tetrahydropyridin-2-one  
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Lactam 2.53 (20 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. Valeryl 
chloride (1.8 mL, 15 mmol) in dichloromethane (25 mL) and triethylamine (6.3 mL, 
45 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 20 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.38 as a white solid 0.20 g (10 %); mp 87-88 º C; [α]30D (c = 0.25, 
CHCl3) -87.72; υmax/cm
-1
: 3300 (N-H), 2956, 2931 (saturated C-H) and 1622 (C=O); 
Anal. (C10H18N2O2 requires: C; 60.58, H; 9.15, N; 14.13) found: C; 60.03, H; 9.06, 
N; 13.55; δH (400 MHz, CDCl3) 6.55 (d, 1H, J 5, NH-CH), 6.46 (br.s, 1H, NH-CH2), 
4.24 (dt, 1H, J 11.5, 6, CH), 3.33-3.28 (m, 2H, lactam CH2-NH), 2.52 (ddt, 1H, J 13, 
5.5, 4, lactam CH2-CH), 2.19 (t, 2H, J 8, CH2-CO), 1.92-1.85 (m, 2H, lactam CH2-
CH2NH), 1.59 (quintet, 2H, J 7.5, CH2-CH2CO), 1.54-1.45 (m, 1H, lactam CH2-CH), 
1.31 (sextet, 2H, J 7.5, CH2-CH3) and 0.88 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 
173.5 (C=O), 172.1 (C=O), 50.5 (CH-NH), 41.6 (lactam CH2-NH), 36.3 (CH2-CO), 
27.7 (lactam CH2-CH), 27.2 (CH2-CH2CO), 22.4 (CH2-CH3), 21.0 (lactam CH2-
CH2NH) and 13.8 (CH3); ESI m/z 100 %, 419.0 (M2Na
+
) and  26 %, 221.1 (MNa
+
); 
HR ESI m/z (C14H18N2O2Na
+
 requires 221.1260) found 221.1252. 
3.39, Pentanoylamino-(S)-tetrahydropyridin-2-one 
Lactam 2.53 (10 mmol) was dissolved in H2O (15 mL) and cooled to 0°C. Valeryl 
chloride (1.2 mL, 10 mmol) in dichloromethane (20 mL) and triethylamine (4.2 mL, 
30 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 20 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
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column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.39 as a white solid 0.13 g (7 %); mp 94-95º C; [α]26D (c = 0.491, CHCl3) 
+97.08; υmax/cm
-1
: 3290, 3206 (N-H), 2946 (saturated C-H) and 1654, 1638 (C=O); 
Anal. (C10H18N2O2 requires: C; 60.58, H; 9.15, N; 14.13) found: C; 60.42, H; 9.13, 
N; 13.96; δH (400 MHz, CDCl3) 6.53 (d, 1H, J 4, NH-CH), 6.38 (br.s, 1H, NH-CH2), 
4.24 (dt, 1H, J 11.5, 6, CH), 3.33-3.29 (m, 2H, lactam CH2-NH), 2.53 (ddt, 1H, J 
12.5, 5.5, 4, lactam CH2-CH), 2.20 (t, 2H, J 8, CH2-CO), 1.93-1.86 (m, 2H, lactam 
CH2-CH2NH), 1.59 (quintet, 2H, J 7.5, CH2-CH2CO), 1.53-1.45 (m, 1H, lactam 
CH2-CH), 1.31 (sextet, 2H, J 7.5, CH2-CH3) and 0.88 (m, 3H, J 7.5, CH3); δC (100 
MHz, CDCl3) 173.5, 172.0 (C=O), 50.5 (CH), 41.7 (lactam CH2-NH), 36.3 (CH2-
CO), 27.7 (lactam CH2-CH), 27.2 (CH2-CH2CO), 22.4 (CH2-CH3), 21.0 (lactam 
CH2-CH2NH) and 13.8 (CH3); ESI m/z 100 %, 419.0 (M2Na
+
) and  17 %, 221.1 
(MNa
+
); HR ESI m/z (C10H18N2O2Na
+
 requires 221.1260) found 221.1262.  
3.40, Butanoylamino-(S)-tetrahydropyridin-2-one  
Lactam 2.53 (10 mmol) was dissolved in H2O (50 mL) and cooled to 0°C. Butryl 
chloride (8 mmol) in dichloromethane and triethylamine (3.4 mL, 24 mmol) were 
added and stirred over night. The reaction was extracted with dichloromethane (3 × 
20 mL), the organic layer was washed with a pH 2 buffer (3 × 20 mL), dried over 
Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 3.40 as a white solid 0.047 g (3 %); mp 70-71 º C; [α]27D (c = 0.24, 
CHCl3) +104.17; υmax/cm
-1
: 3247 (N-H), 2962 (saturated C-H) and 1649 (C=O); 
Anal. (C9H16N2O2 requires: C; 58.67, H; 8.75, N; 15.21) found: C; 55.49, H; 8.40, N; 
14.37; δH (400 MHz, CDCl3) 6.79 (br.s, 1H, NH-CH2), 6.68 (d, 1H, J 6, NH-CH), 
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4.21 (dt, 1H, J 11.5, 5.5, CH), 3.30-3.23 (m, 2H, lactam CH2-NH), 2.44 (ddt, 1H, J 
12.5, 5.5, 4, lactam equatorial CH2-CH), 2.14 (t, 1H, J 7, CH2-CO), 2.13 (t, 1H, J 7, 
CH2-CO), 1.87-1.81 (m, 2H, lactam CH2-CH2NH), 1.60 (sextet, 2H, J 7, CH2-
CH2CO), 1.53-1.44 (m, 1H, lactam CH2-CH) and 0.88 (t, 3H, J 7.5, CH3); δC (100 
MHz, CDCl3) 173.4, 172.2 (C=O), 50.3 (CH-NH), 41.5 (lactam CH2-NH), 38.4 
(CH2-CO), 27.3 (lactam CH2-CH), 21.0 (CH2-CH2CO), 19.0 (lactam CH2-CH2NH) 
and 13.7 (CH3); ESI m/z 100 %, 391.0 (M2Na
+
) and 43 %, 207.1 (MNa
+
); HR ESI 
m/z (C9H16N2O2Na
+
 requires 207.1104) found 207.1105. 
6.3.2 6-Membered Exupéry Compounds 
3.41, (L)-Orn-(Cbz)-OMe.HCl 
Acetyl chloride (5 mL, 70 mmol) was dissolved in MeOH (80 mL) and cooled to 0 
°C. (L)-Ornithine-(Cbz) (9.12 g, 34.2 mmol) was added and the reaction was stirred 
over night, the organic solvents were removed in vacuo to give compound 3.41 as a 
white solid; mp 137-138 °C; δH (400 MHz, MeOD) 7.39-7.30 (m, 5H, phenyl), 5.10 
(s, 2H, CH2-phenyl), 4.10 (t, 1H, J 6, CH), 3.86 (s, 3H, OCH3), 3.20 (m, 2H, J 7, 
CH2-NH), 2.0-1.86 (m, 2H, CH2-CH2NH) and 1.74-1.55 (m, 1H, CH2-CH); δC (400 
MHz, MeOD) 170.9 (ester C=O), 159.0 (carbamate C=O), 138.4 (phenyl C), 129.6, 
129.1, 128.8 (CH phenyl), 67.5 (CH2-phenyl), 53.8 (OCH3 and CH), 41.0 (CH2-NH), 
28.8 (CH2-CH) and 26.6 (CH2-CH2NH). 
3.42, 2-Methylpropanoylamino-(L)-Orn-(Cbz)-OMe  
Amine 3.41 (2.49 g, 7.8 mmol) was dissolved in dichloromethane (50 mL), H2O (20 
mL) and cooled to 0 °C. Triethlyamine (3.2 mL, 23.4 mmol) and isobutyryl chloride 
(0.83 mL, 7.8 mmol) were added and the reaction stirred over night. The 
dichloromethane was removed in vacuo and the aqueous layer was extracted with 
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ethyl acetate. The organic layer was then washed with pH 2 buffer (3 × 15 mL), 
dried over Na2SO3 and reduced in vacuo to give compound 3.42 as a white solid 
(2.28 g, 83 %); δH (400 MHz, CDCl3) 7.37-7.28 (m, 5H, phenyl), 6.28 (d, 1H, J 8, 
NH-CH), 5.15 (t, 1H, J 5.5, NH-CH2), 5.09 (s, 2H, CH2-phenyl), 4.60 (dt, 1H, J 7.5, 
5.5, CH-NH), 3.73 (s, 3H, OCH3), 3.59 (q, 2H, J 6.5, CH2-NH), 2.42 (sextet, 1H, J 7, 
CH-C(CH3)2), 1.93-1.83 (m, 1H, CH2-CH), 1.73-1.63 (m, 1H, CH2-CH), 1.55 
(quintet, 2H, J 7, CH2-CH2NH) 1.17 (d, 3H, J 7, (CH3)2) and 1.16 (d, 3H, J 7, 
(CH3)2); δC (100 MHz, CDCl3) 177.0 (ester C=O), 173.0 (amide C=O), 156.6 
(carbamate C=O), 136.6 (C phenyl), 128.5, 128.1 (phenyl CH), 66.6 (CH2-phenyl), 
52.4 (OCH3), 51.6 (CH), 40.5 (CH2-NH), 35.4 (CH(CH3)2), 29.7 (CH2-CH), 26.0 
(CH2-CH2NH) and 19.6, 19.4 (C(CH3)2; ESI m/z 100 %, 351.2 (MH
+
), 12 %, 345.1 
(MNa
+
). 
3.43, Propanoylamino-(L)-Orn-(Cbz)-OMe  
Amine 3.41 (3.89 g, 12 mmol) was dissolved in dichloromethane (50 mL) and H2O 
(20 mL) and cooled to 0 °C. Triethlyamine (5 mL, 36 mmol) and propionyl chloride 
(1 mL, 12 mmol) were added and the reaction stirred over night. The 
dichloromethane was removed in vacuo and the aqueous layer was extracted with 
ethyl acetate. The organic layer was then washed with pH 2 buffer (3 × 15 mL), 
dried over Na2SO3 and reduced in vacuo to give compound 3.43 as a white solid 
(2.58 g, 64 %); δH (400 MHz, CDCl3) 7.37-7.29 (m, 5H, phenyl), 6.17 (d, 1H, J 7, 
NH-CH), 5.09 (s, 2H, CH2-phenyl), 4.99 (br.s, 1H, NH-CH2), 4.62 (q, 1H, J 7, CH-
NH), 3.73 (s, 3H, OCH3), 3.21 (q, 2H, J 6.5, CH2-NH), 2.55 (q, 2H, J 7.5, CH2-
CH3), 1.92-1.83 (m, 1H, CH2-CH), 1.73-1.63 (m, 1H, CH2-CH), 1.59-1.50 (m, 2H, 
CH2-CH2NH) and 1.15 (t, 3H, J 7, CH3-CH2); δC (100 MHz, CDCl3) 173.7 (ester 
235 
 
C=O), 173.0 (amide C=O), 156.5 (carbamate C=O), 136.6 (phenyl C), 128.5, 128.1, 
(phenyl CH), 66.7 (CH2-phenyl), 52.5 (OCH3), 51.7 (CH), 40.5 (CH2-NH), 29.8 
(CH2-CH), 29.5 (CH2-CO), 26.0 (CH2-CH2NH) and 9.7 (CH3-CH2); ESI m/z 100 %, 
337.1 (MH
+
), 58 %, 359.1 (MNa
+
). 
3.44, Acetylamino-(L)-Orn-(Cbz)-OMe  
Amine 3.41 (1.92 g, 6 mmol) was dissolved in dichloromethane (50 mL) and H2O 
(30 mL) and cooled to 0 °C. Triethlyamine (2.5 mL, 18 mmol) and acetyl chloride 
(0.43 mL, 6 mmol) were added and the reaction stirred over night. The 
dichloromethane was removed in vacuo and the aqueous layer was extracted with 
ethyl acetate. The organic layer was then washed with pH 2 buffer (3 × 15 mL), 
dried over Na2SO3 and reduced in vacuo to give compound 3.44 as a white solid 
(1.76 g, 92 %); δH (400 MHz, CDCl3) 7.36-7.26 (m, 5H, phenyl), 6.35 (d, 1H, J 8, 
NH-CH), 5.09 (s, 3H, CH2-phenyl and NH-CH2), 4.57 (q, 1H, J 7, CH-NH), 3.70 (s, 
3H, OCH3), 3.18 (q, 2H, J 7, CH2-NH), 1.99 (s, 3H, CH3), 1.88-1.75 (m, 1H, CH2-
CH), 1.70-1.60 (m, 1H, CH2-CH) and 1.57-1.48 (m, 2H, CH2-CH2NH); δC (100 
MHz, CDCl3) 172.9, 170.1 (ester and amide C=O), 156.6 (carbamate C=O), 136.6 
(phenyl C), 128.5, 128.13, 128.09 (phenyl CH), 66.7 (CH2-phenyl), 52.5 (OCH3), 
51.8 (CH), 40.5 (CH2-NH), 29.6 (CH2-CH), 26.0 (CH2-CH2NH) and 23.1 (CH3); ESI 
m/z 100 %, 323.1 (MH
+
), 36 %, 345.1 (MNa
+
). 
3.45, 2-Methylpropanoylamino-(S)-tetrahydropyridin-2-one  
Carbamate 3.42 (2.28 g, 6.51 mmol) was dissolved in MeOH (70 mL), palladium 
activated charcoal (0.7 g, catalytic) was added and the reaction stirred under 
hydrogen over night. The palladium was removed through filtration and the organic 
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solvents were removed in vacuo to give compound 3.45 as a white solid (1.06 g, 88 
%) mp 129-130 °C; [α]24D (c = 0.24, CHCl3) +112.85; υmax/cm
-1
: 3290, 3223 (N-H), 
2933 (saturated C-H) and 1654, 1637 (C=O); Anal. (C9H16N2O2 requires: C; 58.67, 
H; 8.75, N; 15.21) found: C; 58.57, H; 8.74, N; 15.08; δH (400 MHz, MeOD) 4.60 
(dd, 1H, J 10, 6, CH-NH), 3.536-3.34 (m, 2H, CH2-NH obscured by MeOD), 2.55 
(sextet, 1H, J 7, CH-C(CH3)2), 2.20-2.13 (m, 1H, CH2-CH), 2.03-1.90 (m, 2H, CH2-
CH2-NH) 1.84 (qd, 1H, J 11, 4, CH2-CH) 1.21 (d, 3H, J 7, (CH3)2) and 1.20 (d, 3H, J 
7, (CH3)2; δC (100 MHz, MeOD) 179.9, 173.1 (C=O), 50.7 (CH), 42.9 (lactam CH2-
NH), 36.2 (CH(CH3)2), 28.9 (lactam CH2-CH), 22.4 (lactam CH2-CH2NH) and 20.0, 
19.8 (C(CH3)2; ESI m/z 100 %, 391.0 (M2Na
+
), 78 %, 207.1 (MNa
+
); HR ESI m/z 
(C9H16N2O2Na
  
requires 207.1104) found 207.1104. 
3.46, Propanoylamino-(S)- tetrahydropyridin-2-one  
Carbamate 3.43 (2.28 g, 6.80 mmol) was dissolved in MeOH (70 mL), palladium 
activated charcoal (0.7 g, catalytic) was added and the reaction stirred under 
hydrogen over night. The palladium was removed through filtration and the organic 
solvents were removed in vacuo to give compound 3.46 as a white solid (0.9 g, 78 
%) mp 119-120 °C; [α]24D (c = 0.242, CHCl3) +128.44; υmax/cm
-1
: 3292 (N-H), 2942 
(saturated C-H) and 1620 (C=O); Anal. (C8H14N2O2 requires: C; 58.45, H; 8.26, N; 
16.46) found: C; 56.19, H; 8.25, N; 16.13; δH (400 MHz, MeOD) 4.35 (dd, 1H, J 11, 
6, CH), 3.36-3.32 (m, 2H, lactam CH2-NH), 2.30 (q, 2H, J 8, CH2-CH3), 2.18-2.11 
(m, 1H, lactam CH2-CH), 2.10-1.87 (m, 2H, lactam CH2-CH2NH) 1.81 (qd, 1H, J 
11.5, 4, lactam CH2-CH) and 1.18 (t, 3H, J 7.5, CH3-CH2); δC (100 MHz, MeOD) 
176.7, 173.1 (C=O amide), 50.9 (CH), 42.8 (lactam CH2-NH), 30.1 (CH2-CO), 
28.9(lactam CH2-CH), 22.4 (lactam CH2-CH2NH) and 10.3 (CH3-CH2); ESI m/z 100 
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%, 193.1 (MNa
+
), 78 %, 363.0 (M2Na
+
); HR ESI m/z (C8H14N2O2Na
 
requires 
193.0947) found 193.0958.  
3.47, Acetylamino-(S)-tetrahydropyridin-2-one  
Carbamate 3.44 (1.76 g, 5.46 mmol) was dissolved in MeOH (50 mL), palladium 
activated charcoal (0.5 g, catalytic) was added and the reaction stirred under 
hydrogen over night. The palladium was removed through filtration and the organic 
solvents were removed in vacuo to give compound 3.47 as a white solid (0.49 g, 58 
%) mp 159-160 °C; [α]25D (c = 0.24, CHCl3) +132.71; υmax/cm
-1
: 3290, 3219 (N-H), 
2933 (saturated C-H) and 1627 (C=O); Anal. (C7H12N2O2 requires: C; 53.83, H; 
7.74, N; 17.94) found: C; 53.58, H; 7.69, N; 17.48; δH (400 MHz, CDCl3) 6.56 (br.s, 
1H, NH-CH), 6.19 (br.s, 1H, NH-CH2), 4.27 (dt, 1H, J 11.5, 6, CH), 3.34-3.30 (m, 
2H, lactam CH2-NH), 2.52 (ddt, 1H, J 13, 5.5, 4.5, equatorial CH2-CH), 2.00 (s, 3H, 
CH3-CO), 1.95-1.88 (m, 2H, lactam CH2-CH2NH) and 1.51 (tt, 1H, J 12, 8.5, lactam 
axial CH2-CH); δC (100 MHz, CDCl3) 171.9, 170.5  (C=O), 50.6 (CH), 41.7 (CH2-
NH), 27.2 (CH2-CH), 22.3 (CH3-CO) and 21.0 (CH2-CH2NH); ESI m/z 100 %, 179.1 
(MNa
+
), 62 %, 335.0 (MNa
+
); HR ESI m/z (C7H12N2O2Na
 
requires 179.0791) found 
179.0791. NMR Data is consistent with previously reported data for this 
compound.
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6.3.3 5-Membered Exupéry Compounds 
3.48, Nα-Boc-(L)-2,4-diaminobutyric acid 
N-Boc-(L)-Glutamine (2.47 g, 10.0 mmol) was dissolved in THF (35 mL) and H2O 
(25 mL) and was cooled to 0 °C. Iodobenzene diacetate (3.59 g, 11.2 mmol) was 
added and the reaction stirred for 6 hours. The THF was removed in vacuo and the 
aqueous layer was extracted with diethyl ether. The aqueous layer was then reduced 
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in vacuo to give compound 3.48 as a light yellow solid (1.40 g, 64 %); δH (400 MHz, 
d
6
DMSO) 6.18 (br.s, 1H, NH-COO), 3.57-3.52 (m, 1H, CH), 2.93-2.81 (m, 2H, 
CH2-NH2), 1.90-1.85 (m, 1H, CH2-CH), 1.77-1.66 (m, 1H, CH2-CH), and 1.40 (s, 
9H, C(CH3)3); ESI m/z 100 %, 163.2 (MH
+
-C4H8), 93 %, 219.2 (MH
+
) and 7.5 % 
(MNa
+
). Data is consistent with that previously reported.
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3.49, Nα-Boc-(D)-2,4-diaminobutyric acid 
N-Boc-(D)-Glutamine (1.76 g, 7.15 mmol) was dissolved in tetrahdrofuran (50 mL) 
and H2O (20 mL) and was cooled to 0 °C.  Iodobenzene diacetate (2.30 g, 7.15 
mmol) was added and the reaction stirred over night. The THF was removed in 
vacuo and the aqueous layer was extracted with diethyl ether. The aqueous layer was 
then reduced in vacuo to give compound 3.49 as a light yellow solid (1.53 g, 98 %). 
3.50, Nα-Boc-Nγ-Cbz-(L)-2,4-diaminobutyric acid 
Amine 3.48 (7.64 g, 35.0 mmol) was dissolved in THF (80 mL) and H2O (40 mL) 
and cooled to 0 °C. KOH (2.0 g, 36 mmol), K2CO3 (9.66 g, 70.0 mmol) and benzyl 
chloroformate (5.0 mL, 35 mmol) were added and the reaction was stirred over 
night. The THF was removed in vacuo and the aqueous layer was extracted with 
diethyl ether. The aqueous layer was then acidified to pH 4 with citric acid and 
extracted with ethyl acetate. The organic layer was then washed with NaCl (aq), 
dried over Na2SO3 and reduced in vacuo to give compound 3.50 as a colourless oil 
(10 g, 80 %); δH (400 MHz, d
6
DMSO) 7.38-7.29 (m, 6H, phenyl and NH-Cbz), 7.09 
(d, 1H, J 8, NH-CH), 5.00 (s, 2H, CH2-phenyl), 3.91 (m, 1H, CH), 3.09-3.01 (m, 2H, 
CH2-NH), 1.84 (m, 1H, CH2-CH), 1.67 (m, 1H, CH2-CH) and 1.36 (C(CH3)3; δC 
(100 MHz, d
6
DMSO) 174.0 (acid C=O), 156.0, 155.6 (carbamate C=O), 137.2 (C 
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phenyl), 128.3, 127.7 (phenyl CH), 78.0 (C(CH3)3), 65.2 (CH2-phenyl), 51.2 (CH), 
37.5 (CH2-NH), 30.8 (CH2-CH) and 28.2 (C(CH3)3); ESI m/z 100 %, 375.1 (MNa
+
), 
70 %, 253.2 (MH
+
-C5H8O2) and 12 %, 297.1 (MH
+
-C6H8). 1H data is available for 
this compound however run in another solvent.
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3.51, Nα-Boc-Nγ-Cbz-(D)-2,4-diaminobutyric acid 
Amine 3.49 (1.56 g, 7.14 mmol) was dissolved in THF (50 mL) and H2O (30 mL) 
and cooled to 0 °C.  KOH (0.44 g, 7.86 mmol), K2CO3 (2.22 g, 16.01 mmol) and 
benzyl chloroformate (1.14 mL, 8 mmol) were added and the reaction was stirred 
over night. The THF was removed in vacuo and the aqueous layer was extracted 
with diethyl ether. The aqueous layer was then acidified to pH 4 with citric acid and 
extracted with ethyl acetate. The organic layer was then washed with NaCl (aq), 
dried over Na2SO3 and reduced in vacuo to give compound 3.51 as a colourless oil 
(1.46 g, 61 %); δH (400 MHz, CDCl3) 7.37-7.29 (m, 5H, phenyl), 6.38 & 5.70 (br.t, 
1H, NH-CH2 rotamers), 5.39 & 5.44 (br.d, 1H, NH-CH rotamers), 5.12 (d, 1H, CH2-
phenyl), 5.05 (d, 1H, CH2-phenyl), 4.40-4.33 (m, 1H, CH), 3.48, 3.31, 3.18 & 3.10 
(m, 2H, CH2-NH rotamers), 1.92 & 1.78 (m, 2H, CH2-CH) and 1.42 (C(CH3)3;  ESI 
m/z 100 %, 375.1 (MH
+
-C5H8O2) and 63 %, 253.1 (MNa
+
). 
3.52, Nγ-Cbz-(L)-2,4-Diaminobutyric acid-OMe.HCl 
Acetyl chloride (4 mL, 56 mmol) was dissolved in MeOH (70 mL) and cooled to 0 
°C. Carbamate 3.50 (9.87 g, 28 mmol) was added and the reaction stirred on ice over 
night then reduced in vacuo to give compound 3.52 as a light brown oil (6 g, 71 %); 
δH (400 MHz, CDCl3) 8.53 (br.s, 3H, NH), 7.29-7.25 (m, 5H, phenyl), 5.04 (d, 1H, J 
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12,  CH2-phenyl), 5.00 (d, 1H, J 12, CH2-phenyl), 4.25-4.00 (m, 1H, CH), 3.65 (s, 
3H, OCH3), 3.24-3.31 (m, 2H, CH2-NH) and 2.29-2.20 (m, 2H, CH2-CH). 
3.53, Nγ-Cbz-(D)-2,4-Diaminobutyric acid-OMe.HCl 
Acetyl chloride (1.2 mL, 17 mmol) was dissolved in MeOH (60 mL) and cooled to 0 
°C, compound 3.51 (3 g, 8.51 mmol) was added and the reaction stirred over night 
then reduced in vacuo to give compound 3.53 as a light brown oil (2.42 g, 94 %). 
3.54, Adamantante acetyl chloride 
Adamantane carboxylic acid (1.47 g, 8.16 mmol) was dissolved in dichloromethane 
and cooled to 0 °C. Oxalyl chloride (0.71 mL, 8.16 mmol) and DMF (1 drop) were 
added and the reaction was stirred for 4 hours. The organic solvents were removed in 
vacuo to give compound 352 which was not isolated and reacted on. 
3.55, Adamantane acetyl-Nγ-Cbz-(L)-2,4-Diaminobutyric acid-OMe 
Amine 3.52 (1.51 g, 5 mmol) was dissolved in THF (35 mL) and H2O (20 mL) and 
cooled to 0 °C. Triethylamine (2.1 mmol, 15 mmol) and compound 3.54 (8 mmol) 
were added and stirred over night. The reaction was reduced in vacuo, dissolved in 
ethyl acetate, washed with pH 2 buffer (3 × 15 mL), the product was purified by 
silica column chromatography (petroleum ether:ethyl acetate 50:50) to give 
compound 3.55 as a colourless oil (0.96 g, 45 %); δH (400 MHz, CDCl3) 7.37-7.27 
(m, 5H, phenyl), 6.54 (d, 1H, J 8, NH-CH), 5.86 (br.t, 1H, J 6, NH-CH2), 5.13 (d, 
1H, J 12, CH2-phenyl), 5.08 (d, 1H, J 12, CH2-phenyl), 4.67 (td, 1H, J 8, 4, CH), 
3.72 (s, 3H, OCH3), 3.54-3.44 (m, 1H, CH2-NH), 2.99-2.91 (m, 1H, CH2-NH), 2.15-
2.07 (m, 2H, CH2-CH), 2.07-2.03 (br.s, 3H, adamantane CH-CH2), 1.89 (br.s, 6H, 
adamantane CH2-CCO) and 1.73 (q, 6H, J 11, adamantane CH2-CH); δC (100 MHz, 
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CDCl3) 178.5 (ester C=O), 173.1 (amide C=O), 156.6 (carbamate C=O), 136.6 
(phenyl C), 128.4, 128.0 (phenyl CH), 66.5 (CH2-phenyl), 52.5 (OCH3), 49.3 (CH), 
40.7 (adamantane C-CO), 39.1 (adamantane CH-CCO), 36.9 (CH2-NH), 36.4 
(adamantane CH2-CH), 33.12 (CH2-CH) and 28.0 (adamantane CH2-CH2); ESI m/z 
100 %, 451.2 (MNa
+
), 29 %, 429.2 (MH
+
). 
3.56, tert-Butanoyl-Nγ-Cbz-(L)-2,4-Diaminobutyric acid-OMe 
Amine 3.52 (5.71 g, 18.7 mmol) was dissolved in dichloromethane (80 mL) and 
cooled to 0 °C. Triethylamine (7.9 mL, 56.4 mmol) and trimethyl acetyl chloride 
(2.3 mL, 2.3 mmol) were added and stirred over night. The reaction was reduced in 
vacuo and dissolved in ethyl acetate, washed with pH 2 buffer (3 × 15 mL) reduced 
in vacuo. The product was then purified by silica column chromatography 
(petroleum ether:ethyl acetate 50:50) to give compound 3.546as a colourless oil 
(3.15 g, 48 %); δH (400 MHz, CDCl3) 7.37-7.29 (m, 5H, phenyl), 6.61 (d, 1H, J 8, 
NH-CH), 5.76 (br.t, 1H, J 5, NH-CH2), 5.12 (d, 1H, J 12, CH2-phenyl), 5.08 (d, 1H, 
J 10, CH2-phenyl), 4.66 (dt, 1H, J 8, 4, CH), 3.72 (s, 3H, OCH3), 3.54-3.45 (m, 1H, 
CH2-NH), 3.00-2.92 (m, 1H, CH2-NH), 2.17-2.06 (m, 1H, CH2-CH), 1.80-1.72 (m, 
1H, CH2-CH) and 1.23 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 179.2, 173.1 (C=O 
ester and amide), 156.7 (carbamate C=O), 136.6 (phenyl C), 128.4, 128.0 (phenyl 
CH), 66.6 (CH2-phenyl), 52.5 (OCH3), 49.6 (CH), 38.8 (C(CH3)3), 36.9 (CH2-NH), 
33.0 (CH2-CH) and 27.4 (C(CH3)3); ESI m/z 100 %, 351.2 (MH
+
) and 48 %, 373.2 
(MNa
+
). 
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3.57, tert-Butanoyl-Nγ-Cbz-(D)-2,4-diaminobutyric acid-OMe 
Amine 3.53 (2.42 g, 8 mmol) was dissolved in dichloromethane (50 mL) and cooled 
to 0 °C.  Triethylamine (3.4 mL, 24 mmol) and trimethyl acetyl chloride (0.99 mL, 8 
mmol) were added and stirred over night. The reaction was reduced in vacuo and 
dissolved in ethyl acetate, washed with pH 2 buffer (3 × 15 mL) reduced in vacuo. 
The product was then purified by silica column chromatography (petroleum 
ether:ethyl acetate 50:50) to give compound 3.57 as a colourless oil (0.51 g, 18 %); 
δH (400 MHz, CDCl3) 7.38-7.28 (m, 5H, phenyl), 6.71 (d, 1H, J 8, NH-CH), 5.90 
(br.t, 1H, J 6, NH-CH2), 5.12 (d, 1H, J 12.5, CH2-phenyl), 5.08 (d, 1H, J 12.5, CH2-
phenyl), 4.66 (ddd, 1H, J 16, 8, 5, CH), 3.70 (s, 3H, OCH3), 3.53-3.43 (m, 1H, CH2-
NH), 3.04-2.95 (m, 1H, CH2-NH), 2.15-2.06 (m, 1H, CH2-CH), 1.87-1.78 (m, 1H, 
CH2-CH) and 1.25 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 179.0 (ester C=O), 173.0 
(amide C=O), 156.7 (carbamate C=O), 136.6 (phenyl C), 128.6, 128.1, (phenyl CH), 
66.6 (CH2-phenyl), 53.0 (OCH3), 49.5 (CH), 38.8 (C(CH3)3), 36.9 (CH2-NH), 32.5 
(CH2-CH) and 27.3 (C(CH3)3); ESI m/z 100 %, 351.2 (MH
+
) and 12 %, 373.2 
(MNa
+
). 
3.58, (S)-3-(Adamantanecarbonylamino)-pyrrolidin-2-one 
Carbamate 3.55 (0.96 g, 2.24 mmol) was dissolved in MeOH (20 mL), palladium 
activated charcoal (0.18 g, catalytic) was added and the reaction stirred under 
hydrogen for 48 hours. The organic solvents were removed in vacuo, the product 
purified by recrystallisation from ethyl acetate to give compound 3.58 as a white 
solid (0.36 g, 61 %) mp 80-90 °C decomposed; [α]20D  (c = 0.44, MeOH) - 26.04; 
υmax/cm
-1
: 3282 (N-H), 2901 (saturated C-H) and 1635 (C=O); δH (400 MHz, 
MeOD) 4.36 (t, 1H, J 10, CH), 3.34-3.22 (m, 2H, CH2-NH), 2.46 (dddd, 1H, J CH2-
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CH), 2.00-1.90 (m, 4H, CH2-CH, adamantane CH), 1.83 (d, 6H, J 3, adamantane 
CH2-CCO and 1.70 (q, 6H, J 10.5, adamantane CH2-CHCH2); δC (100 MHz, MeOD) 
181.0 (C=O lactam), 177.8 (C=O amide), 51.7 (CH), 41.9 (CH2-NH), 40.1 
(adamantane CH2-CCO), 37.7 (adamantane CH2-CHCH2), 29.8 (adamantane CH) 
and 29.1 (CH2-CH); ESI m/z 100 %, 547.1 (M2Na
+
), 56 %, 285.2 (MNa
+
) and 11 %, 
263.2 (MH
+
); HR ESI m/z (C15H22N2O2Na
+
 requires 285.1573) found 285.1578. 
3.59, (S)-3-(2', 2'-Dimethylpropanoylamino)-pyrrolidin-2-one 
Carbamate 3.56 was dissolved in MeOH, palladium activated charcoal was added 
and the reaction stirred under hydrogen for 24 hours. The charcoal was removed 
through filtration and the MeOH was removed in vacuo, the product was purified by 
recrystallisation was ethyl acetate to give compound 3.59 as a white solid (0.24 g, 33 
%); mp 183-184 °C; [α]20D  (c = 0.458, MeOH) - 37.15; υmax/cm
-1
: 3340, 3198 (N-H), 
2961 (saturated C-H) and 1704, 1641 (C=O); δH (400 MHz, MeOD) 4.47 (dd, 1H, J 
10, 9, CH), 3.45-3.38 (m, 2H, CH2-NH), 2.48 (dddd, 1H, J 12.5, 9, 7, 1.5, CH2-CH), 
2.08 (dq, 1H, J 12.5, 10, CH2-CH) and 1.24 (s, 9H, C(CH3)3);  δC (100 MHz, MeOD) 
181.6 (lactam C=O), 177.8 (C=O), 51.9 (CH), 40.1 (C(CH3)3, 40.0 (CH2-NH), 29.0 
(CH2-CH) and 27.8 (C(CH3)3); δH (400 MHz, CDCl3) 6.72 (br.s, 1H, NH-CH2), 6.32 
(br.d, 1H, J 4, NH-CH), 4.25 (ddd, 1H, J 11, 8.5, 5, CH), 3.41-3.32 (m, 2H, CH2-
NH), 2.48 (dddd, 1H, J 13, 9, 5, 3, CH2-CH), 2.08 (dq, 1H, J 12.5, 9.5, CH2-CH) and 
1.19 (s, 9H, C(CH3)3);  δC (100 MHz, CDCl3) 179.3 (C=O lactam), 176.1 (C=O 
amide), 51.0 (CH), 39.4 (CH2-NH), 38.7 (C(CH3)3, 30.2 (CH2-CH) and 27.5 
(C(CH3)3); ESI m/z 100 %, 391.0 (M2Na
+
) and 22 %, 207.1 (MNa
+
); HR ESI m/z 
(C9H16N2O2H
+
 requires 185.1285) found 185.1279. 
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3.60, (S)-3-Amino-pyrrolidin-2-one   
Acetyl chloride (2.0 mL, 28 mmol) was dissolved in MeOH (35 mL), L-2,4 
diaminobutyric acid (1.25 g, 6.54 mmol) was added and the reaction stirred under 
reflux conditions for 3 hours. The reaction was cooled to under 0°C brought to pH 8 
with NaOMe then stirred at room temperature for 48 hours. The reaction was 
deemed to be 50 % complete by NMR and the product compound 3.60 was used in 
the next step without purification. 
3.61, Acetylamino-(S)-pyrrolidin-2-one 
Lactam 3.60 (3.27 mmol) was dissolved in H2O (5 mL), dichloromethane (15 mL) 
and cooled to 0 °C. Acetylchloride (0.70 mL, 9.8 mmol) in dichloromethane (5 mL) 
and triethylamine (4.10 mL, 29.4 mmol) were added and stirred over night. The 
reaction was reduced in vacuo purified by silica column chromatography (ethyl 
acetate:MeOH 100:0 to 80:20) to give compound 3.61 as a white solid (0.13 g, 14 
%); mp 179-180 °C; [α]29D (c = 0.125, MeOH) -45.47; υmax/cm
-1
: 3271 (N-H) and 
1693, 1635 (C=O); δH (400 MHz, MeOD) 4.53 (dd, 1H, J 10, 9, CH), 3.44-3.33 (m, 
2H, lactam CH2-NH), 2.51 (dddd, 1H, J 15, 8.5, 6, 2.5, lactam CH2-CH), 2.07-1.96 
(m, 1H, lactam CH2-CH) and 2.03 (s, 3H, CH3); δC (100 MHz, MeOD) 177.7 
(lactam C=O), 173.5 (C=O), 51.7 (lactam CH), 40.0 (lactam CH2-NH), 29.5 (lactam 
CH2-CH) and 22.6 (CH3); ESI m/z 100 %, 165.1 (MNa
+
) and 98 %, 307.0 (M2Na
+
); 
HR ESI m/z (C6H10N2O2Na
+ 
requires 165.0634) found 165.0642. Data is consistent 
with previously reported data for this compound.
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3.62, Propanioylamino-(S)-pyrrolidin-2-one 
Lactam 3.58 (3.27 mmol) was dissolved in H2O (5 mL), dichloromethane (15 mL) 
and cooled on ice. Propionoyl chloride (0.80 mL, 9.8 mmol) in dichloromethane (5 
mL) and triethylamine (4.10mL, 29.4 mmol) were added and stirred over night. The 
reaction was reduced in vacuo purified by silica column chromatography (ethyl 
acetate:MeOH 100:0 to 80:20) to give compound 3.62 as a white solid (0.072 g, 6 
%); mp 151-152 °C; [α]31D (c = 0.135, MeOH) -76.05; υmax/cm
-1
: 3270 (N-H) and 
1690, 1636 (C=O); δH (400 MHz, CDCl3) 4.52 (dd, 1H, J 10.5, 9, CH), 3.39, 3.40 (2 
× q, 2H, J 10, lactam CH2-NH), 2.51 (dddd, 1H, J 15, 9, 6.5, 2.5, lactam CH2-CH), 
2.24 (qd, 2H, J 7, 2, CH2-CH3), 2.02 (ddt, 1H, J 12.5, 10.5, 9.5, lactam CH2-CH) and 
1.78 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 177.8 (lactam C=O), 177.2 (C=O), 
51.6 (lactam CH), 40.0 (lactam CH2-NH), 30.0 (CH2-CH3), 29.5 (lactam CH2-CH) 
and 10.2 (CH3); ESI m/z 100 %, 335.0 (M2Na
+
) and 78 %, 179.1 (MNa
+
); HR ESI 
m/z (C7H12N2O2Na
+ 
requires 179.0791) found 179.0793.  
3.63, Isobutyrylamino-(S)-pyrrolidin-2-one 
Lactam 3.60 (3.27 mmol) was dissolved in H2O (5 mL) and dichloromethane (15 
mL) and cooled to 0 °C.  Isobutyryl chloride (1.40 mL, 13.4 mmol) in 
dichloromethane (5 mL) and triethylamine (5.60 mL, 40.2 mmol) were added and 
stirred over night. The reaction was reduced in vacuo purified by silica column 
chromatography (ethyl acetate:MeOH 100:0 to 80:20) to give compound 3.63 as a 
white solid (0.062 g, 6 %); mp 208-209 °C; [α]22D (c = 0.11, MeOH) -54.43; Anal. 
(C6H10N2O2 requires: C; 50.69, H; 7.69, N; 19.71) found: C; 50.58, H; 6.98, N; 
19.51; υmax/cm
-1
: 3270 (N-H), 2972 (saturated C-H) and 1692 (C=O); δH (400 MHz, 
MeOD) 4.49 (dd, 1H, J 10, 9, lactam CH), 3.44-3.32 (m, 2H, lactam CH2-NH), 2.57-
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2.46 (m, 2H,lactam CH2-CH and CH(CH3)2), 2.00 (ddt, 1H, J 12.5, 10, 9, equatorial 
CH2-CH), and 1.16, 1,18 (d, 3H, J 7, CH(CH3)2); δC (100 MHz, MeOD) 180.4, 177.7 
(C=O), 51.6 (lactam CH), 40.0 (lactam CH2-NH), 36.2 (CH-(CH3)2), 29.5 (lactam 
CH2-CH) and 19.8 ((CH3)2); ESI m/z 100 %, 363.0 (M2Na
+
) and 34 %, 193.1 
(MNa
+
); HR ESI m/z (C8H14N2O2Na
+ 
requires 193.0947) found 193.0948.  
The other product isolation after column chromatography was a result of the (L)-2,4 
diaminobutyric acid which did not cyclise in the synthesis of compound 3.58. 
Consequently the isobutyryl chloride has added twice. δH (400 MHz, CDCl3) 6.59 
(br.t, 1H, J 5, NH-CH2), 6.40 (d, 1H, J 8, NH-CH), 4.59 (ddd, 1H, J 10, 8.5, 4, CH-
NH), 3.73 (s, 3H, OCH3), 3.77-3.69 (m, 1H, CH2-NH), 2.75(ddt, 1H, J 14.5, 10, 4.5, 
CH2-NH), 2.09 (ddt, 1H, J 14, 10, 4.5, CH2-CH), 1.61 (ddt, 1H, J 14, 10.5, 4.5, CH2-
CH) and 1.19-1.13 (m, 12H, CH(CH3)2); δC (100 MHz, CDCl3) 177.9, 177.4, 173.1 
(C=O), 52.7 (OCH3), 49.3 (CH), 40.0 (lactam CH2-NH), 36.6 (CH-(CH3)2), 35.0 
(CH2-NH), 33.2 (CH2-CH) and 19.7, 19.5 ((CH3)2); ESI m/z 100 %, 295.1 (MNa
+
) 
and 95 %, 566.8 (M2Na
+
). 
6.3.4 Reverse Compounds 
3.64, (S)-N-1'-Adamantanyl pyrrolidin-2-one-5-carboxamide 
(S)-(−)-2-Pyrrolidone-5-carboxylic acid (1.33 g, 10.3 mmol) was dissolved in 
dichloromethane (50 mL) and cooled to 0°C. HATU (3.86 g, 10.2 mmol) was added 
and the reaction stirred for 10 minutes. 1-Adamantamine.HCl (1.92 g, 10.2 mmol) 
and triethylamine (4.3 mL, 31 mmol) were added and the reaction was stirred over 
night. The dichloromethane was removed in vacuo, the product dissolved in ethyl 
acetate and washed with a pH 2 buffer (3 × 15 mL), 0.1M HCl (3 × 15 mL) and ½ 
saturated NaHCO3 (3 × 15 mL). The organic layer was dried over Na2SO4 and 
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reduced in vacuo. The product was purified by recrystallation from dichloromethane 
to give compound 3.64 as a white solid (1.30 g, 48 %); mp 192-193 º C; [α]21D (c = 
0.53, MeOH) 8.46; υmax/cm
-1
: 3503 (N-H), 2908 (saturated C-H) and 1653 (amide 
C=O); δH (500 MHz, CDCl3) 7.23 (s, 1H, NH-CH), 5.84 (s, 1H, NH-C), 4.00 (dd, 
1H, J 8, 5, CH-NHCO), 2.49-2.23 (m, 3H, lactam CH2-CH and CH2-CONH), 2.16-
2.09 (m, 1H, lactam CH2-CH), 2.05 (br.s, 3H, adamantane CH-CH2), 1.96 (d, 6H, J 
3, adamantane CH2-CNH) and 1.64 (t, 6H, J 2.5, adamantane CH2-CH); δC (100 
MHz, CDCl3) 179.6, 177.0 (C=O), 57.6 (CH-NHCO), 41.4 (adamantane CH2-C), 
36.3 (adamantane CH2-CH), 29.6 (lactam CH2-CONH), 29.4 (adamantane CH-CH2) 
and 26.0 (lactam CH2-CH2-CONH); ESI  m/z 100 %, 285.1 (MNa
+
), 23 %, 547.1 
(M2Na
+
); HR ESI  m/z (C15H22N2O2Na requires 285.1573) found 285.1573. Data 
consistent with reference.
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3.65, (R)-N-1'-Adamantanyl pyrrolidin-2-one-5-carboxamide 
(R)-(+)-2-Pyrrolidone-5-carboxylic acid (1.55 g, 12.0 mmol) was dissolved in 
dichloromethane (90 mL) and cooled to 0°C. HATU (4.72 g, 12.4 mmol) was added 
and the reaction stirred for 4 hours. 1-Adamantamine.HCl (2.32 g, 12.4 mmol) and 
triethylamine (5.0 mL, 36 mmol) were added and the reaction was stirred over night. 
The dichloromethane was removed in vacuo and the product was dissolved in ethyl 
acetate and washed with a pH 2 buffer (3 × 15 mL), 0.1 M HCl (3 × 15 mL) and ½ 
saturated NaHCO3 (3 × 15 mL). The organic layer was dried over Na2SO4 and 
reduced in vacuo. The product was purified by washing with hot ethyl acetate to give 
compound 3.65 as a white solid (0.76 g, 24 %); mp 193-194 º C; [α]20D (c = 0.52, 
MeOH) -10.79; υmax/cm
-1
: 3305, 3242 (N-H), 2905 (saturated C-H) and 1673, 1639 
(C=O); δH (400 MHz, CDCl3) 4.01 (dd, 1H, J 9.5, 6.5, 1, CH-CONH), 2.50-2.41 (m, 
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2H, lactam CH2-CONH), 2.39-2.24 (m, 1H, lactam CH2-CH2-CONH), 2.16-2.08 (m, 
1H, lactam CH2-CH2-CONH), 2.05 (s, 3H, adamantane CH-CH2), 1.97 (d, 6H, J 3, 
CH2-C) and 1.65 (t, 6H, J 4, adamantane CH2-CH); δC (100 MHz, CDCl3) 179.6, 
177.0 (C=O), 57.6 (CH-CONH), 41.4 (adamantane CH2-C), 36.2 (adamantane CH2-
CH), 29.6 (lactam CH2-CONH), 29.4 (adamantane CH-CH2) and 26.0 (lactam CH2-
CH2-CONH); m/z ESI 100 %, 263.2 (MH
+
), 54 %, 525.2 (M2H
+
), 26 %, 547.2 
(M2Na
+
) and 16 %, 285.2 (MNa
+
); HR ESI (C15H22N2O2Na requires 285.1573) found 
285.1570. 
3.66, (L)-Glu-(OMe)-OH.HCl 
(L)-Glutamic acid (7.72 g, 52.5 mmol) was dissolved in MeOH (150 mL), 
chlorotrimethylsilane (13.3 mL, 105 mmol) was added dropwise. The clear solution 
was stirred for 10 minutes and then the solvent was removed in vacuo to give 
compound 3.66 as a white solid. 
1
H NMR of the crude product showed the 
monomethylation as the major product (96 %), the crude product was used in the 
next step without further purification; δH (400 MHz, MeOD) 4.11 (t, 1H, J 7, CH), 
3.74 (s, 3H, OCH3), 2.68 (dt, 1H, J 16.5, 7, CH2-COOCH3), 2.62 (dt, 1H, J 16.5, 7, 
CH2-COOCH3), 2.29 (dq, 1H, J 14, 7, CH2-CH) and 2.21 (dq, 1H, J 14, 7, CH2-CH); 
δC (100 MHz, MeOD) 174.3, 171.4 (C=O), 53.3 (O-CH3), 52.5 (CH), 30.5 (CH2-
COOMe) and 26.6 (CH2-CH). Data is consistent with previously reported data for 
this compound. 
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3.67, (D)-Glu-(OMe)-OH.HCl 
(D)-Glutamic acid (7.36 g, 50.0 mmol) was dissolved in MeOH (150 mL), 
chlorotrimethylsilane (12.7 mL, 100 mmol) was added dropwise. The clear solution 
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was stirred for 10 minutes and then the solvent was removed in vacuo to give 
compound 3.67 as a white solid (9.6 g, 96 %). 
1
H NMR of the crude product showed 
the monomethylation as the major product (96 %), the crude product was used in the 
next step without further purification; δH (400 MHz, MeOD) 8.52 (br.s, 1H, OH), 
4.12 (t, 1H, J 7, CH), 3.74 (s, 3H, OCH3), 2.69 (ddd, 1H, J 17, 8, 7, CH2-COOCH3), 
2.64 (dt, 1H, J 17, 7.5, CH2-COOCH3), 2.29 (tt, 1H, J 14.5, 7, CH2-CH) and 2.23 (tt, 
1H, J 14.5, 7.5, CH2-CH); δC (100 MHz, MeOD) 174.3, 171.4 (C=O ester), 53.3 (O-
CH3), 52.5 (CH), 30.5 (CH2-COOMe) and 26.6 (CH2-CH); ESI mz 100 %, 162.2 
(MH
+
-HCl). 
3.68, Nα-Cbz-L-Glu-(OMe)-OH 
Amine 3.66 (9.6 g, 48 mmol) was dissolved in dioxane (80 mL) and H2O (30 mL) 
and the reaction cooled to 0 °C. Benzylchloroformate (8.24 mL, 57.6 mmol) and 
NaHCO3 (10.1 g, 120  mmol) were added and stirred for 15 hours. The reaction was 
reduced in vacuo, dissolved in 10 % NaHCO3 and washed with ether. The aqueous 
layer was then acidified to pH 4 using citric acid, extracted with ethyl acetate and 
wash with NaCl (3 × 20 mL). The organic layer was then dried over Na2SO4 and 
reduced in vacuo to give compound 3.68 as a colourless oil (3.87 g, 27 %); δH (400 
MHz, MeOD) 7.40-7.29 (m, 5H, phenyl), 5.13 (d, 1H, J 12.5, CH2-phenyl), 5.09 (d, 
1H, J 12.5, CH2-phenyl), 4.5-4.44 and 4.27-4.18 (1H, CH rotamers), 3.67 (s, 3H, 
OCH3), 2.5-2.42 (m, 2H, CH2-COOCH3), 2.26-2.17 (m, 1H, CH2-CH) and 2.01-1.90 
(m, 1H, CH2-CH); ESI mz 86 %, 318.0 (MNa
+
). 
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3.69, Nα-Cbz-(D)-Glu-(OMe)-OH 
Amine 3.67 (9.6 g, 48 mmol) was dissolved in dioxane (70 mL) and H2O (30 mL) 
and the reaction cooled to 0 °C. Benzylchloroformate (8.3 mL, 58 mmol) and 
NaHCO3 (10.5 g, 125 mmol) were added and stirred for 15 hours. The reaction was 
reduced in vacuo, dissolved in 10 % NaHCO3 and washed with ether. The aqueous 
layer was then acidified to pH 4 using citric acid, extracted with ethyl acetate and 
wash with NaCl (3 × 20 mL). The organic layer was then dried over Na2SO4 and 
reduced in vacuo to give compound 3.69 as a colourless oil (10.42 g, 73 %); δH (400 
MHz, MeOD) 7.36-7.27 (m, 5H, phenyl), 5.73 (d, 1H, J 8, NH-CH), 5.11 (d, 1H, J 
12, CH2-phenyl), 5.07 (d, 1H, J 12, CH2-phenyl), 4.6-4.53 and 4.45-4.3 (1H, CH 
rotamers), 3.65-3.60 (m, 3H, OCH3), 2.48-2.37 (m, 2H, CH2-COOCH3), 2.27-2.16 
(m, 1H, CH2-CH) and 2.07-1.93 (m, 1H, CH2-CH). 
3.70, Nα-Cbz-(L)-Glu-(OMe)-NHC(CH3)3 
Acid 3.68 (8.0 g, 27 mmol) was dissolved in dichloromethane (50 mL) and cooled to 
0° C. HATU (10.26 g, 26.98 mmol) was added and the mixture was stirred for 4 
hours. Tertiary butylamine (2.8 mL, 27 mmol) and triethylamine (11.4 mL, 81 
mmol) were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 20 mL), 0.1 M HCl (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 
mL) and purified by silica column chromatography (petroleum ether:ethyl acetate 
50:50) to give compound 3.70 as a colourless oil 3.18 g (33 %); υmax/cm
-1
: 3336 (N-
H), 2965 (saturated C-H), 1710 (ester C=O), 1657 (C=O), 1530 (aromatic); δH (400 
MHz, CDCl3) 7.36-7.29 (m, 5H, phenyl), 6.26 (s, 1H, NH-
t
Bu), 5.88 (d, 1H, J NH-
COO), 5.09 (s, 2H, CH2-phenyl), 4.15 (m, 1H, CH), 3.66 (s, 3H, OCH3), 2.48 (dt, 
251 
 
1H, J 16, 7.5, CH2-COOCH3), 2.38 (dt, 1H, J 16, 7, CH2-COOCH3), 2.12 (dq, 1H, J 
21, 9.5, 6.5, CH2-CH) and 2.12  (dq, 1H, J 7.5, 14, CH2-CH); δC (100 MHz, CDCl3) 
173.8, 170.3 (C=O), 156.3 (carbamate C=O), 136.3 (phenyl C), 128.5 (m-phenyl 
CH), 128.1 (p-phenyl CH), 128.0 (o-phenyl CH), 66.9 (CH2-phenyl), 54.4 (O-CH3), 
51.8 (CH), 51.4 (C(CH3)3), 30.1 (CH2-COOMe), 28.6 (C(CH3)3) and 28.5 (CH2-
CH);ESI m/z 100 %, 373.2 (MNa
+
). 
3.71, Nα-Cbz-(D)-Glu-(OMe)-NHC(CH3)3 
Acid 3.69 (10.42 g, 35 mmol) was dissolved in dichloromethane (80 mL) and cooled 
to 0° C. HATU (12.8 g 33.7 mmol,) was added and the mixture was stirred for 4 
hours. Tertiary butylamine (3.7 mL, 35 mmol) and triethylamine (14 mL, 105 mmol) 
were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 20 mL), 0.1 M HCl (3 × 20 mL) and ½ saturated NaHCO3 (3 × 20 
mL) and purified by silica column chromatography (petroleum ether:ethyl acetate 
75:25) to give compound 3.71 as a colourless oil 3.98 g (32 %); υmax/cm
-1
: 3324 (N-
H), 2967 (saturated C-H), 1732 (C=O ester), 1656 (C=O amide, carbamate) and 
1529 (aromatic); δH (400 MHz, CDCl3) 7.37-7.28 (m, 5H, phenyl), 6.38 (br.s, 1H, 
NH-
t
Bu), 6.0 (d, 1H, J 8, NH-CH), 5.08 (s, 2H, CH2-phenyl), 4.18 (m, 1H, CH), 3.66 
(s, 3H, OCH3), 2.47 (dt, 1H, J 16, 8, CH2-COO), 2.38 (dt, 1H, J 16, 7, CH2-COO), 
2.10 (dq, 1H, J 14, 7, CH2-CH), 1.94 (dq, 1H, J 14, 7, CH2-CH) and 1.33 (s, 9H, 
C(CH3)3); δC (100 MHz, CDCl3) 173.7, 170.4 (C=O), 156.3 (carbamate C=O), 136.3 
(phenyl  C), 128.5 (m-phenyl CH), 128.1 (p-phenyl CH), 127.9 (o-phenyl CH), 82.8 
(C(CH3)3), 66.8 (CH2-phenyl), 54.4 (OCH3), 51.8 (CH), 30.1 (CH2-COO), 28.6 
(C(CH3)3) and 28.4 (CH2-CH); ESI m/z 100 %, 373.2 (MNa
+
), 19 %, 351.2 (MH
+
). 
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3.72, (S)-N-1', 1'-Dimethylethyl pyrrolidin-2-one-5-carboxamide 
Carbamate 3.70 (1.11 g, 3.17 mmol) was dissolved in MeOH (20 mL), palladium 
activated charcoal (0.2 g, catalytic) was added and the reaction stirred under 
hydrogen for 48 hours. The palladium was removed bu filtration, the organic 
solvents were removed in vacuo and the product was purified by recrystallisation 
from ethyl acetate and petroleum ether to give compound 3.72 as a white solid (0.2 
g, 45 %); mp 151-152 °C; [α]21D (c = 0.5, MeOH) +16.43; υmax/cm
-1
: 3224 (N-H), 
2968 (saturated C-H), 1683, 1647 (C=O); Anal. (C9H16N2O2 requires: C; 58.45, H; 
8.77, N; 15.11) found: C; 58.67, H; 8.75, N; 15.21; δH (100 MHz, CDCl3) 6.95 (s, 
1H, NH), 5.93 (s, 1H, NH), 4.02 (ddd, 1H, 9, 5.5, 1, CH), 2.47 (tq, 1H, J 9, 6, CH2-
CH), 2.38 (ddd, 1H, J 18, 12, 6, CH2-C=O), 2.30 (ddd, 1H, J 18, 12, 6, CH2-C=O) 
and 1.34 (s, 9H, C(CH3)3); δC (100 MHz, MeOD) 178.8, 171.1 (C=O), 52.5 (CH), 
51.6 (C(CH3)3), 29.5 (CH2-CO) 28.7 (C(CH3)3) and 25.9 (CH2-CH); ESI m/z 100 %, 
391.1 (M2Na
+
), 16 %, 207.2 (MNa
+
); HR ESI m/z (C9H16N2O2Na
+
 requires 
207.1104) found 207.1114; Data consistent with known compound. 
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3.73, (R)-N-1', 1'-Dimethylethyl pyrrolidin-2-one-5-carboxamide 
Carbamate 3.71 (3.98 g, 11.36 mmol) was dissolved in MeOH (40 mL), palladium 
activated charcoal (0.45 g) was added and the reaction stirred under hydrogen for 48 
hours. The palladium was removed by filtration, the organic solvents were removed 
in vacuo and the product was purified by recrystallisation from ethyl acetate to give 
compound 3.73 as a white solid (0.3 g, 24 %) mp 139-142 °C (decomposed); [α]20D 
(c = 0.474, MeOH) -15.35; δH (400 MHz, MeOD) 7.60 (s, 1H, NH), 4.14 (dd, 1H, 
8.5, 4.5, CH), 2.49-2.37 (m, 2H, CH2-CH & CH2-C=O), 2.35-2.27 (m, 1H, CH2-
C=O), 2.10-2.01 (m, 1H, CH2-CH), 1.39 (s, 9H, C(CH3)3); δC (100 MHz, MeOD) 
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181.6, 174.1 (C=O), 58.5 (CH), 52.3 (C(CH3)3), 30.6 (CH2-CO), 28.9 (C(CH3)3) and 
26.8 (CH2-CH); υmax/cm
-1
: 3302, 3222 (NH), 2971 (CH), 1685, 1648 (C=O); ESI m/z 
100 %, 391.1 (M2Na
+
), 12 %, 207.2 (MNa
+
); ESI m/z (C9H16N2O2H
+
 requires 
185.1285) found 185.1282. 
3.74, Nα-Cbz-(L)-Glu-(OMe)-NHCH(CH3)2 
Acid 3.68 (1.41 g, 4.77 mmol) was dissolved in dichloromethane (20 mL) and 
cooled to 0° C. HATU (2.11 g 5.55 mmol) was added and the mixture was stirred for 
4 hours. Isopropylamine (0.43 mL, 5 mmol) and triethylamine (2.1 mL, 15 mmol) 
were added and the reaction was stirred over night. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and washed with a 
pH 2 buffer (3 × 15 mL), 0.1 M HCl (3 × 15 mL) and ½ saturated NaHCO3 (3 × 15 
mL) and purified by silica column chromatography (petroleum ether:ethyl acetate 
50:50) to give compound 3.74 as a colourless oil (0.80 g, 46 %); δH (400 MHz, 
CDCl3) 7.35-7.29 (m, 5H, phenyl), 6.07 (br.s, 1H, NH-COO), 5.67 (d, 1H, J 7, NH-
CH(CH3)2), 5.08 (s, 2H, CH2-phenyl), 4.15 (br.q, 1H, J 8, CH-CH2), 3.66 (s, 3H, 
OCH3), 2.49 (dt, 1H, J 16.5, 7.5, CH2-COO), 2.36 (dt, 1H, J 16.5, 7, CH2-COO), 
2.10 (dtd, 1H, J 14, 7, 5.5, CH2-CH), 1.92 (quin., 1H, J 7.5, CH2-CH), 1.13 (d, 3H, J 
7, C(CH3)2) and 1.11 (d, 3H, J 7, C(CH3)2); δC (100 MHz, CDCl3) 173.9, 170.1 
(C=O), 163.3 (C=O carbamate), 138.0 (phenyl C ), 128.6 (phenyl m-CH), 128.2 
(phenyl p-CH), 128.1 (phenyl o-CH), 67.0 (CH2-phenyl), 54.2 (OCH3), 51.9 (CH), 
41.6 CH(CH3)2, 30.2 (CH2-COO), 28.4 (CH2-CH) and 22.6 (CH(CH3)2); ESI m/z 
100 %, 359.1 (MNa
+
), 34 %, 336.0 (MH
+
) and 20 % 694.5 (M2Na
+
). 
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3.75, (S)-N-1'-Methylethyl pyrrolidin-2-one-5-carboxamide 
Carbamate 3.74 (0.8 g, 2.18 mmol) was dissolved in MeOH (30 mL), palladium 
activated charcoal (0.2 g, catalytic) was added and the reaction stirred under 
hydrogen for 48 hours. The palladium was removed by filtration, the organic 
solvents were removed in vacuo and the product was purified by recrystallisation 
from ethyl acetate and petroleum ether to give compound 3.75 as a white solid 
(0.265 g, 72 %) mp 134-135 °C; [α]31D (c = 0.474, MeOH) +4.42; ; υmax/cm
-1
: 3298 
(N-H), 2969 (saturated C-H) and 1701, 1650 (C=O);  δH (400 MHz, MeOD) 4.16 
(dd, 1H, J 9.5, 5, CH-CH2), 4.01 (septet, 1H, J 7, CH(CH3)2), 2.56-2.40 (m, 2H, C 
H2-CH and CH2-COO), 2.38-2.28 (m, 1H, CH2-COO), 2.12-2.02 (m, 1H, CH2-CH), 
1.20 (d, 3H, J 7.5, (CH3)2) and 1.19 (d, 3H, J 7.5, C(CH3)2); δC (100 MHz, MeOD) 
181.6, 173.9 (C=O), 58.3 (CH), 42.7 CH(CH3)2, 30.6 (CH2-COO), 26.8 (CH2-CH) 
and 22.4 (CH(CH3)2); ESI m/z 100 %, 363.0 (M2Na
+
) and 18 %, 193.1 (MNa
+
); ESI 
m/z (C8H14N2O2Na
+
 requires 193.0947) found 193.0950.  
 
6.3.5 7-Membered Exupéry Compounds 
3.76, Acetylamino-(S)-azepan-2-one 
Lactam 2.65 (1.61 g, 9.82 mmol) was dissolved in dichloromethane (35 mL) and 
cooled on ice. Acetylchloride (0.70 mL, 10 mmol) in dichloromethane (5 mL) and 
triethylamine (2.8 mL, 20 mmol) were added and the reaction stirred over night. 
Diethyl ether (60 mL) was added and the precipitate removed by filtration, the filtrate was 
reduced in vacuo and the product purified by silica column chromatography (ethyl 
acetate:MeOH 100:0 to 80:20) to give compound 3.76 as a white solid (1.00 g, 60 
%); mp 143-144 °C; [α]28D (c = 0.258, CHCl3) +82.82; Anal. (C8H14N2O2 requires: 
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C; 56.45, H; 8.29, N; 16.46) found: C; 56.04, H; 8.25, N; 15.83; υmax/cm
-1
: 3283 (N-
H), 2928 (saturated C-H) and 1650 (C=O); δH (400 MHz, CDCl3) 6.89 (br.s, 1H, 
NH-CH), 6.35 (br.s, 1H, NH-CH2), 4.51 (ddd, 1H, J 13, 6, 2, CH), 3.32-3.17 (m, 2H, 
lactam CH2-NH), 2.06 (br.d, 1H, J 14.5, equatorial CH2-CH), 2.00-1.94 (m, 1H, 
CH2-CH2NH), 1.99 (s, 3H, CH3), 1.87-1.78 (m, 2H, lactam CH2-CH2CH) and 1.51-
1.31 (m, 2H, lactam CH2-CH and CH2-CH2NH); δC (100 MHz, CDCl3) 175.7, 169.2 
(C=O), 52.2 (lactam CH), 42.2 (lactam CH2-NH), 31.7 (lactam CH2-CH), 28.9 
(lactam CH2-CH2CH), 27.9 (lactam CH2-CH2NH) and 23.3 (CH3-CO); ESI m/z 100 
%, 193.1 (MNa
+
) and 89 %, 362.9 (M2Na
+
); HR ESI m/z (C8H14N2O2Na
+ 
requires 
193.0947) found 193.0946. Data is consistent with previously reported data for this 
compound.
209
  
3.77, Propanoyllamino-(S)-azepan-2-one 
Lactam 2.65 (2.02 g, 12.3 mmol) was dissolved in dichloromethane (25 mL) and 
cooled on ice. Propanioylchloride (1.10 mL, 12.3 mmol) in dichloromethane (5 mL) 
and triethylamine (3.5 mL, 25 mmol) were added and the reaction stirred over night. 
Diethyl ether (60 mL) was added and the precipitate removed by filtration, the 
filtrate was reduced in vacuo and the product purified by silica column 
chromatography (ethyl acetate:MeOH 100:0 to 80:20) to give compound 3.77 as a 
white solid (1.47 g, 65 %); mp 135-136 °C; [α]27D (c = 0.232, CHCl3) +60.34; 
υmax/cm
-1
: 3341, 3313 (N-H), 2938 (saturated C-H) and 1676 (C=O); δH (400 MHz, 
CDCl3) 6.86 (br.s, 1H, NH-CH), 6.26 (br.s, 1H, NH-CH2), 4.51 (ddd, 1H, J 11, 6, 
1.5, CH), 3.32-3.18 (m, 2H, lactam CH2-NH), 2.23 (q, 2H, CH2-CO), 2.06 (br.d, 1H, 
J 14.5, equatorial lactam CH2-CH), 2.00-1.94 (m, 1H, lactam CH2-CH2NH), 1.88-
1.75 (m, 2H, lactam CH2-CH2CH), 1.50-1.34 (m, 2H, lactam CH2-CH and CH2-
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CH2NH) and 1.14 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 175.8, 173.0 (C=O), 
52.1 (lactam CH), 42.2 (lactam CH2-NH), 31.7 (CH2-CO), 29.7 (lactam CH2-CH), 
28.9 (lactam CH2-CH2CH), 28.0 (lactam CH2-CH2NH) and 9.73 (CH3); ESI m/z 100 
%, 207.1 (MNa
+
) and 71 %, 390.9 (M2Na
+
); HR ESI m/z (C9H16N2O2Na
+ 
requires 
207.1104) found 207.1105.  
3.78, 2-Methylpropanoyllamino-(S)-azepan-2-one 
Lactam 2.65 (1.64 g, 10.0 mmol) was dissolved in dichloromethane (35 mL) and 
cooled on ice. Isobutyrylchloride (1.1 mL, 10 mmol) in dichloromethane (5 mL) and 
triethylamine (2.8 mL, 20 mmol) were added and the reaction stirred over night. 
Diethyl ether (60 mL) was added and the precipitate removed by filtration, the 
filtrate was reduced in vacuo and the product purified by silica column 
chromatography (ethyl acetate:MeOH 100:0 to 80:20) to give compound 3.78 as a 
white solid (1.29 g, 65 %); mp 154-155 °C; [α]28D (c = 0.248, CHCl3) +45.23; Anal. 
(C10H18N2O2 requires: C; 60.58, H; 9.15, N; 14.13) found: C; 60.44, H; 9.19, N; 
14.00; υmax/cm
-1
: 3285 (N-H), 2927 (saturated C-H) and 1665, 1636 (C=O); δH (400 
MHz, CDCl3) 6.90 (br.d, 1H, J 5, NH-CH), 6.57 (br.s, 1H, NH-CH2), 4.48 (ddd, 1H, 
J 11, 6, 2, CH), 3.30-3.16 (m, 2H, lactam CH2-NH), 2.39 (sep., 1H, J 7, CH(CH3)2), 
2.62 (br.d, 1H, J 14, equatorial CH2-CH), 1.98-1.92 (m, 1H, lactam CH2-CH2NH), 
1.85-1.92 (m, 2H, lactam CH2-CH2CH), 1.48-1.31 (m, 2H, lactam CH2-CH and CH2-
CH2NH) and 1.13, 1,11 (d, 3H, J 7, CH(CH3)2); δC (100 MHz, CDCl3) 176.2, 176.0 
(C=O), 51.9 (lactam CH), 42.1 (lactam CH2-NH), 35.4 (CH-(CH3)2), 31.7 (lactam 
CH2-CH), 28.9 (lactam CH2-CH2CH), 28.0 (lactam CH2-CH2NH) and 19.6, 19.4 
((CH3)2); ESI m/z 100 %, 419.0 (M2Na
+
) and 45 %, 221.1 (MNa
+
); HR ESI m/z 
(C10H18N2O2Na
+ 
requires 221.1260) found 221.1261.  
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6.4 Chapter 4 Experimental 
6.4.1 4-Carboxy Compounds 
4.01, 4-Ethylbenzoyl chloride 
4-Ethylbenzoic acid (1.55 g, 10.3 mmol) was dissolved in dichloromethane (25 mL), 
oxalyl chloride (0.88 mL, 10.3 mmol) and DMF (1 drop) were added and the 
reaction was stirred for 3 hours. The organic solvents were removed in vacuo to give 
compound 4.01 which was not isolated and used in the next stage.  
4.02, 4-Butylbenzoyl chloride 
4-Butylbenzoic acid (1.84 g, 10.3 mmol) was dissolved in dichloromethane (30 mL), 
oxalyl chloride (0.88 mL, 10.3 mmol) and DMF (1 drop) were added and the 
reaction was stirred for 3 hours. The organic solvents were removed in vacuo to give 
compound 4.02 which was not isolated and used in the next stage.  
4.03, 4-tert-Butylbenzoyl chloride 
4-tert-Butylbenzoic acid (2.04 g, 11.45 mmol) was dissolved in dichloromethane (40 
mL), oxalyl chloride (0.98 mL, 11.45 mmol) and DMF (1 drop) were added and the 
reaction was stirred for 3 hours. The organic solvents were removed in vacuo to give 
compound 4.03 which was not isolated and used in the next stage.  
4.05, 4-Octylbenzoyl chloride 
4-Octylbenzoic acid (0.54 g, 2.22 mmol) was dissolved in dichloromethane (15 mL), 
oxalyl chloride (0.2 mL, 2.23 mmol) was added and DMF (1 drop) the mixture was 
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stirred for 3 hours. The organic solvents were removed in vacuo to give compound 
4.05 which was not isolated and used in the next stage.  
4.06, 4-Ethylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.58 (1.65 g, 10 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Acid chloride 4.01 (10.3 mmol) in dichloromethane (25 mL) and triethylamine (4.2 
mL, 30 mmol) were added and stirred over night. H2O (20 mL) was added and the 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by recrystallisation from chloroform and cold petroleum 
ether to give compound 4.06 as a white solid 0.94 g (36 %); mp 218-219 º C; [α]23D 
(c = 0.49, CHCl3) +70.48; υmax/cm
-1
: 3200 (N-H), 2956 (saturated C-H), 1642 (C=O) 
and 1543 (aromatic); Anal. (C15H20N2O2 requires: C; 69.20, H; 7.74, N; 10.76) 
found: C; 69.13, H; 7.75, N; 10.71; δH (400 MHz, CDCl3) 7.66 (d, 2H, J 8, CH-CO), 
7.62 (d, 1H, J 5.5, NH-CH), 7.24 (d, 2H, J 8, CH-CEt), 6.55 (br.t, 1H, J 6, NH-CH2), 
4.70 (dd, 1H, J 11, 5.5, lactam CH), 3.37-3.32 (m, 2H, lactam CH2-NH), 2.67 (q, 2H, 
J 7.5, CH2-aryl), 2.21 (br.d, 1H, J 13, lactam equatorial CH2-CH), 2.02 (dt, 1H, J 14, 
4, lactam equatorial CH2-CH2CH), 1,95-1.82 (m, 2H, lactam equatorial CH2-CH2NH 
and axial CH2-CH2CH), 1.53 (br.q, 1H, J 12.5, lactam axial CH2-CH), 1.40 (br.q, 
1H, J 13, lactam axial CH2-CH2NH) and 1.22 (t, 3H, J 7.5, CH3); δC (100 MHz, 
CDCl3) 175.9 (lactam C=O), 166.2 (C=O), 148.2 (C-Et), 131.6 (C-CO), 128.0 (CH-
CEt), 127.2 (CH-CO), 52.6 (CH-NH), 42.2 (lactam CH2-NH), 28.9 (CH2-aryl), 28.8 
(lactam CH2-CH), 28.0, 27.9 (lactam CH2-CH2-NH and CH2-CH2CH) and 15.4 
(CH3); ESI m/z 100 %, 542.9 (M2Na
+
), 70%, 283.1 (MNa
+
) and 10 %, 261.2 (MH
+
); 
HR ESI m/z (C15H20N2O2Na requires 283.1417) found 283.1414. 
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4.07, 4-Ethylbenzoyl-(R)-3-amino-azepan-2-one  
Lactam 2.66 (0.12 g, 0.47 mmol) was dissolved in H2O (5 mL) and cooled to 0°C. 
Acid chloride 4.01 (1.60 mmol) in dichloromethane (10 mL) was added and 
triethylamine (2.1 mL, 1.5 mmol) and the reaction was stirred over night. H2O (15 
mL) was added and the reaction was extracted with dichloromethane (3 × 15 mL), 
the organic layer was washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 
and reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate 75:25:0 to 0:90:10 to give compound 4.07 as a white 
solid 0.027 g (22 %); [α]27D (c = 0.306, CHCl3) -64.60; υmax/cm
-1
: 3200 (NH), 2925 
(C-H), 1647 (amide C=O) and 1571 (aromatic); mp 217-218 º C; δH (400 MHz, 
CDCl3) 7.76 (d, 2H, J 8.5, CH-CO), 7.60 (d, 1H, J 5.5, NH-CH), 7.26 (d, 2H, J 8.5, 
CH-CEt), 6.04 (br.s, 1H, NH-CH2), 4.61 (ddd, 1H, J 11, 5.5, 2, lactam CH), 3.40-
3.22 (m, 2H, lactam CH2-NH), 2.68 (q, 2H, J 8, CH2-aryl), 2.24 (br.d, 1H, J 13.5, 
lactam equatorial CH2-CH), 2.08-2.01 (m, 1H, lactam equatorial CH2-CH2CH ), 
1.97-1.85 (m, 2H, lactam equatorial CH2-CH2NH and axial CH2-CH2CH), 1.55 (br.q, 
1H, J 12.5, lactam axial CH2-CH), 1.43 (br.q, 1H, J 13.5, lactam axial CH2-CH2NH) 
and 1.22 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 175.9, 166.2 (C=O), 148.2 (C-
Et), 131.6 (C-CO), 128.0 (CH-CEt), 127.2 (CH-CO), 52.6 (CH-NH), 42.3 (lactam 
CH2-NH), 31.7 (lactam CH2-CH), 29.0 (CH2-aryl), 28.8, 28.0 (lactam CH2-CH2NH 
and CH2-CH2CH) and 15.4 (C6); ESI m/z 100 %, 283.1 (MNa
+
) and 37 %, 542.8 
(M2Na
+
); HR ESI m/z (C15H20N2O2Na
+
 requires 283.1417) found 283.1413. 
4.08, 4-Ethyl benzoyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (25 mL) and cooled to 0°C. Acid 
chloride 4.01 (16 mmol) in dichloromethane (30 mL) and triethylamine (6.7 mL, 48 
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mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 4.08 as a white solid 1.46 g (37 %); mp 112-113 º C; [α]23D (c = 0.491, 
CHCl3) +103.95; υmax/cm
-1
: 3334, 3245 (N-H), 2932 (saturated C-H), 1656, 1634 
(C=O) and 1528 (aromatic); δH (400 MHz, CDCl3) 7.71 (d, 2H, J 8.5, CH-CO), 7.55 
(d, 1H, J 5.5, NH-CH), 7.19 (d, 2H, J 8.5, CH-CEt), 6.69 (br.s, 1H, NH-CH2), 4.39 
(dt, 1H, J 11, 5.5, CH-CH2), 3.35-3.28 (m, 2H, lactam CH2-NH), 2.67 (q, 2H, J 7.5, 
CH2-aryl), 2.63-2.56 (m, 1H, lactam equatorial CH2-CH), 1.94-1.87 (m, 2H, lactam 
CH2-CH2NH), 1.68 (tt, 1H, J 12.5, 8, lactam axial CH2-CH), and 1.20 (t, 3H, J 7.5, 
CH3); δC (100 MHz, CDCl3) 172.2, 167.5 (C=O), 148.2 (C-Et), 131.5 (C-C=O), 
127.9 (CH-CEt), 127.2 (CH-CO), 50.9 (CH-NH), 41.7 (C1), 28.8 (C4), 27.2 (C3), 
21.1 (C2) and 15.3 (C5); ESI m/z 100 %, 514.9 (M2Na
+
) and 35%, 269.1 (MNa
+
); 
HR ESI m/z (C14H18N2O2Na requires 269.1260) found 269.1261. 
4.09, 4-Ethyl benzoyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (10 mmol) was dissolved in H2O (25 mL) and cooled to 0°C. Acid 
chloride 4.01 (9 mmol) in dichloromethane (25 mL) and triethylamine (3.8 mL, 27 
mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 30 mL), the organic layer was washed with a pH 2 buffer (3 × 
20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 4.09 as a white solid 1.00 g (45 %); mp 109-110 º C; [α]28D (c = 0.51, 
CHCl3) -95.54; υmax/cm
-1
: 3335, 3245 (N-H), 2962 (saturated C-H), 1666 (C=O) and 
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1545 (aromatic); δH (400 MHz, CDCl3) 7.74 (d, 2H, J 8, CH-CO), 7.23 (d, 2H, J 8, 
CH-CEt), 7.18 (d, 1H, J 4.5, NH-CH), 6.06 (br.s, 1H, NH-CH2), 4.42 (dt, 1H, J 12, 
4.5, CH-CH2), 3.39-3.35 (m, 2H, lactam CH2-NH), 2.72 (ddt, 1H, J 13, 6, 4.5, lactam 
equatorial CH2-CH), 2.67 (q, 2H, J 7.5, CH2-aryl), 2.04-1.94 (m, 2H, lactam CH2-
CH2NH), 1.60-1.56 (m, 1H, lactam axial CH2-CH) and 1.22 (t, 3H, J 8, CH3); δC 
(100 MHz, CDCl3) 171.9, 167.6 (C=O), 148.3 (C-Et), 131.5 (C-CO), 128.0 (CH-
CEt), 127.2 (CH-CO), 51.1 (CH-NH), 41.8 (lactam CH2-NH), 28.8 (CH2-aryl), 27.2 
(lactam CH2-CH), 21.1 (lactam CH2-CH2NH) and 15.3 (CH3); ESI m/z 100 %, 514.9 
(M2Na
+
) and 26 %, 269.1 (MNa
+
); HR ESI m/z (C14H18N2O2Na
+
 requires 269.1260) 
found 269.1258. 
4.10, 4-Butylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (1.65 g, 10 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Acid chloride 4.02 (8 mmol) in dichloromethane and triethylamine (4.2 mL, 30 
mmol) were added and stirred over night. H2O (20 mL) was added and the reaction 
was extracted with dichloromethane (3 × 20 mL), the organic layer was washed with 
a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo. The product 
was purified by silica column chromatography (petroleum ether:ethyl acetate 75:25 
to 0:100) to give compound 4.10 as a white solid 0.42 g (18 %); mp 183-184 º C; 
[α]25D (c = 0.515, CHCl3) +64.88; υmax/cm
-1
: 3359, 3207 (N-H), 2951 (saturated C-
H), 1671, 1650 (C=O) and 1543 (aromatic); Anal. (C17H24N2O2 requires: C; 70.80, 
H; 8.39, N; 9.70) found: C; 70.74, H; 8.37, N; 9.70; δH (400 MHz, CDCl3) 7.73 (d, 
2H, J 8, CH-CO), 7.63 (d, 1H, J 5.5, NH-CH), 7.21 (d, 2H, J 8, CH-C-
n
Bu), 6.80 
(br.t, 1H, J 6, NH-CH2), 4.69 (dd, 1H, J 10.5, 5.5, CH), 3.35-3.20 (m, 2H, lactam 
CH2-NH), 2.61 (t, 2H, J 7.5, CH2-aryl), 2.19 (br.d, 1H, J 13.5, lactam equatorial 
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CH2-CH), 2.00 (br.d, 1H, J 12.5, lactam equatorial CH2-CH2CH), 1.93-1.80 (m, 2H, 
lactam equatorial CH2-CH2NH and axial CH2-CH2CH), 1.57 (quintet, 2H, J 7.5, 
CH2-CH2-aryl), 1.55-1.46 (m, 1H, lactam axial CH2-CH), 1.38 (br.q, 1H, J 13, 
lactam axial CH2-CH2CH), 1.31 (sextet, H2, J 7, CH2-CH3) and 0.89 (t, 3H, J 7.5, 
CH3); δC (100 MHz, CDCl3) 176.0, 166.3 (C=O), 146.7 (C-
n
Bu), 131.6 (C-CO), 
128.5 (CH-C
n
Bu), 127.1 (CH-CO), 52.5 (CH-NH), 42.2 (lactam CH2-NH), 35.5 
(CH2-aryl), 33.4 (lactam CH2-CH), 31.6 (CH2-CH2-aryl), 28.9, 28.0 (lactam CH2-
CH2NH and CH2-CH2CH), 22.3 (CH2-CH3) and 13.9 (CH3); ESI m/z 100 %, 311.2 
(MNa
+
) and 22 %, 289.2 (MH
+
); HR ESI m/z (C17H24N2O2Na requires 311.1730) 
found 311.1732. 
4.11, 4-Butylbenzoyl-(R)-3-amino-azepan-2-one  
Lactam 2.66 (0.50 mL, 1.94 mmol) was dissolved in H2O (10 mL) and cooled to 
0°C. Acid chloride 4.02 (3 mmol) in dichloromethane (15 mL) and triethylamine 
(0.84 mL, 6 mmol) were added and stirred over night. H2O (10 mL) was added and 
the reaction was extracted with dichloromethane (3 × 15 mL), the organic layer was 
washed with a pH 2 buffer (3 × 10 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 75:25 to 0:100) to give compound 4.11 as a white solid 0.28 g (48 %); mp 
182-183 º C; [α]30D (c = 0.676, CHCl3) -52.86; υmax/cm
-1
: 3204 (N-H), 2928 
(saturated C-H), 1677, 1641 (C=O) and 1544 (aromatic); δH (400 MHz, CDCl3) 7.74 
(d, 2H, J 8, CH-CCO), 7.62 (d, 1H, J 5.5, NH-CH), 7.21 (d, 2H, J 8, CH-CBu), 6.69 
(br.t, 1H, J 6.5, NH-CH2), 4.69 (ddd, 1H, J 11, 6, 2 CH), 3.36-3.21 (m, 2H, lactam 
CH2-NH), 2.62 (t, 2H, J 8, CH2-aryl), 2.20 (br.d, 1H, J 13, lactam equatorial CH2-
CH), 2.05-1.98 (br.d, 1H, lactam equatorial CH2-CH2CH), 1.94-1.81 (m, 2H, lactam 
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equatorial CH2-CH2NH and axial CH2-CH2CH), 1.61-1.37 (m, 4H, J 7.5, CH2-CH2-
aryl, lactam axial CH2-CH, lactam axial CH2-CH2CH), 1.32 (sextet, CH2-CH3, J 7.5, 
CH2-CH3) and 0.90 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 175.9, 166.3 (C=O), 
146.9 (C-
n
Bu), 131.6 (C-CO), 128.5 (CH-C-
n
Bu), 127.1 (CH-CCO), 52.5 (CH-NH), 
42.2 (lactam CH2-NH), 35.5 (CH2-aryl), 33.4 (lactam CH2-CH), 31.7 (CH2-CH2-
aryl), 28.9, 28.0 (lactam CH2-CH2NH and CH2-CH2CH), 22.3 (CH2-CH3) and 13.9 
(CH3); ESI m/z 100 %, 598.7 (M2Na
+
) and 75 %, 311.1 (MNa
+
); HR ESI m/z 
(C17H24N2O2Na requires 311.1730) found 311.1737. 
4.12, 4-Butyl benzoyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (20 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. Acid 
chloride 4.02 in dichloromethane and triethylamine (4.2 mL, 30 mmol) were added 
and stirred over night. H2O (20 mL) was added and the reaction was extracted with 
dichloromethane (3 × 20 mL), the organic layer was washed with a pH 2 buffer (3 × 
15 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:80:20) to 
give compound 4.12 as a white solid 0.45 g (16 %); mp 117-118 º C; [α]24D (c = 
0.523, CHCl3) +98.73; δH (400 MHz, CDCl3) 7.70 (d, 2H, J 8, CH-CO), 7.36 (d, 1H, 
J 6, NH-CH), 7.17 (d, 2H, J 8, CH-C-
n
Bu), 6.67 (br.s, 1H, NH-CH2), 4.69 (dt, 1H, J 
12, 6, CH), 3.36-3.29 (m, 2H, CH2-NH), 2.60 (t, 3H, J 7.5, CH2-aryl and lactam 
CH2-CH), 1.93-1.86 (m, 2H, lactam CH2-NH), 1.67-1.54 (m, 1H, CH2-CH), 1.55 
(quintet, 2H, J 7.5, CH2-CH2-aryl), 1.30 (sextet, 2H, J 7, H7.5, CH2-CH3) and 0.89 
(t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 172.2, 167.5 (C=O), 146.9 (C-
n
Bu), 131.5 
(C-CO), 128.5 (CH-C
n
Bu), 127.2 (CH-CCO), 50.8 (CH-NH), 41.7 (lactam CH2-
NH), 35.5 (CH2-aryl), 33.3 (CH2-CH2-aryl), 27.2 (lactam CH2-CH), 22.3 (CH2-CH3), 
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21.1 (lactam CH2-CH2NH) and 13.9 (CH3); ESI m/z 100 %, 297.2 (MNa
+
) and 26 %, 
275.2 (MH
+
); HR ESI m/z (C16H22N2O2Na requires 297.1573) found 297.1573;  
4.13, 4-Butyl benzoyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (10 mmol) was dissolved in H2O (25 mL) and cooled to 0°C. Acid 
chloride 4.02 (8.5 mmol) in dichloromethane (30 mL) and triethylamine (4.2 mL, 30 
mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 15 mL), the organic layer was washed with a pH 2 buffer (3 × 
15 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:80:20) to 
give compound 4.13 as a white solid 1.10 g (40 %); mp 116-117 º C; [α]25D (c = 
0.493, CHCl3) -89.45; υmax/cm
-1
: 3319, 3245 (N-H), 2949 (saturated C-H), 1651, 
1634 (C=O) and 1521 (aromatic); δH (400 MHz, CDCl3) 7.72 (d, 2H, J 8, CH-CO), 
7.25 (d, 1H, J 5.5, NH-CH), 7.20 (d, 2H, J 8, CH-C-
n
Bu), 6.41 (br.s, 1H, NH-CH2), 
4.41 (dt, 1H, J 11.5, 5.5, CH), 3.37-3.32 (m, 2H, lactam CH2-NH), 2.66 (ddt, 1H, J 
13, 6, 4.5, lactam equatorial CH2-CH), 2.62 (t, 3H, J 8, CH2-aryl), 1.98-1.90 (m, 2H, 
lactam CH2-CH2NH), 1.67-1.53 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 
1.32 (quintet, 2H, J 7.5, CH2-CH3) and 0.90 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 
172.1, 167.6 (C=O), 147.0 (C-
n
Bu), 131.5 (C-CO), 128.5 (CH-C
n
Bu), 127.2 (CH-
CCO), 51.0 (CH-NH), 41.7 (lactam CH2-NH), 35.5 (CH2-aryl), 33.3 (CH2-CH2-
aryl), 27.2 (lactam CH2-CH), 22.3 (CH2-CH3), 21.1 (lactam CH2-CH2NH) and 13.9 
(CH3); ESI m/z 100 %, 297.1 (MNa
+
); HR ESI m/z (C16H22N2O2Na requires 
297.1573) found 297.1574. 
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4.14, 4-tert-Butylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (2.04 g, 12.44 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Acid chloride 4.03 in dichloromethane and triethylamine (4.2 mL, 30 mmol) were 
added and stirred over night. H2O (20 mL) was added and the reaction was extracted 
with dichloromethane (3 × 20 mL), the organic layer was washed with a pH 2 buffer 
(3 × 20 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by 
recrystallisation from chloroform and cold petroleum ether and washed with boiling 
ethyl acetate to give compound 4.14 as a white solid 1.44 g (50 %); mp 204-205 º C; 
[α]23D (c = 0.523, CHCl3) +63.77; υmax/cm
-1
: 3210 (N-H), 2906 (saturated C-H), 1640 
(C=O) and 1566 (aromatic); Anal. (C17H24N2O2 requires: C; 70.80, H; 8.39, N; 9.70) 
found: C; 70.74, H; 8.37, N; 9.70; δH (400 MHz, CDCl3) 7.76 (d, 2H, J 8.5, CH-CO), 
7.66 (d, 1H, J 6, NH-CH), 7.42 (d, 2H, J 8.5, CH-C-
t
Bu), 6.00 (br.s, 1H, NH-CH2), 
4.67 (ddd, 1H, J 11, 6, 1.5, CH), 3.34-3.19 (m, 2H, lactam CH2-NH), 2.18 (br.d, 1H, 
J 13, lactam equatorial CH2-CH), 2.00 (br.d, 1H, J 12.5, lactam equatorial CH2-
CH2CH), 1.92-1.78 (m, 2H, lactam equatorial CH2-CH2NH and axial CH2-CH2CH), 
1.51 (q, 1H, J 13, lactam axial CH2-CH), 1.33 (br.q, 1H, J 11, lactam axial CH2-
CH2NH), and 1.29 (s, 3H, C(CH3)3); δC (100 MHz, CDCl3) 176.0, 166.2 (C=O), 
155.0 (C-C(CH3)3), 131.4 (C-CO), 127.9 (CH-C
t
Bu), 125.4 (CH-CCO), 52.5 (CH), 
42.1 (lactam CH2-NH), 34.9 (C(CH3)3), 31.6 (lactam CH2-CH), 31.2 (C(CH3)3) and 
28.9, 28.0 (lactam CH2-CH2NH and CH2-CH2CH); ESI m/z 100 %, 598.8 (M2Na
+
) 
and 32 %, 289.2 (MH
+
); HR ESI m/z (C17H24N2O2Na requires 311.1730) found 
311.1736.  
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4.15, 4- tert-Butylbenzoyl-(R)-3-amino-azepan-2-one  
Lactam 2.66 (0.17 g, 1.04 mmol) was dissolved in H2O (10 mL) and cooled to 0°C. 
Acid chloride 4.03 (1.04 mmol) in dichloromethane (15 mL) and triethylamine (0.43 
mL, 3.12 mmol) were added was stirred over night. H2O (20 mL) was added and the 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 20 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate:MeOH 50:50:0 to 0:80:20) to give compound 4.15 as a white solid 0.15 g (50 
%); mp 200-201 º C; [α]27D (c = 0.23, CHCl3) -46.16; υmax/cm
-1
: 3211 (N-H), 2933 
(saturated C-H), 1644 (C=O) and 1566 (aromatic); δH (400 MHz, CDCl3) 7.77 (d, 
2H, J 8.5, CH-CO), 7.62 (d, 1H, J 5.5, NH-CH), 7.44 (d, 2H, J 8.5, CH-C-
t
Bu), 6.29 
(br.t, 1H, J 6, NH-CH2), 4.70 (ddd, 1H, J 11, 6, 2, CH), 3.39-3.32 (m, 2H, lactam 
CH2-NH), 2.22 (br.d, 1H, J 13, lactam equatorial CH2-CH), 2.07-2.0 (m, 1H, lactam 
equatorial CH2-CH2CH), 1.95-1.83 (m, 2H, lactam equatorial CH2-CH2NH and axial 
CH2-CH2CH), 1.54 (q, 1H, J 13, lactam axial CH2-CH), 1.42 (br.q, 1H, J 13, lactam 
axial CH2-CH2NH) and 1.32 (s, 3H, C(CH3)3); δC (100 MHz, CDCl3) 175.8, 166.2 
(C=O), 155.0 (C-C(CH3)3), 131.3 (C-CO), 126.9 (CH-C
t
Bu), 125.5 (CH-CCO), 52.6 
(CH), 42.3 (lactam CH2-NH), 34.9 (C(CH3)3), 31.7 (lactam CH2-CH), 31.2 
(C(CH3)3) and 29.0, 28.0 (lactam CH2-CH2NH and CH2-CH2CH); ESI m/z 100 %, 
599.3 (M2Na
+
) and 17 %, 311.1 (MNa
+
); HR ESI m/z (C17H24N2O2Na requires 
311.1730) found 311.1727. 
4.16, 4-tert-Butyl benzoyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (33 mmol) was dissolved in H2O (100 mL) and cooled to 0°C. Acid 
chloride 4.03 (20 mmol) in dichloromethane and triethylamine (6.3 mL, 45 mmol) 
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were added and stirred over night. The reaction was extracted with dichloromethane 
(3 × 20 mL), the organic layer was washed with a pH 2 buffer (3 × 20 mL), dried 
over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:80:20) to give 
compound 4.16 as a white solid 3.13 g (53 %) mp 195-196 °C; [α]23D (c = 0.515, 
CHCl3) +82.52; υmax/cm
-1
: 3251 (N-H), 2959 (saturated C-H), 1683, 1648 (C=O) and 
1558 (aromatic); δH (400 MHz, CDCl3) 7.24 (d, 2H, J 8.5, CH-CO), 7.49 (d, 1H, J 6, 
NH-CH), 7.36 (d, 2H, J 8.5, CH-C-
t
Bu), 6.94 (br.s, 1H, NH-CH2), 4.62 (dt, 1H, J 11, 
6, 1.5, CH), 3.31-3.26 (m, 2H, CH2-NH), 2.52 (ddt, 1H, J 13, 6, 4.5, lactam 
equatorial CH2-CH), 1.90-183 (m, 2H, lactam CH2-CH2NH), 1.63 (tt, 1H, J 12.5, 
8.5, lactam axial CH2-CH) and 1.27 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 172.3, 
167.4 (C=O), 154.9 (C-C(CH3)3), 131.2 (C-CO), 127.0 (CH-C
t
Bu), 126.7 (CH-
CCO), 50.8 (CH), 41.6 (lactam CH2-NH), 34.9 (C(CH3)3), 31.2 (C(CH3)3), 27.2 
(lactam CH2-CH) and 21.1 (lactam CH2-CH2NH); ESI m/z 100 %, 297.2 (MNa
+
) and 
38 %, 275.2 (MH
+
). HR ESI m/z (C16H23N2O2 requires 275.1754) found 275.1752. 
4.17, 4-tert-Butyl benzoyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (15 mmol) was dissolved in H2O (100 mL) and cooled to 0°C. Acid 
chloride 4.03 (10 mmol) in dichloromethane and triethylamine (4.2 mL, 30 mmol) 
were added and stirred over night. The reaction was extracted with dichloromethane 
(3 × 20 mL), the organic layer was washed with a pH 2 buffer (3 × 20 mL), dried 
over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:80:20) to give 
compound 4.17 as a white solid 1.03 g (38 %) mp 193-194 °C; [α]23D (c = 0.512, 
CHCl3) -84.08; υmax/cm
-1
: 3247 (N-H), 2958 (saturated C-H), 1682, 1647 (C=O) and 
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1544 (aromatic); δH (400 MHz, CDCl3) 7.72 (d, 2H, J 8.5, CH-CO), 7.49 (d, 1H, J 6, 
NH-CH), 7.36 (d, 2H, J 8.5, CH-C-
t
Bu), 6.93 (br.s, 1H, NH-CH2), 4.39 (dt, 1H, J 
11.5, 6, CH), 3.31-3.26 (m, 2H, lactam CH2-NH), 2.52 (ddt, 1H, J 12.5, 5.5, 4.5, 
lactam equatorial CH2-CH), 1.90-1.87 (m, 2H, lactam CH2-CH2NH), 1.63 (tt, 1H, J 
12.5, 8.5, lactam axial CH2-CH) and 1.27 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 
172.3, 167.4 (C=O), 154.9 (C-C(CH3)3), 131.2 (C-C=O), 127.0 (CH-C
t
Bu), 125.3 
(CH-CCO), 50.8 (CH), 41.6 (lactam CH2-NH), 34.9 (C(CH3)3), 31.2 (C(CH3)3), 27.2 
(lactam CH2-CH) and 21.1 (lactam CH2-CH2NH); ESI m/z 19 %, 297.2 (MNa
+
) and 
13 %, 275.2 (MH
+
); HR ESI m/z (C16H22N2O2 requires 297.1573) found 275.1750.  
4.18, 4-Hexylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.95 g, 5.79 mmol) was dissolved in H2O (15 mL) and cooled to 0°C. 
4-Hexylbenzoyl chloride 4.04 (1.2 mL, 5 mmol) in dichloromethane and 
triethylamine (2.1 mL, 15 mmol) were added and the reaction was stirred over night. 
H2O (20 mL) was added and the reaction was extracted with dichloromethane (3 × 
20 mL), the organic layer was washed with a pH 2 buffer (3 × 15 mL), dried over 
Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 4.18 as a white solid 0.76 g (48 %); mp 167-168 º C; [α]25D (c = 0.507, 
CHCl3) +60.06; υmax/cm
-1
: 3244 (N-H), 2956 (saturated C-H), 1658, 1644 (C=O) and 
1543 (aromatic); Anal. (C19H28N2O2 requires: C; 72.12, H; 8.92, N; 8.85) found: C; 
72.11, H; 8.92, N; 7.82; δH (400 MHz, CDCl3) 7.74 (d, 2H, J 8, CH-CO), 7.61 (d, 
1H, J 6, NH-CH), 7.21 (d, 2H, J 8, CH-CHex), 6.54 (br.t, 1H, J 6, NH-CH2), 4.69 
(ddd, 1H, J 11, 6, 1.5, CH), 3.37-3.22 (m, 2H, lactam CH2-NH), 2.62 (t, 2H, J 7.5, 
CH2-aryl), 2.21 (d, 1H, J 13, lactam equatorial CH2-CH), 2.03 (dt, 1H, J 14, 3.5, 
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lactam equatorial CH2-CH2CH), 1.95-1.82 (m, 2H, lactam equatorial CH2-CH2NH 
and axial CH2-CH2CH), 1.64-1.49 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 
1.41 (q, 1H, J 13, lactam axial CH2-CH2NH) 1.33-1.23 (m, 6H, CH3-CH2-CH2-CH2) 
and 0.86 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 175.9, 166.3 (C=O), 147.0 (C-
Hex), 131.6 (C-CO), 128.5 (phenyl CH-CHex), 127.1 (phenyl CH-CO), 52.6 (CH), 
42.2 (lactam CH2-NH), 35.8 (CH2-aryl), 31.7 (lactam CH2-NH), 31.2 (CH2-CH2-
aryl), 29.0, 28.9, 28.0, (lactam CH2-CH2NH, CH2-CH2CH and CH2-CH2CH2-aryl, 
CH2-CH2CH3), 22.6 (CH2-CH3) and 14.1 (CH3); ESI m/z 43 %, 317.2 (MH
+
), 6% 
339.2 (MNa
+
) and 6 %, 654.7 (M2Na
+
); HR ESI m/z (C19H28N2O2Na requires 
339.2043) found 339.2050. 
4.19, 4-Hexylbenzoyl-(R)-3-amino-azepan-2-one  
Lactam 2.66 (0.27 g, 1.62 mmol) was dissolved in H2O (15 mL) and cooled to 0°C. 
4-Hexylbenzoyl chloride 4.04 (0.23 mL, 1.04 mmol) in dichloromethane and 
triethylamine (0.42 mL, 3.12 mmol) were added and stirred over night. H2O (20 mL) 
was added and the reaction was extracted with dichloromethane (3 × 20 mL), the 
organic layer was washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give compound 4.19 as a white 
solid 0.23 g (69 %); mp 168-169 º C; [α]27D (c = 0.518, CHCl3) -52.77; υmax/cm
-1
: 
3201 (N-H), 2926 (saturated C-H), 1678, 1640 (C=O) and 1543 (aromatic); δH (400 
MHz, CDCl3) 7.74 (d, 2H, J 8.5, CH-CO), 7.61 (d, 1H, J 6, NH-CH), 7.22 (d, 2H, J 
8.5, CH-CHex), 6.36 (br.t, 1H, J 6, NH-CH2), 4.70 (ddd, 1H, J 11, 5, 2.5, CH), 3.37-
3.22 (m, 2H, lactam CH2-NH), 2.62 (t, 2H, J 8, CH2-aryl), 2.22 (d, 1H, J 14, lactam 
equatorial CH2-CH), 2.06-1.99 (m, 1H, lactam equatorial CH2-CH2CH), 1.95-1.83 
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(m, 2H, lactam equatorial CH2-CH2NH and axial CH2-CH2CH), 1.62-1.51 (m, 3H, 
lactam axial CH2-CH and CH2-CH2-aryl), 1.39 (q, 1H, J 13, lactam axial CH2-
CH2NH), 1.33-1.24 (m, 6H, CH3-CH2-CH2-CH2) and 0.86 (t, 3H, J 7.5, CH3); δC 
(100 MHz, CDCl3) 175.8, 166.3 (C=O), 150.0 (C-Hex), 131.6 (C-CO), 128.5 
(phenyl CH-CHex), 127.1 (CH-CCO), 52.6 (CH-NH), 42.3 (lactam CH2-NH), 35.9 
(CH2-aryl), 31.7 (lactam CH2-CH), 31.2 (CH2-CH2-aryl), 29.0, 28.9, 28.0, (lactam 
CH2-CH2NH and CH2-CH2CH, and CH2-CH2-CH2-CH3), 22.6 (CH2-CH3) and 14.1 
(CH3); ESI m/z 100 %, 655.3 (M2Na
+
) and 45 % 339.1 (MNa
+
); HR ESI m/z 
(C19H28N2O2Na
+
 requires 339.2043) found 339.2049. 
4.20, 4-Hexylbenzoyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (10 mmol) was dissolved in H2O (35 mL) and cooled to 0°C. 4-
Hexylbenzoyl chloride 4.04 (1.2 mL, 5 mmol) in dichloromethane and triethylamine 
(2.1 mL, 15 mmol) were added and stirred over night. The reaction was extracted 
with dichloromethane (3 × 15 mL), the organic layer was washed with a pH 2 buffer 
(3 × 15 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by 
silica column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to 
give compound 4.20 as a white solid 0.95 g (63 %); mp 118-119 º C; [α]23D (c = 
0.511, CHCl3) +79.55; υmax/cm
-1
: 3338, 3247 (N-H), 2921 (saturated C-H), 1656, 
1637 (C=O) and 1562 (aromatic); δH (400 MHz, CDCl3) 7.70 (d, 2H, J 8, CH-CO), 
7.38 (d, 1H, J 6, NH-CH), 7.17 (d, 2H, J 8, CH-CHex), 6.81 (br.s, 1H, NH-CH2), 
4.39 (dt, 1H, J 11.5, 6, CH), 3.33-3.26 (m, 2H, lactam CH2-NH), 2.58 (t, 2H, J 7.5, 
lactam CH2-aryl), 2.57-2.52 (m, 1H, lactam equatorial CH2-CH), 1.92-1.84 (m, 2H, 
lactam CH2-CH2NH), 1.67-1.52 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 
1.29-1.23 (m, 6H, CH3-CH2-CH2-CH2) and 0.84 (t, 3H, J 7.5, CH3); δC (100 MHz, 
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CDCl3) 172.3, 167.5 (C=O), 146.9 (C-Hex), 131.5 (C-CO), 128.4 (CH-CHex), 127.2 
(CH-CCO), 50.8 (CH-NH), 41.6 (lactam CH2-NH), 35.8 (CH2-aryl), 31.7 (lactam 
CH2-CH), 31.2 (CH2-CH2-aryl), 28.9 (CH2-CH2-CH2-aryl), 27.2, (CH2-CH2CH3), 
22.6 (CH2-CH3), 21.1 (lactam CH2-CH2NH) and 14.1 (CH3); ESI m/z 100 %, 325.2 
(MNa
+
) and 37% 303.2 (MH
+
); HR ESI m/z (C18H26N2O2Na requires 325.1886) 
found 325.1883. 
4.21, 4-Hexylbenzoyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (10 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 4-
Hexylbenzoyl chloride 4.04 (1.2 mL, 5 mmol) in dichloromethane and triethylamine 
(2.1 mL, 15 mmol) was added and stirred over night. The reaction was extracted 
with dichloromethane (3 × 15 mL), the organic layer was washed with a pH 2 buffer 
(3 × 15 mL), dried over Na2SO4 and reduced in vacuo. The product was purified by 
silica column chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to 
give compound 4.21 as a white solid 0.53 g (35 %); mp 117-118 º C; υmax/cm
-1
: 
3328, 3240 (N-H), 2954 (saturated C-H), 1651, 1635 (C=O) and 1533 (aromatic); 
[α]25D (c = 0.496, CHCl3) -81.17; H (400 MHz, CDCl3) 7.71 (d, 2H, J 8, CH-CO), 
7.28 (d, 1H, J 5, NH-CH), 7.19 (d, 2H, J 8, CH-CHex), 6.52 (br.s, 1H, NH-CH2), 
4.41 (dt, 1H, J 11.5, 5.5, CH), 3.35-3.31 (m, 2H, lactam CH2-NH), 2.67-2.60 (m, 1H, 
lactam equatorial CH2-CH), 2.61 (t, 2H, J 7.5, CH2-aryl), 2.00-1.89 (m, 2H, CH2-
CH2NH), 1.67-1.54 (m, 3H, equatorial CH2-CH and CH2-CH2-aryl), 1.32-1.23 (m, 
6H, CH2-CH2-CH2-CH3) and 0.85 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 172.1, 
167.6 (C=O), 147.0 (C-Hex), 131.5 (C-CO), 128.5 (CH-CHex), 127.2 (CH-CCO), 
50.9 (CH), 41.7 (lactam CH2-NH), 35.8 (CH2-aryl), 31.7 (lactam CH2-CH), 31.2 
(CH2-CH2-aryl), 28.9 (CH2-CH2CH2-aryl), 27.2, (CH2-CH2-CH3), 22.6 (CH2-CH3), 
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21.1 (lactam CH2-CH2NH) and 14.1 (CH3); ESI m/z 100 %, 325.2 (MNa
+
) and 33% 
303.2 (MH
+
); HR ESI m/z (C18H26N2O2Na requires 325.1886) found 325.1888. 
4.22, 4-Octylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.91 g, 5.55 mmol) was dissolved in H2O (15 mL) and cooled to 0°C. 
Acid chloride 4.05 in dichloromethane and triethylamine (0.84 mL, 6 mmol) were 
added and the reaction was stirred over night. H2O (20 mL) was added and the 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 50:50:0 to 0:80:20) to give compound 4.22 as a white solid 0.087 g (4 %); 
mp 159-160 º C; [α]25D (c = 0.124, CDCl3) +68.01; υmax/cm
-1
: 3204 (N-H), 2923 
(saturated C-H), 1637 (amide C=O) and 1544 (aromatic); δH (400 MHz, CDCl3) 7.73 
(d, 2H, J 8, CH-CO), 7.64 (d, 1H, J 5.5, NH-CH), 7.20 (d, 2H, J 8, CH-C-Oct), 6.94 
(br.t, 1H, J 6, NH-CH2), 4.68 (dd, 1H, J 11, 6, CH), 3.35-3.20 (m, 2H, lactam CH2-
NH), 2.60 (t, 2H, J 7.5, CH2-aryl), 2.19 (d, 1H, J 13, lactam equatorial CH2-CH), 
2.00 (br.d, 1H, equatorial CH2-CH2NH), 1.92-1.79 (m, 2H, lactam axial CH2-
CH2NH), 1.62-1.46 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 1.38 (q, 1H, J 
11.5, lactam axial CH2-CH2NH), 1.30-1.19 (m, 10H, H7, H8, H9, H10 & H11) and 
0.84 (t, 3H, J 7.5, H12); δC (100 MHz, CDCl3) 176.0, 166.3 (C=O), 146.9 (C-Oct), 
131.6 (C-CO), 128.5 (CH-COct), 127.1 (CH-CCO), 52.5 (CH), 42.1 (lactam CH2-
NH), 35.8 (CH2-aryl),  31.9 (lactam CH2-CH), 31.6 (CH2-CH2-aryl), 31.2 (CH2-CH2-
CH2-aryl), 29.4, 29.3, 28.9, 28.0, (lactam CH2-CH2NH and CH2-CH2CH and CH2-
CH2-CH2-CH2CH3), 22.7 (CH2CH3) and 14.1 (CH3); ESI m/z 100 %, 345.2 (MH
+
) 
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and 9 %, 710.8 (M2Na
+
); HR ESI m/z (C21H32N2O2Na requires 367.2356) found 
367.2361. 
4.23, 4-Octylbenzoyl-(R)-3-amino-azepan-2-one  
Lactam 2.66 (0.112 g, 0.44 mmol) was dissolved in H2O (5 mL) and cooled to 0°C. 
Acid chloride 4.05 (2 mmol) in dichloromethane (10 mL) and triethylamine (0.21 
mL, 1.5 mmol) were added and the reaction was stirred over night. H2O (10 mL) was 
added and the reaction was extracted with dichloromethane (3 × 15 mL), the organic 
layer was washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in 
vacuo. The product was purified by silica column chromatography (petroleum 
ether:ethyl acetate 50:50:0 to 0:90:10) to give compound 4.23 as a white solid 0.018 
g (10 %); mp 157-158 º C; [α]27D (c = 0.12, CDCl3) -72.36; υmax/cm
-1
: 3206 (N-H), 
2922 (saturated C-H), 1642 (amide C=O) and 1544 (aromatic); δH (400 MHz, 
CDCl3) 7.74 (d, 2H, J 8, CH-CO), 7.61 (d, 1H, J 5.5, NH-CH), 7.22 (d, 2H, J 8, CH-
C-Oct), 6.48 (br.t, 1H, J 5.5, NH-CH2), 4.70 (ddd, 1H, J 11, 6, 2, CH), 3.37-3.22 (m, 
2H, lactam CH2-NH), 2.62 (t, 2H, J 7, CH2-aryl), 2.21 (d, 1H, J 13, lactam equatorial 
CH2-CH), 2.06-1.99 (m, 1H, lactam equatorial CH2-CH2CH), 1.95-1.87 (m, 3H, 
lactam axial CH2-CH2NH and CH2-CH2CH), 1.63-1.50 (m, 3H, lactam axial CH2-
CH and CH2-CH2-aryl), 1.40 (q, 1H, J 12, lactam equatorial CH2-CH2NH) 1.30-1.20 
(m, 11H, CH2-CH2-aryl and CH2-CH2-CH2-CH2-CH2-CH3) and 0.86 (t, 3H, J 7, 
CH3); δC (100 MHz, CDCl3) 175.9, 166.3 (C=O), 147.0 (C-Oct), 131.6 (C-CO), 
128.5 (CH-COct), 127.1 (CH-CCO), 52.6 (CH), 42.2 (lactam CH2-NH), 35.9 (CH2-
aryl),  31.9 (lactam CH2-CH), 31.7 (CH2-CH2-aryl), 31.2 (CH2-CH2-CH2-aryl), 29.4, 
29.2, 29.0, 28.9, 28.0, (lactam CH2-CH2NH and CH2-CH2CH and CH2-CH2-CH2-
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CH2-CH3 ), 22.7 (CH2-CH3) and 14.1 (CH3); ESI m/z 100 %, 367.2 (MNa
+
) and 21 
%, 710.8 (M2Na
+
); HR ESI m/z (C21H32N2O2Na
+
 requires 367.2356) found 367.2349. 
4.24, 4-Octylbenzoyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (10 mmol) was dissolved in H2O (35 mL) and cooled to 0°C. Acid 
chloride 4.05 (2 mmol) in dichloromethane and triethylamine (0.85 mL, 6 mmol) 
were added and stirred over night. The reaction was extracted with dichloromethane 
(3 × 10 mL), the organic layer was washed with a pH 2 buffer (3 × 10 mL), dried 
over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 4.24 as a white solid 0.55 g (83 %); mp 122-123 º C; [α]23D (c = 0.509, 
CHCl3) +75.74; υmax/cm
-1
: 3240 (N-H), 2921 (saturated C-H), 1653, 1615 (C=O) and 
1563 (aromatic); δH (400 MHz, CDCl3) 7.71 (d, 2H, J 8, CH-CO), 7.26 (d, 1H, J 5.5, 
NH-CH), 7.19 (d, 2H, J 8, CH-C-Oct), 6.47 (br.s, 1H, NH-CH2), 4.41 (dt, 1H, J 11.5, 
5.5, CH), 3.33-3.27 (m, 2H, lactam CH2-NH), 2.84-2.58 (m, 1H, J 13, lactam 
equatorial CH2-CH), 2.60 (t, 2H, J 7.5, CH2-aryl), 1.97-1.90 (m, 2H, CH2-CH2NH), 
1.67-1.54 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 1.29-1.23 (m, 10H, 
CH2-CH2-CH2-CH2-CH2-CH3) and 0.86 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 
172.1, 167.6 (C=O), 147.0 (C-Oct), 131.5 (C-C=O), 128.5 (CH-C-Oct), 127.2 (CH-
CO), 50.9 (CH), 41.7 (lactam CH2-NH), 35.8 (CH2-aryl),  31.9 (CH2-CH2-aryl), 31.2 
(lactam CH2-CH), 29.4 (CH2-CH2-CH2-aryl), 29.3 (CH2-CH2-CH2-CH2-CH2-aryl), 
27.2 (CH2-CH2CH3), 22.3 (CH2-CH3), 21.1 (lactam CH2-CH2NH) and 14.1 (CH3); 
ESI m/z 100 %, 353.2 (MNa
+
) and 47 %, 331.2 (MH
+
); HR ESI m/z (C20H30N2O2Na 
requires 353.2199) found 353.2198. 
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4.25, 4-Octylbenzoyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (5 mmol) was dissolved in H2O (25 mL) and cooled to 0°C. Acid 
chloride 4.05 (2 mmol) in dichloromethane and triethylamine (0.85 mL, 6 mmol) 
were added and stirred over night. The reaction was extracted with dichloromethane 
(3 × 10 mL), the organic layer was washed with a pH 2 buffer (3 × 10 mL), dried 
over Na2SO4 and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:50:0 to 0:80:20) to give 
compound 4.24 as a white solid 0.16 g (25 %); mp 122-123 º C; [α]23D (c = 0.485, 
CHCl3) -77.80; υmax/cm
-1
: 3250 (N-H), 2955 (saturated C-H), 1653 (C=O) and 1540 
(aromatic); δH (400 MHz, CDCl3) 7.71 (d, 2H, J 8.5, CH-CO), 7.23 (d, 1H, J 6.5, 
NH-CH), 7.20 (d, 2H, J 8.5, CH-C-Oct), 6.34 (br.s, 1H, NH-CH2), 4.41 (dt, 1H, J 
11.5, 5.5, CH), 3.37-3.33 (m, 2H, lactam CH2-NH), 2.68 (ddt, 1H, J 13, 5.5, 4.5, 
lactam equatorial CH2-CH), 2.61 (t, 2H, J 7.5, CH2-aryl), 1.98-1.91 (m, 2H, lactam 
CH2-CH2NH), 1.67-1.55 (m, 3H, lactam axial CH2-CH and CH2-CH2-aryl), 1.31-
1.22 (m, 10H, CH2-CH2-CH2-CH2-CH2-CH3) and 0.86 (t, 3H, J 7, CH3); δC (100 
MHz, CDCl3) 172.1, 167.6 (C=O), 147.0 (C-Oct), 131.5 (C-C=O), 128.5 (CH-COct), 
127.2 (CH-CCO), 51.0 (CH), 41.7 (lactam CH2-NH), 35.8 (CH2-aryl), 31.9 (CH2-
CH2-aryl), 31.2 (lactam CH2-CH), 29.4 (CH2-CH2CH2-aryl), 29.3 (CH2-
CH2CH2CH2CH2-aryl), 27.2 (CH2-CH2CH3), 22.7 (CH2CH3), 21.1 (lactam CH2-
CH2NH) and 14.1 (CH3); ESI m/z 39 %, 353.2 (MNa
+
), 19 %, 331.2 (MH
+
) and 14 
%, 682.7 (M2Na
+
); HR ESI m/z (C20H30N2O2H
+
 requires 331.2380) found 331.2381. 
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6.4.2 4-Sulfonyl Compounds 
4.26, 4-Ethylbenzenesulfonylchloride 
4-Ethylbenzoic acid (1.5 mL, 10 mmol) was dissolved in dichloromethane (20 mL), 
oxalyl chloride (1.3 mL, 15 mmol) and DMF (1 drop) were added and the reaction 
was stirred for 4 hours. The organic solvents were removed in vacuo to give 
compound 4.26 was not isolated and used in the next stage. 
4.28, 4-Octylbenzenesulfonyl chloride 
4-Octylbenzoic acid (1.25 g, 1.34 mmol) was dissolved in dichloromethane (25 mL), 
oxalyl chloride (0.12 mL, 1.3 mmol), DMF (1 drop) and tetrabutylammonium 
chloride (0.037 g, 0.134 mmol) were added and the reaction was stirred for 4 hours. 
The organic solvents were removed in vacuo to give compound 4.28 which was not 
isolated and used in the next stage. 
4.29, 4-Ethylbenzenesulfonyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.55 g, 3.3 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Sulfonyl chloride 4.26 (5 mmol) in dichloromethane (30 mL) and triethylamine (1.3 
mL, 9.0 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane and washed with pH 2 buffer (3 × 20 mL) and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 75:25 to 0:100) to give compound 4.29 as a white solid (0.17 g, 19 %); mp 
159-160 º C; [α]25D (c = 0.235, CHCl3) +128.79; υmax/cm
-1
: 3389, 3228 (N-H), 2927 
(saturated C-H), 1660 (amide C=O) and 1362, 1163 (SO2); Anal. (C14H20N2O3S 
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requires: C; 56.73, H; 6.80, N; 9.45) found: C; 56.65, H; 6.80, N; 9.44; δH (400 
MHz, CDCl3) 7.72 (d, 2H, J 8, CH-CSO2), 7.28 (d, 2H, J 8, CH-CEt), 6.40 (br.t, 1H, 
J 6, NH-CH2), 6.18 (d, 1H, J 5, NH-CH), 3.83-3.74 (m, 1H, CH), 3.19-3.11 (m, 1H, 
lactam CH2-NH), 3.03 (ddd, 1H, J 16, 11.5, 5.5, lactam CH2-NH), 2.08 (q, 2H, J 8, 
CH2-aryl), 2.15-2.09 (m, 1H, lactam CH2-CH), 2.0-1.95 (m, 1H, lactam CH2-
CH2NH), 1.80-1.77 (m, 1H, lactam CH2-CH2CH), 1.66-1.52 (m, 2H, lactam CH2-
CH2CH and CH2-CH), 1.37-1.26 (m, 1H, lactam CH2-CH2NH) and 1.23 (t, 3H, J 8, 
CH3); δC (100 MHz, CDCl3) 174.4 (C=O), 149.5 (C-Et), 137.2 (C-SO2), 129.1 (CH-
CEt), 126.2 (CH-CSO2), 55.4 (CH-NH), 42.2 (lactam CH2-NH), 33.4 (lactam CH2-
CH), 28.8 (CH2-aryl), 28.6 (lactam CH2-CH2NH), 28.0 (lactam CH2-CH2CH) and 
15.1 (CH3); ESI m/z 100 %, 319.1 (MNa
+
) and 58 %, 614.6 (M2Na
+
); HR ESI m/z 
(C114H20N2O3SNa
+
 requires 319.1087) found 319.1085. 
4.30, 4-Ethylbenzenesulfonyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (4.8 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. Sulfonyl 
chloride 4.26 (1.50 mL, 10.9 mmol) in dichloromethane (20 mL) and triethylamine 
(4.2 mL, 30 mmol) were added and stirred over night. The dichloromethane was 
removed in vacuo and the product was dissolved in ethyl acetate and washed with 
pH 2 buffer (3 × 20 mL) and reduced in vacuo. The product was purified by silica 
column chromatography (petroleum ether:ethyl acetate 75:25 to 0:100) to give 
compound 4.30 as a white solid (0.67 g, 24 %); mp 142-143 º C; [α]26D (c = 0.54, 
CHCl3) +130.12;  υmax/cm
-1
: 3212, 3105 (N-H), 2938, 2876 (saturated C-H), 1656 
(C=O), 1597 (aromatic) and 1323, 1131 (SO2); δH (400 MHz, CDCl3) 7.79 (d, 2H, J 
8, CH-CSO2), 7.31 (d, 2H, J 8, CH-CEt), 6.01 (br.s, 1H, NH-CH2), 5.89 (d, 1H, J 2, 
NH-CH), 3.50-3.45 (m, 1H, CH), 3.30-3.24 (m, 2H, lactam CH2-NH), 2.70 (q, 2H, J 
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7, CH2-aryl), 2.50-2.45 (m, 1H, lactam CH2-CH), 1.95-1.85 (m, 1H, lactam CH2-
CH2NH), 1.84-1.68 (m, 2H, lactam CH2-CH2NH and CH2-CH), and 1.24 (t, 3H, J 7, 
CH3); δC (100 MHz, CDCl3) 169.9 (C=O), 149.3 (C-C(CH3)3), 136.2 (C-SO2), 128.6 
(CH-CEt), 127.5 (CH-CSO2), 53.3 (CH), 41.9 (lactam CH2-NH), 28.8 (CH2-aryl), 
28.5 (lactam CH2-CH), 20.8 (lactam CH2-CH2NH) and 15.1 (CH3); ESI m/z 100 %, 
586.6 (M2Na
+
) and 59 %, 305.0 (MNa
+
); HR ESI m/z (C13H18N2O3SNa
+
 requires 
305.0930) found 305.0931. 
4.31, 4-Ethylbenzenesulfonyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (4 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. Sulfonyl 
chloride 4.26 (4 mmol) in dichloromethane (25 mL) and triethylamine (1.7 mL, 12 
mmol) were added and the reaction was stirred over night. The reaction was 
extracted with dichloromethane and washed with pH 2 buffer (3 × 20 mL) and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate:MeOH 75:25:0 to 0:90:10) to give compound 4.31 as 
a white solid (0.25 g, 21 %); δH (400 MHz, CDCl3) 7.80 (d, 2H, J 8, CH-CSO2), 7.32 
(d, 2H, J 8, CH-CEt), 6.09 (br.s, 1H, NH-CH2), 5.90 (d, 1H, J 2, NH-CH), 3.50-3.45 
(m, 1H, CH), 3.28-3.23 (m, 2H, lactam CH2-NH), 2.69 (q, J 7.5, 2H, CH2-aryl), 
2.49-2.45 (m, 1H, lactam CH2-CH), 1.95-1.90 (m, 1H, lactam CH2-CH2NH), 1.82-
1.71 (m, 2H, lactam CH2-CH2NH and CH2-CH) and 1.24 (t, 3H, CH3); δC (100 MHz, 
CDCl3) 170.0 (C=O), 149.7 (C-Et), 136.2 (C-SO2), 129.1 (CH-CEt), 128.6 (CH-
CSO2), 55.3 (CH), 41.9 (lactam CH2-NH), 28.8 (lactam CH2-CH), 28.5 (CH2-aryl), 
20.8 (lactam CH2-CH2NH) and 15.1 (CH3); ESI m/z 100 %, 305.1 (MNa
+
) and 56 %, 
586.7 (M2Na
+
); HR ESI m/z (C13H18N2O3SH
+
 requires 283.1111) found 283.1114. 
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4.32, 4-
t
Butylbenzenesulfonyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (2.35 g, 9.18 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
4-
t
Buytlbenzenesulfonyl chloride 4.27 (1.92 g, 8.25 mmol) in dichloromethane (40 
mL) and triethylamine (3.5 mL, 25 mmol) were added and the reaction was stirred 
over night. The dichloromethane was removed in vacuo and the product was 
dissolved in ethyl acetate and washed with pH 2 buffer (3 × 20 mL) and reduced in 
vacuo. The product was purified by silica column chromatography (petroleum 
ether:ethyl acetate 50:50:0 to 0:80:20) to give compound 4.32 as a white solid (0.67 
g, 25 %); mp 189-190 º C; [α]23D (c = 0.532, CHCl3) +109.68; υmax/cm
-1
: 3219 (N-H), 
2968 (saturated C-H), 1668 (amide C=O), 1594 (aromatic) and 1361 (SO2); Anal. 
(C16H24N2O3S requires: C; 59.23, H; 7.46, N; 8.63) found: C; 59.46, H; 7.48, N; 
8.65; δH (400 MHz, CDCl3) 7.74 (d, 2H, J 8.5, CH-CSO2), 7.47 (d, 2H, J 8.5, CH-
C
t
Bu), 6.27 (br.t, 1H, J 6.5, NH-CH2), 6.19 (d, 1H, J 4.5, NH-CH), 3.88-3.81 (m, 
1H, CH), 3.21-3.12 (m, 1H, lactam CH2-NH), 3.05 (ddd, 1H, J 14.5, 11.5, 5, lactam 
CH2-NH), 2.19-2.13 (m, 1H, lactam CH2-CH), 2.02-1.96 (m, 1H, lactam CH2-
CH2NH), 1.81-1.74 (m, 1H, lactam CH2-CH2NH), 1.71-1.54 (m, 2H, lactam CH2-
CH and lactam CH2-CH2CH), 1.33-1.29 (m, 1H, lactam CH2-CH2CH) and 1.31 (s, 
3H, C(CH3)3); δC (100 MHz, CDCl3) 175.5 (C=O), 156.4 (C-C(CH3)3), 137.0 (C-
CO), 126.8 (CH-C
t
Bu), 126.1 (CH-CSO2), 55.4 (CH), 42.3 (lactam CH2-NH), 35.2 
(C(CH3)3), 33.5 (lactam CH2-CH), 31.1 (C(CH3)3), 28.7 (lactam CH2-CH2NH) and 
28.0 (lactam CH2-CH2CH); ESI m/z 100 %, 347.1 (MNa
+
) and 26 %, 670.6 (M2Na
+
); 
HR ESI m/z (C16H24N2O3SH
+
 requires 325.1580) found 325.1580. 
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4.33, 4-tert-Butylbenzenesulfonyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53  (10 mmol) was dissolved in H2O (40 mL) and cooled to 0°C. 4-tert-
Buytlbenzenesulfonyl chloride 4.27 (1.88 g, 8.08 mmol) in dichloromethane (25 mL) 
and triethylamine (3.5 mL, 25 mmol) were added and was stirred over night. The 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 20 mL) and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate:MeOH 
50:50:0 to 0:80:20) to give compound 4.33 as a white solid (0.76 g, 30 %); mp 155-
156 º C; [α]23D (c = 0.525, CHCl3) +122.92; υmax/cm
-1
: 3220 (N-H), 2946 (saturated 
C-H), 1665, 1596 (aromatic) and 1331, 1134 (SO2); δH (400 MHz, CDCl3) 7.79 (d, 
2H, J 8.5, CH-SO2), 7.47 (d, 2H, J 8.5, CH-C
t
Bu), 6.38 (br.s, 1H, NH-CH2), 5.98 (d, 
1H, J 3.5, NH-CH), 3.51-3.46 (m, 1H, CH), 3.28-3.22 (m, 2H, lactam CH2-NH), 
2.49-2.42 (m, 1H, lactam CH2-CH), 1.93-1.87 (m, 1H, lactam CH2-CH2NH), 1.86-
1.67 (m, 2H, lactam CH2-CH2NH and CH2-CH) and 1.31 (s, 9H, C(CH3)3); δC (100 
MHz, CDCl3) 170.1 (C=O lactam), 156.5 (C-C(CH3)3), 136.0 (C-SO2), 127.1 (CH-
C
t
Bu), 126.2 (CH-CSO2), 53.2 (CH), 41.8 (lactam CH2-NH), 35.2 (C(CH3)3), 31.1 
(C(CH3)3), 28.4 (lactam CH2-CH) and 20.7 (lactam CH2-CH2NH); ESI m/z 100 %, 
333.1 (MNa
+
) and 44 %, 642.6 (M2Na
+
); HR ESI m/z (C15H22N2O3SH
+ 
requires 
311.1424) found 311.1425. 
4.34, 4-tert-Butylbenzenesulfonyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (2.5 mmol) was dissolved in H2O (30 mL) and cooled to 0°C. 4-tert-
Buytlbenzenesulfonyl chloride 4.27 (0.61 g, 2.6 mmol) in dichloromethane (25 mL) 
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and triethylamine (1.1 mL, 7.5 mmol) were added and stirred over night. The 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 20 mL) and reduced in vacuo. The product was 
purified by silica column chromatography (petroleum ether:ethyl acetate 75:25 to 
0:100) to give compound 4.34 as a white solid (0.33 g, 43 %) mp 155-156 °C; [α]25D 
(c = 0.114, CHCl3) -116.52; υmax/cm
-1
: 3384, 3226 (N-H), 2927 (saturated C-H), 
1663 (amide C=O) and 1330, 1163 (SO2); δH (400 MHz, CDCl3) 7.80 (d, 2H, J 8.5, 
CH-SO2), 7.50 (d, 2H, J 8.5, CH-C-
t
Bu), 5.99 (br.s, 1H, NH-CH2), 5.90 (br.d, 1H, J 
2, NH-CH), 3.51-3.46 (m, 1H, CH), 3.31-3.26 (m, 2H, lactam CH2-NH), 2.53-2.43 
(m, 1H, lactam CH2-CH), 1.96-1.89 (m, 1H, lactam CH2-CH2NH), 1.85-1.69 (m, 2H, 
lactam CH2-CH2NH and CH2-CH) and 1.32 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 
169.9 (C=O), 156.6 (C-C(CH3)3), 135.8 (C-SO2), 127.2 (CH-C
t
Bu), 126.2 (CH-
CSO2), 53.3 (CH), 42.0 (lactam CH2-NH), 35.2 (C(CH3)3), 31.1 (C(CH3)3), 28.5 
(lactam CH2-CH) and 20.8 (lactam CH2-CH2NH); ESI m/z 37 %, 642.6 (M2Na
+
); 
HR ESI m/z (C15H22N2O3SH
+
 requires 311.1424) found 311.1427. 
4.35, 4-Octylbenzenesulfonyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.73 g, 4.5 mmol) was dissolved in H2O (30 mL) and cooled to 0°C. 
Sulfonyl chloride 4.28 (2.2 mmol) in dichloromethane (25 mL) and triethylamine 
(0.90 mL, 6.6 mmol) were added and stirred over night. The reaction was extracted 
with dichloromethane (3 × 20 mL) the organic layer was washed with a pH 2 buffer 
(3 × 20 mL) and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:5 to 0:100) to give compound 4.35 
as a white solid  (0.49 g, 59 %); mp 98-99 º C; [α]30D (c = 0.26, CHCl3) +91.15; 
υmax/cm
-1
: 3396, 3250 (N-H), 2920 (saturated C-H), 1663 (amide C=O) and 1363, 
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1161 (SO2); Anal. (C21H34N2O2 requires: C; 73.22, H; 9.36, N; 8.13) found: C; 72.5, 
H; 9.35, N; 9.98; δH (400 MHz, CDCl3) 7.71 (d, 2H, J 8.5, CH-CSO2), 7.25 (d, 2H, J 
8.5, CH-COct), 6.68 (dd, 1H, J 7.5, 5,5 NH-CH2), 6.22 (d, 1H, J 5, NH-CH), 3.81 
(ddd, 1H, J 2, 5, 11 CH), 3.20-3.311 (m, 1H, lactam CH2-NH), 3.02 (ddd, 1H, J 16, 
11.5, 5, lactam CH2-NH), 2.63 (t, 2H, J 8, CH2-aryl), 2.12-2.07 (m, 1H, lactam CH2-
CH), 1.98-1.93 (m, 1H, lactam CH2-CH2CH), 1.79-1.72 (m, 1H, lactam CH2-
CH2NH), 1.65-1.55 (m, 4H, lactam CH2-CH, CH2-CH2CH and lactam CH2-aryl), 
1.33-1.21 (m, 11H, lactam CH2-CH2NH and CH2-CH2-CH2-CH2-CH2-CH3) and 0.86 
(t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 174.6 (C=O), 148.4 (C-Oct), 137.2 (C-SO2), 
129.1 (CH-COct), 128.8 (CH-CSO2), 127.0 (phenyl CH), 55.3 (CH), 42.1 (lactam 
CH2-NH), 35.8 (lactam CH2-CH), 33.3 (CH2-aryl), 31.8 (lactam CH2-CH2CH), 31.0 
(CH2-CH2-aryl), 29.4 (CH2-CH2CH2-aryl), 29.2 (CH2-CH2CH2CH2-aryl), 28.6 (CH2-
CH2CH2CH3), 28.0 (CH2-CH2CH3), 22.7 (lactam CH2-CH2NH), 22.6 (CH2-CH3) and 
14.1 (CH3); ESI m/z 100 %, 403.2 (MNa
+
) and 40 %, 381.2 (MH
+
); HR ESI m/z 
(C20H32N2O3SH
+
 requires 381.2206) found 381.2205.  
4.36, 4-Octylbenzenesulfonyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (2.5 mmol) was dissolved in H2O (40 mL) and cooled to 0°C. Sulfonyl 
chloride 4.28 (1.34 mmol) in dichloromethane (25 mL) and triethylamine (0.6 mL, 4 
mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 20 mL) the organic layer was washed with a pH 2 buffer (3 × 
20 mL) and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate:MeOH 50:50:0 to 0:80:20) to give 
compound 4.36 as a white solid (0.31 g, 63 %); mp 98-99 º C; [α]24D (c = 0.515, 
CHCl3) +99.97; υmax/cm
-1
: 3207 (N-H), 2920 (saturated C-H), 1664, (C=O), 1544 
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(aromatic) and 1310, 1188 (SO2); Anal. (C10H18N2O2 requires: C; 62.26, H; 8.25, N; 
7.64) found: C; 62.30, H; 8.26, N; 7.65; δH (400 MHz, CDCl3) 7.76 (d, 2H, J , CH-
CSO2), 7.27 (d, 2H, J 8, CH-C-Oct ), 6.50 (br.s, 1H, NH-CH2), 6.00 (d, 1H, J 2.5, 
NH-CH), 3.51-3.45 (m, 1H, lactam CH), 3.27-3.31 (m, 2H, lactam CH2-NH), 2.62 (t, 
2H, J 7, CH2-aryl), 2.45-2.36 (m, 1H, lactam CH2-CH), 1.92-1.85 (m, 1H, lactam 
CH2-CH2NH), 1.80-1.67 (m, 2H, lactam CH2-CH2NH and lactam CH2-CH), 1.62-
1.55 (m, 2H, CH2-CH2-aryl), 1.31-1.20 (m, 10H, CH2-CH2-CH2-CH2-CH2-CH3) and 
0.85 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 170.1 (C=O), 148.5 (C-Oct), 136.3 (C-
SO2), 129.1 (CH-COct), 127.3 (CH-CSO2), 53.2 (CH-NH), 41.8 (lactam CH2-NH), 
35.9 (CH2-aryl),  31.8 (CH2-CH2-aryl), 31.0 (lactam CH2-CH), 29.4 (CH2-CH2-CH2-
aryl), 29.3 (CH2-CH2CH2CH2CH3), 29.2 (CH2-CH2CH2CH3), 28.4 (CH2-CH2CH3), 
22.7 (CH2-CH3), 20.7 (lactam CH2-CH2NH) and 14.1 (CH3); ESI m/z 100 %, 389.2 
(MNa
+
) and 36 %, 367.2 (MH
+
); HR ESI m/z (C19H30N2O3SNa
+
 requires 389.1869) 
found 389.1865. 
4.37, 4-Octylbenzenesulfonyl-(R)-3-amino-tetrahydropyridin-2-one  
Lactam 2.54 (2.5 mmol) was dissolved in H2O (30 mL) and cooled to 0°C. Sulfonyl 
chloride 4.28 (1.34 mmol) in dichloromethane (25 mL) and triethylamine (0.57 mL, 
4.0 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 20 mL) the organic layer was washed with a pH 2 buffer (3 × 
20 mL) and reduced in vacuo. The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 50:50 to 0:100) to give compound 
4.37 as a white solid (0.22 g, 45 %); mp 98-99 º C; [α]25D (c = 0.238, CHCl3) 
+102.94; υmax/cm
-1
:  3226 (N-H), 2920 (saturated C-H), 1663 (amide C=O) and 
1328, 1160 (SO2); δH (400 MHz, CDCl3) 7.76 (d, 2H, J 8, CH-CSO2), 7.26 (d, 2H, J 
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8, CH-C-Oct), 6.85 (br.s, 1H, NH-CH2), 6.14 (d, 1H, J 3, NH-CH), 3.52-3.46 (m, 
1H, lactam CH), 3.23-3.16 (m, 2H, lactam CH2-NH), 2.62 (t, 2H, J 7, CH2-aryl), 
2.38-2.31 (m, 1H, lactam CH2-CH), 1.87-1.81 (m, 1H, lactam CH2-CH2NH), 1.74-
1.65 (m, 2H, lactam CH2-CH2NH and lactam CH2-CH), 1.62-1.54 (m, 2H, CH2-CH2-
aryl), 1.32-1.20 (m, 10H, CH2CH2CH2CH2CH2CH3) and 0.84 (t, 3H, J 7, CH3); δC 
(100 MHz, CDCl3) 170.2 (C=O), 148.4 (C-Oct), 136.5 (C-SO2), 129.0 (CH-COct), 
127.3 (CH-CSO2), 53.2 (CH-NH), 41.5 (lactam CH2-NH), 35.8 (CH2-aryl),  32.0 
(CH2-CH2-aryl), 31.8 (lactam CH2-CH), 29.4 (CH2-CH2-CH2-aryl), 29.3 (CH2-
CH2CH2CH2CH3), 29.1 (CH2-CH2CH2CH3), 25.5 (CH2-CH2CH3), 22.7 (CH2-CH3), 
20.7 (lactam CH2-CH2NH) and 14.1 (CH3); ESI m/z 15 %, 389.2 (MNa
+
); HR ESI 
m/z (C19H30N2O3SNa
+
 requires 389.1869) found 389.1872. 
4.38, 4-Chlorobenzene isopropylsulfonate 
4-(Dimethylamino) pyridine (3.75 g, 30.1 mmol) was dissolved in dichloromethane 
(40 mL) and propan-2-ol (2 mL, 30 mmol) and cooled to 0 °C. A solution of 4-
chlorobenzenesulfonyl chloride (1.63 g, 7.7 mmol) in dichloromethane (10 mL) was 
added drop wise and the reaction was allowed to stir at room temperature for 3 
hours. The reaction was washed with 1 M HCl (3 × 15mL) and NaCl (3 × 15mL), 
dried over Na2SO4 and reduced in vacuo to give compound 4.38 as a colourless oil 
1.64 g (64 %); υmax/cm
-1
: 2984 (saturated C-H), 1583 (aromatic), 1362, 1184 (SO2) 
and 779 (C-Cl); δH (400 MHz, CDCl3) 7.77 (d, 2H, J 8.5, CH-CSO2), 7.44 (d, 1H, J 
8.5, CH-C-Cl), 4.69 (septet, 1H, J 6.5, CH-O) and 1.21 (d, 6H, J 6.5, (CH3)2); δC 
(100 MHz, CDCl3) 140.0 (C-Cl), 136.0 (C-SO2), 129.3 (CH-C-SO2), 129.0 (CH-C-
Cl), 78.1 (CH-O) and 22.8 (CH3)2; ESI m/z 100 %, 257.0 (MNa
+
), 54 %, 490.7 
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(M2Na
+
) and 32 %, 215.9 (M-(C3H6)Na
+
). Data is consistent with previously 
reported data for this compound.
246
 
4.39, 4-
n
Butylbenzene isopropylsulfonate 
Compound 4.38 (7 mmol) was dissolved in THF (25 mL) and cooled to 0 °C. 
Fe(acac)3 (0.136 g, 0.39 mmol) and NMP (4 mL, 56 mmol) were added. The reaction 
was stirred under nitrogen gas and BuMgCl (4.2 mL, 2M in THF) was added drop 
wise with a syringe. The reaction was stirred for 5 minutes before quenching with 
pH 2 buffer and extracting with ethyl acetate (3 × 15mL) and washing with pH 2 
buffer  (3 × 15mL). The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate 75:25) to give compound 4.39 as a colourless oil 1.02 
g (57 %); υmax/cm
-1
: 2932 (saturated C-H), 1598 (aromatic) and 1348, 1173 (SO2); δH 
(400 MHz, CDCl3) 7.76 (d, 2H, J 8.5, CH-CSO2), 7.29 (d, 1H, J 8.5, CH-CBu), 4.68 
(septet, 1H, J 6, CH-O), 2.64 (t, 2H, J 8, CH2-aryl), 1.57 (quin., 2H, J 8, CH2-CH2-
aryl), 1.30 (sextet, 2H, J 8, CH2-CH3), 1.21 (d, 6H, J 6, (CH3)2) and 0.87 (t, 3H, J 8, 
CH3); δC (100 MHz, CDCl3) 149.3 (C-Bu), 134.6 (C-SO2), 128.9 (CH-CBu), 127.5 
(CH-CSO2), 77.0 (CH-O), 35.7 (CH2-aryl), 33.1 (CH2-CH2-aryl), 22.7 (CH3)2, 22.2 
(CH2-CH3) and 13.8 (CH3);  ESI m/z 100 %, 534.7 (M2Na
+
) and 23 %, 279.1 
(MNa
+
). 
4.40, 4-
n
Hexylbenzene isopropylsulfonate 
Compound 4.38 (2.46 g, 10.5 mmol) was dissolved in THF (25 mL) and cooled to 0 
°C. Fe(acac)3 (0.22 g, 0.525 mmol) and NMP (6 mL, 63 mmol) were added. The 
reaction was stirred under nitrogen gas and HexMgCl (6.6 mL, 2M in THF) was 
added drop wise with a syringe. The reaction was stirred for 5 minutes before 
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quenching with pH 2 buffer and extracting with ethyl acetate (3 × 15mL) and 
washing with pH 2 buffer  (3 × 15mL). The product was purified by silica column 
chromatography (petroleum ether:ethyl acetate 75:25) to give compound 4.40 as a 
colourless oil 1.30 g (44 %); δH (400 MHz, CDCl3) 7.78 (d, 2H, J 8, CH-CSO2), 7.30 
(d, 1H, J 8, CH-CBu), 4.70 (septet, 1H, J 6, CH-O), 2.65 (t, 2H, J 8, CH2-aryl), 1.60 
(quin., 2H, J 7.5, CH2-CH2-aryl), 1.33-1.22 (m, 12H, CH2-CH2-CH2-CH3 and 
(CH3)2)) and 0.84 (t, 3H, J 7, CH3); δC (100 MHz, CDCl3) 149.3 (C-Hex), 134.7 (C-
SO2), 128.8 (CH-CHex), 127.7 (CH-CSO2), 77.1 (CH-O), 35.9 (CH2-aryl), 33.0 
(CH2-CH2-aryl), 29.9 (CH2-CH2CH2-aryl), 28.6 (CH2-CH2CH3), 22.8 (CH3)2, 22.7 
(CH2-CH3) and 14.2 (CH3); ESI m/z 100 %, 590.6 (M2Na
+
) and 73 %, 307.1 (MNa
+
). 
4.41, 4-(Butylbenzenesodiumsulfonate) 
Sulphanate ester 4.39 (7 mmol) and NaI (5.2 g, 34.69 mmol) were dissolved in 
acetone (25 mL) and stirred under nitrogen and in the absence of light under reflux 
conditions for 16 hours. The acetone was removed in vacuo and the product was 
washed with ethyl acetate (3 × 25 mL) and acetone (3 × 25 mL) to give compound 
4.41 as a white solid, the product still contains NaI so the yield was not calculated; 
δH (400 MHz, CDCl3) 7.49 (d, 2H, J 8, CH-CSO2), 7.12 (d, 1H, J 8, CH-CBu), 2.56 
(t, 2H, J 8, CH2-aryl), 1.53 (quin., 2H, J 8, CH2-CH2-aryl), 1.29 (sextet, 2H, J 7.5, 
CH2-CH3) and 0.89 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 149.3 (C-Bu), 134.6 
(C-SO2), 128.9 (CH-CBu), 127.5 (CH-CSO2), 77.0 (CH-O), 35.7 (CH2-aryl), 33.1 
(CH2-CH2-aryl), 22.7 (CH3)2, 22.2 (CH2-CH3) and 13.8 (CH3). 
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4.42, 4-(Hexylbenzenesodiumsulfonate)  
Sulfonate ester 4.40 (1.30 g, 4.57 mmol) and NaI (8 g, 53.37 mmol) were dissolved 
in acetone (20 mL) and stirred under nitrogen and in the absence of light under 
reflux conditions for 16 hours. The acetone was removed in vacuo and the product 
was washed with ethyl acetate (3 × 25 mL) and acetone (3 × 25 mL) to give 
compound 4.42. The product still contains NaI so the yield was not calculated; δH 
(400 MHz, CDCl3) 7.50 (d, 2H, J 8.5, CH-CSO2), 7.13 (d, 1H, J 8.5, CH-C-Bu), 
2.55 (t, 2H, J 7.5, C1), 1.54 (quintet, 2H, J 7.5, H2), 1.28-1.22 (m, 6H, J 7.5, H3, H4 
& H5) and 0.84 (t, 3H, J 7.5, H6); δC (100 MHz, CDCl3) 145.6 (C-Hex), 142.7 (C-
SO2ONa), 127.5 (CH-CHex), 125.5 (CH-CSO2), 34.7 (CH2-aryl), 31.1 (CH2-CH2-
aryl), 30.8 (CH2-CH2CH2-aryl), 28.2 (CH2-CH2CH3), 22.0 (CH2-CH3) and 14.2 
(CH3). 
4.43, 4-(Butylbenzenesulfonylchloride) 
Sodium salt 4.41 (7 mmol) was dissolved in pH 2 buffer and extracted with ethyl 
acetate (3 × 15 mL). The organic layer was dried over Na2SO3 and reduced in vacuo 
to give the corresponding sulfonic acid, which was dissolved in dichloromethane. 
Oxalyl chloride (0.50 mL, 7.7 mmol) and DMF (1 drop) were added and the reaction 
stirred for 3 hours. The organic solvents were removed in vacuo to give compound 
4.43 which was not isolated and used in the next step. 
4.44, 4-(Hexylbenzenesulfonylchloride) 
Sodium salt 4.24 (4.57 mmol) was dissolved in pH 2 buffer and extracted with ethyl 
acetate (3 × 15 mL). The organic layer was dried over Na2SO3 and reduced in vacuo 
to give the corresponding sulfonic acid, which was dissolved in dichloromethane. 
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Oxalyl chloride (0.33 mL, 5.03 mmol) and DMF (1 drop) were added and the 
reaction stirred for 3 hours. The organic solvents were removed in vacuo to give 
compound 4.44 which was not isolated and used in the next step. 
4.45, 4-Butylbenzenesulfonyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (1.15 g, 7.01 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Sulfony chloride 4.43 (7 mmol) in dichloromethane (30 mL) and triethylamine (3 
mL, 21 mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane and washed with pH 2 buffer (3 × 20 mL) and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 75:25 to 0:100) to give compound 4.45 as a white solid (0.17 g, 19 %); mp 
155-156 º C; [α]28D (c = 0.11, CHCl3) +94.39;  υmax/cm
-1
: 3219 (N-H), 2914 
(saturated C-H), 1668 (amide C=O), 1596 (aromatic) and 1328, 1121 (SO2); δH (400 
MHz, CDCl3) 7.76 (d, 2H, J 8, CH-CSO2), 7.31 (d, 2H, J 7.5, CH-C
n
Bu), 6.76 (br.t, 
1H, J 6, NH-CH2), 6.28 (d, 1H, J 5, NH-CH), 3.85 (ddd, 1H, J 11, 5, 2, CH), 3.24-
3.16 (m, 1H, lactam CH2-NH), 3.06 (ddd, 1H, J 15, 12, 5, lactam CH2-NH), 2.68 (t, 
2H, J 8, CH2-aryl), 2.18-2.11 (m, 1H, lactam CH2-CH), 2.03-1.93 (m, 1H, lactam 
CH2-CH2CH), 1.84-1.73 (m, 1H, lactam CH2-CH2NH), 1.69-1.55 (m, 4H, lactam 
CH2-CH2CH, CH2-CH and CH2-CH2-aryl), 1.38 (sextet, 2H, J 7.5, CH2-CH3), 1.36-
1.25 (m, 1H, lactam CH2-CH2NH) and 0.95 (t, 3H, J 7.5, CH3); δC (100 MHz, 
CDCl3) 175.6 (C=O), 148.3 (C-Bu), 137.1 (C-SO2), 129.1 (CH-C
n
Bu), 127.0 (CH-
CSO2), 55.3 (CH), 42.1 (lactam CH2-NH),  35.5 (lactam CH2-CH), 33.3 (CH2-aryl), 
33.1 (lactam CH2-CH2CH), 28.6 (CH2-CH2-aryl), 28.0 (CH2-CH3), 22.3 (lactam 
CH2-CH2NH) and 13.9 (CH3); ESI m/z 100 %, 670.6 (M2Na
+
), 86 %, 347.1 (MNa
+
) 
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and 43 %, 325.1 (MH
+
); HR ESI m/z (C16H24N2O3SNa
+
 requires 347.1400) found 
347.1397. 
4.46, 4-Butylbenzenesulfonyl-(S)-3-amino-tetrahydropyridin-2-one  
Lactam 2.53 (0.5 mmol) was dissolved in H2O (2 mL) and cooled to 0°C. Sulfonyl 
chloride 4.43 (0.1 mmol) in dichloromethane (3 mL) and triethylamine (42 µL, 0.30 
mmol) were added and stirred over night. The reaction was extracted with 
dichloromethane (3 × 5 mL) and washed with pH 2 buffer (3 × 5 mL) and reduced in 
vacuo. The product was purified by silica column chromatography (petroleum 
ether:ethyl acetate 50:50 to 0:100) to give compound 4.46 as a white solid (0.0.15 g, 
48 %); mp 107-108 º C; [α]28D (c = 0.44, CHCl3) +109.70; υmax/cm
-1
: 3192 (N-H), 
2928 (saturated C-H), 1662 (C=O), 1597 (aromatic) and 1312, 1160 (SO2); δH (400 
MHz, CDCl3) 7.76 (d, 2H, J 8, CH-C-SO2), 7.27 (d, 2H, J 8, CH-C
n
Bu), 6.45 (br.s, 
1H, NH-C1), 5.98 (d, 1H, J 2.5, NH-CH), 3.51-3.44 (m, 1H, CH-C3), 3.28-3.20 (m, 
2H, H1), 2.63 (t, 2H, J 8, H4), 2.44-2.38 (m, 1H, H3), 1.92-1.83 (m, 1H, H2), 1.81-
1.66 (m, 2H, H2 and H3), 1.58 (quartet, 2H, J 7.5, H5), 1.33 (sextet, 2H, H6) and 
0.95 (t, 3H, J 7.5, H7); δC (100 MHz, CDCl3) 170.1 (C=O), 148.5 (C-Bu), 136.3 (C-
SO2), 129.1 (CH-C
n
Bu), 127.3 (CH-CSO2), 53.2 (CH-NH), 41.8 (C1),  35.6 (C3), 
33.1 (C4), 28.4 (C5), 22.3 (C6), 20.7 (C2) and 13.9 (C7); ESI m/z 100 %, 642.6 
(M2Na
+
) and 71 %, 333.1 (MNa
+
); HR ESI m/z (C15H22N2O3SNa
+
 requires 333.1243) 
found 333.1247. 
4.47, 4-Hexylbenzenesulfonyl-(S)-3-amino-azepan-2-one   
Lactam 2.65 (1.03 g, 4.00 mmol) was dissolved in H2O (10 mL) and cooled to 0°C. 
Sulfonyl chloride 4.44 (3 mmol) in dichloromethane (10 mL) and triethylamine (1.3 
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mL, 9.0 mmol) were added and the reaction was stirred over night. The reaction was 
extracted with dichloromethane and washed with pH 2 buffer (3 × 20 mL) and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate 75:25 to 0:100) to give compound 4.47  as a white 
solid 0.49 g (46 %); mp 115-116 º C; [α]28D (c = 0.227, CHCl3) +104.41; υmax/cm
-1
: 
3371, 3242 (N-H), 2928 (saturated C-H), 1661 (C=O), 1599 (aromatic) and 1329, 
1161 (SO2); Anal. (C18H28N2O3S requires: C; 61.33, H; 8.01, N; 7.95) found: C; 
61.21, H; 8.04, N; 7.97; δH (400 MHz, CDCl3) 7.66 (d, 2H, J 8.5, CH-C-SO2), 7.20 
(d, 2H, J 8.5, CH-CHex), 7.06 (br.t, 1H, J 6, NH-CH2), 6.29 (d, 1H, J 5, NH-CH), 
3.75 (br.d, 1H, J 11, lactam CH), 3.14-3.97 (m, 1H, lactam CH2-NH), 2.98-2.88 (m, 
1H, lactam CH2-NH), 2.57 (t, 2H, J 8, CH2-aryl), 2.00 (br.d, 1H, J 13, lactam CH2-
CH), 1.87 (br.d, 1H, J 13, lactam CH2-CH2CH), 1.68 (br.d, 1H, J 13.5, lactam CH2-
CH2NH), 1.61-1.45 (m, 3H, lactam CH2-CH and CH2-CH2-aryl), 1.29-1.17 (m, 8H, 
lactam CH2-CH2NH, lactam CH2-CH2CH and CH2-CH2-CH2-CH3) and 0.82-0.77 
(m, 3H, CH3); δC (100 MHz, CDCl3) 174.7 (C=O), 148.3 (C-Hex), 137.2 (C-SO2), 
129.0 (CH-CHex), 126.9 (CH-CSO2), 55.3 (CH-NH), 42.0 (lactam CH2-NH),  35.8 
(lactam CH2-CH), 33.2 (CH2-aryl), 31.5 (lactam CH2-CH2CH), 30.9 (CH2-CH2-aryl), 
28.8 (CH2-CH2CH2-aryl), 28.5 (CH2-CH2CH3), 27.9 (lactam CH2-CH2NH), 22.5 
CH2-CH3) and 14.0 (CH3); ESI m/z 100 %, 375.1 (MNa
+
) and 15 %, 353.1 (MH
+
); 
HR ESI m/z (C18H28N2O3SH
+
 requires 353.1893) found 353.1896. 
4.48, 4-Hexylbenzenesulfonyl-(S)-3-tetrahydropyridin-2-one  
Lactam 2.53 (1 mmol) was dissolved in H2O (5 mL) and cooled to 0°C. Sulfonyl 
chloride (0.25 mmol) in dichloromethane (5 mL) and triethylamine (0.10 mL, 0.75 
mmol) were added and stirred over night. The reaction was extracted with 
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dichloromethane and washed with pH 2 buffer (3 × 5 mL) and reduced in vacuo. The 
product was purified by silica column chromatography (petroleum ether:ethyl acetate 
75:25 to 0:100) to give compound 4.48 as a white solid (0.042 g, 17 %); mp 97-98 
ºC; [α]30D (c = 0.508, CHCl3) +106.77;  υmax/cm
-1
: 3209 (N-H), 2925 (saturated C-H), 
1662 (C=O), 1595 (aromatic) and 1326, 1107 (SO2); δH (400 MHz, CDCl3) 7.77 (d, 
2H, J 8, CH-CSO2), 7.29 (d, 2H, J 8, CH-CHex), 6.14 (br.s, 1H, NH-CH2), 5.91 
(br.s, 1H, NH-CH), 3.51-3.45 (m, 1H, lactam CH), 3.31-3.22 (m, 2H, lactam CH2-
NH), 2.64 (t, 2H, J 7.5, CH2-aryl), 2.49-2.42 (m, 1H, lactam CH2-CH), 1.94-1.87 (m, 
1H, lactam CH2- CH2NH), 1.82-1.69 (m, 2H, lactam CH2-CH and lactam CH2-
CH2NH), 1.60 (q, 2H, J 7.5, CH2-CH2-aryl), 1.35-1.25 (m, 6H, CH2-CH2-CH2-CH3) 
and 0.86 (dd, 3H, J 6.5, CH3); δC (100 MHz, CDCl3) 170.0 (C=O), 148.6 (C-Hex), 
136.2 (C-SO2), 129.1 (CH-CHex), 127.4 (CH-CSO2), 53.3 (CH-NH), 41.9 (lactam 
CH2-NH), 35.9 (lactam CH2-CH), 31.6 (CH2-aryl), 31.0 (CH2-CH2-aryl), 28.9 (CH2-
CH2CH2-aryl), 28.5 (CH2-CH2CH3), 22.6 (CH2-CH3), 20.7 (lactam CH2-CH2NH), 
and 14.1 (CH3); ESI m/z 100 %, 698.6 (M2Na
+
) and 80 %, 361.1 (MNa
+
); HR ESI 
m/z (C17H26N2O3SNa
+
 requires 361.1556) found 361.1564. 
6.4.3 2- and 3-Carboxy Compounds 
4.49, Methyl-meta-chloro-benzoate 
Acetyl chloride (1.3 mL, 15 mmol) was dissolved in MeOH (25 mL) and 3-
chlorobenzoic acid (1.95 g, 12.5 mmol) was added, the reaction was heated under 
reflux conditions over night then reduced in vacuo to give compound 4.49 as a 
colourless oil, 
1
H NMR showed 100 % conversion; δH (400 MHz, CDCl3) 7.92 (s, 
1H, C-CH-C), 7.83 (d, 1H, J 8, CH-CCOO), 7.43 (d, 1H, J 8.5, CH-CCl), 7.29 (t, 
1H, J 8, CH-CH-CCl) and 3.85 (s, 3H, OCH3); δC (100 MHz, CDCl3) 167.7 (C=O), 
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134.4 (C-Cl), 132.9 (CH-CCl), 131.8 (C-COO), 129.9, 129.8 (C-CH-C and CH-CH-
CCl), 127.9 (CH-COO) and 52.3 (CH). Data is consistent with data previously 
reported for this compound.
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4.50, Methyl-ortho-chloro-benzoate 
Acetylchloride (4.0 mL, 56 mmol) was dissolved in MeOH (60 mL) and 2-
chlorobenzoic acid (2.49 g, 15.9 mmol) was added, the reaction heated under reflux 
conditions over night then reduced in vacuo to give compound 4.50 as a white solid 
(2.68 g, 99 %); δH (400 MHz, CDCl3) 7.76 (dd, 1H, J 7.5, 2, CH-CCl), 7.39-7.31 (m, 
2H, CH-CCO and CH-CH-CCl), 7.23 (td, 1H, J 7.5, 2, CH-CH-CH-CCl), and 3.87 
(s, 3H, OCH3). Data is consistent with data previoulsy reported for this compound.
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4.51, Methyl-3-
n
butylbenzoate 
Compound 4.49 (12.5 mmol) was dissolved in THF (30 mL) and cooled to 0 °C. 
Fe(acac)3 (0.23 g, 0.65 mmol) and NMP (7.23 mL, 75 mmol) were added. The 
reaction was stirred under nitrogen gas and BuMgCl (6.3 mL, 2M in THF) was 
added drop wise. The reaction was stirred for 15 minutes before quenching with pH 
2 buffer (25 mL), extracting with ethyl acetate (3 × 15mL) and washing with pH 2 
buffer  (3 × 15mL). The NMP was removed by silica column chromatography 
(petroleum ether:ethyl acetate 75:25) to give compound 4.51 as a colourless oil 
which also contained some unreacted starting material.  
4.52, Methyl-3-hexylbenzoate 
Compound 4.49 (3.86 g, 24.7 mmol) was dissolved in THF with Fe(acac)3 (0.88 g, 
2.8 mmol) and NMP (14.3 mL, 148 mmol) were added. The reaction was stirred 
under nitrogen and HexMgCl (15.4 mL, 2M) was added drop wise. The reaction was 
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stirred for 15 minutes before quenching with pH 2 buffer (35 mL), extracting with 
ethyl acetate (3 × 15mL) and washing with pH 2 buffer (3 × 15mL). The NMP was 
removed by silica column chromatography (petroleum ether:ethyl acetate 75:25) and 
the unreacted started material was removed by hydrolysing the methyl-meta-chloro-
benzoate ester and extracting out the product with ethyl acetate to give compound 
4.52 as a colourless oil (0.64 g, 12 %); δH (400 MHz, CDCl3) 7.87-7.82 (m, 2H, CH), 
7.36-7.28 (m, 2H, CH), 3.88 (s, 3H, OCH3), 2.63 (t, 2H, J 8, CH3-aryl), 1.61 
(quintet, 2H, J 7.5, CH2-CH2-aryl), 1.36-1.24 (m, 6H, CH2-CH2-CH2-CH3) and 0.87 
(dd, 3H, J 8.5, 7.5, CH3); δC (100 MHz, CDCl3) 167.3 (C=O), 143.2 (C-Hex), 133.1 
(CH-CCO), 130.1 (C-CO), 129.5 (CH-CCO), 128.3, 127.0 (CH-CH-CHex), 31.4 
(CH2-CH2CH2-aryl), 28.9 (CH2-CH2CH3), 23.4 (CH2-CH3) and 14.1 (CH3); ESI m/z 
100 %, 243.1 (MNa
+
) and 38 %, 462.8 (M2Na
+
). Data is consistent with previously 
reported data for this compound.
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4.53, Methyl-2-Butylbenzoate 
Compound 4.50 (2.68 g, 15.7 mmol) was dissolved in THF (40 mL) with Fe(acac)3 
(0.56 g, 1.6 mmol) and NMP (9.0 mL, 94 mmol). The reaction was stirred under 
nitrogen and BuMgCl (11.8 mL, 2 M) was added drop wise. The reaction was stirred 
for 15 minutes before quenching with pH 2 buffer (25 mL), extracted with ethyl 
acetate (3 × 15mL) and washed with pH 2 buffer (3 × 15mL). The NMP was 
removed by silica column chromatography (petroleum ether:ethyl acetate 75:25) to 
give the product compound 4.53 containing some unreacted starting material, the 
compound was reacted on and purified in  the final step. 
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4.54, 3-Butylbenzoic 
Ester 4.51 was dissolved in H2O and NaOH was added, the reaction was heated over 
night at 60 °C. The reaction was extracted with ethyl acetate the acidified with pH 2 
buffer and extracted again with ethyl acetate, this layer was dried over Na2SO3 and 
reduced in vacuo to give compound 4.54 as a colourless oil.  
4.55, 3-Hexylbenzoic Acid 
Ester 4.52 (0.62 g, 2.8 mmol) was dissolved in H2O with NaOH (0.56 g, 14 mmol) 
the reaction was stirred overnight at 50 °C. The reaction was brought to pH 7, 
extracted with ethyl acetate and reduced in vacuo to give compound 4.55 as a white 
oily solid (0.56 g, 97 %); δH (400 MHz, MeOD) 7.83 (br.s, 1H, CH-COOH), 7.81-
7.79 (CH), 7.31-7.29 (m, 2H, CH), 2.68 (dd, 2H, J 8, 7.5, CH3-aryl), 1.68 (br.quintet, 
2H, J 7.5, CH2-CH2-aryl), 1.41-1.32 (m, 6H, CH2-CH2-CH2-CH3) and 0.95-0.91 (m, 
3H, CH3); δC (100 MHz, MeOD) 174.7 (C=O), 143.7 (C-Hex), 137.4 (C-CO), 132.0 
(CH-CCOOH), 130.4 (CH-CCOOH), 128.8, 127.8 (CH-CH-CHex), 36.9 (CH2-aryl), 
32.9 (CH2-CH2-aryl), 32.7 (CH2-CH2CH2CH2CH3), 30.1 (CH2-CH2CH3), 23.7 (CH2-
CH3) and 14.5 (CH3); ESI m/z 46 %, 229.3 (MNa
+
). 
4.56, 2-Butylbenzoic acid 
Ester 4.53 containing some unreacted starting material was dissolved in H2O (10 
mL) and NaOH (0.24 g, 6 mmoles) was added, the reaction was stirred at 50 °C 
overnight. The aqueous layer was extracted with ethyl acetate which was dried over 
Na2SO3 and reduced in vacuo to give compound 4.56 as a colourless oil; δH (400 
MHz, CDCl3) 8.04 (d, 1H, J 8, CH-CCOOH), 7.47 (t, 1H, J 7.5, CH-CH-CBu), 7.30-
7.25 (m, 2H, CH-CBu and CH-CH-CCOOH), 3.04 (dd, 1H, J 8.5, 7.5, CH2-aryl), 
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1.62 (quintet, 2H, J 7.5, CH2-CH2-aryl), 1.41 (sextet, 2H, J 7.5, CH2-CH3) and 0.95 
(t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 173.5 (C=O), 146.0 (C-Bu), 132.8 (CH-
CH-CBu), 131.7 (CH-CCOOH), 131.3 (CH-CBu), 128.1 (C-COOH), 125.8 (CH-
CH-CCOOH), 34.4 (CH2-aryl), 34.0 (CH2-CH2-aryl), 22.8 (CH2-CH3) and 13.9 
(CH3); ESI m/z 100 %, 179.1 (MH
+
) and 34 %, 201.1 (MNa
+
).
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4.57, 3-Butylbenzoyl chloride 
Acid 4.54 was dissolved in dichloromethane, oxalyl chloride and DMF (1 drop, 
catalytic) were added and the reaction was stirred for 3 hours. The organic solvents 
were removed in vacuo and compound 4.57 was used straight away in the next step. 
4.58, 3-Hexylbenzoyl chloride 
Acid 4.55 (0.50 g, 2.4 mmol) was dissolved in dichloromethane (25 mL), oxalyl 
chloride (0.4 mL, 4.8 mmol) and DMF (1 drop, catalytic) were added and the 
reaction was stirred for 3 hours. The organic solvents were removed in vacuo and 
compound 4.58 was used straight away in the next step. 
4.59, 2-Butylbenzoyl chloride 
Acid 4.56 was dissolved in dichloromethane (5 mL), oxalyl chloride (0.3 mL, 2 
mmol) and DMF (1 drop, catalytic) were added and the reaction was stirred for 3 
hours. The organic solvents were removed in vacuo and compound 4.59 was used 
straight away in the next step. 
4.60, 3-Butylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.72 g, 4.39 mmol) was dissolved in H2O (20 mL) and cooled to 0°C. 
Acid chloride 4.57 in dichloromethane was added and triethylamine (1.3 mL, 9 
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mmol) and the reaction was stirred over night. H2O (20 mL) was added and the 
reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 75:25 to 0:100) to give compound 4.60 as a white solid 0.05 g (6 %); mp 
105-106 º C; Anal. (C10H18N2O2 requires: C; 70.80, H; 8.39, N; 9.71) found: C; 
70.68, H; 8.48, N; 9.68; δH (400 MHz, CDCl3) 7.71-7.62 (m, 3H, Ar & NH-CH), 
7.35-7.29 (m, 2H,  Ar), 7.06 (br.t, 1H, J 6, NH-CH2), 4.72 (dd, 1H, J 11, 6, lactam 
CH), 3.37-3.32 (m, 2H, lactam CH2-NH), 2.65 (t, 2H, J 8, CH2-aryl), 2.22 (br.d, 1H, 
J 13.5, equatorial lactam CH2-CH), 2.03 (br.d, 1H, J 14, equatorial lactam CH2-
CH2CH), 1.95-1.81 (m, 2H, equatorial lactam CH2-CH2NH and axial lactam CH2-
CH2CH), 1.61 (quintet, 2H, J 7, CH2-CH2-aryl), 1.57-1.48 (m, 1H, axial lactam CH2-
CH), 1.46-1.36 (m, 1H, J 13, axial lactam CH2-CH2NH), 1.34 (sextet, H2, J 7.5, 
CH2-CH3) and 0.92 (t, 3H, J 7.5, CH3); δC (100 MHz, CDCl3) 176.0 (C=O), 166.6 
(C=O), 143.4 (C-
n
Bu), 134.2 (C-C=O), 128.4 (CH-CH-CBu), 127.2 (CH-CH-CBu), 
126.8 (CH-CBu), 124.0 (CH-CCO), 52.6 (CH-NH), 42.1 (lactam CH2-NH), 35.6 
(lactam CH2-CH), 33.5 (CH2-aryl), 31.6 (CH2-CH2-aryl), 28.9 (lactam CH2-CH2CH), 
28.0 (CH2-CH3), 22.3 (lactam CH2-CH2NH) and 13.9 (CH3); υmax/cm
-1
: 3244 (NH), 
2931 (C-H), 1648 (C=O) and 1559 (aromatic); ESI m/z 100 %, 598.8 (M2Na
+
) and 
95 %, 311.2 (MNa
+
); HR ESI m/z (C17H24N2O2Na
+
 requires 311.1730) found 
311.1725; [α]26D (c = 0.228, CHCl3) +68.89. 
4.61, 3-Hexylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.40 g, 2.4 mmol) was dissolved in H2O (10 mL) and cooled to 0°C. 
Acid chloride 4.58 (0.56 g, 2.7 mmol) in dichloromethane (25 mL) and triethylamine 
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(1 mL, 8 mmol) were added and the reaction was stirred over night. H2O (20 mL) 
was added and the reaction was extracted with dichloromethane (3 × 20 mL), the 
organic layer was washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and 
reduced in vacuo. The product was purified by silica column chromatography 
(petroleum ether:ethyl acetate 75:25 to 0:100) to give compound 4.61 as a white 
solid 0.45 g (53 %); mp 104-105 º C; [α]29D (c = 0.4, CHCl3) +64.63; υmax/cm
-1
: 3203 
(NH), 2925 (C-H), 1680, 1646 (C=O) and 1541 (aromatic); δH (400 MHz, CDCl3) 
7.65-7.60 (m, 3H, Ar & NH-CH), 7.35-7.29 (m, 2H, Ar), 6.27 (br.t, 1H, J 6, NH-
CH2), 4.71 (ddd, 1H, J 11.5, 5.5, 2, CH), 3.39-3.22 (m, 2H, lactam CH2-NH), 2.63 (t, 
2H, J 7.5, CH2-aryl), 2.23 (br.d, 1H, J 12.5, equatorial lactam CH2-CH), 2.08-2.00 
(m, 1H, lactam CH2-CH), 1.97-1.89 (m, 2H, lactam CH2-CH2NH and CH2-CH2CH), 
1.65-1.50 (m, 2H, CH2-CH2-aryl), 1.42 (br.q, 1H, J 13.5, axial lactam CH2-CH2NH), 
1.36-1.24 (m, 6H, CH2-CH2-CH2-CH3) and 0.86 (dd, 3H, J 7, 8, CH3); δC (100 MHz, 
CDCl3) 175.8 (lactam C=O), 166.5 (C=O), 143.5 (C-Hex), 134.2 (C-C=O), 131.7 
(CH-CH-CHex), 128.4 (CH-CH-CHex), 127.1 (CH-CHex), 124.3 (CH-CCO), 52.6 
(CH-NH), 42.3 (lactam CH2-NH), 35.9 (lactam CH2-CH), 35.9 (CH2-aryl), 31.4 
(CH2-CH2-aryl), 29.0 (lactam CH2-CH2CH), 28.9 (CH2-CH2CH2-aryl), 28.0 (CH2-
CH2CH3), 22.6 (lactam CH2-CH2NH), 22.5 (CH2-CH3) and 14.1 (CH3); ESI m/z 100 
%, 339.2 (MNa
+
) and 17 %, 654.6 (M2Na
+
); HR ESI m/z (C19H29N2O2Na
+
 requires 
317.2224) found 311.2227. 
4.62, 2-Butylbenzoyl-(S)-3-amino-azepan-2-one  
Lactam 2.65 (0.16 g, 1.0 mmol) was dissolved in H2O (5 mL) and cooled to 0°C. 
Acid chloride 4.59 in dichloromethane (5 mL) and triethylamine (0.4 mL, 3 mmol) 
were added, the reaction was stirred over night. H2O (10 mL) was added and the 
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reaction was extracted with dichloromethane (3 × 20 mL), the organic layer was 
washed with a pH 2 buffer (3 × 15 mL), dried over Na2SO4 and reduced in vacuo. 
The product was purified by silica column chromatography (petroleum ether:ethyl 
acetate 50:50 to 0:100) to give the product compound 4.62 as a white solid (0.08 g, 2 
% over 4 steps); δH (400 MHz, CDCl3) 7.37 (dd, 1H, CH-CCO), 7.31 (td, 1H,  CH-
CH-CBu), 7.23-7.15 (m, 3H, CH-CBu , CH-CH-CCO and NH-CH) 6.28 (br.t, 1H, J 
5.5, NH-CH2), 4.71 (ddd, 1H, J 11, 6, 1.5, lactam CH), 3.39-3.21 (m, 2H, lactam 
CH2-NH), 2.80, 2.74 (dt, 1H, J 14, 8, CH2-aryl), 2.57 (br.d, 1H, J 12, equatorial 
lactam CH2-CH), 2.09-2.00 (m, 1H, equatorial lactam CH2-CH2CH), 1.97-1.83 (m, 
2H, equatorial lactam CH2-CH2NH and axial lactam CH2-CH2CH), 1.62-1.50 (m, 
3H, CH2-CH2-aryl and axial lactam CH2-CH), 1.48-1.38 (m, 1H, J 13, axial lactam 
CH2-CH2NH), 1.34 (sextet, H2, J 7, CH2-CH3) and 0.89 (t, 3H, J 7.5, CH3); δC (100 
MHz, CDCl3) 175.5 (C=O), 169.3 (C=O), 141.1 (C-
n
Bu), 136.5 (C-C=O), 130.1 
(CH-CH-CBu), 129.8 (CH-CBu or CH-CH-CO), 127.2 (CH-CCO), 125.7 (C CH-
CBu or CH-CH-CO), 52.5 (CH-NH), 42.1 (lactam CH2-NH), 33.0 (lactam CH2-CH), 
33.0 (CH2-aryl), 31.6 (CH2-CH2-aryl), 29.0 (lactam CH2-CH2CH), 28.0 (CH2-CH3), 
22.7 (lactam CH2-CH2NH) and 14.0 (CH3); ESI m/z 100 %, 289.1 (MNa
+
), 60 %, 
311.1 (MNa
+
) and 16 %, 598.6 (M2Na
+
); HR ESI m/z (C17H24N2O2Na
+
 requires 
311.1730) found 311.1733. 
6.445 Iron-Cross Coupling on Amides 
4.63, 4-Chlorobenzoyldimethylamide 
4-(Chlorobenzoylchloride) (2.5 mL, 20 mmol) was dissolved in dichloromethane (25 
mL) and cooled on ice. Dimethylamine (1.0 mL, 20 mmol) and triethylamine (8.4 
mL, 60 mmol) and the reaction was stirred over night. The dichloromethane was 
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removed in vacuo and the product dissolved in ethyl acetate, washed with pH 2 
buffer (3 × 10 mL), dried over Na2SO3 and reduced in vacuo to give compound 4.63 
as a brown oil (2.28 g, 62 %); δH (400 MHz, CDCl3) 7.23 (s, 4H, aryl) and 2.94, 2.82 
(br.s, 3H, N(CH3)2; δC (100 MHz, CDCl3) 170.3 (C=O), 135.4 (C-Cl), 134.7 (C-CO), 
128.6 (aryl CH) and 39.4, 35.3 (NCH3); ESI m/z 100 %, 206.0 (MH
+
), 62 %, 388.8 
(M2Na
+
) and 9 %, 284.2 (MH
+
). Data is consistant with data previously reported for 
this compound.
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4.64, 4-Butylbenzoyldimethylamide 
Compound 4.63 (1.04 g, 5.67 mmol) was dissolved in THF (20 mL) and cooled on 
ice. Fe(acac)3 (0.20 g, 0.57 mmol) and NMP (3.3 mL, 34 mmol) were added. The 
reaction was stirred under nitrogen gas and HexMgCl (3.8 mL, 2M in THF) was 
added drop wise with a syringe. The reaction was stirred for 2 hours before 
quenching with pH 2 buffer and extracting with ethyl acetate (3 × 10 mL) and 
washing with pH 2 buffer  (3 × 10 mL). The NMP was removed using silica column 
chromatography (petroleum ether:ethyl acetate 75:25) to give compound 4.64 as a 
light brown colourless oil (0.76 g, 58 %); δH (400 MHz, CDCl3) 7.29 (d, 2H, J 8, 
CH-CO), 7.16 (d, 2H, J 8, CH-C-Bu), 3.06, 2.95 (br.s, 3H, N(CH3)2), 2.58 (t, 2H, J 
8, CH2-aryl), 1.57 (quintet, 2H, J 7.5, CH2-CH2-aryl), 1.33-1.23 (m, 6H, CH2-CH2-
CH2-CH3) and 0.84 (dd, 3H, J 8.5, 7.5, CH3); δC (100 MHz, CDCl3) 171.8 (C=O), 
144.6 (C-Hex), 133.5 (C-CO), 128.3 (CH-C-Bu), 127.2 (CH-CO), 39.7 (CH2-aryl), 
35.6 (CH2-CH2-aryl), 31.5 (CH2-CH2CH2-aryl), 28.9 (CH2-CH2CH3), 22.6 (CH2-
CH3) and 14.1 (CH3); ESI m/z 100 %, 489.0 (M2Na
+
), 11 %, 256.1 (MNa
+
), 7 %, 
467.0 (M2H
+
) and 5 %, 234.2 (MH
+
). Data is consistent with data previously 
reported for this compound.
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4.65, 4-Chlorobenzonyl-(S)-3-amino-azepan-2-one  
4-(Chlorobenzoylchloride) (1.42 g, 9.07 mmol) was dissolved in dichloromethane 
(20 mL) and cooled on ice. Lactam 2.65 (1.38 g, 8.41 mmol) was dissolved in H2O 
(15 mL) and added as was triethylamine (3.5 mL, 25.2 mmol) and the reaction was 
stirred over night. The reaction was extracted with dichloromethane (3 × 10 mL) and 
washed with pH 2 buffer (3 × 10 mL), dried over Na2SO3 and recued in vacuo. The 
product was purified by washing with hot ethyl acetate to give compound 4.65 as a 
white solid (0.46 g, 20 %); mp 217-218 °C; [α]31D (c = 0.592, MeOH) +0.318; 
υmax/cm
-1
: 3198 (NH), 2927 (C-H), 1660, 1641 (C=O) and 856 (C-Cl);   δH (400 
MHz, CDCl3) 7.77 (d, 2H, J 8.5, CH-CCl), 7.61 (d, 1H, J 5.5, NH-CH), 7.40 (d, 1H, 
J 8.5, CH-CO), 6.08 (br.t, 1H, NH-CH2), 4.68 (ddd, 1H, J 11, 6, 2, lactam CH), 3.39-
3.24 (m, 2H, lactam CH2-NH), 2.29 (br.d, 1H, J 14.5, lactam CH2-CH), 2.10-2.01 
(m, 1H, lactam CH2-CH2NH), 1.96-1.89 (m, 2H, lactam CH2-CH2CH), 1.61-1.50 (m, 
1H, lactam CH2-CH) and 1.43 (br.q, 1H, J 14, lactam CH2-CH2NH); δC (100 MHz, 
CDCl3) 175.7 (lactam C=O), 165.2 (C=O), 137.8 (C-Cl), 132.6 (C-CO), 128.8 (C-
CCl), 128.5 (C-CCO), 52.7 (CH), 42.2 (lactam CH2-NH), 31.6 (lactam CH2-CH), 
28.9 (lactam CH2-CH2CH) and 28.0 (lactam CH2-CH2NH); ESI m/z 100 %, 289.0 
(MNa
+
) and 41 %, 554.6 (M2Na
+
); HR ESI m/z (C13H15N2O2ClNa
+ 
requires 
289.0714) found 289.0718. 
4.66, 4-Chlorobenzenesulphonyl-(S)-3-amino-azepan-2-one  
4-(Chlorobenzenesulfonylchloride) (1.20 g, 5.69 mmol) was dissolved in 
dichloromethane (15 mL) and cooled on ice. Lactam 2.65 (0.96 g, 5.85 mmol) was 
dissolved in H20 (10 mL) and added as was triethylamine (2.4 mL, 17.1 mmol) and 
the reaction was stirred over night. The reaction was extracted with dichloromethane 
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(3 × 10 mL) and washed with pH 2 buffer (3 × 10 mL), dried over Na2SO3 and 
recued in vacuo. The product was purified by washing with hot ethyl acetate to give 
compound 4.66 as a white solid; [α]28D (c = 0.52, CHCl3) +123.56; δH (400 MHz, 
CDCl3) 7.77 (d, 2H, J 8, CH-CCl), 7.45 (d, 1H, J 8, CH-CSO2), 6.21 (d, 1H, J 5.5, 
NH-CH), 6.06 (br.t, 1H, J 4, NH-CH2), 3.82 (ddd, 1H, J 11, 6, 2, CH), 3.23-3.14 (m, 
1H, lactam CH2-NH), 3.11-3.02 (m, 1H, lactam CH2-NH), 2.23 (br.d, 1H, J 11, 
lactam CH2-CH), 2.00 (br.d, 1H, J 13, lactam CH2-CH2CH), 1.80 (br.d, 1H, J 12, 
lactam CH2-CH2NH), 1.70-1.55 (m, 2H, lactam CH2-CH2CH and CH2-NH) and 1.34 
(br.q, 1H, J 14, lactam CH2-CH2NH); δC (100 MHz, CDCl3) 174.0 (C=O), 139.2 (C-
SO2), 138.6 (C-Cl), 129.4 (CH-CSO2), 128.5 (CH-CCl) 55.5 (CH), 42.3 (lactam 
CH2-NH), 33.4 (lactam CH2-CH), 28.6 (lactam CH2-CH2CH) and 28.0 (lactam CH2-
CH2NH); ESI m/z 100 %, 325.0 (MNa
+
) and 60 %, 626.7 (M2Na
+
); HR ESI m/z 
(C12H15N2SO3ClNa
+
 requires 325.0384) found 325.0386. 
4.67, 4-Chlorobenzonyl-(S)-3-amino-tetrahydropyridin-2-one  
4-(Chlorobenzoylchloride) (13 mmol) was dissolved in dichloromethane (30 mL) 
and cooled on ice. Lactam 2.53 (10 mmol) was dissolved in H2O (20 mL) and added 
as was triethylamine (4.2 mL, 30 mmol) and the reaction was stirred over night. The 
reaction was extracted with dichloromethane (3 × 15 mL) and washed with pH 2 
buffer (3 × 15 mL), dried over Na2SO3 and recued in vacuo. The product was 
purified by washing with hot ethyl acetate to give compound 4.67 as a white solid 
(1.16 g, 46 %); mp 194-195 °C; υmax/cm
-1
: 3211 (NH), 2937 (C-H), 1670, 1649 
(C=O) and 845 (C-Cl); δH (400 MHz, d
6
 DMSO) 8.70 (d, 1H, J 8.5, NH-CH), 7.88 
(d, 2H, J 8.5, CH-CCl), 7.66 (br.t, 1H, NH-CH2), 7.53 (d, 1H, J 8.5, CH-CO), 4.37 
(8, 1H, J 8.5, lactam CH), 3.19-3.14 (m, 2H, lactam CH2-NH), 2.04-1.99 (m, 1H, 
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lactam CH2-CH) and 1.87-1.74 (m, 2H, lactam CH2-CH and lactam CH2-CH2NH); 
δC (100 MHz, d
6
 DMSO) 169.7 (lactam C=O), 164.7 (C=O), 136.0 (C-Cl), 133.0 (C-
CO), 129.2 (CH-CCl), 128.3 (CH-CCO), 49.6 (CH), 41.2 (lactam CH2-NH), 27.6 
(lactam CH2-CH) and 21.3 (lactam CH2-CH2NH); ESI m/z 100 %, 275.0 (MNa
+
) and 
71 %, 526.6 (M2Na
+
); HR ESI m/z (C12H13N2O2ClNa
+ 
requires 275.0558) found 
275.0554. 
4.68, 4-Chlorobenzenesulphonyl-(S)-3-amino-tetrahydropyridin-2-one  
4-(Chlorobenzenesulfonylchloride) (1.95 g, 9.24 mmol) was dissolved in 
dichloromethane (25 mL) and cooled on ice. Lactam 2.53 (10 mmol) was dissolved 
in H2O (10 mL) and added as was triethylamine (8.4 mL, 60 mmol) and the reaction 
was stirred over night. The reaction was extracted with dichloromethane (3 × 10 mL) 
and washed with pH 2 buffer (3 × 10 mL), dried over Na2SO3 and reduced in vacuo. 
The product was purified by washing with hot ethyl acetate to give compound 4.68 
as a white solid (1.11 g, 41 %); mp 136-137 °C; [α]30D (c = 0.526, CHCl3) +123.42; 
υmax/cm
-1
: 3213, 3089 (NH), 2945 (saturated CH), 1655 (C=O), 1331, 1157 (SO2), 
827 (C-Cl); δH (400 MHz, CDCl3) 7.81 (d, 2H, J 8.5, CH-CCl), 7.44 (d, 1H, J 8.5, 
CH-CSO2), 6.55 (br.s, 1H, NH-CH2), 6.19 (d, 1H, J 4, NH-CH), 3.52 (ddd, 1H, J 11, 
6, 4, CH), 3.26-3.19 (m, 2H, lactam CH2-NH), 2.39-2.30 (m, 1H, lactam CH2-CH), 
1.94-1.84 (m, 1H, lactam CH2-CH2CH) and 1.82-1.62 (m, 2H, lactam CH2-CH2CH 
and lactam CH2-CH); δC (100 MHz, CDCl3) 170.1 (C=O), 139.1 (C-SO2), 138.2 (C-
Cl), 129.7 (CH-CSO2), 128.5 (CH-CCl), 53.3 (CH), 41.7 (lactam CH2-NH), 28.6 
(lactam CH2-CH), and 20.7 (lactam CH2-CH2NH); ESI m/z 100 %, 311.0 (MNa
+
) 
and 25 %, 598.4 (M2Na
+
); HR ESI m/z (C11H13N2SO3Na
+
 requires 311.0228) found 
311.0234. 
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6.6 Biological Testing 
6.6.1 SSTR2 Binding Assay 
The FP assay was run by Tilly Sharp or Glenda Chandler or Total Scientific 
(Babraham Research Campus, Cambridge). The test compounds are dissolved in an 
aqueous 4 % DMSO solution and are added to a 96-well plate along with unlabelled 
somatostatin. Somatostatin labelled with fluorescein isothiocyanate (SS14-FITC) 
was added, and finally the SSTR2 in phosphate buffer solution (PBS). The plate is 
shaken for one minute and left at room temperature for one hour, after which the FP 
data is collected. 
6.6.2 Leukocyte Migration Assay 
The leukocyte migration assay was run by Dr Jill Reckless of The Department of 
Medicine, The University of Cambridge following a standard protocol.
200
 A 96-well 
plate was used - each well with a lower compartment which contains the 
chemoattractant IL-8. The upper compartment contains the cells, which were 
neutrophils suspended in Gey's buffer. A polycarbonate filter membrane separates 
the compartments. The test compound was placed in each compartment at equal 
concentration, which was either 1 µM or 1 nM to ensure there was no concentration 
gradient. The experiments were randomised across the plate rather than spatially 
grouping the replications. The number of cells that migrated from the upper to the 
lower compartment was determined. The migrated cells were quantified using the 
dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The 
neutrophils were given 90 minutes to migrate after which 3µl of MTT (5mg/ml in 
Roswell Park Memorial Institute media [RPMI]) was added per well and the cells are 
incubated at 37 ˚C for 2 hours. A standard curve was set up with a known number of 
cells per well (in triplicate). After 2 hours the media was removed and the formazan 
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precipitate was solubilised with 20 µL DMSO. The absorbance at 595 nm was taken 
and the number of cells per well was interpolated from the standard curve of known 
number of cells.  
6.7 Chromatograms 
The optical purity was measured by HPLC analysis using a Varian Prostar 335 
Photodiode Array Detector, using a Varian Prostar Solvent Delivery Module and a 
Varian Prostar 420 Autosampler. The e.e.s were determined using a CHIRALPAK 
AS column (4.6 mm × 250 mm) (n-hexane/propan-2-ol = 1:1; flow rate, 0.5 mL/min, 
λ = 207 nm). 
 
Figure 86 Chromatogram for Cbz protected lactam, pre-resolution compound 2.52 
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Figure 87 Chromatogram for compound 2.63 
 
Figure 88 Chromatogram for compound 2.64 
 
 
 Figure 89 Chromatogram for compound 2.61 
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Figure 90 Chromatogram for compound 2.62 
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